PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22716951-6 2013 The levels of phospho-Akt and phospho-extracellular signal-related kinase (ERK) were reduced in cells treated with maslinic acid, and the phosphoinositide 3-kinase inhibitor LY294002 and the mitogen-activated protein kinase kinase inhibitor PD98059 reduced HIF-1alpha levels and VEGF secretion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 174-182 AKT serine/threonine kinase 1 Homo sapiens 22-25 23710442-8 2013 The PI3K inhibitor LY294002 blocked p-Akt and p-GSK3 beta expressions in podocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 38-41 23351384-7 2013 The protective effect of Hsp90beta against apoptosis was negated by LY294002, an Akt inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 81-84 23420486-3 2013 The activation of Akt in ovarian cancer cells, as marked by its phosphorylation on Ser473, was not modified by cytostatic concentrations of mifepristone, but it was blocked upon treatment with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 193-201 AKT serine/threonine kinase 1 Homo sapiens 18-21 24592124-4 2013 CONCLUSIONS: Akt protein phosphorylation of trastuzumab drug-resistance cells is activated; LY294002, a PI3K/Akt inhibitor, can obviously inhibit Akt protein phosphorylation of trastuzumab drug-resistance cells and there is a clear association between the PI3K/Akt signal transduction pathway and trastuzumab resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 13-16 24592124-4 2013 CONCLUSIONS: Akt protein phosphorylation of trastuzumab drug-resistance cells is activated; LY294002, a PI3K/Akt inhibitor, can obviously inhibit Akt protein phosphorylation of trastuzumab drug-resistance cells and there is a clear association between the PI3K/Akt signal transduction pathway and trastuzumab resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 109-112 24592124-4 2013 CONCLUSIONS: Akt protein phosphorylation of trastuzumab drug-resistance cells is activated; LY294002, a PI3K/Akt inhibitor, can obviously inhibit Akt protein phosphorylation of trastuzumab drug-resistance cells and there is a clear association between the PI3K/Akt signal transduction pathway and trastuzumab resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 109-112 24592124-4 2013 CONCLUSIONS: Akt protein phosphorylation of trastuzumab drug-resistance cells is activated; LY294002, a PI3K/Akt inhibitor, can obviously inhibit Akt protein phosphorylation of trastuzumab drug-resistance cells and there is a clear association between the PI3K/Akt signal transduction pathway and trastuzumab resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 109-112 23992306-5 2013 In addition, the levels of phospho-Akt and phospho- NF-kappaB in BxPC-3 and Panc-1 cells were reduced by both resveratrol and LY294002 (a PI3-K inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 35-38 24094245-4 2013 The relationship between PI3K/Akt pathway and Nrf2/HO-1 axis was demonstrated by the finding that pretreatment with PI3K inhibitors (wortmannin, LY294002) attenuated the upregulation of Nrf2 expression induced by HBCDs exposure. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 30-33 23762109-5 2013 Western blot analysis findings further indicated that TSD medicated serum upregulated p-Akt and p-eNOS expressions, which were significantly inhibited by LY294002 or L-NAME and completely inhibited by both LY294002 and L-NAME; these results indicated that TSD medicated serum induced HUVECs VEGF expression via PI3K/Akt-eNOS signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 88-91 23762109-5 2013 Western blot analysis findings further indicated that TSD medicated serum upregulated p-Akt and p-eNOS expressions, which were significantly inhibited by LY294002 or L-NAME and completely inhibited by both LY294002 and L-NAME; these results indicated that TSD medicated serum induced HUVECs VEGF expression via PI3K/Akt-eNOS signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 206-214 AKT serine/threonine kinase 1 Homo sapiens 88-91 23762109-5 2013 Western blot analysis findings further indicated that TSD medicated serum upregulated p-Akt and p-eNOS expressions, which were significantly inhibited by LY294002 or L-NAME and completely inhibited by both LY294002 and L-NAME; these results indicated that TSD medicated serum induced HUVECs VEGF expression via PI3K/Akt-eNOS signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 206-214 AKT serine/threonine kinase 1 Homo sapiens 316-319 23326131-11 2012 Furthermore, p-Akt and MMP9 was down-regulated in response to the inhibitor LY294002 (p-Akt 100.00% +- 8.87% vs 58.27% +- 5.01%, P < 0.05; MMP9 100.00% +- 9.17% vs 50.03% +- 4.88%, P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 15-18 23437382-7 2013 Further analysis showed that inhibition of PI3K/Akt pathway with specific inhibitor (LY294002) attenuated the promotive effects on cancer growth following interfering with klotho shRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 48-51 23063593-7 2013 Additionally, HER effectively inhibited the phosphorylation of Akt and the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 increased the inhibition effect of HER on Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 173-176 22975582-6 2013 More importantly, PI3K/AKT signaling pathway inhibitor, LY294002, also reduced tumor cell proliferation, which is similar to the result with or without sCLU siRNA treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 23-26 22902327-7 2013 Consistent with Akt inhibition as the basis of piperine"s action on HUVECs, inhibition of the phosphoinositide-3 kinase/Akt signaling pathway with LY-294002 also inhibited HUVEC proliferation and collagen-induced angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 147-156 AKT serine/threonine kinase 1 Homo sapiens 120-123 23603894-4 2013 We further demonstrated that the blockage of radiation-induced activation of the PI3K/AKT pathway and its downstream regulator NF-kappaB by either curcumin or specific PI3/AKT inhibitors (LY294002 for PI3K or SH-5 for AKT) enhance apoptosis in three human Burkitt"s lymphoma cell lines (Namalwa, Ramos, and Raji) that were treated with ionizing radiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 86-89 23603894-4 2013 We further demonstrated that the blockage of radiation-induced activation of the PI3K/AKT pathway and its downstream regulator NF-kappaB by either curcumin or specific PI3/AKT inhibitors (LY294002 for PI3K or SH-5 for AKT) enhance apoptosis in three human Burkitt"s lymphoma cell lines (Namalwa, Ramos, and Raji) that were treated with ionizing radiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 172-175 23603894-4 2013 We further demonstrated that the blockage of radiation-induced activation of the PI3K/AKT pathway and its downstream regulator NF-kappaB by either curcumin or specific PI3/AKT inhibitors (LY294002 for PI3K or SH-5 for AKT) enhance apoptosis in three human Burkitt"s lymphoma cell lines (Namalwa, Ramos, and Raji) that were treated with ionizing radiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 172-175 23001846-8 2013 HBx-induced increase in the autophagic level was increased by mTOR inhibitor rapamycin and was blocked by treatment with the PI3K-Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 AKT serine/threonine kinase 1 Homo sapiens 130-133 23142153-8 2013 In addition, although RA activates both the AKT and ERK phosphorylation signaling pathways, only pretreatment with LY294002, an inhibitor of PI3-kinase in the AKT pathway, removed the protective effect of RA from the cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 44-47 23142153-8 2013 In addition, although RA activates both the AKT and ERK phosphorylation signaling pathways, only pretreatment with LY294002, an inhibitor of PI3-kinase in the AKT pathway, removed the protective effect of RA from the cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 159-162 23132328-8 2013 Notably, the p-AKT inhibitor LY294002 attenuated the impact of Scriptaid, providing mechanistic evidence that Scriptaid functions partly by modulating the prosurvival AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 15-18 23132328-8 2013 Notably, the p-AKT inhibitor LY294002 attenuated the impact of Scriptaid, providing mechanistic evidence that Scriptaid functions partly by modulating the prosurvival AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 167-170 23909734-6 2013 Moreover LY294002 not only downregulated the level of phospho-Akt but also enhanced the inhibition of Mcl-1 expression when combined with Triticuside A. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 62-65 23255946-13 2013 The Akt inhibitor LY294002 caused a significant decrease in TNF-alpha-induced NF-kappaB activity and MMP-9 gene expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 4-7 23590603-8 2013 It was then further demonstrated that the effects of rhNRG-1 could be blocked by the phosphoinositole-3-kinase inhibitor LY294002, indicating the involvement of the Akt process in mediating the process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 121-129 AKT serine/threonine kinase 1 Homo sapiens 165-168 23383347-6 2013 The involvement of Akt and NF-kappaB signaling pathways in the EGF-induced IL-1beta gene expression was confirmed by knockdown of RelA and Akt in cells or treating cells with Akt and NF-kappaB inhibitors, LY294002 and parthenolide, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 205-213 AKT serine/threonine kinase 1 Homo sapiens 19-22 23326131-11 2012 Furthermore, p-Akt and MMP9 was down-regulated in response to the inhibitor LY294002 (p-Akt 100.00% +- 8.87% vs 58.27% +- 5.01%, P < 0.05; MMP9 100.00% +- 9.17% vs 50.03% +- 4.88%, P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 88-91 23027625-7 2012 Moreover, tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 103-106 22980246-7 2013 However, XJP-1 alone upregulation of Akt and eNOS phosphorylation were blocked by LY294002 and SH-6. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 37-40 22729368-7 2012 Phosphor-EGFR and its downstream signal transducer, phosphor-Akt, were fully attenuated only by simultaneous treatment with Ly294002 and AG1478. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-132 AKT serine/threonine kinase 1 Homo sapiens 61-64 23027183-6 2012 Using chemical inhibitors of insulin downstream pathways, we demonstrated that the insulin-induced Zbtb7A gene expression was completely blocked by LY294002, a PI3K/AKT inhibitor, and partially attenuated by the MAPK inhibitor PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 165-168 23290651-6 2012 RESULTS: HBE cell line exposed to silica can induce Akt phosphorylation, in which expressions of p-Akt were up regulated 1 times at 48 and the highest at 72 h. The expressions of TGFbeta increased remarkably at 12 h and the peak at 48 h after silica exposure, while the expressions of alpha-SMA increased at 24 h and the highest at 72 h. However, the PI3K inhibitor (Ly294002) significantly down regulated alpha-SMA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 367-375 AKT serine/threonine kinase 1 Homo sapiens 52-55 23290651-6 2012 RESULTS: HBE cell line exposed to silica can induce Akt phosphorylation, in which expressions of p-Akt were up regulated 1 times at 48 and the highest at 72 h. The expressions of TGFbeta increased remarkably at 12 h and the peak at 48 h after silica exposure, while the expressions of alpha-SMA increased at 24 h and the highest at 72 h. However, the PI3K inhibitor (Ly294002) significantly down regulated alpha-SMA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 367-375 AKT serine/threonine kinase 1 Homo sapiens 99-102 22909461-6 2012 PCA enhanced the phosphorylation of Akt, which could be blocked by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 36-39 23026832-7 2012 The PI3K/Akt inhibitor LY294002 enhanced the apoptosis-inducing effect of ISO. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 22941773-4 2012 In contrast, the PI3K/Akt inhibitor LY294002 and the PDE3B antagonist cilostamide enhanced LA-induced lipolysis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 22-25 22249269-7 2012 Blocking the phosphoinoside 3-kinase (PI3K)/Akt pathway with LY294002 or si-Akt also suppressed the self-renewal of sphere-cultured glioma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 61-69 AKT serine/threonine kinase 1 Homo sapiens 44-47 22927331-5 2012 CXCL16 increased Akt phosphorylation (Thr(308)/Ser(473)), an effect abrogated by phosphatidylinositide 3-kinase inhibitors wortmannin (100 nmol/L) and LY294002 (25 micromol/L). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 17-20 23369170-0 2012 Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 59-62 22841670-7 2012 It was also found that the inhibition of Akt expression and phosphorylation was involved in apoptosis induction, and specific Akt inhibitor LY294002 or siRNA targeting Akt can synergistically enhanced bufotalin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 41-44 22841670-7 2012 It was also found that the inhibition of Akt expression and phosphorylation was involved in apoptosis induction, and specific Akt inhibitor LY294002 or siRNA targeting Akt can synergistically enhanced bufotalin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 126-129 22841670-7 2012 It was also found that the inhibition of Akt expression and phosphorylation was involved in apoptosis induction, and specific Akt inhibitor LY294002 or siRNA targeting Akt can synergistically enhanced bufotalin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 126-129 22556157-8 2012 LY294002 and wortmannin inhibited TNF-alpha-induced Akt activation, whereas only LY294002 inhibited CD38 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 52-55 22644804-4 2012 Furthermore, we confirmed that the inhibition of phosphotidyl inositol 3-kinase (PI3K)/Akt pathway with LY294002 or Akt shRNA vector blocked the effect of high glucose on XBP-1 splicing and cellular triglyceride. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 87-90 22924393-3 2012 To selectively target advanced prostate tumors with a constitutive activated PI3K/Akt pathway, a prostate cancer-specific PI3K inhibitor was generated by coupling the chemically modified form of the quercetin analogue LY294002 (HO-CH(2)-LY294002, compound 8) with the peptide Mu-LEHSSKLQL, in which the internal sequence HSSKLQ is a substrate for the prostate-specific antigen (PSA) protease. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 218-226 AKT serine/threonine kinase 1 Homo sapiens 82-85 22985566-3 2012 RESULTS: Blocking PI3K/AKT/mTOR pathway with rapamycin and LY294002 significantly reduced drug resistance of both A549 and A549/CDDP cells to cisplatin and obviously decreased the expression of CA916798 gene mRNA (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 23-26 22824823-5 2012 Simultaneously, the apoptosis induced by MATP was reversed by SP600125 (a JNK inhibitor) whereas it was aggravated by LY294002 (an Akt inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 131-134 23156673-3 2012 Also, MAP-2 expression and neurite outgrowth were much increased with activation of serine/threonine protein kinase (Akt) and blocked by addition of an Akt inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 117-120 23156673-3 2012 Also, MAP-2 expression and neurite outgrowth were much increased with activation of serine/threonine protein kinase (Akt) and blocked by addition of an Akt inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 152-155 22828512-12 2012 Accordingly, inhibition of MEK/ERK-signaling by UO126 or inhibition of PI3K/Akt-signaling by LY294002 abolished the anti-apoptotic effects of ATP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 76-79 22487193-8 2012 Analysis of RAF-1 S259 phosphorylation, being a major mediator of the negative regulation of RAF-1 by AKT, showed decreased pRAF-1 S259 levels in LY294002 treated M13MDA435-1 hybrid cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 146-154 AKT serine/threonine kinase 1 Homo sapiens 102-105 22820188-5 2012 Suppression Akt/mTOR complex 1(mTORC1) activation by LY 294002 and rapamycin inhibited TNF-alpha-mediated MMP-9 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-62 AKT serine/threonine kinase 1 Homo sapiens 12-15 22611165-14 2012 Furthermore, while the phosphoinositide-3-kinase (PI3K)/AKT signaling pathway did not alter GJA1 phosphorylation, treatment with PI3K/AKT inhibitor LY294002 significantly (P=0.024) inhibited the EGF-stimulated increase in GJA1 total protein levels at 24 h. Immunolocalization indicated that loss of PI3K/AKT signaling was associated with increased cytosolic localization of Cx43 in this cell line. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 134-137 22611165-14 2012 Furthermore, while the phosphoinositide-3-kinase (PI3K)/AKT signaling pathway did not alter GJA1 phosphorylation, treatment with PI3K/AKT inhibitor LY294002 significantly (P=0.024) inhibited the EGF-stimulated increase in GJA1 total protein levels at 24 h. Immunolocalization indicated that loss of PI3K/AKT signaling was associated with increased cytosolic localization of Cx43 in this cell line. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 134-137 22843181-9 2012 However, the PI3K/Akt pathway inhibitor, LY294002, abrogated the protective effect of Ang1 preconditioning. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 18-21 22954111-7 2012 CONCLUSION: LY294002 could reverse the adriamycin-induced epithelial-mesenchymal transition in human breast carcinoma cells by regulating the expressions of Snail and E-cadherin through suppressing PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 203-206 22716253-4 2012 LY294002 (PI3K inhibitor) can reverse alpha-NF-induced ERK, Akt, Smad-3 activation, pro-collagen synthesis and alpha-NF-suppressed AP-1 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 60-63 22016349-5 2012 Inhibition of Akt phosphorylation by the phosphatidylinositol 3-kinase inhibitor LY294002 resulted in reduction of PSA expression in LNCaP cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 14-17 22618230-7 2012 Inhibition of PI3K/Akt pathway by LY294002 reversed the proliferation and cell cycle progression of MDA-MB-231 and MCF-7 cells induced by IL-7delta5. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 19-22 22426819-0 2012 The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 22426819-11 2012 Taken together, these results suggest that LY294002 inhibits BCRP-mediated drug transport not by BCRP translocation through the PI3K/Akt signal but putatively as a competitive inhibitor in a major subset of cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 145-148 22943759-9 2012 LY294002, the specific inhibitor of PI3K, could suppress the activation of PI3K/Akt and the induced expression of HO-1 in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 80-83 21780115-7 2012 Although inactivation of the PI3K/AKT pathway with LY294002 inhibited RPTC dedifferentiation, blocking the ERK1/2 pathway with U0126 did not show such an effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 34-37 22173835-11 2012 Pretreatment of these cells with the PI 3-Kinase inhibitor LY294002 significantly suppressed 8-CPT-2Me-cAMP-dependent p-Akt(S473) and p-Akt(S473) kinase activities, and both effects were rapamycin insensitive. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 120-123 22173835-11 2012 Pretreatment of these cells with the PI 3-Kinase inhibitor LY294002 significantly suppressed 8-CPT-2Me-cAMP-dependent p-Akt(S473) and p-Akt(S473) kinase activities, and both effects were rapamycin insensitive. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 136-139 22173988-2 2012 We report here that LY294002, a small molecule inhibitor of PI3K/AKT signal pathway, can inhibit proliferation and promote neuronal differentiation of MSCs after MSCs incubated with LY294002 for 6 and 12 h. RT-PCR results indicated that mRNA expression of alpha5beta1 integrin significantly increased in neuron-like cell from MSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 65-68 22173988-2 2012 We report here that LY294002, a small molecule inhibitor of PI3K/AKT signal pathway, can inhibit proliferation and promote neuronal differentiation of MSCs after MSCs incubated with LY294002 for 6 and 12 h. RT-PCR results indicated that mRNA expression of alpha5beta1 integrin significantly increased in neuron-like cell from MSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-190 AKT serine/threonine kinase 1 Homo sapiens 65-68 23050643-6 2012 Blockade of Akt phosphorylation with the PI3-kinase inhibitor LY294002 negated this vascular neuroprotective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 12-15 22809065-6 2012 This response was strongly inhibited by pretreatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, indicating that eriodictyol increased Akt phosphorylation by activating the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 157-160 22809065-6 2012 This response was strongly inhibited by pretreatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, indicating that eriodictyol increased Akt phosphorylation by activating the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 200-203 22707636-6 2012 Inhibition of PI3K/AKT by LY294002 reactivated GSK-3beta and suppressed the TNF-alpha-induced EMT of RCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 19-22 22683349-7 2012 However, when blocking the PI3K/Akt pathway with LY294002, the neuroprotective effect of guanosine was abolished. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 32-35 22641480-10 2012 The Akt inhibitor LY294002 did not mimic the effect of UA on caspase-8 and -9, but inhibited the viability of MIA PaCa-2 cells to some extent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 4-7 22799881-6 2012 RESULTS: The activation of the ER by E2 is unable to induce the cell cycle progression when the phosphatidyl inositol-3 kinase (PI3K)/Akt signaling is blocked by a chemical inhibitor (LY 294002) or by shRNA targeting Akt1 and Akt2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 184-193 AKT serine/threonine kinase 1 Homo sapiens 134-137 22534171-8 2012 RESULTS: We show that PI3K inhibitors LY294002, wortmannin and A6730 significantly inhibited TF promoter activity, and reduced TF mRNA and protein levels due to the inhibition of Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 179-182 22705730-10 2012 Atorvastatin (10 mumol/L) significantly increased the levels of phosphorylated PDK1, Akt and mTOR in the cortical neurons, which were prevented by LY294002 (30 mumol/L). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 147-155 AKT serine/threonine kinase 1 Homo sapiens 85-88 22510476-6 2012 However, LY294002, an inhibitor of the PI3K/Akt signaling pathway, diminished this effect, suggesting that enhanced expression of miR-126 increased the sensitivity of NSCLC cells to anticancer agents through negative regulation of a VEGF/PI3K/Akt/MRP1 signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 44-47 22510476-6 2012 However, LY294002, an inhibitor of the PI3K/Akt signaling pathway, diminished this effect, suggesting that enhanced expression of miR-126 increased the sensitivity of NSCLC cells to anticancer agents through negative regulation of a VEGF/PI3K/Akt/MRP1 signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 243-246 22263786-4 2012 Moreover, the synergetic effects were observed when genistein was replaced by PI3K/Akt-pathway inhibitor (LY-294002) or NF-kappaB inhibitor (BAY11-7082). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-115 AKT serine/threonine kinase 1 Homo sapiens 83-86 22461520-2 2012 In this study, we report that the treatment of LNCaP cells with epidermal growth factor (EGF) in the presence of LY294002, an inhibitor of the phosphoinositol 3"-kinase (PI3K)-AKT pathway, induced an increase of levels and activity of ErbB2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 176-179 22461520-4 2012 When we treated with wortmannin, another PI3K inhibitor, or we knocked down PI3K or AKT isoforms in the presence of EGF, ErbB2 up-regulation was not observed, suggesting that the increase of ErbB2 induced by EGF plus LY294002 is not mediated by the PI3K-Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 217-225 AKT serine/threonine kinase 1 Homo sapiens 84-87 22426488-11 2012 The insulin-induced Akt activation was inhibited by LY294002 in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 20-23 22426850-10 2012 In addition, LY294002, a PI3K/Akt inhibitor, sensitized ZR-75-1 breast cancer cells to cerulenin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 30-33 22822374-5 2012 Inhibition of PI3K/Akt/eNOS by LY294002 or L-NAME suppressed X-13-induced angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 19-22 22487193-10 2012 Inhibition of PI3K/AKT signalling by Ly294002 relieves the AKT mediated phosphorylation of RAF-1, thereby restoring MAPK signalling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 19-22 22487193-10 2012 Inhibition of PI3K/AKT signalling by Ly294002 relieves the AKT mediated phosphorylation of RAF-1, thereby restoring MAPK signalling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 59-62 22289388-9 2012 Inhibitors of p38 alpha/beta (SB203580) and PI3K/Akt pathway (LY294002), but not that of JNK (SP600125), reduced LPS-induced LD accumulation and eliminated the activating effect of LPS on perilipin-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 49-52 22309289-4 2012 The Akt-dependent phosphorylation of HBx was abrogated in the presence of the phosphatidylinositol 3-kinase inhibitor LY294002 or Akt1 gene silencing by specific siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 4-7 21544845-9 2012 Furthermore, pretreatment with gefitinib and the pharmacological inhibitors of PI3K (LY294002) and ERK1/2 (PD98059) prevented cigarette smoke-mediated Akt and ERK1/2 phosphorylation responses, HIF-1alpha production, HIF-1 activity and MUC5AC expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 151-154 22286127-7 2012 NBP increased the phosphorylation of Akt and eNOS at serine 1177, which was blocked by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 37-40 22420994-10 2012 Also, LY294002, an inhibitor of the Akt/PI3K pathway, abrogated the MA-mediated induction of IL-6 and IL-8 by 77.9 +- 6.6% and 81.4 +- 2.6%, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 6-14 AKT serine/threonine kinase 1 Homo sapiens 36-39 22464569-8 2012 Further blocking experiments showed that LY294002, phosphatidylinositol-3-kinase (PI3K)/Akt activation inhibitor, could mitigate the protective effects of insulin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 88-91 22801313-9 2012 Furthermore, the expression level of phosphorylation eNOS(Ser(1179)) was significantly lower in PIK3/AKT inhibitors LY294002 and NSC154020 treated cells compared with ox-LDL + genistein treated cells (all P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 101-104 22315058-7 2012 LY294002, but not U0126, suppressed foetal bovine serum or heregulin-beta1-induced phosphorylation of Akt/GSK-3beta and snail expression together with the inhibition of 81B-Fb cell motility. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 102-105 22235114-8 2012 The role of the PI3K/Akt pathway in the regulation of repression was clarified by the use of the PI3K inhibitor, LY294002, and by transfection with Akt siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 21-24 22155408-4 2012 Knockdown of HN1 expression by siRNA silencing leads to an increase in Akt((S473)) phosphorylation, resulting in the translocation of androgen receptor (AR) to the nucleus; these effects can be abrogated by the non-specific Akt inhibitor LY294002 but not by the ERK inhibitor PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 238-246 AKT serine/threonine kinase 1 Homo sapiens 71-74 25774181-3 2012 These effects of curcumin on PI3K, Akt and Nrf2 were blocked by LY294002 (PI3k inhibitor) and NF-E2-related factor-2 siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 35-38 22245726-8 2012 A VEGFR kinase inhibitor, Ki8751, and a phosphatidylinositol 3-kinase-Akt inhibitor, LY294002, blocked tumor CM-induced MDR1 up-regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 70-73 22357207-8 2012 Ly294002 (a PI3K inhibitor) and rapamycin (an mTOR inhibitor) could prevent the regulatory effects of leptin on the proliferation and apoptosis of HCT-116 cells via abrogating leptin-mediated PI3K/Akt/mTOR pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 197-200 22265823-3 2012 The presence of PI3K inhibitor LY294002 completely blocked puerarin-induced activation of Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 90-93 22187427-6 2012 HPIP overexpression in both CD34(+) and K562 cells was associated with increased activation of the PI3K/AKT pathway, and corresponding treatment with a PI3K-specific inhibitor, LY-294002, caused a reduction in clonogenic progenitor number in HPIP-expressing CD34(+) cells and decreased K562 cell differentiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-186 AKT serine/threonine kinase 1 Homo sapiens 104-107 21445974-10 2012 Moreover, LY294002, a PI3K inhibitor, sensitized melanoma cells to Bortezomib treatment, suggesting that downregulation of phospho-Akt by Sunitinib mediates the synergy obtained by Bortezomib + Sunitinib cotreatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 131-134 22419429-8 2012 Pharmacological inhibition of AKT by LY294002 effectively suppressed NF-kappaB activation and PON1 gene expression, suggesting that AKT was an upstream regulator of GP50E-mediated biological events. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 30-33 22081709-7 2012 When the endogenous Akt was abolished by LY294002, the antiapoptotic actions of mitochondrial Akt remained effective. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 20-23 22081709-7 2012 When the endogenous Akt was abolished by LY294002, the antiapoptotic actions of mitochondrial Akt remained effective. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 94-97 22287731-3 2012 MATERIALS AND METHODS: Inhibition of PI3K/Akt pathway signaling via LY294002 and Akti-1/2 was demonstrated by immunoblotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 42-45 21922131-5 2012 HIF-1alpha could be blocked by PI3K inhibitor LY294002, indicating HIF-1alpha activation was regulated by PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 123-126 22298254-5 2012 The enhancement of HKII levels and lactate production in MM cells by OCs were mostly abrogated by the PI3K inhibitor LY294002, suggesting activation of glycolysis in MM cells by OCs via the PI3K-Akt-HKII pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 195-198 22379573-9 2012 On western blots, Akt-phosphorylation was induced during pretreatment with midazolam; it was diminished during co-treatment with LY-294002, an inhibitor of Akt-phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-138 AKT serine/threonine kinase 1 Homo sapiens 18-21 22379573-9 2012 On western blots, Akt-phosphorylation was induced during pretreatment with midazolam; it was diminished during co-treatment with LY-294002, an inhibitor of Akt-phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-138 AKT serine/threonine kinase 1 Homo sapiens 156-159 21480393-7 2012 For study of mechanism, the ADAM17 inhibitor TAPI-2 and the PI3K-AKT inhibitor LY294002 were used to counteract high-ADAM17 expression and the activated PI3K-AKT pathway, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 65-68 21480393-7 2012 For study of mechanism, the ADAM17 inhibitor TAPI-2 and the PI3K-AKT inhibitor LY294002 were used to counteract high-ADAM17 expression and the activated PI3K-AKT pathway, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 158-161 21480393-15 2012 ADAM17 activated, whereas ADAM17 siRNA, TAPI-2, and LY294002 deactivated the EGFR-PI3K-AKT signal pathway, which correlated with U87 cell malignant phenotype changes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 87-90 21617941-5 2012 Furthermore, the inhibitory effect of bufalin on pERK was blocked by the PI3kinase inhibitor LY294002, suggesting that the reduction in pERK induced by bufalin might be mediated by AKT in these two HCC cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 181-184 22086271-0 2012 LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 100-103 22086271-9 2012 In addition, p-Akt and Bcl-2, which can promote TMZ resistance, were markedly decreased by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 15-18 22086271-10 2012 These findings suggest that LY294002 enhances the cytotoxicity of TMZ by down-regulation of the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 101-104 22455747-19 2012 LY294002 reversed the effects of FSH on increasing the expression of p-Akt and the ratio of NF-kappaB p65 in the nucleus versus cytoplasm, there were significant differences among LY294002 group, FSH + LY294002 group and FSH group (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 71-74 22172327-5 2012 Furthermore, LY294002 (Akt inhibitor) or PD98059 (ERK1/2 inhibitor) significantly enhanced active lipids of Ganoderma lucidum spores-induced apoptosis in THP-1 cells, whereas caspase inhibitors or SP600125 (JNK inhibitor), decreased apoptosis in THP-1 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 23-26 22419429-8 2012 Pharmacological inhibition of AKT by LY294002 effectively suppressed NF-kappaB activation and PON1 gene expression, suggesting that AKT was an upstream regulator of GP50E-mediated biological events. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 132-135 21861235-11 2012 LY294002 inhibitor could abrogate the activation of PI3K/Akt pathway in those cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 57-60 22994717-5 2012 LY294002 prevented phosphorylation of protein kinase B (PKB/Akt) by inhibition of PI3K phosphorylation activity, thereby inducing G0/G1 cell cycle arrest and apoptosis in osteosarcoma CSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 56-63 21932108-7 2012 The additions of siRNA c-Met to block HGF or LY294002 to inhibit p-AKT could downregulate beta-catenin and inhibit the proliferation promotion caused by HGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 67-70 22938480-9 2012 Phosphorylation of JNK and Akt were abolished by the specific inhibitors SP600125 and LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 27-30 22193240-6 2012 A pharmacological inhibitor of the phosphoinositide 3-kinase (PI3K)-Akt pathway, LY294002, abrogated IKK/IkappaB/NF-kappaB-mediated iNOS gene expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 68-71 22122966-8 2012 Incubation with LY294002 or Akt-I decreased the activity of PI3K and Akt but augmented the elevation of cGMP caused by NO. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 69-72 22080879-2 2012 LY294002 (PI3K inhibitor) and metformin (5"-adenosine monophosphate [AMP]-activated protein kinase [AMPK] activator) are 2 drugs that were known to inhibit mTOR expression through the AKT-dependent and AKT-independent pathways, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 184-187 22080879-2 2012 LY294002 (PI3K inhibitor) and metformin (5"-adenosine monophosphate [AMP]-activated protein kinase [AMPK] activator) are 2 drugs that were known to inhibit mTOR expression through the AKT-dependent and AKT-independent pathways, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 202-205 22080879-7 2012 RESULTS: Our study showed that LY294002 and metformin in combination could simultaneously enhance the repression of the PI3K/AKT/mTOR pathway and the activation of the AMPK/ACC pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 125-128 22408435-5 2012 In addition, A549 cells were treated by Akt inhibitor LY294002 in combination with bufalin and the activation of Akt and Caspase-3 as well as the expression levels of Bax, Bcl-2 and livin were examined by Western blot analysis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 40-43 22072736-9 2012 AKT was highly phosphorylated in OsisSC compared with HSC and inhibition of phosphatidylinositol 3-kinase, with LY294002, increased levels of FOXO1 protein as well as IGFBP1 mRNA in the presence of M+A. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 0-3 21892609-9 2012 LY294002, a specific Akt inhibitor, reduced both basal and HGF-induced uPA secretion and migration of MDA-MB-231 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 21-24 21879332-5 2012 Furthermore, the combined treatment with LY294002, a specific inhibitor of the PI3K/Akt kinase pathway, and GNA showed a synergistic or additive effect on the growth of U251 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 84-87 22509106-10 2012 Furthermore, NGF affected cell cycle progression of HCECs by regulating cyclin D through Akt and Erk activation upon treatment with the pathway inhibitors, LY294002 for Akt or PD98059 for Erk pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 169-172 22519916-6 2012 Furthermore, the treatment of inhibitors specific for Akt (LY294002) and ERK1/2 (U0126) to A549 cells resulted in reduced activity of proMMP-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 54-57 23285096-9 2012 GTP-induced apoptosis was attenuated with JNK inhibitor, SP600125 in both cell lines; whereas PI3K-Akt inhibitor, LY294002 resulted in increased cell death prominently in LNCaPshp53 cells, establishing the role of two distinct pathways of GTP-mediated apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 99-102 23272133-9 2012 PC-3M-MM2 cells also exhibited high levels of phospho-Akt (pAkt), which were reduced by both resveratrol and LY294002 (a PI3-kinase inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 54-57 23272133-10 2012 MiR-21 expression in these cells appeared to be dependent on Akt, as LY294002 reduced the levels of miR-21 along with a concurrent increase in PDCD4 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 61-64 23144836-7 2012 Treatment with CSC increased the concentration of phosphorylated Akt, while addition of the PI3K inhibitor LY294002 blocked doxorubicin extrusion, suggesting that Akt activation is required for CSC-induced drug efflux. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 107-115 AKT serine/threonine kinase 1 Homo sapiens 163-166 22879882-5 2012 Pre-treatment with PI3K inhibitor wortmannin or LY294002 prevented activation of spinal AKT induced by ephrinB1-Fc. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 88-91 22761812-7 2012 The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126, both significantly suppressed EMT and CSC phenotype, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT and CSC phenotype. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 137-140 22355314-5 2012 Using AG1295 (a PDGFR kinase inhibitor), LY294002 (a PI3K inhibitor), and sc-221226 (an Akt inhibitor), we further showed that the PI3K/Akt signaling pathway participates in the PDGF-BB-induced proliferation, migration, and angiogenesis of EPCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 136-139 21964931-9 2011 The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 75-78 22185378-8 2011 Matuzumab exhibited a synergic effect with LY294002, leading to a reduction of Akt phosphorylation that was followed by a decrease in A431 and Caski cells survival. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 79-82 21889928-8 2011 Importantly, co-treatment with MEK/ERK inhibitor (U0126) and PI3K/Akt (LY294002) or mTOR (rapamycin) inhibitors, instead of ATO, also potentiates lonidamine-provoked apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 66-69 21850380-10 2011 Inhibition of Akt with LY294002 completely prevented the LMP1-induced FLIP expression and TRAIL resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 14-17 20628892-7 2011 Akt signaling was inhibited by the upstream kinase inhibitors, LY294002, Wortmannin, as well as by the specific Akt Inhibitor VIII in all three hepatoma cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 0-3 21885991-9 2011 Up4A also increased the phosphorylation of Akt, which was blocked by the PI3-kinase inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 43-46 21617882-8 2011 Furthermore, transduction with constitutively active Akt protected against the quercetin-induced dephosphorylation of Akt and Bad as well as poly(ADP-ribose)polymerase (PARP) degradation, while combined treatment with quercetin and LY294002 enhanced the dephosphorylation of Akt, Bad and PARP cleavage in U2-OS/MTX300 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 232-240 AKT serine/threonine kinase 1 Homo sapiens 53-56 21641013-10 2011 LY294002 and RAD001 significantly reduced AKT activity and cell viability and induced a G(1) cell cycle arrest. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 42-45 21904903-5 2011 Signaling transduction inhibitors, LY294002 and PD98059, were used to block PI3K/Akt and MAPK/ERK1/2 signaling pathways, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 81-84 21904903-8 2011 Remarkably, inhibition of Akt phosphorylation by LY294002 completely blocked the effects on IGF-1-induced VEGF-C up-regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 26-29 21935931-7 2011 Our results also demonstrate that the AKT signaling pathway is involved in the regulation of Jab1 by Bcr-Abl because the AKT inhibitor LY294002 but not the ERK inhibitor PD98059 reduces Jab1 promoter activity and mRNA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 38-41 21935931-7 2011 Our results also demonstrate that the AKT signaling pathway is involved in the regulation of Jab1 by Bcr-Abl because the AKT inhibitor LY294002 but not the ERK inhibitor PD98059 reduces Jab1 promoter activity and mRNA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 121-124 21867737-5 2011 Pre-treatment of the PI3K inhibitor LY294002, 20min prior to Post C, significantly attenuated Post C-induced elevation of p-Akt and p-GSK3beta, as well as prevented Post C enhancement of mitochondrial integrity and Post C neuroprotection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 124-127 21807062-7 2011 Furthermore, the p38 inhibitor SB203580 and the Akt inhibitor LY294002 also decreased the effect of retinol on RAGE levels, suggesting the involvement of these protein kinases in such effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 48-51 21904878-8 2011 Lowering the phospho-Akt level by HNMPA or LY294002, a PI3K inhibitor, further augmented exe-4-induced cAMP formation and Erk phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 21-24 21757005-7 2011 Inhibitors of GSK3beta (lithium) and p38 MAPK (SB203580) signaling pathways restored the depressed histone acetylation and Nrf2-related transcription whereas an inhibitor of Akt (Ly294002) caused a further decrease in Nrf2-related transcription. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-187 AKT serine/threonine kinase 1 Homo sapiens 174-177 22026163-12 2011 Furthermore, the PI3K inhibitor LY294002 significantly abolished the anti-apoptotic effect of ibrolipim, and decreased Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 119-122 23275900-7 2012 Both RAPA and LY294002 reduced levels of phospho-AKT, phospho-mTOR, phospho-p70S6k and phospho-4EBP1 expression (P <0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 49-52 23275900-10 2012 The inhibitors of PI3K/AKT/mTOR signaling pathway, RAPA and LY294002, could inhibited the PI3K/AKT/mTOR signaling pathway by reducing the levels of phosphorylation of mTOR pathway components. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 23-26 23275900-10 2012 The inhibitors of PI3K/AKT/mTOR signaling pathway, RAPA and LY294002, could inhibited the PI3K/AKT/mTOR signaling pathway by reducing the levels of phosphorylation of mTOR pathway components. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 95-98 22509540-8 2011 However, the increased expressions of P-AKT and P-ERK could be suppressed by AG1478 and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 40-43 21904110-6 2011 Treatment with TNF-alpha resulted in a strong increase in the phosphorylation of Akt on Ser-473 and when cells were treated with phosphatidylinositol (PI) 3-kinase inhibitors such as LY294002 or wortmannin, or Akt inhibitor (Akt inhibitor IV), induction of STS mRNA expression by TNF-alpha was significantly prevented. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 81-84 22321426-2 2011 METHODS: With cell growth assay, flow cytometric analysis and Western blotting, the effects of TRAIL and PI3-K-Akt special inhibitor (LY294002) on cell growth, apoptosis and related proteins expressions in CNE-2 cell lines were studied. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 134-142 AKT serine/threonine kinase 1 Homo sapiens 111-114 21128229-7 2011 The data demonstrated that Akt activity inhibitor LY294002 synergistically promoted tetrandrine-induced apoptosis of HCC, whereas ectopic expression of Akt contrastly abrogated partial of the tetrandrine-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 27-30 21765100-7 2011 Pretreatment with phosphatidylinositide 3-kinase/Akt inhibitor (LY-294002) prior to Ucn2 led to downregulation of CREB phosphorylation and hence reduced Bcl-2 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-73 AKT serine/threonine kinase 1 Homo sapiens 49-52 21693693-5 2011 Insulin-mediated decrease in menin expression was abrogated by the PI3K/Akt inhibitor LY-294002 at early time points, from 2 to 7 h. Furthermore, exposure to insulin resulted in the cytoplasmic localization of menin and increased interaction with FOXO1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-95 AKT serine/threonine kinase 1 Homo sapiens 72-75 22082269-4 2011 This effect was found to depend on Akt kinase activity: the Akt activity inhibitor Ly 294002 increased the amount of MRP1 mRNA in KB 8-5 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-92 AKT serine/threonine kinase 1 Homo sapiens 35-38 22082269-4 2011 This effect was found to depend on Akt kinase activity: the Akt activity inhibitor Ly 294002 increased the amount of MRP1 mRNA in KB 8-5 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-92 AKT serine/threonine kinase 1 Homo sapiens 60-63 21620964-6 2011 In addition, PI3K/Akt inhibitor (LY294002) blocked Bay-induced HO-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 18-21 21802413-6 2011 Under inhibition of PI3 kinase by LY294002, the suppressive effect of miR-491 on HCV replication was abolished, indicating that suppression of HCV replication by miR-491 was dependent on the PI3 kinase/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 202-205 21765447-8 2011 AA inhibited Akt activation, which was attenuated by pretreatment of the cells with LY294002 (20 mumol/L) or wortmannin (50 nmol/L). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 13-16 21480865-8 2011 ACEA, JWH133 and HU210 induced a time-dependent phosphorylation of Akt and mTOR, whereas the inhibitors of PI3K/Akt (LY294002) or of mTOR (rapamycin) reversed the effects of HU-210 on oligodendrocyte differentiation and kinase activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 67-70 21550417-11 2011 LY294002 that suppressed phosphorylated Akt but not phosphorylated focal adhesion kinase inhibited cell proliferation but had no effect on cell adhesion or migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 40-43 21616916-3 2011 Our data here show that hyperactive AKT leads to the decrease of IGF1R at the transcriptional level, which could be partly restored by phosphatidylinositol-3 kinase (PI3K) inhibitors including wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 36-39 21520056-5 2011 The addition of serum might block the Abeta(25-35)-induced cytotoxic effect via elevated telomerase activity in according with stimulating phospho-AKT protein expression, which was blocked by adding AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 213-221 AKT serine/threonine kinase 1 Homo sapiens 147-150 21520056-5 2011 The addition of serum might block the Abeta(25-35)-induced cytotoxic effect via elevated telomerase activity in according with stimulating phospho-AKT protein expression, which was blocked by adding AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 213-221 AKT serine/threonine kinase 1 Homo sapiens 199-202 21429662-7 2011 Although LY294002 alone did not affect the cell viability, it suppressed the Akt and S6K activities and induced the sub-G1 arrest/apoptosis when paclitaxel was co-administered, as well as the Akt siRNA and rapamycin did. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 77-80 21513816-6 2011 Treatment with PI3K inhibitors, wortmannin and LY294002, inhibited LTA-induced phosphorylation of AKT and GSK-3, demonstrating that these events require PI3K activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 98-101 21683105-2 2011 Here we show that inhibition of PI3K/Akt by means of LY294002 induces apoptosis via a caspase-dependent and calpain-independent pathway in cerebellar granule neurons (CGNs). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 37-40 21544242-8 2011 The AKT and ERK inhibitors, LY294002 and U0126, suppressed HIF-1alpha and VEGF expression and angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 4-7 23554696-5 2011 Blocking PI3K/Akt signalling with LY294002 or Akt siRNA remarkably inhibited both EGF-induced PAK1 activation and cell migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 14-17 21073857-8 2011 EGF increased p-Akt level, an effect inhibited by LY-294002 and 1L-6-hydroxymethyl-chiro-inositol2-[(R)-2-O-methyl-3-O-octadecylcarbonate] (Akt inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-59 AKT serine/threonine kinase 1 Homo sapiens 16-19 21513489-5 2011 This effect can be inhibited by the PI3K/Akt inhibitor Ly294002, indicating the important role of this pathway in the insulin-induced inefficacy of chemotherapy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 41-44 21338617-6 2011 Inhibition of phosphatidylinositol 3-kinase or Akt with LY 294002 or Akti-1/2 stimulates HSP27 phosphorylation while rapamycin, which inhibits mTORC1, does not. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-65 AKT serine/threonine kinase 1 Homo sapiens 47-50 21684102-6 2011 Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 112-115 20848249-7 2011 Then pretreatment of Panc-1 cells with LY294002, an inhibitor of the PI3K/AKT pathway, significantly inhibited BMP-2-induced EMT and invasiveness. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 74-77 21454688-4 2011 Treatment with a potent PI3K inhibitor (LY294002) blocked the prosurvival and promotility effects of TGFbeta, indicating that TGFbeta-mediated promotion of cell survival and motility is dependent upon activation of the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 224-227 21300060-6 2011 Selective inhibition of PI3K/Akt using LY294002 or wortmannin in these cells increases serum starvation-induced HEK293 cell apoptosis with a concomitant decrease in cell proliferation and higher caspase-3 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 29-32 21472003-4 2011 Inhibition of PI3K/Akt by LY294002 significantly enhanced PEITC-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 19-22 21295016-7 2011 Inactivation of Akt pathway by the PI3K inhibitor LY294002 blocked the expression of HSP27 and HSP70 induced by FLZ. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 16-19 21352809-8 2011 The phosphorylation of Akt, PI3K and eNOS were up-regulated by oxLDL, which was attenuated by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 23-26 21056559-5 2011 Inhibition of the upstream regulators of Akt or ERK1/2, i.e. phosphoinositide 3-kinase (PI3K; using wortmannin or LY294002) or MEK1/2 (using UO126 or PD98509), abrogated the respective phosphorylation responses, and significantly impaired pro-survival activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 41-44 21193390-7 2011 The increase in FBLN5 mRNA levels observed in hypoxic cells was blocked by inhibitors of the PI3K/Akt/mTOR pathway (LY294002 and rapamycin) and mimicked by dimethyl oxal glycine, which prevents proline hydroxylase-mediated degradation of HIF-1alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 98-101 21205080-5 2011 Inhibiting the PI3K/Akt pathway by LY294002 upregulated PR expression and diminished cell growth, especially in progestin-resistant endometrial cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 20-23 21239435-3 2011 The phosphatidylinositol 3 kinase (PI3K)/Akt pathway is involved in beta-catenin-dependent signaling, and pretreatment of these human ovarian cancer cells with a PI3K/Akt inhibitor, LY294002, attenuated GnRH-II-stimulated phosphorylation of GSK3beta and inhibited GnRH-II-induced invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-190 AKT serine/threonine kinase 1 Homo sapiens 41-44 21163530-7 2011 However, LY294002 did not inhibit c-myc or hTERT mRNA expression despite inhibiting STAT5 and AKT phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 94-97 20956948-6 2011 Inhibition of Akt activity by small interfering RNA or LY294002 efficiently downregulated the Mre11 expression in CNE2 cells, and transfection with myr-Akt plasmid in HeLa cells upregulated the Mre11 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 14-17 20956948-7 2011 In addition, luciferase reporter analysis revealed that Mre11 reporter activity increased after transfection with myr-Akt1 plasmids, and this myr-Akt1-induced transcriptional activity was blocked in the presence of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 215-223 AKT serine/threonine kinase 1 Homo sapiens 118-122 20956948-7 2011 In addition, luciferase reporter analysis revealed that Mre11 reporter activity increased after transfection with myr-Akt1 plasmids, and this myr-Akt1-induced transcriptional activity was blocked in the presence of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 215-223 AKT serine/threonine kinase 1 Homo sapiens 146-150 21310961-5 2011 In HEK293T cells, insulin and constitutively active mutants of small GTPase H-Ras and PI3K could induce HM phosphorylation of both AKT mutants, which was blocked by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 184-192 AKT serine/threonine kinase 1 Homo sapiens 131-134 20857409-7 2011 Also, inhibitors of KIT downstream effectors, U0126 that blocks MEK1/2 as well as wortmannin and LY294002 that inhibit phosphatidylinositol 3-kinase-dependent AKT phosphorylation, inhibited the proliferation of MCC-1 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 159-162 20717763-12 2011 IL-6 up-regulated the levels of phosphorylated STAT3 and Akt, and this was blocked by AG490 and LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 57-60 21284537-9 2011 Akt phosphorylation was inhibited by the PI3K inhibitor, LY294002, but not by the specific estrogen receptor antagonist, fulvestrant. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 0-3 21320517-5 2011 And inhibition of phosphatidylinositol-3-kinase (PI3K)/Akt cascade by LY294002 and wortmannin significantly blocked the protective effects of PQQ, and alleviated the increase in Bcl-2/Bax ratio. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 55-58 20927568-7 2011 Although LA activated the phosphatidylinositol-3-kinase (PI3-kinase)/Akt pathway in HUVECs, inhibition of Akt by LY294002 did not affect inhibition of TNFalpha-induced IkappaBalpha degradation by LA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 106-109 21426646-12 2011 The synthesis and secretion of VEGF can be inhibited by blocking TrkB-BDNF signal pathway with K252a or blocking the TrkB-BDNF downstream signal pathway PI3K/Akt with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 158-161 21350711-7 2011 AMD3100 and LY294002 inhibited the phosphorylation of PI3K/AKT and beta-catenin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 59-62 21304902-11 2011 Akt knockdown, and inhibition of Akt signaling by LY294002 and mTOR inhibitor rapamycin reduced leptin expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 33-36 21240525-3 2011 Inhibition of PI3K/Akt pathway by chemical LY294002 or specific short hairpin RNA (shRNA) vector prevented SREBP-1 and TGF-beta1 up-regulation, as well as ameliorated HKC cells lipogenesis and extracellular matrix accumulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 19-22 21136025-9 2011 In addition, the Cur3-induced increase in cell viability was attenuated by the treatment with wortmannin or LY294002, the upstream inhibitors of Akt, and was enhanced by the treatment with 2-[2"-amino-3"-methoxyphenyl]-oxanaphthalen-4-one (PD98059), an upstream inhibitor of ERK1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 145-148 21361663-4 2011 LY294002 loaded microspheres and 5-Aza-2-deoxycytidine are applied to MCF-10A cells for combinatory PI3K/AKT inhibition and deoxyribonucleic acid (DNA) demethylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 105-108 21040800-10 2011 Inhibition of phosphatidylinositol 3-kinase (PI3K) with LY294002 attenuated the 14,15-EETs-induced activating phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 129-132 21114978-8 2011 On the other hand, metformin induced Akt activation in cisplatin-treated cells and Akt inhibitor 10-DEBC hydrochloride or phosphoinositide 3-kinase/Akt inhibitor LY294002 abolished metformin-mediated antioxidant and antiapoptotic effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 37-40 21114978-8 2011 On the other hand, metformin induced Akt activation in cisplatin-treated cells and Akt inhibitor 10-DEBC hydrochloride or phosphoinositide 3-kinase/Akt inhibitor LY294002 abolished metformin-mediated antioxidant and antiapoptotic effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 83-86 21114978-8 2011 On the other hand, metformin induced Akt activation in cisplatin-treated cells and Akt inhibitor 10-DEBC hydrochloride or phosphoinositide 3-kinase/Akt inhibitor LY294002 abolished metformin-mediated antioxidant and antiapoptotic effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 83-86 20855443-6 2010 Blockage of ERK1/2 or AKT activation by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126; MKK1/2 inhibitor) or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; phosphatidyl inositol 3-kinase inhibitor), respectively, decreased the gemcitabine-induced Rad51 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-170 AKT serine/threonine kinase 1 Homo sapiens 22-25 21430412-5 2011 Further studies showed that PI3K inhibition using LY294002 leads to a decrease in PI3K substrate Akt and mitogen-activated protein kinase extracellular signal-regulated kinase and p38 phosphorylation/activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 97-100 22056597-8 2011 In high glucose-induced, insulin-resistant HepG2 cells, aromadendrin reversed the inhibition of Akt/PKB phosphorylation in response to insulin, which could be abrogated by pretreatment with LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 100-103 22046442-6 2011 By Western blotting, we found that combination treatment showed lower levels of phosphorylated Akt(Ser473) and GSK-3beta(Ser9) than a single treatment of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 95-98 21984893-5 2011 Here we show that the pan-inhibitor of PI3Ks LY294002 is able to abrogate the TGF-beta-induced increase in cell proliferation, in alpha- smooth muscle actin expression and in collagen production besides inhibiting Akt phosphorylation, thus demonstrating the centrality of the PI3K/Akt pathway in lung fibroblast proliferation and differentiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 214-217 21984893-5 2011 Here we show that the pan-inhibitor of PI3Ks LY294002 is able to abrogate the TGF-beta-induced increase in cell proliferation, in alpha- smooth muscle actin expression and in collagen production besides inhibiting Akt phosphorylation, thus demonstrating the centrality of the PI3K/Akt pathway in lung fibroblast proliferation and differentiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 281-284 21738655-7 2011 Combination treatment of ERK pathway inhibitor PD98059 or AKT pathway inhibitor LY294002 and berberine could result in a synergistic reduction on MMP-9 expression along with an inhibition of cell invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 58-61 21625476-6 2011 Disruption of the PI3K/Akt pathway using the pharmacological inhibitor LY294002, siRNA targeting the p85 regulatory subunit of phosphatidylinositol-3 kinase, or by PTEN over-expression, partially restored TRAIL-mediated apoptosis in these cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 23-26 21625476-7 2011 Moreover, the Akt inhibitor, LY294002, restituted normal cell proliferation index in HeLa cells expressing TRAIL-R4. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 14-17 21130731-6 2011 Inhibition of AKT activation by phosphoinocitide 3-kinase (PI3K) inhibitor LY294002 resulted in reduced Bcl-2 expression and enhanced Bax expression and thus induced apoptosis in the resistant cells, whereas inhibition of ERK1/2 activation by mitogen-activated protein kinase (MEK) inhibitor U0126 did not induce apoptosis without affecting the expression of Bcl-2 and Bax but decreased cell growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 AKT serine/threonine kinase 1 Homo sapiens 14-17 21245990-8 2011 In MKN45 and AGS cells, oxaliplatin treatment promoted both protein kinase B (Akt) and NFkappaB activation, while pretreatment with LY294002 significantly attenuated oxaliplatin-induced Akt activity and NFkappaB binding. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 186-189 21245990-10 2011 In vivo, LY294002 inhibited oxaliplatin-induced activation of Akt and NFkappaB, and increased oxaliplatin-induced expression of FasL, inhibition of c-FLIP(S), and activation of caspase-8, Bid, and caspase-3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 62-65 20934465-6 2011 Akt phosphorylation was inhibited by the PI3K inhibitor LY294002 (10muM), farnyltranferase inhibitor FTI-276, or transfection with a dominant negative Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 0-3 21239735-7 2011 LY294002, a specific inhibitor of PI3K, blocked HBXIP-stimulated Akt phosphorylation and suppressed the cell cycle promotion induced by HBXIP in HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 65-68 21330835-7 2011 RESULTS: The combination of LY294002 and radiation resulted in significant and synergistic suppression of cervical cancer cells in a dose-dependent manner in clonogenic assays (P < 0.05), higher ratio of apoptosis cells, and more remarkable reduction of Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 257-260 21330835-10 2011 CONCLUSIONS: Phosphoinositide-3-kinase inhibition by LY294002 can synergistically enhance radiation efficacy via dephosphorylation of Akt in cervical cancer, and PI3K inhibition alone can also suppress tumor regrowth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 134-137 21422731-6 2011 Inhibition studies using LY294002 (20 microM) revealed the requirement of the PI3K/Akt pathway for LPS-stimulated IL-6 production and NF-kappaB activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 83-86 21541882-9 2011 The phosphoinositol 3-kinase (PI3K)-specific inhibitor LY294002 abolished the cytoprotective effects induced by triphlorethol-A, suggesting that OGG1 restoration by triphlorethol-A is involved in the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 205-208 21850177-5 2011 After the pretreatment with 30 muM of LY294002, a PI3-K/Akt pathway inhibitor, apoptosis was assessed by flow cytometry, protein levels of phospho-Akt and Akt were quantified by western blot, and cell localization of phospho-Akt was determined by immunofluorescence staining. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 56-59 21850177-5 2011 After the pretreatment with 30 muM of LY294002, a PI3-K/Akt pathway inhibitor, apoptosis was assessed by flow cytometry, protein levels of phospho-Akt and Akt were quantified by western blot, and cell localization of phospho-Akt was determined by immunofluorescence staining. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 147-150 21850177-5 2011 After the pretreatment with 30 muM of LY294002, a PI3-K/Akt pathway inhibitor, apoptosis was assessed by flow cytometry, protein levels of phospho-Akt and Akt were quantified by western blot, and cell localization of phospho-Akt was determined by immunofluorescence staining. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 147-150 21850177-5 2011 After the pretreatment with 30 muM of LY294002, a PI3-K/Akt pathway inhibitor, apoptosis was assessed by flow cytometry, protein levels of phospho-Akt and Akt were quantified by western blot, and cell localization of phospho-Akt was determined by immunofluorescence staining. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 147-150 21850177-9 2011 Furthermore, pretreatment of LY294002 inhibited the phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 71-74 20875857-8 2011 Co-treatment with the specific PI3K inhibitor LY294002 reversed the restoration of Akt activity and attenuation of hippocampal apoptosis, while it had no significant effect on these parameters on its own. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 83-86 20959443-6 2010 The MerTK (Mer receptor tyrosine kinase) and PI3K/Akt pathways played a key role in this immunomodulatory effect as shown using specific MerTK-blocking antibodies and PI3K inhibitors LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 50-53 21215240-7 2010 In addition, pretreatment with LY294002 reduced H2O2 (10 muM, 10 min)-induced phosphorylation of Akt at Ser473. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 97-100 20698845-9 2010 In addition, TGF-beta enhanced MMP-2 production and activity, which could be abrogated by pretreatment with an AKT inhibitor (LY294002) but not with rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 111-114 21098703-6 2010 Treatment of cells with the well-known PI3K inhibitor LY294002, and its structural analogue LY303511, which does not inhibit PI3K, increased homotypic GJIC; however, we found the effect to be independent of PI3K/AKT inhibition. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 212-215 20855443-6 2010 Blockage of ERK1/2 or AKT activation by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126; MKK1/2 inhibitor) or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; phosphatidyl inositol 3-kinase inhibitor), respectively, decreased the gemcitabine-induced Rad51 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 22-25 21205476-5 2010 RESULTS: LY294002 not only blocked Akt activation efficiently but also increased ERK phosphorylation markedly under endoplasmic reticulum stress in SMMC-7721 and Hep3B cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 35-38 19859713-10 2011 TNFalpha- or hypoxia-induced secretion of VEGF and IL-8 and expression of HIF-1alpha were hampered by treatment with the PI3 kinase inhibitor LY294002, suggesting that inhibition of PI3 kinase/Akt activation might inhibit VEGF and IL-8 secretion and HIF-1alpha expression induced by TNFalpha or hypoxia. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 142-150 AKT serine/threonine kinase 1 Homo sapiens 193-196 20826199-9 2010 More importantly, microinjection of PI3K inhibitor (LY294002) or mTOR inhibitor (Rapamycin) into the CA3 prevented the acquisition of CPP and inhibited the activation of PI3K-Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 175-178 21080918-14 2010 CONCLUSIONS: Our data suggest that constitutive Akt activation and survival are controlled by different different molecular mechanisms in the two prostate cancer cell lines - one which is sensitive to the Akt-inhibitor ErPC3 and one which is more sensitive to the PI3K-inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 279-287 AKT serine/threonine kinase 1 Homo sapiens 48-51 20495838-12 2010 LY294002 (a PI3-K inhibitor) blocked apelin-induced activation of Akt and abolished the apelin-induced antiapoptotic activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 66-69 20512574-8 2010 Moreover, Tan I treatment remarkably downregulated the phosphorylation of both P85/PI3K and Akt in a time-dependent manner, and the PI3K/AKT-specific inhibitor (LY294002) mimicked the apoptosis-inducing effects of Tan I. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 161-169 AKT serine/threonine kinase 1 Homo sapiens 92-95 20512574-8 2010 Moreover, Tan I treatment remarkably downregulated the phosphorylation of both P85/PI3K and Akt in a time-dependent manner, and the PI3K/AKT-specific inhibitor (LY294002) mimicked the apoptosis-inducing effects of Tan I. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 161-169 AKT serine/threonine kinase 1 Homo sapiens 137-140 20544350-10 2010 Pharmacological inhibition of Akt by LY294002 restored sensitivity of activated B-CLL cells to fludarabine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 30-33 21205476-2 2010 METHODS: PI3K inhibitor LY294002 and MEK inhibitor U0126 were used to block the PI3K/Akt and MEK/ERK pathways respectively, and constitutively activated Akt mutant construct was used to activate the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 85-88 20506505-7 2010 Inhibitors of PI3K (LY294002 and Wortmannin) prevented the phosphorylation of ERK1/2, p38 MAPK, and Akt PI3K). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 100-103 20947290-4 2010 Our work demonstrates that blocking PI3K/Akt by LY294002 inhibits the NF-kappaB activity with significantly increased apoptosis in gastric cancer cell. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 41-44 21040406-7 2010 As expected, LY294002 inhibited activation of Akt kinase by PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 46-49 20336745-4 2010 Coating with collagen I induced activation of ERK and Akt but not FAK, and treatment with PD98059 and LY294002 blocked the activation of ERK and Akt, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 AKT serine/threonine kinase 1 Homo sapiens 145-148 20536682-9 2010 The neuroprotective effect was prevented by chelerythrine, LY294002, and Sn (IV) protoporphyrin IX dichloride (SnPP), indicating the participation of the PKC/PI3K/Akt activation and induction of the antioxidant enzyme heme oxygenase-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 163-166 20836715-5 2010 Since Akt is a critical downstream regulator of PI3K, we investigated the phosphorylation status of Akt in M-SMCs after treatment with poly I:C for 1 h and found that Akt was phosphorylated, but the phosphorylated Akt band was undetectable in LY294002 plus poly I:C-treated cultures. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 243-251 AKT serine/threonine kinase 1 Homo sapiens 6-9 20836715-5 2010 Since Akt is a critical downstream regulator of PI3K, we investigated the phosphorylation status of Akt in M-SMCs after treatment with poly I:C for 1 h and found that Akt was phosphorylated, but the phosphorylated Akt band was undetectable in LY294002 plus poly I:C-treated cultures. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 243-251 AKT serine/threonine kinase 1 Homo sapiens 100-103 20836715-5 2010 Since Akt is a critical downstream regulator of PI3K, we investigated the phosphorylation status of Akt in M-SMCs after treatment with poly I:C for 1 h and found that Akt was phosphorylated, but the phosphorylated Akt band was undetectable in LY294002 plus poly I:C-treated cultures. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 243-251 AKT serine/threonine kinase 1 Homo sapiens 100-103 20836715-5 2010 Since Akt is a critical downstream regulator of PI3K, we investigated the phosphorylation status of Akt in M-SMCs after treatment with poly I:C for 1 h and found that Akt was phosphorylated, but the phosphorylated Akt band was undetectable in LY294002 plus poly I:C-treated cultures. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 243-251 AKT serine/threonine kinase 1 Homo sapiens 100-103 20956467-13 2010 Immunoblots displayed rapid phosphorylation of PI3K and Akt within minutes of E(2) treatment, and the specific PI3K inhibitors wortmannin and LY294002 abolished the ability of E(2) to elevate (18)F-FDG uptake. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 142-150 AKT serine/threonine kinase 1 Homo sapiens 56-59 20658310-8 2010 Further, treatment with PI3K inhibitor (LY294002) and quercetin showed decreased p-Akt levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 83-86 20869949-8 2010 Contrarily, blockade of HIF-1alpha by siRNA and inhibition of Akt by either wortmannin or LY294002 abrogated upregulation of HP-induced CXCR4 and CXCR7 in MSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 62-65 20633628-6 2010 This process increased the protein expressions of phosphorylated Akt, and an inhibitor of phosphatidylinositol 3-kinase (PI3K)/Akt, LY294002, significantly decreased this protective effect of Yi-Gan San. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 127-130 20836878-9 2010 The use of PI3K inhibitor LY294002 or Akt siRNA abrogated the t-DARPP-mediated phosphorylation of AKT(ser473) and led to a significant reduction in cell growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 98-101 20704765-0 2010 LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 73-76 20664988-4 2010 When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a >60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-111 AKT serine/threonine kinase 1 Homo sapiens 14-17 19757167-7 2010 Moreover LY294002 (a PI3K inhibitor) partially attenuated (P < 0.05) ES-induced cell migration in wound healing assay while completely inhibited (P < 0.05) ES-induced AKT1 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 173-177 20649564-11 2010 IL-1beta-stimulated activation and translocation of Akt and NF-kappaB (p65); the recruitment of activated NF-kappaB (p65) to the MMP-9 promoter region was attenuated by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 52-55 20382513-11 2010 However, HG-down-regulated MT-1 MMP expression was independent of activation of ERK1/2 and Akt when using their inhibitors of DB98059 (ERK1/2) and LY294002 (Akt) alone or in combination. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 147-155 AKT serine/threonine kinase 1 Homo sapiens 157-160 20562903-10 2010 Compared with individual drug treatment, Akt phosphorylation and the ratio of p-eNOS/eNOS were up-regulated in the combination group, and this effect was inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 234-242 AKT serine/threonine kinase 1 Homo sapiens 41-44 20177740-9 2010 TGF-beta1-induced down-regulation of E-cadherin was recovered by a PI3K/Akt inhibitor, LY294002, without affecting the expression of FAK. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 72-75 20488538-9 2010 Inhibition of the PI3K-Akt pathway with the PI3K-specific inhibitor LY294002 leads to decreased sFlt1 levels and unchanged or increased VEGF and PlGF levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 23-26 20299603-8 2010 We have demonstrated that exposure of HIMEC to low levels of irradiation induced Akt and mTOR phosphorylation, which was attenuated by curcumin, rapamycin, LY294002, and mTOR small interference RNA (siRNA). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 81-84 20338993-7 2010 Both the SP 600125 (JNK inhibitor) and LY 294002 (PI-3K/Akt inhibitor) can inhibit chloramphenicol-induced c-Jun phosphorylation, MMP-13 expression, and cell invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-48 AKT serine/threonine kinase 1 Homo sapiens 56-59 20361045-8 2010 The PDK1-IFPC::IFPN-AKT1 complex was sufficient for phosphorylation of known AKT substrates, and conferred resistance to inhibitors of PI3K (LY294002, PI103, GDC0941 and TGX286) but not inhibitors of the downstream TORC1 complex (rapamycin). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 20-24 20333467-9 2010 In addition, application of PI3K/Akt inhibitor LY294002 could abrogate both the protective effects of bilobalide against Abeta 1-42-, H(2)O(2)- and serum deprivation-induced apoptotic cell damage and bilobalide-induced increase in PI3K activity and levels of p-Akt (Ser473 and Thr308). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 33-36 20333467-9 2010 In addition, application of PI3K/Akt inhibitor LY294002 could abrogate both the protective effects of bilobalide against Abeta 1-42-, H(2)O(2)- and serum deprivation-induced apoptotic cell damage and bilobalide-induced increase in PI3K activity and levels of p-Akt (Ser473 and Thr308). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 261-264 20412566-2 2010 METHODS: The activation of the PI3K/Akt and its effect on CNE-2Z cells in vivo and in vitro was investigated by MTT assay, flow cytometry, western blot, ELISA, terminal deoxyribonucleotide transferase-mediated nick-end labeling assays (TUNEL), and immunohistochemical analyses, using PI3K inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 300-308 AKT serine/threonine kinase 1 Homo sapiens 36-39 20412566-3 2010 RESULTS: The results showed that LY294002 inhibited the phosphorylating of Akt (S473), cell proliferation, and induced apoptosis in CNE-2Z cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 75-78 20419107-3 2010 Specifically, we found that TRAIL treatment activates the Akt survival pathway and that inhibition of this pathway by the PI3K inhibitor LY294002 or knockdown of Akt sensitizes resistant cancer cells to TRAIL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 58-61 20214883-3 2010 Specifically, we found that cisplatin treatment activates the Akt/mTOR survival pathway and that inhibition of this pathway by the PI3K inhibitor LY294002 or knockdown of Akt sensitizes ovarian cancer cells to cisplatin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 146-154 AKT serine/threonine kinase 1 Homo sapiens 62-65 20213282-3 2010 Inhibition of PI3K/Akt by treatment with a PI3K-specific inhibitor (LY294002) prior to PRRSV infection reduced virus replication. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 19-22 20213282-4 2010 Furthermore, inhibition of PI3K/Akt by LY294002 at 90 min and 8 h after virus infection still significantly reduced virus production, suggesting that virus replication may be dependent on the activation of PI3K/Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 32-35 20213282-4 2010 Furthermore, inhibition of PI3K/Akt by LY294002 at 90 min and 8 h after virus infection still significantly reduced virus production, suggesting that virus replication may be dependent on the activation of PI3K/Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 211-214 20506627-5 2010 Blocking the activation of the PI3K/Akt pathway using LY294002 abolished Akt activation in response to cobalt chloride, suggesting that Akt phosphorylation by cobalt chloride is dependent on PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 36-39 20506627-5 2010 Blocking the activation of the PI3K/Akt pathway using LY294002 abolished Akt activation in response to cobalt chloride, suggesting that Akt phosphorylation by cobalt chloride is dependent on PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 73-76 20506627-5 2010 Blocking the activation of the PI3K/Akt pathway using LY294002 abolished Akt activation in response to cobalt chloride, suggesting that Akt phosphorylation by cobalt chloride is dependent on PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 73-76 20664988-4 2010 When the PI3K/Akt signaling inhibitor LY294002 and the MEK/Erk signaling inhibitor U0126 were applied, LY294002 reduced cell proliferation in MDA-MB-468 PTEN and MDA-MB-468 vec by 20%, while U0126 led to a >60% reduction in MDA-MB-468 PTEN and a 20% reduction in MDA-MB-468 vec cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 14-17 19767100-5 2010 Tax-induced OPN activation was abrogated by treatment with LY294002 (PI3K inhibitor) or co-transfection with AKT siRNA, suggesting PI3K/AKT pathway is involved in Tax-mediated transactivation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 136-139 20560677-10 2010 Inhibition of Akt by the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 induced PDCD4 activity and enhanced TRAIL sensitivity in TRAIL-resistant gastric cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 14-17 20428814-10 2010 Similarly, treatment of HepG2 cells with the PI3K/Akt pharmacological inhibitor, LY294002, potently suppressed cell migration and invasion as well as expression of MMPs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 50-53 20484843-10 2010 Moreover, NaHS increased Akt phosphorylation, which was prevented with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 (5 microM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 25-28 20225234-7 2010 The inhibition of the PI3K/Akt pathway by Ly294002 abrogated the protective effects induced by either Epo or atRA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 27-30 20411591-8 2010 Bradykinin-mediated migration was attenuated by phosphoinositide 3-kinase (PI-3 kinase)/AKT inhibitors LY 294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-112 AKT serine/threonine kinase 1 Homo sapiens 88-91 20361045-8 2010 The PDK1-IFPC::IFPN-AKT1 complex was sufficient for phosphorylation of known AKT substrates, and conferred resistance to inhibitors of PI3K (LY294002, PI103, GDC0941 and TGX286) but not inhibitors of the downstream TORC1 complex (rapamycin). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 20-23 19874928-9 2010 Wortmannin and LY294002 also blocked HA oligosaccharide-induced serine and threonine Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 85-88 20338106-9 2010 Furthermore, nicotine induced activation of AKT and MAPK pathways, while inhibition of MAPK using U0126 and AKT by phosphatidylinositol 3-kinase inhibitor, LY294002, in part, blocked the antiapoptotic effects of nicotine against cisplatin and etoposide-induced apoptosis in NC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 44-47 20338106-9 2010 Furthermore, nicotine induced activation of AKT and MAPK pathways, while inhibition of MAPK using U0126 and AKT by phosphatidylinositol 3-kinase inhibitor, LY294002, in part, blocked the antiapoptotic effects of nicotine against cisplatin and etoposide-induced apoptosis in NC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 108-111 19815837-7 2010 Unexpectedly, treatment with thalidomide elicited an increase in fibronectin-induced Akt phosphorylation through phosphoinositide 3-kinase-independent pathways since thalidomide decreased fibronectin-induced phosphoinositide 3-kinase phosphorylation and reversed the inhibition of Akt phosphorylation achieved by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 369-377 AKT serine/threonine kinase 1 Homo sapiens 85-88 20080299-9 2010 The PI3K/AKT and p38 MAPK pathway inhibitors (LY294002 and SB202190, respectively) decreased dNK-CM-stimulated ICAM-1 induction, HTR8/SVneo migration, and reversed tube and network formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 9-12 19070520-9 2010 Even if Akt activation is sufficient in promoting invasion, its inactivation by LY294002 (PI-3 kinase inhibitor) is less efficient on invasion than inhibition of N-cadherin and phospho-EGFR by GC-4 (monoclonal antibody) and gefitinib (anti-tyrosine kinase), respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 8-11 19866475-10 2010 The addition of a PI3K/AKT inhibitor Ly294002 reversed the CCL2 protection and was additive to docetaxel-induced toxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 23-26 20008098-8 2010 Inhibition of PI3K activity by its inhibitor LY294002 abrogated leptin-mediated PI3K/AKT signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 85-88 20135719-9 2010 Inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway by the PI3K inhibitor, LY294002, markedly suppressed HGF-stimulated invasion of both CCA cell lines, and inhibition of the ERK pathway by U0126 suppressed HGF-induced invasion of the KKU-M213 cell line but had a moderate effect on HuCCA-1 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 51-54 20103665-10 2010 Inhibition of MAP/ERK kinase/ERK signaling with U0126 had no effect on radiosensitization, whereas inhibition of activated Akt with LY294002 (enhancement ratio, 1.2-1.8) or nelfinavir (enhancement ratio, 1.2-1.4) radiosensitized cells regardless of K-ras mutation status. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 123-126 21048307-8 2010 Moreover, the combination of Tan IIA and LY294002, a specific PI3K inhibitor, enhanced PARP cleavage of LNCaP and PC-3, but not in MDA-MB-231 breast cancer cells which do not contain detectable active AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 201-204 20015475-8 2010 To investigate the involvement of additional signaling pathways, U87-MG cells were pretreated with wortmannin or LY294002 to inhibit the PI3-kinase/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 148-151 19962417-7 2010 The phosphorylation of Akt and CREB induced by KMUP-1 was inhibited by tyrosine kinase (TrK) inhibitor K252a and phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 160-168 AKT serine/threonine kinase 1 Homo sapiens 23-26 21048308-8 2010 Consistently, LY294002, a specific PI3K inhibitor, enhanced the inactivation of HIF-1alpha and AKT by PGG in LNCaP cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 95-98 21364639-7 2010 Downregulation of PI3K by the expression of a dominant-negative mutant or inhibition by LY294002 abrogated the ability of alphaA-crystallin to phosphorylate Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 157-160 19835871-9 2010 Pretreatment of gastric cancer cells with PI-3 kinase/Akt kinase inhibitor (kinase-dead Akt [DN-Akt], Akt siRNA, or LY294002) significantly inhibited BMP-2-induced EMT and invasiveness. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 54-57 19956899-10 2010 The activity of Akt was also inhibited in PCC-treated cells, and phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor, LY294002, sensitized the cells to PCC-induced apoptosis indicating that the down-regulation of the Akt signaling pathway plays a key role in PCC-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 16-19 19956899-10 2010 The activity of Akt was also inhibited in PCC-treated cells, and phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor, LY294002, sensitized the cells to PCC-induced apoptosis indicating that the down-regulation of the Akt signaling pathway plays a key role in PCC-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 102-105 19956899-10 2010 The activity of Akt was also inhibited in PCC-treated cells, and phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor, LY294002, sensitized the cells to PCC-induced apoptosis indicating that the down-regulation of the Akt signaling pathway plays a key role in PCC-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 102-105 19669229-8 2009 LY294002 significantly inhibited the PI3K-Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 42-45 19726550-11 2010 In addition, blockade of the phosphatidylinositol-3 kinase/Akt pathway with LY294002 and silencing of Akt expression with Akt small interfering RNA induced p38 MAPK phosphorylation in the absence of HG. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 59-62 20003467-10 2009 The phosphorylation level of Akt was apparently elevated in Lewis y-overexpressing cells and the inhibitor of PI3K, LY294002, dramatically inhibited the growth of Lewis y-overexpressing cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 29-32 19624598-9 2009 Furthermore, fibronectin-mediated protection of T24 cells was dependent on the activity of the PI3-K/Akt signalling pathway, and the protection could be abolished by the PI3-K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-194 AKT serine/threonine kinase 1 Homo sapiens 101-104 19923913-5 2009 Selective inhibition of the PI3K-AKT-mTOR pathway using pharmacologic inhibitors (LY294002, AKT inhibitor VIII, Rapamycin) significantly attenuated expression of p-AKT and p-70S6K, respectively and radiosensitized SKBR3 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 33-36 20120770-7 2009 The inhibition of phosphorylated Akt by LY294002 led to the inhibition of NF-kappaB in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 33-36 20120770-8 2009 Inhibition of Akt with LY294002 caused further increase in apoptosis of U937 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 14-17 19956885-8 2010 LY294002 and PD98059 inhibited SCF-induced Akt and Erk activation in H209 cells, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 43-46 19956887-12 2010 Moreover, inhibition of Akt by LY294002, a specific PI3K inhibitor, down-regulated c-FLIP expression in MCF-7 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 24-27 19551863-5 2009 Treatment with the PI3K inhibitor LY294002 attenuated the tumor promotion effects of Id-1, indicating that the effects were mediated by the PI3K/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 145-148 19892399-7 2009 PD98059 (a MEK1/2 inhibitor) at 20microM and LY294002 (a PI3K inhibitor) at 5microM attenuated FGF2- and VEGF-induced phosphorylation of ERK1/2 and AKT1, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 148-152 19883517-8 2009 However, when LY294002 was used, p-Akt and p-Bad proteins inK562 cells showed a significant reduction, while no distinct variation was seen in the nonphosphorylated Akt and Bad protein levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 35-38 19657064-7 2009 For both cell types, p-Akt was higher in the ZD than in the ZN cells and was normalized to that of the ZN cells by treatment with a PI3K inhibitor, LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-157 AKT serine/threonine kinase 1 Homo sapiens 23-26 19717552-4 2009 CSE stimulated the phosphorylation of c-Src, EGFR, PDGFR, and Akt, which were inhibited by pretreatment with the inhibitor of PKCalpha (Go6976 or Go6983), c-Src (PP1), EGFR (AG1478), PDGFR (AG1296), or PI3K (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 62-65 20032392-8 2009 Apoptosis induced by the combined treatment was markedly increased by the phosphatidylinositol-3"-kinase inhibitor, LY294002 (Akt-upstream inhibitor), through the mitochondrial amplification step and caspase activation, suggesting that interactions of the synergistic effect were at least partially mediated through the Akt-dependent pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 126-129 20032392-8 2009 Apoptosis induced by the combined treatment was markedly increased by the phosphatidylinositol-3"-kinase inhibitor, LY294002 (Akt-upstream inhibitor), through the mitochondrial amplification step and caspase activation, suggesting that interactions of the synergistic effect were at least partially mediated through the Akt-dependent pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 320-323 19588183-6 2009 The cardiomyocytes treated with T3 demonstrated a rapid activation of Akt/GSK-3beta/mTOR signaling pathway, which was completely inhibited by the use of PI3K inhibitors (LY294002, 10 microM and Wortmannin, 200 nM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 70-73 19457607-7 2009 The PI3K/Akt inhibitor LY294002 significantly increased the amount of p53 protein and ATO-induced apoptosis in both cell lines and decreased G2/M phase arrest of MGC803 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 19737348-7 2009 Additionally, Akt, p70 ribosomal protein S6 kinase, and S6 ribosomal protein were also phosphorylated upon sPLA(2)-IIA treatment, effect that was abrogated by N-acetylcysteine or LY294002 treatment indicating that ROS and phosphatidylinositol 3 kinase are upstream signaling regulators. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-187 AKT serine/threonine kinase 1 Homo sapiens 14-17 19669229-12 2009 LY294002 effectively inhibits the PI3K-Akt pathway, suppresses NE tumor markers, and decreases cellular proliferation via apoptosis in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 39-42 19507191-6 2009 PKR inhibition augmented levels of p-S473 AKT and p-S21/9 GSK-3alpha/beta in the presence of the PI3K inhibitor, LY294002, but was unable to augment GSK-3alpha or beta phosphorylation in the presence of the AKT inhibitor, A443654. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 42-45 19631197-8 2009 A PI3K-specific inhibitor, LY294002, abolished the phosphorylated Akt and OGG1 expressions induced by butin, suggesting that OGG1 induction by butin involves the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 66-69 19631197-8 2009 A PI3K-specific inhibitor, LY294002, abolished the phosphorylated Akt and OGG1 expressions induced by butin, suggesting that OGG1 induction by butin involves the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 167-170 19653997-6 2009 PDGF-induced Muller cell proliferation was significantly reduced by pre-treatment with SP600125 and LY294002, inhibitors of c-JNK and Akt phosphorylation, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 100-108 AKT serine/threonine kinase 1 Homo sapiens 134-137 19588205-10 2009 Levels of active, phosphorylated Akt and the NE tumor markers, ASCL1 and CgA, were diminished with both LY294002 and Akt1 siRNA treatments proportional to the degree of Akt inhibition. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 33-36 19644051-11 2009 Inhibition of Akt phosphorylation with LY294002 abolished hypoxia-induced GSK-3beta inactivation, beta-catenin activation, and MMP-7 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 14-17 19507191-7 2009 Pre-treatment with the PKR inhibitor blocked the ability of A443654 and LY294002 to promote phosphorylation of eIF2alpha, indicating the mechanism leading to AKT phosphorylation and activation did not require eIF2alpha phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 158-161 19738051-9 2009 Pharmacologic inhibition of Akt with LY294002 abrogated insulin- or serum-induced eEF1A2 expression and increased the caspase-3 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 28-31 19595723-2 2009 Phosphorylation of Akt occurs early during JUNV infection of Vero cells and is blocked by the PI3K inhibitor, Ly294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 19-22 19595723-5 2009 Inhibition of Akt phosphorylation by Ly294002 impaired viral protein synthesis and expression leading to a reduced infectious virus yield without blocking the onset of persistent stage of infection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 14-17 19775474-9 2009 Testosterone induced ERK and Akt phosphorylation, which could be abrogated by ER-alpha 36 shRNA knockdown or the kinase inhibitors, U0126 and LY294002, and the aromatase inhibitor letrozole. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 142-150 AKT serine/threonine kinase 1 Homo sapiens 29-32 19946410-5 2009 The PI3K/Akt signaling pathway is necessary for mesenchyme outgrowth, as sprouting was inhibited in AVC explant cultures treated with the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 153-161 AKT serine/threonine kinase 1 Homo sapiens 9-12 19139893-12 2009 In addition, we found that PI3K/AKT pathway was activated; Ly294002, a PI3K/AKT specific inhibitor, can enhance the anti-leukemic effect of casticin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 76-79 19656152-3 2009 The PI-3K pathway promoted differentiation of interleukin-3 (IL-3)-stimulated myelopoiesis via Akt, because inhibition of the PI-3K/Akt pathway with LY294002 or SH-5 increased proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 132-135 19571375-8 2009 The Akt inhibitor LY294002 synergistically potentiated paeonol-induced inactivation of Akt and vascular endothelial growth factor in bFGF-treated HUVECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 4-7 19406941-5 2009 Using selective inhibitors of ERK1/2 (UO126) or Akt phosphorylation (LY294002), we show that the ERK1/2 and Akt cascades are both involved in the hCG- and EGF-dependent proliferation of Leydig cells, but only the ERK1/2 cascade is involved in their antiapoptotic actions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 48-51 19406941-5 2009 Using selective inhibitors of ERK1/2 (UO126) or Akt phosphorylation (LY294002), we show that the ERK1/2 and Akt cascades are both involved in the hCG- and EGF-dependent proliferation of Leydig cells, but only the ERK1/2 cascade is involved in their antiapoptotic actions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 108-111 19415692-6 2009 In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 163-172 AKT serine/threonine kinase 1 Homo sapiens 46-49 19533041-7 2009 LY294002 treatment abrogated Lf(Fe(3+))-induced Akt activation, and prevented the cytoplasmic localization of p27(kip1). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 48-51 19269083-4 2009 Inhibition of Akt kinase activation by a PI3K inhibitor LY294002, or exogenous expression of a kinase-dead mutant of Akt abrogated the increase of Snail expression induced by HRG-beta1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 14-17 19473970-7 2009 Hypoxia leads to FOXO3a phosphorylation at an Akt/protein kinase B target site and subsequent nuclear export; these processes are reversed by reoxygenation and blocked by LY294002, a phosphatidylinositol 3-kinase inhibitor that blocks Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 171-179 AKT serine/threonine kinase 1 Homo sapiens 235-238 19571375-8 2009 The Akt inhibitor LY294002 synergistically potentiated paeonol-induced inactivation of Akt and vascular endothelial growth factor in bFGF-treated HUVECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 87-90 19513559-7 2009 Moreover, the activity of Akt was downregulated in WEPN-treated cells and the phosphatidylinositol-3 kinase (PI3K)/Akt inhibitor LY294002 sensitized the cells to WEPN-induced apoptosis through enhancing the activation of caspase-3 and loss of MMP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 26-29 19513559-7 2009 Moreover, the activity of Akt was downregulated in WEPN-treated cells and the phosphatidylinositol-3 kinase (PI3K)/Akt inhibitor LY294002 sensitized the cells to WEPN-induced apoptosis through enhancing the activation of caspase-3 and loss of MMP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 115-118 21475874-11 2009 This is in sharp contrast to LY294002, which is an inhibitor of phosphatidylinositol 3-kinase, an upstream activator for Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 121-124 19371940-7 2009 In 786-O cells, the phosphorylation of both extracellular signal-regulated kinase and Akt was inhibited by gefitinib used in combination with either LY294002 or the knockdown of Akt expression, and the viability of 786-O cells was suppressed significantly by gefitinib used in combination with LY294002 (P < .0001) or Akt small interfering RNA (P = .0044). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 86-89 19371940-7 2009 In 786-O cells, the phosphorylation of both extracellular signal-regulated kinase and Akt was inhibited by gefitinib used in combination with either LY294002 or the knockdown of Akt expression, and the viability of 786-O cells was suppressed significantly by gefitinib used in combination with LY294002 (P < .0001) or Akt small interfering RNA (P = .0044). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 294-302 AKT serine/threonine kinase 1 Homo sapiens 86-89 19429264-4 2009 GSK3beta is known to be a key downstream target of Akt, and LY294002, the PI3K (phosphatidylinositol 3-kinase)/Akt inhibitor, which promoted the dephosphorylation of GSK3beta, significantly attenuated BLM-induced NF-kappaB activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 111-114 19385062-5 2009 The forskolin-induced Akt/eNOS/NO pathway was completely inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, but not significantly suppressed by PKI. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 121-129 AKT serine/threonine kinase 1 Homo sapiens 22-25 19395875-7 2009 For study of mechanism, the ADAM17 inhibitor TAPI-2 and the PI3K-AKT inhibitor LY294002 were used to counteract high ADAM17 expression or the activated PI3K-AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 65-68 19108833-6 2009 The activation of mTOR signaling by oxLDL, requires the upstream activation of PI3K and Akt, as assessed by the inhibitory effect of the PI3K inhibitor Ly294002 on mTOR activation and DNA synthesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 152-160 AKT serine/threonine kinase 1 Homo sapiens 88-91 19347904-8 2009 Although LY294002 and similar inhibitors are effective at blocking prostate cancer cell growth, they act upstream of AKT and PTEN and cancer cells can find a way to bypass this inhibition. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 117-120 19274672-7 2009 Treatment of SGC7901/ADR cells with the PI3K inhibitor LY294002 reduced the expression of both p-Akt and P-gp. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 95-100 19120326-0 2009 Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 40-43 19120326-7 2009 Combined PI3K/mTOR inhibition with LY294002 had pronounced effects on viability but also led to increased AKT phosphorylation after prolonged treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 106-109 19120326-8 2009 In contrast, combination of rapamycin plus LY294002 suppressed AKT phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 63-66 19120326-11 2009 CONCLUSIONS: mTORC1 inhibition with rapamycin and with LY294002 can lead to AKT phosphorylation in melanoma cells via mTORC2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 76-79 19120326-12 2009 Combination of rapamycin and LY294002 suppresses AKT phosphorylation but without significant effect on treatment efficacy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 49-52 19383818-6 2009 Although phospho-Akt (pAkt) levels decreased in all cell lines treated with LY294002, sensitivity was variable. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 17-20 19426673-6 2009 When activation of the PI-3-kinase-Akt pathway was prevented by LY-294002 or Akt Inhibitor IV, the cytoprotective effect of PARP inhibition was significantly diminished showing that the activation of PI-3-kinase-Akt cascade had significantly contributed to the cytostatic resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-73 AKT serine/threonine kinase 1 Homo sapiens 35-38 19357281-6 2009 This result was corroborated by the observation that the selective PI3K inhibitor LY294002 blocked the CB2R stimulation effects on neuronal survival as well as Akt and JNK phosphorylation levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 160-163 19174695-8 2009 Inactivation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway was also involved, as inhibition of PI3K by LY294002 significantly increased UA-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 123-131 AKT serine/threonine kinase 1 Homo sapiens 57-60 19173293-10 2009 This effect of DeltaNp73alpha resulted in increased thyroid cancer cell proliferation and reduced apoptosis and was reverted by the PI3-kinase inhibitor LY294002, indicating the role of Akt pathway in this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 153-161 AKT serine/threonine kinase 1 Homo sapiens 186-189 19401448-9 2009 Pharmacologic inhibition of heregulin-induced phosphoinositide-3-kinase/Akt (with LY294002) and ERK (with U0126) signaling, as well as short interfering RNA-mediated mitogen-activated protein kinase-1 down-regulation, showed ERK signaling as the primary transducer of heregulin signaling to PRL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 72-75 19130609-6 2009 Induction of survivin involves activation of the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) pathway, which was antagonized by the PI3K-inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 147-155 AKT serine/threonine kinase 1 Homo sapiens 79-82 19302476-6 2009 The CXCR4 antagonist (T140) or inhibitors for G proteins (Pertussis toxin) and phosphoinositide 3-kinase (PI3K) (LY294002) abolished CXCL12-mediated NPC proliferation and phosphorylation of Akt-1 and FOXO3a. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 190-195 19292987-3 2009 Treating VSMCs with LY294002, the PI3K/Akt inhibitor, abrogated Am80-induced KLF5 dephosphorylation and reversed Am80-induced suppression of interaction between KLF5 and RAR alpha, whereas treating vascular smooth muscle cells (VSMCs) with SB203580, the p38 kinase inhibitor, attenuated the interaction between KLF5 and RAR alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 39-42 19426671-7 2009 Treatment of SKOV3 cells with PKI-166 (EGFR1/2 inhibitor), LY294002 (AKT inhibitor), and PD98059 (ERK inhibitor) decreased c-FLIP(L) expression and co-treatment with TRAIL further reduced the level of c-FLIP(L,) respectively, as did TSA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 69-72 19429543-5 2009 The induced eNOS and p-Akt expression was inhibited by LY294002, indicating that the effect of nanocomposites could be attributed to the PI3K pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 23-26 19287985-6 2009 The 17beta-estradiol increased HIF-1alpha expression in ovarian cancer cells, and this upregulatory effect was abrogated by Akt inhibitor LY294002 (P<0.05) and Akt siRNA interference (P<0.05), but not affected by MAPK inhibitor PD980059 (P>0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 AKT serine/threonine kinase 1 Homo sapiens 124-127 19395875-7 2009 For study of mechanism, the ADAM17 inhibitor TAPI-2 and the PI3K-AKT inhibitor LY294002 were used to counteract high ADAM17 expression or the activated PI3K-AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 157-160 19395875-14 2009 ADAM17 activated, whereas ADAM17 siRNA, TAPI-2 and LY294002 deactivated the EGFR-PI3K-AKT signal pathway, which correlated with MDA-MB-231 cell malignant phenotype changes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 86-89 19073151-6 2009 In addition, Western blot analysis of Akt showed that, while the total Akt level remained unchanged, the phosphorylated Akt level was increased by UDCA, and this increase was also prevented by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 193-201 AKT serine/threonine kinase 1 Homo sapiens 38-41 19073151-6 2009 In addition, Western blot analysis of Akt showed that, while the total Akt level remained unchanged, the phosphorylated Akt level was increased by UDCA, and this increase was also prevented by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 193-201 AKT serine/threonine kinase 1 Homo sapiens 71-74 19073151-6 2009 In addition, Western blot analysis of Akt showed that, while the total Akt level remained unchanged, the phosphorylated Akt level was increased by UDCA, and this increase was also prevented by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 193-201 AKT serine/threonine kinase 1 Homo sapiens 71-74 19118895-5 2009 The inductions of both eNOS and p-Akt on PU-Au were abolished by the addition of LY294002 (PI3K inhibitor), suggesting that these cellular events may be regulated through the PI3K signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 34-37 18654850-7 2009 Inactivation of Akt by treatment with the PI3K chemical inhibitor LY294002 or by overexpression of the dominant negative mutant of Akt (DNMAkt) prevented the protective effect of S1P on apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 16-19 19255520-6 2009 The inhibition of ERK using PD98059 synergistically enhanced the TET-induced apoptosis of A549 cells whereas the inhibition of Akt using LY294002 had a less significant effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 127-130 19074484-6 2009 The PI3K inhibitor Ly294002 abolished Akt and p70S6K phosphorylation and reversed the dedifferentiated phenotype via induction of sm-calponin, sm-alpha-actin, SM22alpha, and myosin light chain kinase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 38-41 19073151-5 2009 We further investigated the effect of UDCA on the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, and obtained results showing that UDCA-induced increase in the GSH level was prevented by LY294002, a PI3K inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 87-90 19550116-9 2009 LY294002 pretreatment partially inhibited the expression of p-Akt and P-gp, and promoted the intracellular accumulation of DNR and ADR in K562/DNR and SGC7901/ADR cells, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 62-65 19550116-10 2009 CONCLUSION: LY294002 could partially reverse multidrug resistance in K562/DNR and SGC7901/ADR cells in vitro via inhibiting PI3-K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 130-133 19143835-7 2009 Inhibition of the PI3K/Akt pathway by one of its specific inhibitors, LY294002, or by Akt small interfering RNA (siRNA) resulted in decreased multidrug resistance of SGC7901 cells, partly through downregulation of P-gp induced by PrP(C). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 23-26 18844239-5 2009 Interestingly, Egr-1 induction depends on integrin-dependent PI3K/Akt activation, as indicated by the decrease in Egr-1 levels in presence of the pharmacological inhibitor LY294002, the kinase-defective Akt mutant and Akt1/2 shRNAs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 66-69 19059380-9 2009 In addition, treatment of a PI3K inhibitor, LY294002, inhibited Akt phosphorylation by calcium-mediated cell-cell adhesion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 64-67 19064616-8 2009 Western blots revealed that compared with -LMN myocytes, +LMN myocytes showed a significant increase in Akt phosphorylation at Ser-473, which was prevented by LY. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-161 AKT serine/threonine kinase 1 Homo sapiens 104-107 19183465-9 2009 These effects were PI-3k dependent since selective inhibitors of this molecule, wortmannin and LY294002, inhibited both Akt and Bad phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 120-123 18978810-8 2009 Moreover, silibinin reduced hypoxia-induced vascular endothelial growth factor (VEGF) release by HeLa and Hep3B cells, and this effect was potentiated by the PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 163-166 19655410-5 2009 Only LY294002 inhibited Akt activation induced by EGCG, implying that EGCG-induced Akt activation is PI3K dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 AKT serine/threonine kinase 1 Homo sapiens 24-27 19082492-9 2009 Ectopic expression of HA myr-Akt was found to be associated with an increase in pERK, and treatment with LY294002 was shown to block the phosphorylation of Akt and ERK with the restoration of c-JUN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 29-32 19082492-9 2009 Ectopic expression of HA myr-Akt was found to be associated with an increase in pERK, and treatment with LY294002 was shown to block the phosphorylation of Akt and ERK with the restoration of c-JUN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 156-159 19009553-5 2009 Pretreatment of osteoblasts with phosphatidylinositol 3-kinase (PI3K) inhibitor (Ly294002) and Akt inhibitor inhibited the potentiating action of US; these results were further substantiated by transfecting with the dominant negative mutants of p85 and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 253-256 19155632-7 2009 It also caused phosphorylation of Akt and eNOS, which were prevented by MnTMPyP, polyethyleneglycol catalase, PP2, wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 130-138 AKT serine/threonine kinase 1 Homo sapiens 34-37 19139118-6 2009 The simultaneous inhibition of the PI3K/Akt pathway by LY294002 or Akt1 small interfering RNA and Bcl-xL function by ABT-737 or Bcl-xL small interfering RNA greatly enhanced the apoptotic response. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 40-43 19018257-6 2008 TAM67 increased dephosphorylation of Akt induced by LY294002 and reduced the TPA response element DNA-binding of phosphorylated c-Jun. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 37-40 18973754-7 2009 The addition of either the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 or Akt inhibitor LY294002 also led to a marked inhibition of the AngII-induced VEGF mRNA and protein production. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 97-100 19709444-12 2009 When cells were treated with LY294002, a potent phosphoinositide 3-kinase inhibitor, Akt phosphorylation and Bcl-2 levels were reduced and Hsp70 downregulation no longer had a cytoprotective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 85-88 18854312-10 2008 The pathway by which RhoA mediates cardiomyocyte Akt activation is demonstrated to require Rho kinase, FAK and PI3K, but not Src, based on studies with pharmacological inhibitors (Y-27632, LY294002, PF271 and PP2) and inhibitory protein expression (FAK-related nonkinase). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 189-197 AKT serine/threonine kinase 1 Homo sapiens 49-52 18854173-5 2008 U0126 blocked the phosphorylation of ERK, but not Akt, and LY294002 blocked the phosphorylation of Akt, but not ERK. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 99-102 19026161-7 2008 The inhibition of the PI3K/Akt pathway using the LY294002 inhibitor prevented hypoxia-inhibited apoptosis in EPC and altered the phosphorylation state of glycogen synthase kinase-3beta, an effector protein involved in regulation of EPC apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 27-30 18931031-5 2008 HCMVEC exposed to 500 microM H2O2 had increased Akt phosphorylation within 10 min at both Ser-473 and Thr-308 sites, an effect blocked by the phosphatidylinositol 3-kinase inhibitor LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-191 AKT serine/threonine kinase 1 Homo sapiens 48-51 18849546-4 2008 Furthermore, PI3-K inhibitor LY294002 attenuated OPN-mediated Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 62-65 19131705-6 2008 AECM-induced apoptosis was associated with the inhibition of Akt activation in a time-dependent manner, and pretreatment with LY294002, a PI3K/Akt inhibitor, significantly increased AECM-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 61-64 19131705-6 2008 AECM-induced apoptosis was associated with the inhibition of Akt activation in a time-dependent manner, and pretreatment with LY294002, a PI3K/Akt inhibitor, significantly increased AECM-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 143-146 19032736-2 2008 We examined the potential of the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 to enhance the anti-tumor effect of cisplatin and investigated the mechanism of chemoresistance in pancreatic cancer cells using a combination therapy of cisplatin and LY294002, both in vitro and in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 70-73 18628489-8 2008 Inhibition of AKT by LY294002 (a PI3K inhibitor) blocked BCL10 nuclear translocation, NF-kappaB transactivity, and BAFF expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 14-17 18804099-7 2008 Activation of Akt in A172 cells could be reversed by pre-treatment of the cells with the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002, indicating involvement of PI3K activity in this process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 136-144 AKT serine/threonine kinase 1 Homo sapiens 14-17 19330070-4 2008 The crucial role of lipid second messengers in PKB activation has been dissected through the use of the PI3K-specific inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 AKT serine/threonine kinase 1 Homo sapiens 47-50 18773906-11 2008 Inhibition of the PI3-kinase/Akt/mTOR/p70S6kinase signaling pathway negated the biological functions of cultured EPCs, either migration (by LY294002 for PI3-kinase and Rapamycin for mTOR) or survival and tubulogenesis (by Rapamycin). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 29-32 18790053-4 2008 Treatment with LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), abolished ER-mediated up-regulation of a CYP7B1 promoter-luciferase reporter in HepG2 cells, whereas overexpression of PI3K or Akt significantly increased estrogenic up-regulation of CYP7B1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 214-217 18812223-10 2008 However, inhibition of Akt activity through PI3 kinase inhibitor LY294002 did not result in obstruction of p38MAPK phosphorylation by H(2)O(2). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 23-26 18832563-4 2008 Infusion of PI3K inhibitors (wortmannin and LY294002) and an mTOR inhibitor (rapamycin) into the mPFC in vivo suppressed HFS-induced LTP as well as the phosphorylation of PI3K/Akt-mTOR signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 176-179 18805481-4 2008 The increased NF-kappaB activity with subsequent MMP-2 production by HNE was significantly attenuated by transfection with Akt siRNA as well as by pretreatment with the PI3K/Akt inhibitors LY294002 (10 microM) and SH-5 (1.0 microM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 189-197 AKT serine/threonine kinase 1 Homo sapiens 174-177 18786922-7 2008 Blockade of Akt activation by LY294002, FoxO1 translocation by constitutively nuclear FoxO1 mutant, or c-Src activation by the chemical inhibitor PP2, respectively, blunted SDF-1 suppression of gluconeogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 12-15 18675921-6 2008 LY294002 (selective inhibitor of PI3K) blocked Akt phosphorylation and abolished IGF2-driven elevation of the mRNA levels of the proteoglycans, Aggrecan and Versican. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 47-50 18565131-11 2008 Activation of phospho-Akt (p-Akt) was observed and the effect was abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 22-25 18565131-11 2008 Activation of phospho-Akt (p-Akt) was observed and the effect was abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 29-32 18852117-9 2008 Targeted inhibition of the phosphatidylinositol 3-kinase/AKT pathway with LY294002, in combination with docetaxel, resulted in a synergistic effect in previously docetaxel-resistant cell lines but not with cisplatin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 57-60 18691227-5 2008 Furthermore, the enhanced Akt phosphorylation induced by U0126 is inhibited by the PI3-kinase inhibitor LY294002, and is accompanied by the up-regulation of Ras activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 26-29 19051078-7 2008 Both LY294002 and API-2, an Akt inhibitor, decreased the Bcl-2/Bax ratio in menadione-exposed myotubes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 AKT serine/threonine kinase 1 Homo sapiens 28-31 19069650-6 2008 Pretreatment of BEAS-2B cells with the EGFR inhibitor PD153035 and the PI3K inhibitor LY294002 significantly blocked zinc sulfate-induced ICAM-1 expression, CONCLUSION: Zinc sulfate stimulation could activate the EGFR and the PI3K/Akt signaling pathway, further leading to upregulation of ICAM-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 231-234 18341625-3 2008 Also, the phosphorylation of ERK1/2 and Akt was detected by Western blotting, and specific inhibitors of mitogen-activated protein kinase (MAPK) (PD98059; 40 microm) and phosphatidylinositol 3-kinase (PI3-K, LY294002; 40 microm) were used to evaluate the role of these signalling pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 40-43 18395956-10 2008 These pharmacological roles of LY294002 might be played through the PI3K/Akt/mTOR signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 73-76 18586515-5 2008 EPO stimulated the phosphorylation of Akt at serine-473 and co-incubation of the Akt/PI-3 kinase pathway inhibitor LY294002 with EPO abolished its effects on Akt phosphorylation and axonal growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 38-41 18586515-5 2008 EPO stimulated the phosphorylation of Akt at serine-473 and co-incubation of the Akt/PI-3 kinase pathway inhibitor LY294002 with EPO abolished its effects on Akt phosphorylation and axonal growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 81-84 18586515-5 2008 EPO stimulated the phosphorylation of Akt at serine-473 and co-incubation of the Akt/PI-3 kinase pathway inhibitor LY294002 with EPO abolished its effects on Akt phosphorylation and axonal growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 81-84 18670641-4 2008 On the basis of gene expression array studies, we identified Aurora A as one of the genes regulated transcriptionally by Akt inhibitors including Compound A. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, either by PI3K inhibitor LY294002 or by Compound A, dramatically inhibits the promoter activity of Aurora A, whereas the mammalian target of rapamycin inhibitor has little effect, suggesting that Akt might be responsible for up-regulating Aurora A for mitotic progression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 251-259 AKT serine/threonine kinase 1 Homo sapiens 121-124 18670641-4 2008 On the basis of gene expression array studies, we identified Aurora A as one of the genes regulated transcriptionally by Akt inhibitors including Compound A. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, either by PI3K inhibitor LY294002 or by Compound A, dramatically inhibits the promoter activity of Aurora A, whereas the mammalian target of rapamycin inhibitor has little effect, suggesting that Akt might be responsible for up-regulating Aurora A for mitotic progression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 251-259 AKT serine/threonine kinase 1 Homo sapiens 213-216 18670641-4 2008 On the basis of gene expression array studies, we identified Aurora A as one of the genes regulated transcriptionally by Akt inhibitors including Compound A. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, either by PI3K inhibitor LY294002 or by Compound A, dramatically inhibits the promoter activity of Aurora A, whereas the mammalian target of rapamycin inhibitor has little effect, suggesting that Akt might be responsible for up-regulating Aurora A for mitotic progression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 251-259 AKT serine/threonine kinase 1 Homo sapiens 213-216 18690350-14 2008 The inhibitory effect of Adp on TNF-alpha-induced TF synthesis was abrogated in part by pretreatment with the PI3kinase inhibitor LY294002, suggesting that Akt activation might inhibit TF expression induced by TNF-alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 130-138 AKT serine/threonine kinase 1 Homo sapiens 156-159 18632801-8 2008 TNF-alpha also caused PI3-kinase/Akt activation, which was further increased by PDTC and prevented by the PI3-kinase inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 33-36 18632801-10 2008 LY294002 treatment resulted in the appearance of increased apoptosis, compatible with the known anti-apoptotic properties of PI3-kinase/Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 136-139 18599181-14 2008 When resistant cells were treated with LY 294002 (a PI3K inhibitor), the expression level of phosphorylated Akt was distinctly downregulated, and there was induction of apoptosis when these cells were treated with a combination of TRAIL and LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-48 AKT serine/threonine kinase 1 Homo sapiens 108-111 18599181-14 2008 When resistant cells were treated with LY 294002 (a PI3K inhibitor), the expression level of phosphorylated Akt was distinctly downregulated, and there was induction of apoptosis when these cells were treated with a combination of TRAIL and LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 241-250 AKT serine/threonine kinase 1 Homo sapiens 108-111 18483465-6 2008 Furthermore, pretreatment of cells with the PI3-kinase (PI3K)/Akt inhibitor, LY294002, markedly enhanced TNF alpha-induced down-regulation of the ER alpha protein, suggesting that the PI3K/Akt pathway might be involved in control of the ER alpha level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 62-65 18483465-6 2008 Furthermore, pretreatment of cells with the PI3-kinase (PI3K)/Akt inhibitor, LY294002, markedly enhanced TNF alpha-induced down-regulation of the ER alpha protein, suggesting that the PI3K/Akt pathway might be involved in control of the ER alpha level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 189-192 18483465-8 2008 In contrast, the effect of the PI3K/Akt inhibitor on ER alpha was blocked in cells that were treated with LY294002 in the presence of the proteasome inhibitors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 AKT serine/threonine kinase 1 Homo sapiens 36-39 18468786-4 2008 Treatment of C19 with LY294002, which inhibits PI-3 kinase and inhibits AKT, significantly increased apoptosis induction by TNF plus cycloheximide and eliminated phosphorylation of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 72-75 18468786-4 2008 Treatment of C19 with LY294002, which inhibits PI-3 kinase and inhibits AKT, significantly increased apoptosis induction by TNF plus cycloheximide and eliminated phosphorylation of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 181-184 18653476-2 2008 Notably, both are inhibited by wortmannin and LY294002 and signal through phosphatidylinositol-3-kinase (PI3K)-dependent kinases SGK1 and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 138-141 18491231-7 2008 Furthermore, DAP5/p97 expression was upregulated by inhibition of the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway via LY294002 and via rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 75-78 18707587-5 2008 Inhibition of activity of these kinases by treatment of cells with PI-3K/Akt-specific inhibitor LY294002 or Erk-specific inhibitor PD98059 resulted in inhibition of MMP-2 expression and the decrease of invasion in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 73-76 18729215-6 2008 With EGF-induced activation of EGFR, we demonstrated phosphorylation in PI3K/Akt, MEK/ERK, and p38 MAPK pathways; with pathway inhibitors (LY294002, U0126, SB203580) the EGF-mediated decrease in papillae was reversed, and synergistic actions were shown. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 77-80 18574502-6 2008 Pretreatment with LY294002, a phosphoinositide 3-kinase (PI3K)/AKT inhibitor, neutralized the enhanced expression of survivin induced by FSH, but treatment with U0126, a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, had no such effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 63-66 18379876-4 2008 Akt1 activation promoted cell survival, because the phosphatidylinositol 3-kinase(PI3K) inhibitor LY294002 inhibited Akt1 phosphorylation and inhibited cell growth, especially in cells with active Akt1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 0-4 18379876-4 2008 Akt1 activation promoted cell survival, because the phosphatidylinositol 3-kinase(PI3K) inhibitor LY294002 inhibited Akt1 phosphorylation and inhibited cell growth, especially in cells with active Akt1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 117-121 18379876-4 2008 Akt1 activation promoted cell survival, because the phosphatidylinositol 3-kinase(PI3K) inhibitor LY294002 inhibited Akt1 phosphorylation and inhibited cell growth, especially in cells with active Akt1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 117-121 17868340-7 2008 Further decreased Akt activity by LY294002 in detached cells translated to increased cell death after TRAIL treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 18-21 18622747-10 2008 Phosphorylation of Akt, p70S6K and 4E-BP1 were significantly reduced in the cells treated with LY294002 or RAPA (P<0.01), but we failed to find that 5-aza-dC enhance these effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 19-22 18633459-5 2008 Consistently, Akt activation was completely abolished in an SS cell line assay when stimulated by PDGF-AA and treated with the phosphatidylinositol 3-kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 14-17 18332867-5 2008 In mechanistic studies identifying AR degradation, isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was linked with AR degradation as pretreatment with PI3K inhibitor (LY294002)-restored AR level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 220-228 AKT serine/threonine kinase 1 Homo sapiens 100-103 18307411-9 2008 Nedd4 expression was also decreased by a PI3K (phosphoinositide 3-kinase) inhibitor, LY294002, suggesting that the regulation is dependent on the phosphatase-kinase activity of the PTEN-PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 191-194 18498889-9 2008 Selective inhibitors of the ERK (PD98059) and AKT (LY294002) pathways amplified HPC cell damage after HEMA exposure. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 46-49 18058806-2 2008 We investigated the expression of activated Akt (p-Akt) and mTOR (p-mTOR) in patients with adenocarcinoma of the cervix and the involvement of the p-Akt/p-mTOR pathway in response to combination of inhibitor agents, rapamycin and LY294002, with conventional therapy, cisplatin, in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 230-238 AKT serine/threonine kinase 1 Homo sapiens 44-47 18349105-6 2008 We observe here that treatment with LY294002 reduces migration of HRG-stimulated cells but not EGF-stimulated cells, despite comparable levels of reduction of Akt phosphorylation under both conditions, demonstrating that the target inhibition effect is not unilaterally predictive of efficacy against cell phenotypic response. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 159-162 18276798-4 2008 Recombinant Akt dose-dependently increased telomerase activity, and telomerase was inhibited at the transcriptional and post-translational levels by LY294002, suggesting that PI-3K/Akt is one of the key signaling proteins involved in telomerase regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 12-15 18332138-5 2008 Inhibition of PI3K signaling using LY294002 blocked IL-1+OSM-mediated Akt phosphorylation, induction of MMP-1 and MMP-13, and cartilage collagenolysis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 70-73 18375256-9 2008 AKT and eNOS inhibitor, LY294002 and L-NAME, respectively, augmented palmitic and linoleic acids inhibitory effects on EPCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 0-3 18262389-8 2008 Inhibiting Akt activity with the phosphoinositide-3-kinase inhibitor LY294002 or Akt inhibitor X suppressed HGF-induced phosphorylation of GSK-3beta, increased MAP2 phosphorylation, and blocked the ability of HGF to enhance dendritic length. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 11-14 18451140-6 2008 Treatment of FET DNRII cells with a PI3K inhibitor (LY294002) inhibited Akt phosphorylation and reduced survivin expression resulting in increased apoptosis in FET/DNRII cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 72-75 18355352-11 2008 Both extracellular regulated kinase (ERK) inhibitor (PD98059) and protein kinase B (Akt) inhibitor (LY294002) almost completely blocked the inhibitory effect of MIF on apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 100-108 AKT serine/threonine kinase 1 Homo sapiens 84-87 18276798-4 2008 Recombinant Akt dose-dependently increased telomerase activity, and telomerase was inhibited at the transcriptional and post-translational levels by LY294002, suggesting that PI-3K/Akt is one of the key signaling proteins involved in telomerase regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 181-184 18483299-3 2008 We report that inhibition of PI3K/Akt, either by the PI3K inhibitor Ly294002 or by expression of PTEN, synergized the ability of the MDM2 antagonist nutlin-3 to induce apoptosis in acute lymphoblastic leukemia (ALL). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 34-37 18956651-1 2008 OBJECTIVE: To investigate the telomerase activity and to document biological behaviors of HeLa cells upon treatment with specific PI3K/AKT signaling pathway inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 168-176 AKT serine/threonine kinase 1 Homo sapiens 135-138 18956651-8 2008 Western blot showed that LY294002 enabled to decrease P-AKT activity in the presence of same total AKT protein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 56-59 18956651-8 2008 Western blot showed that LY294002 enabled to decrease P-AKT activity in the presence of same total AKT protein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 99-102 18956651-14 2008 CONCLUSION: LY294002 inhibition of PI3K/AKT signaling pathway leads to alteration of telomerase activity along with changes of the biological behaviors of the HeLa cells suggesting that regulation of telomerase activity may be closely related to PI3K/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 40-43 18956651-14 2008 CONCLUSION: LY294002 inhibition of PI3K/AKT signaling pathway leads to alteration of telomerase activity along with changes of the biological behaviors of the HeLa cells suggesting that regulation of telomerase activity may be closely related to PI3K/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 251-254 18182168-5 2008 LPS-stimulated Src, PYK2, EGFR, and Akt phosphorylation and VCAM-1 expression were attenuated by the inhibitors of Src (PP1), EGFR (AG1478), PI3-K (LY294002 and wortmannin), and Akt (SH-5), respectively, or transfection with siRNAs of Src or Akt and shRNA of p110. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 36-39 17992191-11 2008 The prosurvival effect of adenoviral vector carrying the human NGF gene was inhibited in vitro by K252a, LY294002 (a pan-phosphatidyl inositol 3-kinase - PI3K - inhibitor), an Akt small interfering RNA, and adenoviruses carrying a dominant negative mutant form of Akt (Ad.DN.Akt) or an Akt-resistant Foxo-3a (Ad.AAA-Foxo-3a). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 176-179 18409050-7 2008 Pretreatment with phosphatidylinositol 3" kinase (Pl3K) inhibitor LY294002 or eNOS inhibitor NG-nitro-arginine methyl ester (LN or L-NAME) inhibited crocetin effect on p-Akt or eNOS, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 170-173 18164268-7 2008 Ectopic expression of constitutively active Akt (Myc-Akt(Myr)) rendered MCF-7 cells resistant to activation by TGF-beta and the growth inhibitory effects of 4-OHT, while over-expression of kinase-dead Akt (Myc-Akt(K179M)) or LY294002 treatment of Tam-R cells enhanced TGF-beta activation and blocked cell growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 225-233 AKT serine/threonine kinase 1 Homo sapiens 44-47 17721914-9 2008 The levels of phosphorylated Akt (Ser473) were elevated in U937/FN cells and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 suppressed XIAP expression and restored the chemosensitivity to daunorubicin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 29-32 18292946-8 2008 A specific inhibitor for the phosphatidylinositol 3-kinase/AKT pathway, LY294002, inhibited cell growth and AKT and pRB phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 59-62 18292946-8 2008 A specific inhibitor for the phosphatidylinositol 3-kinase/AKT pathway, LY294002, inhibited cell growth and AKT and pRB phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 108-111 17996985-5 2008 Wortmannin (10 nM) and LY 294002 (10 microM) (inhibitors of phosphatidylinositol-3-kinase, PI3-K) reversed the inhibitory effect of memantine on the staurosporine-induced LDH release, suggesting that the PI3-K/Akt prosurvival pathway is a possible target for antiapoptotic action of memantine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-32 AKT serine/threonine kinase 1 Homo sapiens 210-213 18178094-6 2008 LY294002 blocked the increase in phospho-AKT evoked by SC51089 and abolished the associated protective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 41-44 18096819-10 2008 In contrast, the titin switch could be stalled by the phosphatidylinositol 3-kinase inhibitor LY294002, which decreased the proportion of N2B mRNA transcripts within hours and suppressed a rapid T3-induced increase in Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 218-221 18423117-0 2008 [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol]. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 26-29 18423117-3 2008 This study was to investigate the reversal effect of LY294002, a PI-3K/Akt inhibitor, on paclitaxel-resistance of ovarian carcinoma cell line A2780/Taxol. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 71-74 18423117-12 2008 PI-3K/Akt inhibitor, LY294002 has a reversal effect on the paclitaxel-resistance of A2780/Taxol cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 6-9 18005231-6 2008 Inhibition of the PI3K/Akt pathway by LY294002, impeded the short-term effect of H2O2 on nuclear translocation of Nrf2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 23-26 18021765-6 2008 While LY294002, a non-selective phosphotidylinositol 3-kinase (PI3K) inhibitor, was able to reduce brazilin-induced phosphorylation of Akt and the subsequent induction of HO-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 6-14 AKT serine/threonine kinase 1 Homo sapiens 135-138 17971516-10 2008 LY-294002 completely abolished TNF-alpha-induced stimulation of PS as well as phosphorylation of Akt and its downstream targets GSK-3, p70(S6K), and 4E-BP1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-9 AKT serine/threonine kinase 1 Homo sapiens 97-100 18077599-7 2008 In contrast, inhibiting Akt activation by expressing dominant negative (inactive) Akt or using 20 microM LY294002 exacerbated decreases in electron transport rate, state 3 respiration, ATP production, DeltaPsi(m), and activities of complex I, complex III, and F(0)F(1)-ATPase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 24-27 18071906-6 2008 We found that XIAP and Akt were functionally linked in uterine cancer cells, as downregulation of XIAP with RNAi decreased P-Akt levels, and inhibition of PI3-K/Akt activity using LY294002 decreased XIAP content. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 180-188 AKT serine/threonine kinase 1 Homo sapiens 23-26 17992191-11 2008 The prosurvival effect of adenoviral vector carrying the human NGF gene was inhibited in vitro by K252a, LY294002 (a pan-phosphatidyl inositol 3-kinase - PI3K - inhibitor), an Akt small interfering RNA, and adenoviruses carrying a dominant negative mutant form of Akt (Ad.DN.Akt) or an Akt-resistant Foxo-3a (Ad.AAA-Foxo-3a). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 264-267 17992191-11 2008 The prosurvival effect of adenoviral vector carrying the human NGF gene was inhibited in vitro by K252a, LY294002 (a pan-phosphatidyl inositol 3-kinase - PI3K - inhibitor), an Akt small interfering RNA, and adenoviruses carrying a dominant negative mutant form of Akt (Ad.DN.Akt) or an Akt-resistant Foxo-3a (Ad.AAA-Foxo-3a). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 269-278 17992191-11 2008 The prosurvival effect of adenoviral vector carrying the human NGF gene was inhibited in vitro by K252a, LY294002 (a pan-phosphatidyl inositol 3-kinase - PI3K - inhibitor), an Akt small interfering RNA, and adenoviruses carrying a dominant negative mutant form of Akt (Ad.DN.Akt) or an Akt-resistant Foxo-3a (Ad.AAA-Foxo-3a). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 264-267 18314486-7 2008 The phosphorylation of Akt was induced by angiotensin II treatment and inhibited by candesartan, as well as by LY294002, an inhibitor of phosphoinositide 3-kinase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 23-26 17560770-11 2008 The insulin anti-apoptotic effect was prevented by Ly29400, a PI3K/Akt inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-58 AKT serine/threonine kinase 1 Homo sapiens 67-70 18315925-8 2008 Ly294002 and PD98059 blocked the activation of Akt and ERK1/2 respond to BDNF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 47-50 18023419-9 2008 Moreover, Ly 294002, a specific inhibitor of phosphatidylinositol-3-kinase (PI3K)/Akt significantly attenuated the VEGF synthesis stimulated by TGF-beta1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-19 AKT serine/threonine kinase 1 Homo sapiens 82-85 17653089-7 2008 Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta and translocation of beta-catenin/AR into the nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 55-58 17653089-7 2008 Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta and translocation of beta-catenin/AR into the nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 138-141 18769058-7 2008 LY294002, a specific inhibitor of PI-3K, significantly inhibited Akt phosphorylation and completely abrogated HAPO-stimulated proliferation of HUVECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 65-68 18093179-6 2008 Phosphorylation of p44- and p42 MAPK was blocked by the MEK inhibitor PD98058, while Akt phosphorylation was abolished by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 85-88 17579344-7 2008 Under low serum culture conditions, an early (within 1 h) and transient increase in CREB phosphorylation was detected in response to both TRAIL doses and reduced upon pre-treatment with LY294002 or SB253580, demonstrating the PI3-K/Akt- and p38 MAPK-dependency of this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-194 AKT serine/threonine kinase 1 Homo sapiens 232-235 17908985-15 2007 An additional feature of Us3 mutants is enhanced Akt activation compared with wild-type infection, which sensitizes cells to phosphatidylinositol 3-kinase-Akt inhibitors (LY294002, Akt inhibitor IV), shown by synergistic antitumoral activity in vitro and enhanced efficacy in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 171-179 AKT serine/threonine kinase 1 Homo sapiens 49-52 17961125-2 2008 PIF induced transient phosphorylation of Akt at Ser(473) within 30 min, which was attenuated by the PI3K (phosphoinositide 3-kinase) inhibitor LY294002 and the tyrosine kinase inhibitor genistein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 41-44 18289643-11 2008 The involvement of the PI3 kinase/Akt pathway in neutrophil superoxide production was revealed by using LY294002 in isolated neutrophils/platelets experiments, as well as during whole blood aggregation-mediated neutrophil-platelet conjugation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 34-37 17936321-10 2008 LY294002 (an inhibitor of Akt) significantly decreased cell viability and increased the proportion of cells with sub-G1 phase DNA content. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 26-29 18182859-10 2007 The phosphorylation of Raf and Akt proteins induced by 0.05 Gy of ionizing radiation was abolished by pre-treatment with an EGFR inhibitor, AG1478, or a PI3k inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 31-34 17950696-4 2007 Furthermore, we showed that migration toward SDF-1 was reduced by inactivation of either serine/threonine kinase Akt or extracellular signal regulated kinase Erk, which was confirmed by selective pathway inhibitor LY294002 and PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 214-222 AKT serine/threonine kinase 1 Homo sapiens 113-116 17616812-6 2007 Pretreatment of U87MG cells with the PI3K inhibitor LY294002 could prevent Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 75-78 17634901-8 2007 Chemical inhibition of PI3K-Akt by LY294002/wortmannin did not affect EGF-mediated NF-kappaB p65 nuclear translocation; and NF-kappaB inhibition by Bay 11-7082 did not suppress Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 28-31 18201823-7 2008 Akt was phosphorylated 60 min after caffeine administration in a dose dependent manner; PI3K inhibitors, wortmannin and LY294002 canceled this cytoprotective effect of caffeine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 0-3 17638919-4 2007 Transient transfection of Id-1 into HEK293 cells confirmed activation of PI3K/Akt/NFkappaB signaling and the effects were counteracted by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 157-165 AKT serine/threonine kinase 1 Homo sapiens 78-81 17912441-3 2007 We found that two PI 3-K inhibitors, wortmannin and LY294002, markedly suppressed the phosphorylation of Akt in OSCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 105-108 17585340-3 2007 We recently demonstrated that the phosphatidylinositide-3-kinase (PI3K) inhibitor, LY294002, and its inactive analog LY303511, sensitized tumor cells to vincristine-induced apoptosis, independent of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-91 AKT serine/threonine kinase 1 Homo sapiens 204-207 17599831-8 2007 Experiments using the AKT phosphorylation inhibitor LY294002 indicate that AKT phosphorylation downregulates cofilin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 22-25 17599831-8 2007 Experiments using the AKT phosphorylation inhibitor LY294002 indicate that AKT phosphorylation downregulates cofilin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 75-78 17599831-10 2007 LY294002 also stabilized Lyn from phosphorylated AKT, suggesting an interaction between Lyn and AKT phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 49-52 17599831-10 2007 LY294002 also stabilized Lyn from phosphorylated AKT, suggesting an interaction between Lyn and AKT phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 96-99 17786300-9 2007 A dominant negative AKT or the phosphatidylinositol 3-kinase inhibitor, LY294002, also strongly inhibited survivin promoter activity, providing further evidence to support the hypothesis that the inhibitory effect of EGCG on survivin is mediated via the AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 254-257 17372934-9 2007 Basal Akt activation was inhibited 90% by LY294002 and 70% by Akt inhibitor IV. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 6-9 17646428-7 2007 In addition, a phosphoinositide 3-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], a specific AKT inhibitor, and 0.2 to 20 microM CA4 displayed a similar response profile on p-AKT-positive cells, suggesting that CA4-induced effect was mediated by inhibition of the PI3 kinase/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 139-142 17646428-7 2007 In addition, a phosphoinositide 3-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], a specific AKT inhibitor, and 0.2 to 20 microM CA4 displayed a similar response profile on p-AKT-positive cells, suggesting that CA4-induced effect was mediated by inhibition of the PI3 kinase/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 219-224 17646428-7 2007 In addition, a phosphoinositide 3-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], a specific AKT inhibitor, and 0.2 to 20 microM CA4 displayed a similar response profile on p-AKT-positive cells, suggesting that CA4-induced effect was mediated by inhibition of the PI3 kinase/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 221-224 17804301-9 2007 Cell viability was increased by Ang II 10(-6) M and decreased by Ang II 10(-4) M. It was further decreased by pre-treatment with PI-3K/Akt inhibitor LY294002, but unaffected by p38-MAPK inhibitor SB202190. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 135-138 18194602-5 2007 LY294002, a specific inhibitor of PI-3K, effectively blocked Akt phosphorylation induced by AMP-PNP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 61-64 17310986-6 2007 Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF)(-/-) and CD74(-/-)(MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 198-201 17890906-5 2007 Our results show that direct inhibition of PI3K/Akt in G(2)-arrested cells by wortmannin or LY294002 strongly enhanced the cytotoxicity of cisplatin without influencing the G(2) checkpoint. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 48-51 17420722-9 2007 The role of the Akt pathway in the regulation of resistance was corroborated by the use of the Akt inhibitor, LY294002, and by transfection with siRNA Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 16-19 17566113-7 2007 LA"s antiapoptotic activity was reduced by PI 3-kinase inhibitors (wortmannin, LY-294002), being in line with LA-induced Akt phosphorylation (Ser(437), +159 +/- 43%; Thr(308), +98 +/- 25%; P < 0.01). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-88 AKT serine/threonine kinase 1 Homo sapiens 121-124 17582000-6 2007 Furthermore, the Ras inhibitors manumycin A and a dominant-negative form of Ras (RasN17) and the PI3-K inhibitor LY294002 blocked LMP2A-mediated Akt phosphorylation and anchorage-independent cell growth in HSC-39 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 145-148 17666799-12 2007 ABE also triggered the downregulation of Akt, and combined treatment with LY294002 (an inhibitor of Akt) significantly decreased cell viability. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 100-103 17376651-4 2007 Phosphatidylinositol kinase (PI3K) inhibitors, Wortmannin and LY294002 and Akt inhibitor (NL-71-101) significantly inhibited TGF-beta-induced Akt phosphorylation, TIMP-3 expression, TIMP-3 promoter (-940 to +376)-driven luciferase activity and Sp1 transcription factor binding. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 142-145 17388918-4 2007 METHODS: Using a panel of pharmacological inhibitors (BAY 43-9006, PD98059, U0126, wortmannin, LY294002) we inhibited the MAPK and AKT signalling pathways at different levels and evaluated the effects on growth, survival and invasion of melanoma cells in monolayer and organotypic skin culture. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 131-134 17372272-8 2007 Additionally, we describe that the phosphorylation of AKT and eIF4G, as well as the elevation of the Mst1 and RanBP2 protein levels, can be inhibited in vivo in transgenic animals by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 202-210 AKT serine/threonine kinase 1 Homo sapiens 54-57 17581202-14 2007 LTB(4) induced phosphorylation of ERK and Akt, downstream kinase of PI3K; LY294002 suppressed phosphorylation of both kinases while U0126 suppressed only the former. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 42-45 17922342-8 2007 Inhibition of PKA by H-89 did not affect CSB-induced phosphorylation, whereas the PKB inhibitor LY-294002 enhanced it at Ser(1117). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-105 AKT serine/threonine kinase 1 Homo sapiens 82-85 17722999-3 2007 In this study, we tested the hypothesis that the combined inhibition of integrin alphanubeta3 by cRGD and PI3K/Akt by LY294002 would significantly enhance radiation-induced inhibition of angiogenesis by vascular endothelial cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 111-114 17722999-7 2007 Treatment with LY294002 effectively inhibited radiation- and cRGD-induced Akt phosphorylation and up-regulation of COX2 and increased apoptosis of HUVECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 74-77 17539658-8 2007 EGCG also decreased the phosphorylation of Akt and extracellular signal-regulated kinase 1/2 that were demonstrated as selected downstream HRG-beta1-responsive kinases required for FAS expression using dominant-negative Akt, PI3K inhibitors (LY294002 and wortmannin), or MEK inhibitor (PD98059). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 242-250 AKT serine/threonine kinase 1 Homo sapiens 43-46 17559672-10 2007 Inhibition of Akt phosphorylation with LY294002 increased apoptosis and blocked the effects of acid and leptin both alone and in combination. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 14-17 17434462-4 2007 ER stress-induced Akt activation was mediated through phosphatidylinositol 3-kinase (PI3K) because the PI3K inhibitors, LY294002 and wortmannin, inhibited Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 18-21 17434462-4 2007 ER stress-induced Akt activation was mediated through phosphatidylinositol 3-kinase (PI3K) because the PI3K inhibitors, LY294002 and wortmannin, inhibited Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 155-158 17638539-6 2007 In this paper, optimization of the Meso Scale Discovery (MSD) (Gaithersburg, MD) platform to quantify changes in phospho-AKT and phospho-glycogen synthase kinase-3beta in response to a PI3-kinase inhibitor, LY294002, is described, initially in vitro and then within xenografted solid tumors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 207-215 AKT serine/threonine kinase 1 Homo sapiens 121-124 17303382-12 2007 In contrast, LY294002 was able to inhibit Akt activation, but had very little effect on ERK1/2 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 42-45 17545550-10 2007 Pemetrexed induced an epidermal growth factor receptor-mediated activation of the phosphatidylinositol 3-kinase/AKT pathway, which was inhibited by erlotinib and a specific phosphatidylinositol 3-kinase inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 214-222 AKT serine/threonine kinase 1 Homo sapiens 112-115 17341418-11 2007 LY294002, a phosphoinositide-3 kinase (PI3K)/AKT inhibitor, and Trolox, an antioxidant, suppressed indomethacin-induced cytotoxicity and caspase activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 45-48 17317726-7 2007 PI3K inhibitor (LY294002) prevented pressure-stimulated Akt Ser473 and FAK Tyr397, but not FAK576 or Src416 phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 56-59 17371807-6 2007 The stimulation of Akt phosphorylation was inhibited in a concentration-dependent manner by the PI3K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-160 AKT serine/threonine kinase 1 Homo sapiens 19-22 17371807-6 2007 The stimulation of Akt phosphorylation was inhibited in a concentration-dependent manner by the PI3K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 19-22 17939398-5 2007 Phosphorylation of AKT was inhibited by LY294002 and then examined by Western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 19-22 18404453-10 2007 The protection by guanosine was also abolished by the selective inhibitor of the enzyme PI-3-K/Akt/PKB (LY294002), confirming that this pathway plays a decisive role in this effect of guanosine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 99-102 17314215-11 2007 TNF-alpha-induced production of IL-1beta, IL-6 and IL-8 was hampered by treatment with the phosphatidylinositol 3 (PI3) kinase inhibitor LY294002, suggesting that inhibition of Akt activation might inhibit IL-1beta, IL-6 and IL-8 production induced by TNF-alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 177-180 17594810-10 2007 In addition, 100 and 200 micromol/L DHEA treatments for 24 hours markedly inhibited phosphorylations of Akt (Thr308 and Ser473) in HepG2 cells, and these effects were enhanced by exposing them to LY294002 and stopped by exposing them to HGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 196-204 AKT serine/threonine kinase 1 Homo sapiens 104-107 17939398-9 2007 Furthermore treatment with PI3K/AKT inhibitor LY294002 also resulted in decrease of TF expression in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 32-35 17183064-7 2007 Inhibitors of ERK (PD98059) or Akt (LY294002), but not p38 MAPK, resulted in significantly decreased cell viability. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 31-34 17390018-3 2007 The PI 3-K inhibitors wortmannin and LY294002 markedly suppressed phosphorylation of Akt and accelerated TRAIL-mediated apoptosis in OSCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 85-88 17007924-0 2007 Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 32-35 17186497-7 2007 The PI 3 kinase inhibitor Ly294002 and expression of tumor suppressor protein PTEN inhibited Akt kinase activity, resulting in the attenuation of FoxO1 phosphorylation and preventing the downregulating effect of H(2)O(2) on catalase protein level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 93-96 17007924-4 2007 Blockade of Akt signaling by the PI3K inhibitor LY294002 (1-20 microM, 48 h) also resulted in the growth inhibition and G0/G1 cell cycle arrest of HTLV-1-infected cells, with IC50 ranging from 5 to 20muM, and it caused de-phosphorylation of p70S6K and 4E-BP-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 12-15 17307160-4 2007 Treatment of A549 cells with LY 294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, a PI3K inhibitor), an Akt inhibitor, and the dominant negative mutant of Akt (Akt DN) inhibited TGF-beta1-induced HO-1 expression and HO-1-luciferase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-38 AKT serine/threonine kinase 1 Homo sapiens 112-115 17464197-5 2007 In addition, hydroquinone and inhibitors (wortmannin and LY294002) of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway had very similar inhibitory effects on LPS-induced and CD29-mediated macrophage responses, including the phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 111-114 17464197-5 2007 In addition, hydroquinone and inhibitors (wortmannin and LY294002) of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway had very similar inhibitory effects on LPS-induced and CD29-mediated macrophage responses, including the phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 247-250 17349623-6 2007 Pretreatment with phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 completely blocked GRP-initiated Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 107-110 17307160-8 2007 The TGF-beta1-mediated increases in IKKalpha/beta phosphorylation, p65 Ser536 phosphorylation, and kappaB-luciferase activity were inhibited by LY 294002, an Akt inhibitor, and Akt DN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-153 AKT serine/threonine kinase 1 Homo sapiens 158-161 17307160-8 2007 The TGF-beta1-mediated increases in IKKalpha/beta phosphorylation, p65 Ser536 phosphorylation, and kappaB-luciferase activity were inhibited by LY 294002, an Akt inhibitor, and Akt DN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-153 AKT serine/threonine kinase 1 Homo sapiens 177-180 17209135-7 2007 Inhibition of phosphatidylinositol 3-kinase and Akt phosphorylation by LY-294002 abolished TGF-beta-induced increases in elastin hnRNA and mRNA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-80 AKT serine/threonine kinase 1 Homo sapiens 48-51 17332930-9 2007 Downregulation of AKT by inhibitors of PI3K (Wortmannin and LY294002) and AKT, or by dominant negative AKT increased curcumin-induced apoptosis, whereas transfection of constitutively active AKT attenuated this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 18-21 17342093-7 2007 Inhibition of phosphoinositidyl-3 (PI3-K)/Akt pathway with either the small molecule inhibitor LY294002 or dominant-negative Akt resulted in reversal of anoikis resistance induced by HMGA1 overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 42-45 17360480-7 2007 Lipoic acid-dependent Akt phosphorylation and inhibition of NF-kappaB activity were abolished by the PI3K inhibitors LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 22-25 17158602-6 2007 Furthermore, LY294002 or wortmannin inhibited Akt phosphorylation but had no effect on NF-kappaB translocation, which was blocked by helenalin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 46-49 17158602-9 2007 The results showed that LY294002 and curcumin blocked Akt translocation into nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 54-57 17196679-6 2007 Similar simultaneous treatment with PI-3 kinase inhibitor LY294002 prominently blocked Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 87-90 17379415-8 2007 LY294002, a PI3K inhibitor, also abrogated BBS-stimulated phospho-Akt as well as its cell cycle targets. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 66-69 17307160-5 2007 Stimulation of cells with TGF-beta1 caused an increase in Akt phosphorylation in a time-dependent manner, which was inhibited by wortmannin and LY 294002 (PI3K inhibitors). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-153 AKT serine/threonine kinase 1 Homo sapiens 58-61 17325368-5 2007 The PI3K-specific inhibitor LY294002 could suppress Akt phosphorylation, suggesting that influenza A virus-induced Akt phosphorylation is PI3K-dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 52-55 17325368-5 2007 The PI3K-specific inhibitor LY294002 could suppress Akt phosphorylation, suggesting that influenza A virus-induced Akt phosphorylation is PI3K-dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 115-118 17325368-7 2007 Blockage of PI3K/Akt activation by LY294002 and overexpression of the general receptor for phosphoinositides-1 PH domain (Grp1-PH) led to a reduction in virus yield. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 17-20 17348861-6 2007 LY294002, Wortmannin and PP2 also blocked Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 42-45 17187756-3 2007 In this report, we suggest phosphatidylinositol 3-OH kinase (PI3K)/Akt signaling is also necessary for TGF-beta-induced EMT in lens epithelial cells by showing that LY294002, an inhibitor of the p110 catalytic subunit of PI3K, blocked the expression of alpha-smooth muscle actin (alpha-SMA) and morphological changes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 165-173 AKT serine/threonine kinase 1 Homo sapiens 67-70 17363506-3 2007 Although specific blockade of the PI3K-Akt pathway alone with inhibitors such as LY294002 did not induce cell death, it resulted in marked and selective enhancement of the induction of apoptosis by microtubule-destabilizing agents such as vincristine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 39-42 17046344-7 2007 The pretreatment of MG-63 cells with either one of inhibitors for phosphoinositide 3-kinase (PI3K), wortmannin or LY294002 prevented Akt and Bad phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 133-136 17222412-3 2007 PI3K inhibitors, LY294002 and wortmannin, inhibited the activation of Akt and ERK following the treatment with PS-liposomes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 AKT serine/threonine kinase 1 Homo sapiens 70-73 17070899-5 2007 The PI3K/Akt pathway was further examined using pharmacological inhibitors (LY294002 and wortmannin), Akt siRNA, constitutively active Akt adenovirus and treatment with IGF-1/insulin in the SKOV-3 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 9-12 17070899-9 2007 Furthermore, IGF-1 and insulin stimulated SKOV-3 migration by altering the balance between uPA and PAI-1 to favor uPA, and the enhanced migration was attenuated by treatment with LY294002 indicating PI3K/Akt in this pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-187 AKT serine/threonine kinase 1 Homo sapiens 204-207 17234779-4 2007 Blockade of PI3K or ILK signaling with pharmacologic inhibitors LY294002 or QLT0267 specifically inhibited stroma-induced phosphorylation of Akt and glycogen synthase kinase 3beta, suppressed STAT3 and ERK1/2 activation, and decreased Notch1 and Hes1 expression in leukemic cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 141-144 17141276-7 2007 The high glucose-induced downregulation of GLUT-1 was blocked by Wortmanin, LY 294002 (PI-3 kinase inhibitors) and Akt (Akt inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-85 AKT serine/threonine kinase 1 Homo sapiens 87-118 17234779-6 2007 In turn, leukemic cells growing in direct contact with bone marrow stromal elements induce activation of Akt, ERK1/2, and STAT3 signaling in MSC, accompanied by significant increase in Hes1 and Bcl-2 proteins, which were all suppressed by QLT0267 and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 251-259 AKT serine/threonine kinase 1 Homo sapiens 105-108 17234785-7 2007 Parallel experiments in neuroblastoma cell lines revealed that activation of Akt by insulin-like growth factor (IGF)-I significantly inhibited tumor necrosis factor-related apoptosis-inducing ligand- or chemotherapy-induced apoptosis in a PI3K-dependent manner because the PI3K inhibitor LY294002 completely reversed the IGF-I-mediated protection of neuroblastoma cells from apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 288-296 AKT serine/threonine kinase 1 Homo sapiens 77-80 17125737-3 2007 LY294002 inhibits the angiogenin-induced protein kinase B/Akt activation and also angiogenin-induced cell migration in vitro as well as angiogenesis in chick embryo chorioallantoic membrane in vivo without affecting nuclear translocation of angiogenin in HUVE cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 58-61 16940564-7 2007 Blocking Akt activation using a phosphatidylinositol 3-kinase inhibitor, LY294002 (20 muM), or expressing dominant negative (inactive) Akt increased DCVC-induced RPTC necrosis to 42%. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 73-81 AKT serine/threonine kinase 1 Homo sapiens 9-12 17404021-12 2007 Furthermore, inhibition of Akt by specific phosphatidyinositol-3-kinase (PI3K)-Akt inhibitors (Wortmannin, and LY294002) synergistically increased the efficacy of the paclitaxel-induced apoptosis in both cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 27-30 17404021-12 2007 Furthermore, inhibition of Akt by specific phosphatidyinositol-3-kinase (PI3K)-Akt inhibitors (Wortmannin, and LY294002) synergistically increased the efficacy of the paclitaxel-induced apoptosis in both cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 79-82 17136496-8 2007 The inhibition of PI-3-kinase-Akt pathway by LY-294002 or wortmannin significantly decreased the protective effect of the Hsp16.2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-54 AKT serine/threonine kinase 1 Homo sapiens 30-33 17015027-11 2007 Akt was also phosphorylated in NSCLC cells after exposure to nicotine; this effect was inhibited by the PI3K inhibitor LY294002 and antagonists to the neuronal-type nAChR, but not to the muscle-type receptor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 0-3 16842970-7 2007 In the PTEN-positive prostate-derived cell lines PNT2, PNT1a and P4E6, PI3K inhibition by LY294002 caused rapid dephosphorylation of PKB at ser473 (T(1/2)<2 min), leading to its inactivation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 133-136 16842970-11 2007 SiRNA-mediated knockdown of SHIP2 expression markedly slowed PKB inactivation in response to LY294002 in PC3 but not in other SHIP2-positive cells, whereas knockdown of PTEN expression in PNT2, PNT1a and P4E6 resulted in higher steady-state levels of PKB phosphorylation and slowed, but did not prevent, LY294002-induced PKB inactivation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 61-64 17055484-11 2007 HGF also activated AKT, while inhibition of AKT by LY294002 induced a modest decrease of HGF-induced HBMEC migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 44-47 17492691-9 2007 Furthermore, NMDA receptor-mediated Akt activation was reversed by combined treatment with LY294002, the specific blockade of PI-3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 36-39 17143555-9 2007 SB203580 and SP600125 (p38 and JNK inhibitors) reduced diosgenin-induced DNA fragmentation whereas U0126 and LY294002 (MEK and PI3 kinase/Akt inhibitors) caused an amplification of proapoptotic effect of diosgenin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 138-141 17237271-7 2007 The interleukin 6-stimulated activation of STAT3 and Akt was inhibited not only by atiprimod but also by LY294002, a phosphoinositide-3-kinase-specific inhibitor, and by NS398, a cyclooxygenase-2-selective inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 53-56 17259349-8 2007 Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway was found to regulate PDCD4 expression because inhibition of PI3K by LY294002 and wortmannin or of mTOR by rapamycin induced PDCD4 protein and mRNA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 165-173 AKT serine/threonine kinase 1 Homo sapiens 37-40 17068339-6 2006 We found that insulin-induced ERK1/2 and Akt kinase activities were completely abolished 10 min after inhibition of the corresponding upstream kinases with PD98059 and LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 168-176 AKT serine/threonine kinase 1 Homo sapiens 41-44 17071610-7 2006 CEACAM1 binding triggered a phosphatidylinositol 3-kinase-dependent activation of the protein kinase Akt without influencing the activity of extracellular signal-related kinase ERK, whereas the phosphatidylinositol 3-kinase-specific inhibitor LY294002 effectively blocked the protective effect of CEACAM1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 243-251 AKT serine/threonine kinase 1 Homo sapiens 101-104 17178855-8 2006 The role of phosphatidylinositol-3 kinase (PI3K)/Akt in mediating HMGA1-dependent invasiveness was elucidated by a specific PI3K inhibitor (LY294002) and constitutively active and dominant-negative Akt adenoviral constructs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 49-52 17113582-2 2006 We showed that TRAIL-induced apoptosis may be differentially regulated by inhibitors of MEK ERK (U0126) or PI3K/Akt (LY294002) pathway in TRAIL-sensitive (HT-29) and TRAIL-resistant (SW620) human epithelial colon cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 112-115 17052670-9 2006 PD98059 (an inhibitor of ERK) or LY294002 (an inhibitor of Akt), but not an inhibitor of p38 MAPK and JNK, significantly decreased cell viability and increased lactate dehydrogenase (LDH) release. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 59-62 16884765-6 2006 High concentrations of SDF-1alpha activated Akt and ERK1/2 pathways in both cell lines in a dose-dependent manner, which was primarily inhibited by LY294002 for pAkt and by PD98059 for pERK 1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 44-47 16940331-3 2006 Freshly isolated cells present basal Akt phosphorylation, which is PI-3K-dependent, as incubation with the PI-3K inhibitor LY294002 decreased Ser-473 and Thr-308 phosphorylation in most samples analyzed (seven out of 10). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 123-131 AKT serine/threonine kinase 1 Homo sapiens 37-40 17188151-5 2006 RESULTS: Treatment of TT cells with LY294002 significantly suppressed levels of phospho-Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 88-91 16732316-8 2006 Furthermore, phosphatidylinositol 3-kinase (PI3K)/Akt chemical inhibitors LY294002 and wortmannin suppressed radiation-induced MMP-9 mRNA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 50-53 16790501-9 2006 The PI3K inhibitor LY-294002, and Akt small interfering RNA inhibited Akt activation and Hsp70 expression in HEMEC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-28 AKT serine/threonine kinase 1 Homo sapiens 70-73 16563718-7 2006 Furthermore, inhibition of ERK activity by PD98059 and PI3K/Akt activity by LY294002 or wortmannin significantly reduced the LA-induced activation of nuclear factor kappa B (NF-kappaB). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 60-63 16782756-9 2006 Inhibition of phosphatidylinositol 3-kinase (PI3K) activation by LY294002 in mtALDH-A549 cells significantly increased necrotic cell death after hyperoxic exposure, indicating that PI3K-Akt activation by mtALDH played an important role in cell survival after hyperoxia. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 186-189 16973122-3 2006 Cu2+- and Zn2+-induced phosphorylation of Akt was blocked by phosphoinositide 3-kinase (PI3K) inhibitors, wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 121-129 AKT serine/threonine kinase 1 Homo sapiens 42-45 17018612-7 2006 Treatment of CD9(-) parent cells with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, inhibited process outgrowth and survival, suggesting that PI3K/Akt signaling is required for the morphologic change and cell survival. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 161-164 16984382-5 2006 Downregulation of constitutively active Akt by PI3K inhibitors, wortmannin and LY294002, reversed cellular resistance to TRAIL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 40-43 16916320-7 2006 Interestingly, when phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling was blocked simultaneously by either LY294002 or rapamycin, growth inhibition mediated by SU11248 was potentiated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 50-53 17003457-2 2006 METHODS: Cultured human RPE cells were pretreated with medium alone, with LY294002 (LY), an inhibitor of phosphatidylinositol-3 kinase (PI3K) and its downstream effector Akt, or with Akt/protein kinase B signaling inhibitor (API)-2, a specific Akt inhibitor, and then were stimulated with H2O2 at different doses for various times. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 170-173 16865270-7 2006 Phosphorylation of Akt was inhibited by CoCl(2) treatment and LY294002 treatment inhibited HIF-1alpha expression in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 19-22 16598748-7 2006 LY294002, a PI3-kinase inhibitor, blocked the TGF-beta-induced amino acid uptake only partially, but completely blocked TGF-beta-induced Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 137-140 16598748-8 2006 Moreover, the level of phospho-Smad3 was found to be high even when LY294002 blocked TGF-beta-induced phospho-Akt levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 110-113 16732486-6 2006 Akt phosphorylation and cell growth were inhibited by PI3-K specific inhibitor LY294002 in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 0-3 16740979-7 2006 Neither SB203580 nor LY294002 changed the E2-increased levels of resistin mRNA, but they respectively inhibited E2-stimulated phosphorylation of p38 MAPK and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 158-161 16798746-6 2006 Raloxifene also induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase inhibitor, LY294002, significantly attenuated the raloxifene-induced telomerase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 47-50 16870179-5 2006 CpG ODN induced the phosphorylation of Akt, and the inhibition of Akt by LY294002 suppressed CpG ODN-induced TNF-alpha, TNFR-II, and MMP-9 expressions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 73-81 AKT serine/threonine kinase 1 Homo sapiens 66-69 16882030-6 2006 Conversely, the PI3-kinase inhibitor, LY294002, enhanced gonococcal invasion of, and Akt activity within, primary cervical cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 85-88 16845323-10 2006 Epo increased Akt kinase activity, which was abrogated by co-treatment with LY294002, a specific blocker of phosphoinositide 3-kinase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 14-17 16728278-13 2006 IGF-I phosphorylated Akt and upregulated cyclin D1 in the CD56(+) KMS-21-BM cells, which was completely blocked by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 21-24 16709838-5 2006 Treatment of the cells with pharmacological inhibitors of PI3K, wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-1 (LY294002), similarly inhibits FasL-induced apoptosis and Akt/PKB phosphorylation, indicating that PI3K is an upstream mediator of Akt/PKB and is involved in Fas-mediated cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 184-191 16709838-5 2006 Treatment of the cells with pharmacological inhibitors of PI3K, wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-1 (LY294002), similarly inhibits FasL-induced apoptosis and Akt/PKB phosphorylation, indicating that PI3K is an upstream mediator of Akt/PKB and is involved in Fas-mediated cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 257-264 16527514-3 2006 We found that both PI 3-K inhibitors, wortmannin and LY294002, markedly suppressed the phosphorylation of Akt and accelerated Fas-mediated apoptosis in OSCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 106-109 16764985-6 2006 LY294002, a PI3K-inhibitor, blocked SST-induced p-Akt-Ser473 and partially p-eNOS-Ser617, however, it did not reverse SST-induced NHE attenuation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 50-53 16819163-5 2006 LY294002, a phosphatidylinositol 3-kinase inhibitor that inhibits FBS-stimulated Akt phosphorylation, restored the sensitivity of HepG(2) cells to cAMP and API-2 (Akt/protein kinase B signaling inhibitor-2) also showed similar effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 81-84 16819163-5 2006 LY294002, a phosphatidylinositol 3-kinase inhibitor that inhibits FBS-stimulated Akt phosphorylation, restored the sensitivity of HepG(2) cells to cAMP and API-2 (Akt/protein kinase B signaling inhibitor-2) also showed similar effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 163-166 16773206-6 2006 In addition, both the heat-induced phosphorylation of Akt and the accumulation of survivin were suppressed by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 54-57 16773206-7 2006 These results suggest that LY294002 inhibits anti-apoptosis signaling through hsp27 and hsp72 as well as cell survival signaling through Akt and survivin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 137-140 16624972-5 2006 2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002), a specific inhibitor of PI3-kinase, produced a further decrease of phosphorylated AKT in AA+Fe-treated E47 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 158-161 16707436-9 2006 Exposure to LY294002 or wortmannin decreased Akt activation and GSK-3 phosphorylation and reduced cell growth by up to 70% through induction of cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 45-48 16723520-9 2006 The gas6 protective effect was abrogated by the Axl decoy receptor Axl-Fc, by the phosphatidylinositol 3 (PI3) kinase inhibitor LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one], and in Akt1(-/-) oligodendrocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 197-201 16563531-9 2006 Furthermore, LY294002 (PI3 kinase inhibitor) blocked the activation of Akt by apelin and abolished the apelin-induced cell proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 71-74 16650001-9 2006 The PI3K inhibitor, LY294002, blocked cartducin-stimulated Akt phosphorylation and a decrease in cartducin-induced DNA synthesis in N1511 cells was also observed. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 59-62 16525641-7 2006 Treatment with either ZD1839 or LY294002 (the latter, a PI3K inhibitor) suppressed phosphorylation of AKT by Western blot. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 102-105 16380156-12 2006 LY294002 treatment resulted in dose-dependent inhibition of Akt activation and cellular proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 60-63 16731745-3 2006 Similarly, these same metastatic melanoma lines were also resistant to inhibitors of the phosphatidylinositol 3-kinase/Akt pathway (LY294002 and wortmannin). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 119-122 16478297-6 2006 Specific inhibitors of PI3K, wortmannin and LY294002, completely blocked Akt activation and UV-induced TSP1 downregulation in keratinocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 73-76 16490785-5 2006 Treatment of cells with LY294002, an inhibitor of the PI3K-Akt pathway, completely blocked CS-induced FRA-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 59-62 16722795-7 2006 EGF-induced MMP-2 activity was significantly inhibited by treatment of PD153035, U0126, and LY294002, but not SB203580 and JNK inhibitor, suggesting that ERK and the phosphatidylinositol-3-kinase (PI3K)/AKT pathways selectively mediate EGF-stimulated MMP-2 activity and cell migration in cultured HLECs in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 203-206 16567092-4 2006 Inhibitory role of LY294002 on activation of Akt induced by E2 and its estrogen antagonist, ICI182780 were also tested. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 45-48 16567092-8 2006 PI3K inhibitor, LY294002, stopped the activating Akt in a dose-dependent manner and 50 microM LY294002 completely blocked the activation of Akt induced by E2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 49-52 16567092-8 2006 PI3K inhibitor, LY294002, stopped the activating Akt in a dose-dependent manner and 50 microM LY294002 completely blocked the activation of Akt induced by E2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 140-143 16567092-8 2006 PI3K inhibitor, LY294002, stopped the activating Akt in a dose-dependent manner and 50 microM LY294002 completely blocked the activation of Akt induced by E2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 49-52 16567092-8 2006 PI3K inhibitor, LY294002, stopped the activating Akt in a dose-dependent manner and 50 microM LY294002 completely blocked the activation of Akt induced by E2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 140-143 16619474-1 2006 BACKGROUND: This study aimed to evaluate the impact of selective abrogation of either the MEK/ERK1/2 (UO126 or PD98059) or the PI3K/AKT (LY294002) signaling cascade on cell proliferation, motility and invasion and production of VEGF (collectively termed pro-metastasis phenotypes) in cultured malignant pleural mesothelioma (MPM) cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 132-135 16354768-8 2006 In addition, JAK2 inhibitor suppressed PA-induced Akt phosphorylation, and the Akt inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) blocked GAS activation (GAS contains a promoter that responds to PA), suggesting that PA-mediated JAK2 activation leads to phosphatidylinositol 3-kinase/Akt phosphorylation and STAT activation, and the subsequent translocation of STAT to the nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-141 AKT serine/threonine kinase 1 Homo sapiens 79-82 16354768-8 2006 In addition, JAK2 inhibitor suppressed PA-induced Akt phosphorylation, and the Akt inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) blocked GAS activation (GAS contains a promoter that responds to PA), suggesting that PA-mediated JAK2 activation leads to phosphatidylinositol 3-kinase/Akt phosphorylation and STAT activation, and the subsequent translocation of STAT to the nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-141 AKT serine/threonine kinase 1 Homo sapiens 79-82 16354768-8 2006 In addition, JAK2 inhibitor suppressed PA-induced Akt phosphorylation, and the Akt inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) blocked GAS activation (GAS contains a promoter that responds to PA), suggesting that PA-mediated JAK2 activation leads to phosphatidylinositol 3-kinase/Akt phosphorylation and STAT activation, and the subsequent translocation of STAT to the nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 79-82 16354768-8 2006 In addition, JAK2 inhibitor suppressed PA-induced Akt phosphorylation, and the Akt inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) blocked GAS activation (GAS contains a promoter that responds to PA), suggesting that PA-mediated JAK2 activation leads to phosphatidylinositol 3-kinase/Akt phosphorylation and STAT activation, and the subsequent translocation of STAT to the nucleus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 79-82 16546963-8 2006 Treatment of cells with cerulenin and LY294002 down-regulated the protein levels of X chromosome-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 (cIAP-1), and Akt, whereas the levels of mitogen-activated protein/extracellular signal-regulated kinase kinase and other antiapoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xl) did not change. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 183-186 16546963-9 2006 Interestingly, the nonspecific caspase inhibitor, z-VAD-FMK, inhibited the down-regulation of Akt, XIAP, and cIAP-1 in cerulenin- and LY294002-treated cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 134-142 AKT serine/threonine kinase 1 Homo sapiens 94-97 16477012-6 2006 The effects of PDGF/IL-1beta costimulation on contractile marker expression and Akt and p70S6K phosphorylation were blocked by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 and by adenovirus expressing a dominant-negative Akt, and they were mimicked by constitutively active Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 80-83 16477012-6 2006 The effects of PDGF/IL-1beta costimulation on contractile marker expression and Akt and p70S6K phosphorylation were blocked by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 and by adenovirus expressing a dominant-negative Akt, and they were mimicked by constitutively active Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 245-248 16477012-6 2006 The effects of PDGF/IL-1beta costimulation on contractile marker expression and Akt and p70S6K phosphorylation were blocked by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 and by adenovirus expressing a dominant-negative Akt, and they were mimicked by constitutively active Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 245-248 16337154-7 2006 Blocking PI3-kinase by wortmannin or LY294002 reduced the PARP inhibitor-elicited robust Akt and GSK-3beta phosphorylation upon ischemia-reperfusion, and significantly diminished the recovery of ATP and creatine phosphate showing the importance of Akt activation in the recovery of energy metabolism. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 89-92 16337154-7 2006 Blocking PI3-kinase by wortmannin or LY294002 reduced the PARP inhibitor-elicited robust Akt and GSK-3beta phosphorylation upon ischemia-reperfusion, and significantly diminished the recovery of ATP and creatine phosphate showing the importance of Akt activation in the recovery of energy metabolism. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 248-251 16526059-5 2006 Apoptotic cell death was induced by LY294002 (a pharmacological inhibitor of the phosphoinositide 3-kinase/Akt survival pathway), H2O2, and Z-LEHD-FMK (a caspase-9 inhibitor which has been recently reported to induce apoptosis in CEM cells). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 107-110 16439036-4 2006 Activation of Akt by carbachol was antagonized by atropine and inhibited by LY294002 and PP2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 14-17 16472761-6 2006 Moreover, LY294002, but not PD98059, inhibited the PSA and AR suppression effect by EGF in concurrence with the suppression of phosphorylation levels of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 153-156 16378598-3 2006 Although a PI3 kinase inhibitor, LY294002, by itself does not induce apoptotic cell death, LY294002 selectively and markedly enhances the apoptosis-inducing efficacy of doxorubicin: such an enhanced cell death is only detected in tumor cells in which the PI3 kinase/Akt pathway is constitutively activated, and it is totally dependent on the functional p53 pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 266-269 16412023-5 2006 The PI(3)K inhibitor LY294002 demonstrated antiproliferative effects in a dose- and time-dependent manner, which was associated with Akt dephosphorylation on Thr308 and Ser473 sites and dephosphorylation of the downstream ribosomal protein S6. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 133-136 16479173-5 2006 Treatment of HL60 cells with PI3K inhibitors LY294002 and Wortmannin, which decrease the activity of the AKT pathway, induced apoptosis, but this effect was reduced in cells simultaneously treated with 1,25D. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 105-108 16249373-9 2006 DADLE stimulated phosphorylation of membrane-associated Akt; wortmannin and LY294002 ([2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]), specific inhibitors of PI3K, abolished the DADLE-induced phosphorylation of c-jun. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-135 AKT serine/threonine kinase 1 Homo sapiens 56-59 16269654-10 2005 The inhibitory effect of adiponectin on TNF-alpha-induced IL-8 synthesis was abrogated in part by pretreatment with the PI3 kinase inhibitor LY294002 or by Akt siRNA transfection, suggesting that Akt activation might inhibit IL-8 synthesis induced by TNF-alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 196-199 16442704-4 2006 Inhibition of signalling via c-Jun NH2-terminal kinase (JNK) with SP600125 or PI3-kinase/Akt with LY294002 abolished the effects of G-Gly. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 89-92 16343977-7 2006 The phosphatidylinositol 3-kinase inhibitor LY 294002, also, inhibited epidermal growth factor-dependent DNA synthesis and Akt phosphorylation but did not decrease extracellular regulated kinases phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-53 AKT serine/threonine kinase 1 Homo sapiens 123-126 16384957-9 2006 Western blot analysis showed that phosphorylation of Akt and FKHRL1was abolished by LY294002 and SR13668, but downregulated by U0126, which also abolished phosphorylation of p44/42 mitogen-activated protein kinase (MAPK). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 53-56 16394177-4 2006 The BK-induced phosphorylation of PKB/Akt was blocked by LY294002 but not by PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 34-37 16394177-4 2006 The BK-induced phosphorylation of PKB/Akt was blocked by LY294002 but not by PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 38-41 16785763-6 2006 RESULTS: LY294002 suppressed cell proliferation but induced apoptosis with decreased levels of phosphorylated Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 110-113 16123394-9 2005 Apoptotic resistance of mesothelioma cells was significantly reduced by inhibiting either the PI3K/Akt pathway with LY294002 (47 +/- 6% apoptosis) or the mTOR pathway with rapamycin (50 +/- 17% apoptosis). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 99-102 16282450-6 2005 Inhibition of the phosphoinositide-3-OH kinase/Akt pathway by Wortmannin or Ly294002 compounds decreased Ad vector induction of CXCL10 mRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 47-50 16098957-9 2005 MAP kinase kinase (MEK)1/2 inhibitor U0126, phosphatidylinositol (PI) 3-kinase inhibitors (wortmannin and LY294002), and dominant negative Akt mutant significantly prevented stretch-induced SMC proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 AKT serine/threonine kinase 1 Homo sapiens 139-142 16139919-6 2005 In untreated cells, LY294002 but not rapamycin diminished the basal ADAM12 expression related to inhibition of Akt and the glycogen synthase kinase-3 phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 111-114 16144975-8 2005 The phosphoinositide 3-kinase (PI3K)-Akt blocker 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002) reversed the protective effects of galantamine, donepezil, and nicotine but not that of rivastigmine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 37-40 16172130-4 2005 Akt activation was significantly inhibited by LY294002 and wortmannin, specific inhibitors of phosphatidylinositol 3-kinase, but not by H-89. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 0-3 16267010-14 2005 Additional studies showed that the PI3K/AKT-specific inhibitor LY294002 had a more profound effect than the MAPK-specific inhibitor U0126 in blocking EGF-induced cell proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 40-43 16157221-5 2005 Moreover, hTnC-induced Akt activation was blocked by LY294002 and the expression of dominant-negative Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 23-26 16166321-5 2005 Inhibitors of the PI3K/Akt/mTOR pathway (LY294002, rapamycin) but not the MEK/ERK pathway (U0126) abrogated laminin-mediated survival. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 23-26 16061480-5 2005 Under normal growth conditions, blocking PI3K/Akt signals by LY294002 causes LNCaP cell arrest in G1 phase rather than apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 61-69 AKT serine/threonine kinase 1 Homo sapiens 46-49 16061480-6 2005 However, further blocking of AR functions by AR small interfering RNA leads to dramatic LNCaP cell death, suggesting that AR may play important protective roles when the PI3K/Akt signal pathway is blocked by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 175-178 16211241-6 2005 Paclitaxel-induced ERK and AKT activity was inhibited by the EGFR inhibitor, PD153035; ERK inhibitor, U0126; and PI3 kinase inhibitor, LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 27-30 16211288-4 2005 We found that both PI 3-K inhibitors, wortmannin and LY294002, markedly suppressed phosphorylation of Akt and Bad in HL-60 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 102-105 16007163-4 2005 Blocking AKT with the PI3K/AKT inhibitor LY294002 or AKT SiRNA prevented NF-kappaB activation and inhibition of p53. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 9-12 16007163-4 2005 Blocking AKT with the PI3K/AKT inhibitor LY294002 or AKT SiRNA prevented NF-kappaB activation and inhibition of p53. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 27-30 16007163-4 2005 Blocking AKT with the PI3K/AKT inhibitor LY294002 or AKT SiRNA prevented NF-kappaB activation and inhibition of p53. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 27-30 16007163-5 2005 Treatment of C81 cells with LY294002 resulted in an increase in the p53-responsive gene MDM2, suggesting a role for AKT in the Tax-mediated regulation of p53 transcriptional activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 116-119 16209943-4 2005 Suppression of Akt activation by the PI3K-inhibitor PTEN or LY294002, Akt expression by RNA-interference, or Akt function by dominant-negative Akt caused apoptosis in cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 15-18 16174443-4 2005 RESULTS: The PI3K inhibitors wortmannin and Ly294002, but not rapamycin, completely inhibited the phosphorylation of Akt and PRAS40. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 117-120 16044407-6 2005 The induction of COX-2 elicited by TPA correlated with increased activation of Akt kinase and cell treatment with the PI3 kinase inhibitor, LY294002, blocked TPA induction of COX-2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 79-82 16142341-6 2005 Inhibition of PI3K-Akt signaling in LM8 by a PI3K inhibitor, LY294002, or by a dominant negative form of Akt, resulted in suppression of MMP secretion, in vitro invasiveness, cell locomotion and in vivo pulmonary metastasis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 61-69 AKT serine/threonine kinase 1 Homo sapiens 19-22 16081165-8 2005 These analyses also provide support for the involvement of the PI-3K pathway; ipsapirone stimulated the phosphorylation of Akt in control and ethanol-treated neurons, and these effects were antagonized by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 205-213 AKT serine/threonine kinase 1 Homo sapiens 123-126 16115127-7 2005 LY294002 treatment of acute promyelocytic primary blasts with elevated Akt phosphorylation levels resulted in an increased sensitivity to As2O3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 71-74 16103079-5 2005 Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 103-106 16103051-9 2005 The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-132 AKT serine/threonine kinase 1 Homo sapiens 41-44 15946966-7 2005 PE (10 microm) increased phosphorylation of Akt, which was inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 44-47 16133873-4 2005 PI3-K inhibitor, LY294002, reduced IGF-I-stimulated phosphorylation of FKHR, FKHRL1, and Akt, but did not affect Erk phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 AKT serine/threonine kinase 1 Homo sapiens 89-92 15801908-4 2005 The PI3K inhibitors LY294002 and wortmannin blocked IGF-I-stimulated Akt phosphorylation without blocking ERK phosphorylation and this was associated with complete inhibition of proteoglycan synthesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 69-72 15894170-6 2005 Both NO donor and LPS/IFN-gamma markedly activated the PI3K activity and the phosphorylation of Akt and nuclear factor (NF)-kappaB DNA binding activity in mesangial cells, which could be inhibited by LY294002 and transfection of dominant-negative vectors of PI3K/p85 and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 200-208 AKT serine/threonine kinase 1 Homo sapiens 96-99 15894170-6 2005 Both NO donor and LPS/IFN-gamma markedly activated the PI3K activity and the phosphorylation of Akt and nuclear factor (NF)-kappaB DNA binding activity in mesangial cells, which could be inhibited by LY294002 and transfection of dominant-negative vectors of PI3K/p85 and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 200-208 AKT serine/threonine kinase 1 Homo sapiens 271-274 16077404-3 2005 Exposure of mesothelioma cell lines to LY294002, a phosphoinositide-3 kinase inhibitor, results in apoptotic cell death and decreased phosphorylated Akt in vitro and tumor burden reduction in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 149-152 16123141-8 2005 Furthermore, treatment of WM239 cells with LY294002 reduces RNF11/14-3-3 interactions suggesting that RNF11/14-3-3 binding is regulated by AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 139-142 16140203-8 2005 The ability of IGF-I to activate the pro-survival PKB pathway in ATCs was inhibited by LY294002, indicating the importance of PI3K in the response of ATCs to IGF-I. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 50-53 16103079-5 2005 Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 176-179 16103079-5 2005 Wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and S6K1 phosphorylation, whereas rapamycin, a specific inhibitor of Akt downstream effector, mammalian target of rapamycin (mTOR), suppressed only S6K1 phosphorylation induced by 15(S)-HETE suggesting that this eicosanoid activates the PI3K-Akt-mTOR-S6K1 signaling in HDMVEC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 176-179 16024628-1 2005 The phosphoinositide 3-kinase (PI3K)-Akt pathway is constitutively active in many tumors, and inhibitors of this prosurvival network, such as LY294002, have been shown to sensitize tumor cells to death stimuli. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 142-150 AKT serine/threonine kinase 1 Homo sapiens 37-40 21432138-4 2005 METHODS: The inhibitory effects of dibutyryl cAMP (db-cAMP) or LY294002 (a specific inhibitor of the PI3-kinase/Akt pathway) on DHA-induced apoptosis in HL-60 cells were evaluated by the appearance of apoptosis, and from the activities of caspases (3 and 8), the phospholylation of Akt, and cleavage of Bid using DNA indexes, emzymatic measurement of fragmented substrates, and Western blotting, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 112-115 15797868-7 2005 Further studies indicated that LY294002, an inhibitor of phosphoinositide 3-kinase that is an upstream signaling protein of Akt1, could block neuroprotection of preconditioning, and KN62, an inhibitor of calmodulin-dependent protein kinase, also achieved the same effects as LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 124-128 15797868-7 2005 Further studies indicated that LY294002, an inhibitor of phosphoinositide 3-kinase that is an upstream signaling protein of Akt1, could block neuroprotection of preconditioning, and KN62, an inhibitor of calmodulin-dependent protein kinase, also achieved the same effects as LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 275-283 AKT serine/threonine kinase 1 Homo sapiens 124-128 15805105-10 2005 Subsequent analysis revealed not only induction of Akt phosphorylation by recombinant beta ig-h3 but also blockage of Akt phosphorylation by LY294002, an inhibitor of phosphatidylinositol 3-kinase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 118-121 15782121-7 2005 However, Akt is released from the N-terminal domain concomitant with binding to the C-terminal domain of ASK1 in response to ASK1 activator H(2)O(2), inhibitor of Hsp90 17-AAG and Akt inhibitor LY294002, leading to a more stable Hsp90-Akt-ASK1 complex. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 194-202 AKT serine/threonine kinase 1 Homo sapiens 9-12 15573401-5 2005 Inhibition of PI3-K by LY294002 attenuated BK-induced Akt and p42/p44 MAPK phosphorylation and [3H]thymidine incorporation, but had no effect on EGFR phosphorylation, suggesting that EGFR may be an upstream component of PI3-K/Akt and MAPK in these responses. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 54-57 15946254-5 2005 The LTA-induced Akt activation was inhibited by wortmannin, LY 294002, genistein, and tyrphostin AG126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-69 AKT serine/threonine kinase 1 Homo sapiens 16-19 15800029-5 2005 LY294002 or wortmannin, inhibitors of PI-3K, suppressed LPS-induced Akt activity and MMP-9 production. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 68-71 15882878-4 2005 A specific inhibitor of PI3-kinase, LY294002, is used to block Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 63-66 15882878-8 2005 Blockade of Akt phosphorylation with LY294002 abrogates the effects of VEGF upon survivin and phosphorylated Akt protein expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 12-15 15882878-8 2005 Blockade of Akt phosphorylation with LY294002 abrogates the effects of VEGF upon survivin and phosphorylated Akt protein expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 109-112 15964826-4 2005 Inactivation of Akt by chemotherapeutic drugs or the phosphatidylinositide-3-OH kinase inhibitor LY294002 induced G2/M arrest together with the inhibitory phosphorylation of Cdc2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 16-19 15678501-8 2005 Furthermore, the IL-4-induced NF-kappaB activation and nuclear translocation can be blocked by LY294002, a PI3K/Akt specific inhibitor, suggesting that IL-4-induced NF-(kappa)B activation is mediated by activation of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 112-115 15678501-8 2005 Furthermore, the IL-4-induced NF-kappaB activation and nuclear translocation can be blocked by LY294002, a PI3K/Akt specific inhibitor, suggesting that IL-4-induced NF-(kappa)B activation is mediated by activation of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 222-225 16000874-3 2005 We also found that the inhibition of anoikis by COX-2 results from activation of the PI-3K/Akt pathway as evidenced by suppression of the COX-2 effect on anoikis by a PI-3K inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 184-192 AKT serine/threonine kinase 1 Homo sapiens 91-94 21432138-6 2005 However, the inhibition of PI3-kinase/Akt signaling by LY294002 resulted in recovery of the caspases" activities, appearance of apoptotic cells, and cleavage of the Bid molecule when LY294002 was co-treated with db-cAMP before the occurrence of DHA-induced apoptosis in HL-60. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 38-41 21432138-6 2005 However, the inhibition of PI3-kinase/Akt signaling by LY294002 resulted in recovery of the caspases" activities, appearance of apoptotic cells, and cleavage of the Bid molecule when LY294002 was co-treated with db-cAMP before the occurrence of DHA-induced apoptosis in HL-60. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 38-41 21432138-7 2005 It was also confirmed that LY294002 strongly inhibited phospholylation of Akt during db-cAMP induced-reduction of DHA-induced apoptosis in HL-60. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 74-77 15806173-6 2005 Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 34-37 15806173-6 2005 Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 157-160 15806173-6 2005 Treatment with LY294002 abolished AKT activity and potentiated apoptosis induced by FAS inhibitors cerulenin or C75 only in cells with constitutively active AKT, suggesting that constitutive activation of AKT protects against FAS inhibitor-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 157-160 15809062-9 2005 In addition, the PI3 kinase inhibitor, LY294002, upregulates IGFBP-3 expression but downregulates IGF-I and IGF-II, indicating that PTEN controls IGFBP-3 and IGFs by an Akt-dependent pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 169-172 15857394-7 2005 Activation of Akt was also inhibited by pretreatment with pertussis toxin as well as the phosphatidylinositol 3-kinase inhibitors, wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 146-154 AKT serine/threonine kinase 1 Homo sapiens 14-17 15791648-7 2005 The inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt signaling by LY294002 increased the Erk activation induced by the mutant B-raf proteins, as well as by wild-type B-raf. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 55-58 15850772-2 2005 Inhibition of PI3K/Akt pathway with a selective inhibitor (e.g., LY294002, or wortmannin) in leukemic cells markedly potentiated fludarabine-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 19-22 15850772-4 2005 The co-treatment of fludarabine/LY294002 resulted in significant attenuation in the levels of both phospho-Erk1/2 and phospho-Akt, as well as a marked increase in the level of phospho-JNK. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 126-129 15684417-8 2005 Moreover, TRAIL-induced RA FLS proliferation was inhibited by the protein kinase inhibitors PD98059, SB203580, and LY294002, confirming the involvement of the ERK, p38, and PI3 kinase/Akt signaling pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 184-187 15837766-5 2005 We used LY294002 to block PI3"-kinase/AKT activation and assess apoptosis by flow cytometric analysis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 8-16 AKT serine/threonine kinase 1 Homo sapiens 38-41 15833867-8 2005 Enforced expression of active Akt in tumor cells suppressed the combined effects of LY294002 or UCN-01, whereas dominant-negative Akt expression was sufficient to increase the sensitivity of tumor cells to rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 30-33 15837766-11 2005 Similarly, XIAP, a target of AKT, was down-regulated after LY294002 treatment only in sensitive PEL cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 29-32 15657050-7 2005 The activation of Rac was blocked by the PI3K inhibitors LY294002 and wortmannin and by transfection of a kinase-negative mutant of PI3K or a dominant-negative form of Vav2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 18-21 15703783-2 2005 We show that the PI3-kinase/Akt pathway is constitutively active in primary acute myeloid leukaemia (AML) cells and that blockade by the selective inhibitor LY294002 reduces survival of the total blast population (mean 52%). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 157-165 AKT serine/threonine kinase 1 Homo sapiens 28-31 15714461-3 2005 The data show that HIF-1alpha expression is induced by bFGF in a dose- and time-dependent fashion, while increased HIF-1alpha protein expression and transactivity of HIF-1 are due to the phosphorylation of Akt by bFGF, as indicated by application of the phosphatidylinositol 3-kinase (PI-3K) inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 302-310 AKT serine/threonine kinase 1 Homo sapiens 206-209 15632127-5 2005 In addition, IGF-I activated Akt while inhibiting caspase-3 activation, and these effects were reversed by the PI3K inhibitors LY 294002 and wortmannin, but not by the MEK1 inhibitor PD 98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-136 AKT serine/threonine kinase 1 Homo sapiens 29-32 15728533-7 2005 Both IL-4 and IL-13 induced the phosphorylation of Akt and increased the kinase activity of this enzyme in a manner that was sensitive to the phosphatidylinositol 3-kinase inhibitors LY294002 or wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 51-54 15706421-6 2005 The combination of FK228 and a phosphatidylinositol 3-kinase (PI3K)/Akt pathway inhibitor, LY294002, was determined to be synergistically cytotoxic in PC14 cells by isobologram analysis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 68-71 15685229-5 2005 Inhibition studies with LY294002 demonstrated that the serum signal is mediated via the phosphoinositide 3-OH kinase/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 117-120 15501927-8 2005 The activation of p70S6K/S6 pathway was sensitive to inhibition by rapamycin and LY294002, indicating that mTOR and PI3K/Akt are upstream signaling regulators. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 121-124 15558015-10 2005 Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-independent activation of NF-kappaB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 64-67 15316930-4 2005 Selective pharmacological inhibitors of the PI3K/Akt axis (LY294002, wortmannin) were employed to influence the sensitivity to As2O3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 49-52 15526284-11 2005 LY294002, a phosphatidylinositol 3 (PI3) kinase inhibitor, inhibited the association of eNOS/Akt and the phosphorylation of eNOS but had no effect on the interaction between eNOS and HSP90 during early hours of exposure. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 93-96 15671247-6 2005 Inhibition of PI3K with LY294002 or a dominant-negative p85 construct blocked AND-34-mediated Rac and Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 102-105 16037687-9 2005 LY294002, a phosphatidylinositol-3 kinase (P13K)/AKT inhibitor, did suppress the growth of NPC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 49-52 15555556-6 2004 Furthermore, we have shown that inhibition of Akt phosphorylation in U937 cells by the specific PI3K inhibitor, LY294002 significantly, enhanced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 46-49 15489897-7 2004 However, activation of Akt, but not mTOR was inhibited by the PI-3 kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 23-26 15579767-10 2004 Cotreatment of cells with wortmannin or LY294002 inhibited the PGE2-induced phosphorylation of Akt and tuberin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 95-98 15377673-5 2004 PI3K inhibition by LY294002 showed an increase in NAG-1 protein and mRNA expression, and 1l-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate (AKT inhibitor) also induced NAG-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 163-166 15377673-7 2004 Inhibition of GSK-3beta, which is negatively regulated by AKT, using AR-A014418 and lithium chloride completely abolished LY294002-induced NAG-1 expression as well as the NAG-1 promoter activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 58-61 15735908-0 2005 PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 0-7 15735908-7 2005 Furthermore, using a myristoylated PKB/Akt construct, we identified PKB/Akt as the downstream molecule that mediates the synergistic cytotoxicity between LY294002 and radiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 35-42 15735908-7 2005 Furthermore, using a myristoylated PKB/Akt construct, we identified PKB/Akt as the downstream molecule that mediates the synergistic cytotoxicity between LY294002 and radiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 68-75 15734199-6 2005 Both BIBX1382BS as well as the PI3 kinase inhibitor LY294002 led to a blockage (for A549 cells) or reduction (for FaDu cells) of radiation-induced P-AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 149-152 15545271-5 2005 Blocking of phosphoinositide 3-OH kinase by selective inhibitors (LY-294002 and wortmannin) abrogated the stretch-induced PKB/Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-75 AKT serine/threonine kinase 1 Homo sapiens 122-125 15545271-5 2005 Blocking of phosphoinositide 3-OH kinase by selective inhibitors (LY-294002 and wortmannin) abrogated the stretch-induced PKB/Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-75 AKT serine/threonine kinase 1 Homo sapiens 126-129 15889536-7 2005 Because LY294002, an inhibitor of cellular phosphatidylinositol 3-kinase (PI3-K), also prohibited HCMV-mediated activation of Akt and NFkappaB and synthesis of the MIE proteins, PI3-K signalling was necessary for expressing the MIE genes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 8-16 AKT serine/threonine kinase 1 Homo sapiens 126-129 15339911-6 2004 Transcription of cIAP-2 and XIAP was up-regulated by the phosphatidylinositol 3-kinase/Akt pathway as shown by its reversal by dominant-negative Akt or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 152-160 AKT serine/threonine kinase 1 Homo sapiens 87-90 15631803-13 2004 15 micromol/L LY294002 completely blocked the bFGF-induced phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 78-81 15569997-4 2004 We show an association between Akt and IKK and show that the phosphorylation of IKK induced by paclitaxel is blocked by treatment with a phosphatidylinositol 3-kinase inhibitor (wortmannin or LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 192-200 AKT serine/threonine kinase 1 Homo sapiens 31-34 15389877-5 2004 Moreover, inhibition of Akt or ERK activity with respectively a PI-3K inhibitor (LY294002) or MEK inhibitors (PD98059, UO126), partially or totally suppressed the anti-apoptotic capacity of 1,25(OH)2D3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 24-27 15345706-8 2004 The overexpression of dysbindin increased phosphorylation of Akt protein and protected cortical neurons against neuronal death due to serum deprivation and these effects were blocked by LY294002, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-194 AKT serine/threonine kinase 1 Homo sapiens 61-64 15634518-3 2004 Expression of HER2/neu, p53, Akt and p-Akt protein after PI3K pathway inhibitor LY294002 treatment was determined by Western blot. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 39-42 15451068-6 2004 LY294002, a PI3 kinase inhibitor, enhances Akt inactivation and DNA fragmentation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 43-46 15367412-6 2004 The PTEN-negative cell line displayed greater sensitivity to the growth inhibitory effects of the PI3K inhibitor, LY294002 and rapamycin, an inhibitor of the PI3K/Akt downstream mediator mTOR, compared with the PTEN-positive cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 163-166 15319269-4 2004 Activation of Akt and eNOS by HF was completely blocked by the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, LY294002 (10 micromol/L). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 14-17 15634518-6 2004 HER2/neu overexpressing MCF7 cells showed higher p-Akt expression and lower p53 expression than those of parental MCF7 cells, which could be abrogated by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 51-54 15329376-6 2004 Inhibition of the MAP Kinase/ERK pathway had no influence on cell survival, but inhibition of phosphatidylinositol 3 kinase (PI3-Kinase; Akt/protein kinase B) by LY294002 amplified TEGDMA-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 137-140 15319373-7 2004 Further, the PI-3 kinase inhibitor LY294002 and MAPK inhibitor PD98059 were found to significantly reduce leptin-induced HSC proliferation, thereby indicating that leptin induced HSC proliferation is Akt- and Erk-dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 200-203 15184909-7 2004 Functional correlation between Akt activation and the activation of NFkappaB was confirmed in U251MG GBM cells in which inhibition of Akt activation either by stable expression of PTEN or by the PI3-kinase inhibitors, wortmannin and LY294002, led to a concomitant decrease in NFkappaB-binding activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 233-241 AKT serine/threonine kinase 1 Homo sapiens 31-34 15184909-7 2004 Functional correlation between Akt activation and the activation of NFkappaB was confirmed in U251MG GBM cells in which inhibition of Akt activation either by stable expression of PTEN or by the PI3-kinase inhibitors, wortmannin and LY294002, led to a concomitant decrease in NFkappaB-binding activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 233-241 AKT serine/threonine kinase 1 Homo sapiens 134-137 15194442-7 2004 Both adenovirus-mediated expression of dominant-negative Akt and inhibition of PI3 kinase-mediated Akt activation with LY294002 blocked cell cycle progression of low-density cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 99-102 15492414-5 2004 The PI3 kinase inhibitor LY294002 reduced COX-2 expression in HSC-5 cells and, contrary to our expectation, the phosphorylation of Akt was significantly decreased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 131-134 15107457-7 2004 Furthermore, activation of Rac was attenuated by pretreatment of neutrophils with the phosphatidylinositol 3-kinase (PI-3K) inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 134-142 AKT serine/threonine kinase 1 Homo sapiens 27-30 15377841-4 2004 High levels of basal Akt, GSK3 alpha / beta and p70S6 kinase phosphorylation are all inhibited by the PI3 kinase inhibitor, LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-133 AKT serine/threonine kinase 1 Homo sapiens 21-24 15341518-7 2004 However, administration of LY294002, an inhibitor of phosphatidylinositol 3 kinase (PI3K), blocked the phosphorylation of Akt but did not affect the effect of NT3 on the expression of Olig-1 and on NSC differentiation into OLPs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 122-125 15333786-10 2004 LY294002 inhibited Akt phosphorylation, but had no effect on ERK phosphorylation; U0126 suppressed ERK phosphorylation without interfering with the phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 19-22 15208659-5 2004 LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 54-57 15208659-5 2004 LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 86-89 15249422-10 2004 The phosphorylation of Akt in response to RWPCs was abolished by wortmannin and LY294002, and by the membrane-permeant analogue of superoxide dismutase Mn(III)tetrakis(1-methyl-4-pyridyl)porphyrin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 23-26 15370202-4 2004 Inhibition of PI3-kinase with specific inhibitor, LY294002, led to the induction of apoptosis that was caspase 8 dependent, but independent of Akt as LY294002 did not depress a high basal level of Akt activity found in CLL cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 143-146 15370202-4 2004 Inhibition of PI3-kinase with specific inhibitor, LY294002, led to the induction of apoptosis that was caspase 8 dependent, but independent of Akt as LY294002 did not depress a high basal level of Akt activity found in CLL cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 197-200 15300175-9 2004 On Western blot, 200 micromol/L GCDA caused a 3-fold increase in Akt phosphorylation within 20 minutes, which was inhibited by 90% with the addition of PI3 kinase inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 174-182 AKT serine/threonine kinase 1 Homo sapiens 65-68 15208673-6 2004 Pretreatment of SKOV3 cells, which exhibit constitutive AKT activity under low serum conditions, with the PI3K inhibitor LY294002 augmented cisplatin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 121-129 AKT serine/threonine kinase 1 Homo sapiens 56-59 15254091-7 2004 Two structurally unrelated PI3K inhibitors, LY294002 and wortmannin, blocked the DHPG-induced increases in phosphorylation of Akt and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 126-129 15147515-5 2004 Ser9-GSK3beta phosphorylation induced by HNE was abolished by treatment with LY294002 or U0126, two inhibitors of PI3K/AKT and ERK pathways, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 119-122 15024023-7 2004 Inactivation of Akt by either treatment with LY294002 or ectopic expression of a dominant negative Akt mutant (DNMAkt) not only enhanced the caspase-3 activation in polyamine-deficient cells but also prevented the increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 16-19 15047866-5 2004 Blockade of the Akt/phosphoinositide 3-kinase (PI3-kinase) pathway with LY294002 and wortmannin prevents the ability of ET-1 to induce alpha-SMA, ezrin, paxillin, and moesin and to promote matrix contraction. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 16-19 15024023-8 2004 Phosphorylation of glycogen synthase kinase-3, a downstream target of Akt, was also increased in alpha-difluoromethylornithine-treated cells, which was prevented by inactivation of Akt by LY294002 or DNMAkt overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 70-73 15024023-8 2004 Phosphorylation of glycogen synthase kinase-3, a downstream target of Akt, was also increased in alpha-difluoromethylornithine-treated cells, which was prevented by inactivation of Akt by LY294002 or DNMAkt overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 181-184 14691717-5 2004 LY294002, a specific inhibitor of phosphatidylinositol 3-kinase(PI3K)/Akt signaling, also suppressed TGF-beta-induced motility and Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 70-73 15150102-9 2004 LY294002 inhibited AKT activation in BDC cells and, on irradiation, decreased clonogenic survival in a radiation dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 19-22 15067356-11 2004 Inhibition of PI 3-K with Wortmannin and LY294002 blocked Akt phosphorylation and inhibited expression of COX-2 in mutated-PTEN cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 58-61 15140184-10 2004 Most interestingly, only the inhibitor of the PI3K/Akt pathway, LY294002, was able to block the survival effects of both IGF-1 and BDNF; an inhibitor of the MAPK pathway inhibitor, PD98059, being ineffective. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 51-54 14985354-5 2004 Furthermore, androgen receptor phosphorylation was augmented by LY294002, an indirect inhibitor of protein kinase B/Akt that inhibits glycogen synthase kinase-3 beta. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 116-119 14985355-7 2004 Wortmannin and LY294002, inhibitors of phosphoinositide 3-kinase, and PD98059, an inhibitor of MEK, abrogated survival and capillary tube formation, indicating that Akt and Erk1/2 should promote survival and capillary tube formation of these endothelial cells at a locus downstream to stem cell factor/c-kit signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 165-168 15047168-7 2004 Phosphorylation of Akt at serine 473 and its downstream molecular Bad at serine 136 was induced by HAPO, but was blocked by two PI3K inhibitors, LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 19-22 14988229-8 2004 The phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin or LY294002 abolished the activation of Akt/eNOS and reversed the inhibitory effect of rHDL on TF expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 103-106 15044083-3 2004 TGFbeta-mediated phosphorylation of Akt at Ser-473 was inhibited by dominant-negative ILK and PI3K inhibitors, LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 36-39 15013849-6 2004 Suppression of Akt activity by wortmannin, by LY-294002 and by using a dominant negative Akt mutant abolished the anti-apoptotic effect of Andro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-55 AKT serine/threonine kinase 1 Homo sapiens 15-18 15073105-6 2004 The activation of Akt and NF-kappa B was prevented by LY294002, whereas the activity of MAPK(Erk), but not NF-kappa B, was inhibited by U0126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 18-21 14978738-5 2004 Treatment of cells with PI-3K/Akt inhibitor (LY294002) and tyrosine protein kinase inhibitor (genistein) significantly attenuated hypoxia-induced PAI-1 mRNA and protein expression as well as promoter activation, apparently via an inhibition of the hypoxia-induced stabilization of HIF-1alpha protein, attenuation of the steady-state level of HIF-1alpha mRNA, and its DNA-binding activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 30-33 15084985-2 2004 We postulated that LY294002, a PI3K inhibitor, might inactivate Akt, consequently inhibiting cell proliferation in 3 human pancreatic ductal carcinoma cell lines, PSN-1, PANC-1, and KP-4. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 64-67 15084985-3 2004 LY294002 (50 micromol/L) caused a decrease in phosphorylated Akt and inhibition of cell proliferation in a time-dependent manner, but there was no obvious induction of apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 61-64 15050414-11 2004 4-OHE2, but not 2-OHE2, also induced Akt phosphorylation at Ser473 in dose- and time-dependent manners, and LY294002 and wortmannin inhibited Akt phosphorylation at Ser473 induced by 4-OHE2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 142-145 14660586-4 2004 The phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and wortmannin abrogated AdE4(+) induction of both phospho-Akt expression and prolonged EC survival. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 120-123 14691717-5 2004 LY294002, a specific inhibitor of phosphatidylinositol 3-kinase(PI3K)/Akt signaling, also suppressed TGF-beta-induced motility and Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 131-134 15033167-6 2004 Inhibiting the increase in Akt phosphorylation by intravitreal injection of wortmannin and LY294002, inhibitors of PI3K, resulted in premature nuclear fragmentation, caspases-3 and -9 activation in the ganglion cell layer. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 27-30 15026550-8 2004 Inhibition of Akt activation by LY294002 significantly decreased the viability of human cholangiocarcinoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 14-17 14628071-5 2004 In this study, we tested the hypothesis that the inhibition of PI3K by LY294002 results in the dephosphorylation of AKT and BAD, and thus promote leukemia cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 116-119 14988008-3 2004 Pretreatment with the specific inhibitor of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, LY294002 (20 microM), prevented the phosphorylation of Akt but did not affect the phosphorylation of GSK-3beta. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 85-88 14988008-3 2004 Pretreatment with the specific inhibitor of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, LY294002 (20 microM), prevented the phosphorylation of Akt but did not affect the phosphorylation of GSK-3beta. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 153-156 14743465-6 2004 RESULTS: IGF-1, EGF, and heregulin but not PDGF or activators of protein kinase A induced phosphorylation of Akt in DU145 cells and activation was completely blocked by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 109-112 14743465-7 2004 In the hormone-responsive prostate cancer cell line LNCaP that has a constitutively switched-on Akt kinase, LY294002 caused a dose- and time-dependent Akt inhibition, which was absent in long-term androgen-ablated LNCaP sublines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 96-99 14743465-7 2004 In the hormone-responsive prostate cancer cell line LNCaP that has a constitutively switched-on Akt kinase, LY294002 caused a dose- and time-dependent Akt inhibition, which was absent in long-term androgen-ablated LNCaP sublines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 151-154 14628071-7 2004 In MO7E cells, LY294002 reduced AKT kinase activity, induced dephosphorylation of AKT and BAD, and increased apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 32-35 14628071-7 2004 In MO7E cells, LY294002 reduced AKT kinase activity, induced dephosphorylation of AKT and BAD, and increased apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 82-85 15068691-12 2004 Inhibition of the AKT pathway by LY 294002 strongly suppressed colony formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-42 AKT serine/threonine kinase 1 Homo sapiens 18-21 14557259-7 2004 Dominant-negative Akt or the phosphatidylinositol 3-kinase inhibitor LY294002 blocked adiponectin-stimulated Akt and eNOS phosphorylation, migration, and differentiation without altering AMPK phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 109-112 12876075-7 2003 An inhibitor of the phosphatidylinositol 3-kinase pathway, LY-294002, blocked both insulin- and Akt-induced inhibition of protein degradation, again consistent with the hypothesis that both agents were acting on the same pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-68 AKT serine/threonine kinase 1 Homo sapiens 96-99 14762343-4 2004 The effect of LY294002-mediated phosphoinositide 3-kinase inhibition on protein kinase B (Akt) activation and nuclear factor-kappaB signaling was determined by Western blot analysis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 90-93 14762343-8 2004 LY294002 treatment caused a significant dose-dependent inhibition of protein kinase B (Akt) activation and suppression of nuclear factor-kappaB transcriptional activity that was accompanied by elevation of IkappaB, the intrinsic inhibitor of nuclear factor-kappaB, and concomitant reduction of nuclear factor-kappaB-regulated antiapoptotic proteins cIAP1, cIAP2, and BclXL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 87-90 14500571-7 2004 E2 inhibited the paclitaxel-induced JNK activation, and the E2-induced inhibition of the paclitaxel-induced JNK activation was attenuated in cells treated with either ICI182,780 or LY294002 or transfected with ASK1S83A, in which a consensus Akt phosphorylation site at serine-83 was converted to alanine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 181-189 AKT serine/threonine kinase 1 Homo sapiens 241-244 14694442-5 2004 A selective inhibitor of Akt phosphorylation, LY294002, accelerated formation of the death-inducing signaling complex (DISC) not only by FLIP reduction but also by enhancement of recruitment of the FADD to Fas, thereby sensitizing PC3 cells to apoptosis similar to the case with 2-ME stimulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 25-28 15545011-6 2004 Incubation with, Ro-31-8220 rescued neurons from cell death induced by the PI 3-K inhibitor, LY294002, suggesting that Ro-31-8220 may affect Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 141-144 15545011-7 2004 Western blot analysis showed that serum-free, low potassium conditions decreased Akt phosphorylation, which was exacerbated by treatment with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 142-150 AKT serine/threonine kinase 1 Homo sapiens 81-84 14615286-7 2003 ACh exposure increased phosphorylation (Ser473) of protein kinase B (Akt), and this effect was blocked by LY294002 and unaffected in low (0.5 mmol/L) [Ca2+]o. Confocal microscopy revealed that ACh exposure increased NOi at local subsarcolemmal sites, and ACh withdrawal additionally increased NOi by recruiting additional subsarcolemmal release sites. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 AKT serine/threonine kinase 1 Homo sapiens 69-72 14645548-7 2003 We demonstrate that increased Akt activities are largely responsible for cav-1-mediated cell survival using dominant-negative Akt mutants and specific inhibitors to MEK1/MEK and show that cav-1 increases the half-life of phosphorylated PDK1 and Akt after inhibition of PI3-K by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 278-286 AKT serine/threonine kinase 1 Homo sapiens 30-33 14605879-3 2004 Thus, we postulated that LY294002, a PI3 K inhibitor, should inactivate Akt, consequently inhibiting cell proliferation and increase apoptosis in the human gastric carcinoma cell line, MKN-45. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 72-75 14605879-5 2004 LY294002 caused a decrease of phosphorylated-Akt and an inhibition of cell proliferation via cell cycle arrest in the G0/G1 phase by P27/Kip1 accumulation, but there was no obvious induction of apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 45-48 14605879-7 2004 Decreased phosphorylated-Akt by LY294002 treatment led to a down-regulation of Mcl-2 and phosphorylated Bad proteins, which are anti-apoptotic factors and belong to the Bcl-2 family. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 25-28 14605879-9 2004 We concluded that: 1) the PI3K-Akt pathway plays an important role in preventing Fas-mediated apoptosis; and 2) a PI3 K inhibitor, such as LY294002, might be a useful anti-tumoral agent for gastric carcinoma. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 31-34 14637151-4 2003 TRAIL-mediated apoptosis in synovial cells was significantly increased through inactivation of Akt by LY294002, however, that process was not so changed by adding ERK inhibitor, PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 AKT serine/threonine kinase 1 Homo sapiens 95-98 14662022-6 2003 Treatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or with the protein synthesis inhibitor cycloheximide induced a suppression of constitutive Akt activation in SNU-216 cells and a concomitant decrease in the expression of FLIP(S). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 167-170 14662022-7 2003 The reduction of Akt activity by LY294002 affected the transcriptional level of FLIP(S), but not the mRNA stability. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 17-20 14639124-6 2003 This activation was phosphatidylinositol 3 (PI3)-kinase-dependent and promoted survival of Caco-2 cells because the PI3 kinase inhibitor LY294002 inhibited the Akt/PKB activation and induced apoptosis of Caco-2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 160-163 14639124-6 2003 This activation was phosphatidylinositol 3 (PI3)-kinase-dependent and promoted survival of Caco-2 cells because the PI3 kinase inhibitor LY294002 inhibited the Akt/PKB activation and induced apoptosis of Caco-2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 164-167 13130092-10 2003 Treatment of migrating cells with a specific inhibitor of phosphoinositide 3-kinase (PI3-K), LY294002, blocked the phosphorylation of Akt and increased the sensitivity to apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 134-137 14602779-7 2003 The IGF-I-induced up-regulation of VEGF production was associated with activation of AP-1 and HIF-1 alpha and was abrogated by phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002); Jun kinase inhibitor (SP600125); HIF-1 alpha antisense oligonucleotide; or geldanamycin, an inhibitor of the heat shock protein 90 molecular chaperone, which regulates the three-dimensional conformation and function of IGF-I-receptor and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 184-192 AKT serine/threonine kinase 1 Homo sapiens 433-436 14596794-10 2003 LY294002, a specific inhibitor of phosphoinositide 3 kinase (PI3 kinase), blunted the phosphorylation of AKT and inhibited LPC induction of RANTES more strongly than IL-8. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 105-108 12907754-8 2003 The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 abolished cell proliferation and activation of p70S6K and Akt; however, PRL-dependent activation of Erk1/2 was not modified. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 118-121 14617784-7 2003 When specific inhibitors of the phosphatidylinositol 3-kinase (PI3-K) and MAPK kinase (MEK) pathways were used, we found that exposure of MCF7HER2 cells to the PI3-K inhibitor LY294002 inhibited Akt phosphorylation and radiosensitized the cells, whereas the radiosensitization effect by the MEK inhibitor PD98059 was relatively weaker, albeit the phosphorylation of MAPK was reduced by PD98059 treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 176-184 AKT serine/threonine kinase 1 Homo sapiens 195-198 12904602-9 2003 Moreover, doxorubicin, NF-kappaB inhibitor (SN50), and PI3-kinase/Akt inhibitor (wortmannin, LY294002) enhanced the susceptibility of MRT cell lines to TRAIL/Apo2L-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 66-69 12900420-3 2003 In some experiments, LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (a kinase involved in activating Akt) and tumor necrosis factor-alpha (TNF-alpha) were used to activate GSK-3beta. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 118-121 12917431-5 2003 E2 induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, attenuated the E2-induced increases of the telomerase activity and hTERT promoter activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 34-37 14576824-6 2003 Although treatment with LY294002, a specific inhibitor of PI3 K, decreased the phosphorylation of Akt and increased Fkhr translocation to the nucleus, these events were not sufficient to induce FasL expression and apoptosis of C6 glioma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 98-101 13679036-6 2003 LY294002, an inhibitor of PI3K, completely blocked AA-induced phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E, suggesting a role for PI3K in these effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 81-84 12896906-5 2003 Serum treatment increased the pErbB3/p85 complexes and also stimulated phosphorylation of Akt and GSK3beta, increase in cyclin D1 and cell cycle progression, and these events were blocked by the Akt activation inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 220-228 AKT serine/threonine kinase 1 Homo sapiens 195-198 14555504-8 2003 We show here that pharmacologic down-regulation of constitutive PI3K/Akt pathway signaling using the PI3K inhibitor LY294002 similarly restores EGFR-stimulated Akt signaling and sensitizes MDA-468 cells to ZD1839. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 69-72 14555504-8 2003 We show here that pharmacologic down-regulation of constitutive PI3K/Akt pathway signaling using the PI3K inhibitor LY294002 similarly restores EGFR-stimulated Akt signaling and sensitizes MDA-468 cells to ZD1839. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 160-163 14522909-9 2003 Importantly, using pharmacological inhibitors of phosphatidylinositol 3"-kinase (PI3-K) (LY294002 and wortmannin) and extracellular signal-regulated kinase (PD98059), we demonstrate that IGF-I-induced MM cell adhesion to FN is achieved only when PI3-K/AKT is activated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 252-255 12970746-8 2003 Blocking of the Akt pathway by an Akt-specific inhibitor LY294002 abrogates IL-4-induced PSA expression and AR signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 16-19 12970746-8 2003 Blocking of the Akt pathway by an Akt-specific inhibitor LY294002 abrogates IL-4-induced PSA expression and AR signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 34-37 12763754-5 2003 The effects of ANG II on Akt phosphorylation and NO donor-induced CFb apoptosis were abrogated when cells were preincubated with the specific phosphatidylinositol 3-kinase inhibitors wortmannin or LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 197-206 AKT serine/threonine kinase 1 Homo sapiens 25-28 12939602-6 2003 Inhibition of Akt activation by phosphatidylinositol 3-kinase (PI3-kinase) inhibitor LY294002 significantly decreased the viability of Hep3B and HepG2 cells (P <.01). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 14-17 12829832-6 2003 Furthermore, the PI3K-specific inhibitor LY294002 could inhibit Akt activation and cell transformation in all cases, indicating that Akt activation and transformation is PI3K dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 64-67 12810818-4 2003 Phosphorylation of Akt stimulated by OxLDL and epidermal growth factor (EGF) was attenuated by inhibitors of PI3-K (wortmannin and LY294002) and intracellular Ca2+ chelator (BAPTA/AM) plus EDTA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 19-22 12970779-12 2003 At variance with Ly294002, the Akt inhibitor did not negatively affect phosphorylation of protein kinase C-zeta and it was less effective in downregulating p70S6 kinase (p70S6K) activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 AKT serine/threonine kinase 1 Homo sapiens 31-34 12890489-3 2003 We found that the PI3K/Akt inhibitors LY294002 and wortmannin, but not the MEK inhibitor U0126, were capable of inducing apoptosis in growth-arrested Saos-2 cells, as assessed by an increase in the sub-G1 population, pyknotic nuclei, and DNA ladder formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 23-26 12890489-4 2003 We detected the cleavage of caspases 9 and 3, and PARP after LY294002 addition, accompanied by a loss of cytochrome c from the mitochondria, and observed Bax translocation to the mitochondria and down-regulation of phospho-Akt, suggesting that blocking of survival signals triggered the apoptotic signal through the mitochondrial apoptotic pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 61-69 AKT serine/threonine kinase 1 Homo sapiens 223-226 12748184-6 2003 Our results also demonstrate that HA/CD44-mediated oncogenic events (e.g. AKT activation, M-CSF production and breast tumor cell-specific phenotypes) can be effectively blocked by a PI 3-kinase inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 205-213 AKT serine/threonine kinase 1 Homo sapiens 74-77 12773534-5 2003 11,12-EET also stimulated the time-dependent phosphorylation of Akt and of the forkhead factors FOXO1 and FOXO3a, effects prevented by the phosphatidylinositol 3-kinase inhibitor LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-188 AKT serine/threonine kinase 1 Homo sapiens 64-67 12771144-9 2003 However, both pharmacological (wortmannin and LY294002) and genetic (Deltap85) inhibitors of PI 3"-kinase inhibited OPN-induced Akt phosphorylation, IKK activity, and NFkappaB activation through phosphorylation and degradation of IkappaBalpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 128-131 12874004-6 2003 Our study indicates that the synergistic augmentation of the cytotoxicity by LY294002 occurs specifically with antimicrotubule agents, at least partially through an increase in caspase 3-dependent apoptosis, and we suggest that inhibitors of the PI3K/Akt pathway in combination with antimicrotubule agents may induce cell death effectively and be a potent modality to treat patients with malignant gliomas. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 251-254 12714587-8 2003 Blocking this basal Akt phosphorylation with LY294002, an inhibitor of phosphatidylinositol 3-kinase, did not affect their viability but blocking of EGF-induced phosphorylation of Akt sensitized the otherwise resistant A431-RelA cells to EGF-mediated growth inhibition. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 20-23 12738789-3 2003 Whereas both cell lines are equally susceptible to LY294002-mediated Akt dephosphorylation, only LNCaP cells default to apoptosis, as evidenced by DNA fragmentation and cytochrome c release. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 69-72 12742227-7 2003 The expression of constitutively activated Akt partially reversed the inhibitory effects of LY294002 on mitotic entry, which demonstrated that Akt was one PI3K target that was required during G2/M transitions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 43-46 12742227-7 2003 The expression of constitutively activated Akt partially reversed the inhibitory effects of LY294002 on mitotic entry, which demonstrated that Akt was one PI3K target that was required during G2/M transitions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 143-146 12952968-12 2003 However, adenovirus-mediated overexpression of constitutively active Akt completely blocked UV-induced apoptosis observed with PI3K inhibition by LY294002, whereas adenovirus mediated overexpression of dominant negative Akt increased UV-induced apoptosis by 2-fold. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 146-154 AKT serine/threonine kinase 1 Homo sapiens 69-72 12943808-14 2003 Akt was activated by S-1-P at 3 to 5 min; this response was inhibited by Wortmannin and LY294002, but not by SB203580 or pertussis toxin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 0-3 12829832-6 2003 Furthermore, the PI3K-specific inhibitor LY294002 could inhibit Akt activation and cell transformation in all cases, indicating that Akt activation and transformation is PI3K dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 133-136 12621049-7 2003 The abrogation of IGF-1-mediated Akt activation by the dominant-negative PI3K or LY294002 or antisense APPL suggests that APPL may function as an important adapter protein in controlling the IGF-1 --> Akt signal pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 33-36 12808085-9 2003 In addition, inhibition of endogenous Akt activity by the PI3K/Akt inhibitor LY294002 abolishes transcriptional cooperativity between the bHLH proteins and p300. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 38-41 12808085-9 2003 In addition, inhibition of endogenous Akt activity by the PI3K/Akt inhibitor LY294002 abolishes transcriptional cooperativity between the bHLH proteins and p300. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 63-66 12788194-8 2003 In vivo sensitization was measured using clonogenic assays or regrowth assays.A dose of 100 mg/kg of LY294002, but not 50 mg/kg, consistently eliminated the phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 176-179 12676940-2 2003 Pretreatment of neutrophils with LY294002 or PP1 (inhibiting phosphatidylinositol 3-kinase (PI 3-kinase) and Src kinases, respectively) partly reversed the beta2 integrin-induced down-regulation of Rac activities. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 198-201 12761494-10 2003 Neither did the basal Akt activity correlate with the sensitivity towards gemcitabine treatment, nor did the inhibition of PI3K/Akt by LY294002 alter gemcitabine-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 128-131 12731064-7 2003 All TGF-beta 1-mediated effects, but Bcl2 up-regulation, can be reproduced by the LY294002 phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor but not by inhibitors of the MAPK/ERK (MEK) and Janus kinase (Jak)/STAT pathways, which promote cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 128-131 12668516-4 2003 Moreover, experiments performed with a pharmacological inhibitor of the phosphatidylinositol 3-kinase/Akt pathway (LY294002) or a dominant-negative Akt (K179M) demonstrated that TRAIL significantly protected HUVECs from apoptosis induced by trophic withdrawal via Akt and that inhibition of Akt sensitized HUVECs to TRAIL-induced caspase-dependent apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 102-105 12522014-6 2003 HMVECs pretreated with the Src inhibitor (PP2) and the PI3K inhibitor (LY294002) or transfected with Src antisense oligonucleotides or Akt dominant-negative mutants significantly inhibited sE-selectin-mediated HMVEC tube formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 135-138 12754302-8 2003 Consistent with these observations, phospho-AKT remained detectable in erbB-2 cells treated with LY294002 or expressing exogenous PTEN, but was abolished by treatment with the p38MAP kinase inhibitor SB202190. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 44-47 12444071-12 2002 Western blot analysis confirmed that LY294002 and PD98509 inhibited phosphorylation of Akt and ERK1/ERK2, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 87-90 12657951-3 2003 METHODOLOGY AND RESULTS: In PK-45H pancreatic cancer cells, the growth-inhibitory and apoptosis-inducing effects of LY294002, a PI3K inhibitor, were detected in a concentration-dependent manner, followed by the reduction of phosphorylated Akt levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 239-242 12514118-5 2003 Treatment of cells with the phosphatidyl-inositol 3-kinase (PI3-K) inhibitor, LY294002, inhibited Ang-1-induced phosphorylation of Akt, restored the cleavage of the effector caspase-3, and reduced the protective effect of Ang-1 against SD-induced toxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 AKT serine/threonine kinase 1 Homo sapiens 131-134 12646285-6 2003 The two agonists stimulated Akt phosphorylation and the effect was also abolished by beta-FNA and by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 28-31 12644312-5 2003 Phosphorylation of this residue is inhibited by LY294002, which blocks the PI3-kinase/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 86-89 12589789-6 2003 U0126 and LY294002 abolished ERK1/2 and Akt phosphorylation, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 40-43 12546364-5 2003 The LY294002 inhibited the growth of U87MG cells associated with reduced phosphatidylinositol 3,4,5,-trisphosphate and phosphorylated Akt, and also induced growth inhibition in three other cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 4-12 AKT serine/threonine kinase 1 Homo sapiens 134-137 12480711-9 2003 Indirect inhibition of AKT activation by the phosphatidylinositol 3-kinase inhibitor LY294002 reversed the blockade of chlorambucil-induced killing by plasma albumin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 23-26 12692267-2 2003 PC3 cells, which lack the lipid phosphatase PTEN, were treated overnight with a reversible inhibitor of the phosphatidylinositol 3-kinase, LY294002 (a treatment which was found to reversibly decrease Akt enzymatic activity). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 200-203 12692267-8 2003 These results indicate that LY294002 treatment and washout is a useful method to study the activation of Akt in the context of a tumor cell. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 105-108 12514175-5 2003 This effect could be blocked by phosphatidylinositol 3-kinase/Akt pathway inhibitors LY294002 or wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 62-65 12502711-5 2003 Both serum- and PDGF-induced Akt phosphorylation was inhibited by LY294002, an inhibitor of PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 29-32 12527329-8 2003 The PI3K inhibitor LY294002 (50 microM) inhibited PKB phosphorylation in both cells lines, but only induced apoptosis in the MDA-MB-468 line. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 50-53 12789537-6 2003 LY294002 partially inhibited the activation of Akt, and significantly decreased the number of surviving RGCs as compared with that of injury alone. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 47-50 12556562-4 2003 In vitro AKT1 activity was elevated in resistant cells, whereas treatment of the resistant cell clone with two inhibitors of PI3K, wortmannin or Ly294002, strongly reduced phosphatidylinositol (3,4,5) trisphosphate levels and AKT1 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 9-13 12556562-4 2003 In vitro AKT1 activity was elevated in resistant cells, whereas treatment of the resistant cell clone with two inhibitors of PI3K, wortmannin or Ly294002, strongly reduced phosphatidylinositol (3,4,5) trisphosphate levels and AKT1 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 226-230 12495471-7 2002 Phosphorylation of Akt was inhibited by the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and the tyrosine kinase inhibitor genistein in KMP-3 and KMP-4 cells, indicating that upstream signals are required for Akt activation in these two cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 19-22 12473596-6 2002 RESULTS: LY294002 suppressed growth and decreased expression of Akt (Ser(473)) expression in cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 64-67 12482504-4 2002 The activity of AKT, a downstream target of PI3K, was increased by hypoxia and was also inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 16-19 12460191-6 2002 Inhibition of PI-3 kinase activity and Akt phosphorylation with LY294002 totally suppressed IGF-1-mediated protection from Fas killing in activated T cells, but only partially suppressed IGF-1-mediated protection in Jurkat/IGF-1R cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 39-42 12495471-7 2002 Phosphorylation of Akt was inhibited by the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and the tyrosine kinase inhibitor genistein in KMP-3 and KMP-4 cells, indicating that upstream signals are required for Akt activation in these two cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 220-223 12242656-8 2002 LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70(S6K) but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 38-41 12606824-8 2002 Betulinic acid-induced phosphorylation and activation of the Akt protein kinase was inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 61-64 12438278-8 2002 Treatment of U87MG.DeltaEGFR cells with LY294002, a PI3-K inhibitor, caused reduced levels of phosphorylated Akt and concomitantly up-regulated levels of p27. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 109-112 12235151-4 2002 These responses were inhibited by LY294002 and ML-9, blockers of phosphatidylinositol 3-kinase (PI3K) and Akt, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 106-109 12414661-12 2002 In contrast, the phosphatidylinositol 3-kinase inhibitor, LY294002, prevented these cells from adhering and completely blocked SCF- and/or SDF-1alpha-induced Akt or p70 S6 kinase phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 158-161 12438947-11 2002 Akt activation; increase in islet viability; and decrease in Bad phosphorylation, cytochrome release, caspase-9 activation, and translocation of FKHR were observed after simvastatin treatment, effects reversed by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 213-221 AKT serine/threonine kinase 1 Homo sapiens 0-3 12386814-7 2002 Treatment with LY294002, a specific inhibitor of Akt activator, phosphatidylinositol 3-kinase, also induced apoptosis in a dose dependent manner in the control cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 49-52 12171932-6 2002 On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 118-121 12384526-5 2002 Importantly, UV-induced increases in p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424) were dramatically inhibited by pretreatment of cells with rapamycin, LY294002, or PD98059, whereas overexpression of dominant-negative mutants of PKClambda/iota and Akt1 did not inhibit p70(S6k) phosphorylation at Thr(389) and Thr(421)/Ser(424). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 165-173 AKT serine/threonine kinase 1 Homo sapiens 261-265 12225947-4 2002 Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-51 AKT serine/threonine kinase 1 Homo sapiens 211-220 12394246-4 2002 We show here that (i) growth inhibition of breast cancer cells by progesterone is due to the induction of cell differentiation and not to apoptosis; (ii) progesterone activates the PI3-kinase/Akt pathway as shown by the increase in the phosphorylation of Akt protein; (iii) inhibiting PI3-kinase/Akt pathway with LY294002 causes stimulation of apoptosis; and (v) progesterone enhances LY294002 induced-growth inhibition and apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 313-321 AKT serine/threonine kinase 1 Homo sapiens 192-195 12394246-4 2002 We show here that (i) growth inhibition of breast cancer cells by progesterone is due to the induction of cell differentiation and not to apoptosis; (ii) progesterone activates the PI3-kinase/Akt pathway as shown by the increase in the phosphorylation of Akt protein; (iii) inhibiting PI3-kinase/Akt pathway with LY294002 causes stimulation of apoptosis; and (v) progesterone enhances LY294002 induced-growth inhibition and apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 385-393 AKT serine/threonine kinase 1 Homo sapiens 192-195 12242656-11 2002 In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70(S6K) was present, inhibited by LY294002 and enhanced by IGF-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 AKT serine/threonine kinase 1 Homo sapiens 86-89 12105209-6 2002 PI3-kinase inhibitor LY294002 or AS PI3-kinase ODN inhibited Akt expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 61-64 12087097-3 2002 Interference with the Akt cascade either by treatment with PI-3K inhibitor (wortmannin or LY294002) or by exogenous expression of a dominant negative Akt in SW626 cells caused decreased cell viability following treatment with paclitaxel. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 22-25 12087097-11 2002 We demonstrated an association between Akt and Raf-1 and showed that the phosphorylation of Raf-1 on Ser-259 induced by paclitaxel was blocked by treatment with wortmannin or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 175-183 AKT serine/threonine kinase 1 Homo sapiens 39-42 12034359-13 2002 In addition, the specific inhibition of the ERK and the Akt signalling pathways by PD98059 and LY294002, respectively, increased melanin synthesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 56-59 12208743-6 2002 The use of PI3-K inhibitors, Wortmannin or LY-294002, down-regulates the active Akt and reverses cellular resistance to TRAIL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-52 AKT serine/threonine kinase 1 Homo sapiens 80-83 12481412-4 2002 SCF-induced PI3K-Akt activation occurs rapidly but fades within 60 min; IGF-I and FCS-induced activation persists for at least 6 h. SCF and IGF-I-mediated growth was potently inhibited by LY294002 in proportion to its ability to inhibit phosphatidylinositol 3-kinase (PI3K)-Akt signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 274-277 12481412-7 2002 Because LY294002 can also inhibit PI3K-related enzymes, we confirmed the role of the PI3K-Akt pathway in SCLC using doxycycline-regulated expression of a dominant-negative (kinase dead) and a constitutively active (CA; myristolated) Akt allele. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 8-16 AKT serine/threonine kinase 1 Homo sapiens 90-93 12481412-12 2002 The effect of low concentrations of LY294002 could largely be reversed by expression of CA Akt, suggesting that it was mediated by inhibition of Akt signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 91-94 12481412-12 2002 The effect of low concentrations of LY294002 could largely be reversed by expression of CA Akt, suggesting that it was mediated by inhibition of Akt signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 145-148 12479367-3 2002 Akt promoted breast cancer cell survival because a PI3K inhibitor, LY294002, or transient transfection of a dominant-negative Akt mutant inhibited Akt activity and increased apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 0-3 12481421-3 2002 Exposure of the cells to two structurally distinct inhibitors of PI3k (worthmannin and LY294002) resulted in a dose-dependent induction of apoptosis in six of seven of the cell lines that displayed constitutive AKT phosphorylation but not in either of the cell lines that did not. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 211-214 12481421-5 2002 Exposure of orthotopic L3.6pl pancreatic tumors to LY294002 resulted in dose-dependent inhibition of tumor growth, and decreased peritoneal and liver metastases, effects that were associated with an inhibition of AKT phosphorylation and increased terminal deoxynucleotidyl transferase-mediated nick end labeling staining characteristic of apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 213-216 11994280-3 2002 The inhibition of phosphatidylinositol 3-kinase with two unrelated pharmacological inhibitors, wortmannin and LY294002, abrogated both the anti-apoptotic effect and the phosphorylation of AKT induced by Tat. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 188-191 12097303-7 2002 We confirm involvement of PI3k/Akt/NFkappaB signaling because the PI3k inhibitors wortmannin and LY294002 or the inhibitor of NFkappaB (IkappaB) kinase inhibitor PS-1145 block constitutive and cytokine-induced up-regulation of telomerase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 31-34 12089369-10 2002 PI3-K inhibition by LY294002 blocked both Akt phosphorylation and superoxide generation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 42-45 12063252-3 2002 The PI3K inhibitor, LY294002, and a tumor suppressor, PTEN, negatively regulate the PI3K/Akt pathway and repress AR activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 89-92 12063252-6 2002 Moreover, we show that the repression of AR activity by LY294002 is mediated through phosphorylation and inactivation of GSK3beta, a downstream substrate of PI3K/Akt, which results in the nuclear accumulation of beta-catenin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 162-165 12400610-9 2002 Pretreatment of REH cells with a P13 kinase/Akt inhibitor LY 294002 did not inhibit RAFTK tyrosine phosphorylation showing that RAFTK is upstream of P13k/Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-67 AKT serine/threonine kinase 1 Homo sapiens 44-47 12479367-5 2002 Potentiation of apoptosis by LY294002 correlated with induction of Akt by doxorubicin or trastuzumab alone that occurred before the onset of apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 67-70 12479367-7 2002 Combining LY294002 with tamoxifen in estrogen receptor-positive cells greatly potentiated apoptosis, which was correlated with tamoxifen-induced Akt phosphorylation that preceded apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 145-148 12479367-8 2002 To confirm that the effects of LY294002 on chemotherapy-induced apoptosis were attributable to inhibition of Akt, we transiently transfected breast cancer cells with dominant-negative Akt and observed increased doxorubicin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 109-112 12479367-8 2002 To confirm that the effects of LY294002 on chemotherapy-induced apoptosis were attributable to inhibition of Akt, we transiently transfected breast cancer cells with dominant-negative Akt and observed increased doxorubicin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 184-187 12115344-6 2002 RESULTS: LY294002 significantly affected the proliferation and apoptosis of Colo205 cells, suggesting an association with the low phosphorylation level of Akt protein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 155-158 12124352-8 2002 Transduction of BT-474 cells with an adenovirus-encoding active (myristoylated) Akt (Myr-Akt), but not with a beta-galactosidase control adenovirus, prevented the Herceptin- or LY294002-induced down-regulation of cyclin D1 and of phosphorylated GSK-3beta and prevented the accumulation of p27 in the nucleus and cytosol. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 80-83 12124352-8 2002 Transduction of BT-474 cells with an adenovirus-encoding active (myristoylated) Akt (Myr-Akt), but not with a beta-galactosidase control adenovirus, prevented the Herceptin- or LY294002-induced down-regulation of cyclin D1 and of phosphorylated GSK-3beta and prevented the accumulation of p27 in the nucleus and cytosol. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 85-92 12019180-4 2002 Inhibition of Akt activation in the highly metastatic cell line Li7 by transfection with kinase-dead Akt or the phosphatidylinositol 3-kinase inhibitor, LY294002, resulted in formation of fewer colonies in soft agar than was the case with control cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 153-161 AKT serine/threonine kinase 1 Homo sapiens 14-17 11965537-5 2002 In addition, the cytokine-induced Rac activation was inhibited by a phosphatidyl-inositol 3"-kinase (PI3K) inhibitor, LY294002, which also inhibited the Erk activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 34-37 12089343-9 2002 Inhibition of PI3-K activities via treatment with LY294002 disrupted Akt activation and interfered with the endocrine differentiation of trophoblast giant cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 69-72 12056831-5 2002 Lactate dehydrogenase (LDH) assay and Hoechst nucleic staining indicated that U0126, which inhibits Erk1/2 phosphorylation, enhanced ischemia-induced cell death, whereas LY294002, which inhibits Akt phosphorylation, delayed cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 195-198 11919181-3 2002 Exposure of cells to 2-20 mm EtOH resulted in rapid (<10 min) induction of Akt phosphorylation that could be prevented by pertussis toxin or the PI3K inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-187 AKT serine/threonine kinase 1 Homo sapiens 78-81 12051724-3 2002 E2 activates constructs containing multiple copies of the SRF (pSRF) and a GAL4-SRF fusion protein; these responses are accompanied by PI3-K-dependent phosphorylation of Akt and inhibited by wortmannin/LY294002, the antiestrogen ICI 182780, but not by the mitogen-activated protein kinase kinase (MAPKK) inhibitor PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 202-210 AKT serine/threonine kinase 1 Homo sapiens 170-173 12115180-7 2002 Activation of Akt was blocked by the specific PI 3-kinase inhibitor, LY294002, indicating that TGFbeta-mediated phosphorylation of Akt was dependent on PI 3-kinase activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 14-17 12115180-7 2002 Activation of Akt was blocked by the specific PI 3-kinase inhibitor, LY294002, indicating that TGFbeta-mediated phosphorylation of Akt was dependent on PI 3-kinase activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 131-134 12060641-2 2002 We postulated that 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a PI3K inhibitor, should inactivate Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis in vitro and in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 103-110 12060641-6 2002 RESULTS: LY294002 demonstrated a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser(473)). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 170-173 11828365-8 2002 IL-2 mediated rescue of T cells from apoptosis but no induction of proliferation occurred in thepresence of LY294002, an inhibitor of PI3 K, which also blocked subsequent PKB activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 171-174 11733515-4 2002 Conversely, inhibition of PI3K-AKT signaling via the specific pharmacological inhibitor LY294002 up-regulated AP1/Jun- and STAT-dependent transcriptional activities, resulting in suppression of the FasR promoter activities and decreased FasR surface expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 31-34 12503617-4 2002 Both, IL-4 and IGF-1, signaling pathways induced phosphorylation of Akt kinase in a PI 3-kinase-dependent manner, as assessed by addition of the PI 3-kinase inhibitor Ly294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 68-71 11687577-7 2002 Further evidence for the central role of a pathway involving PI 3-K and AKT in preserving cell viability during RSV infection was established by the observation that constitutively active AKT transfected into A549 cells prevented the cytotoxicity and apoptosis of combined RSV and LY294002 treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 281-289 AKT serine/threonine kinase 1 Homo sapiens 72-75 11687577-7 2002 Further evidence for the central role of a pathway involving PI 3-K and AKT in preserving cell viability during RSV infection was established by the observation that constitutively active AKT transfected into A549 cells prevented the cytotoxicity and apoptosis of combined RSV and LY294002 treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 281-289 AKT serine/threonine kinase 1 Homo sapiens 188-191 12373512-5 2002 Akt phosphorylation was completely blocked by the PI-3 kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 0-3 11593406-6 2001 Inhibition of Akt activation by the PI3-K inhibitor LY294002 partially blocked IL-6 triggered MEK/MAPK activation and proliferation in MM.1S cells, suggesting cross-talk between PI3-K and MEK signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 14-17 11804874-5 2002 Moreover, these stimuli appeared to induce the serine and threonine phosphorylation of Akt, which was reduced by the PI 3-kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 87-90 11709727-4 2001 Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 129-132 12086898-9 2001 PI3K inhibition significantly enhanced the antiproliferative and proapoptotic effects of TNF-alpha in both cell lines, Ly294002 also blocked TNF-alpha-induced Akt activation but failed to alter cytoplasmic IkappaBalpha degradation or subsequent NF-kappaB nuclear translocation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 159-162 11788791-12 2001 PI-3-kinase inhibitors, Wortmannin and LY294002 inhibited arsenite-induced phosphorylation of AKT and eNOS but had no effect on phosphorylation of p38. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 94-97 11461904-8 2001 Down-regulation of constitutively active Akt by phosphatidylinositol 3-kinase inhibitors, wortmannin and LY294002, reversed cellular resistance to TRAIL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 41-44 11593415-10 2001 Downregulation of constitutively active Akt by PI-3 kinase inhibitors (wortmannin and LY-294002), dominant negative Akt or PTEN, renders LNCap cells sensitive to TRAIL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-95 AKT serine/threonine kinase 1 Homo sapiens 40-43 11432865-6 2001 Suppression of Akt activity both by wortmannin and LY-294002 or by a dominant negative Akt mutant abolished the anti-apoptotic effect of HDL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-60 AKT serine/threonine kinase 1 Homo sapiens 15-18 11754748-6 2002 Blocking the activation of Akt with LY294002, a specific inhibitor of the Akt up-stream molecule PI 3-kinase, or an with adenoviral vector for a dominant-negative form of Akt prevented the stimulation of osteoclast survival by IL-1alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 27-30 11598110-7 2001 Interestingly, the H(2)O(2)-induced activation of Akt was entirely mediated by upstream stimulation of PI 3"-kinase activity, since treatment of 3T3-L1 adipocytes with the PI 3"-kinase inhibitors wortmannin or LY294002 completely blocked the subsequent activation of Akt by exogenous H(2)O(2). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 210-218 AKT serine/threonine kinase 1 Homo sapiens 50-53 11675379-7 2001 TNF-alpha treatment increased the phosphorylation of Akt in osteoclasts, which was suppressed by a phosphatidylinositol 3-kinase inhibitor LY294002 and an Src family kinase-selective inhibitor PP1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 53-56 11590144-6 2001 Furthermore, the downstream effector of PI3K, protein kinase B/AKT, is activated by NRG in the presence of H(2)O(2), and protein kinase B/AKT activation is inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 63-66 11590144-6 2001 Furthermore, the downstream effector of PI3K, protein kinase B/AKT, is activated by NRG in the presence of H(2)O(2), and protein kinase B/AKT activation is inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 138-141 11549666-2 2001 Insulin stimulation of glycogen synthase activity as well as phosphorylation of MAPK, p70 S6 kinase, and protein kinase B (Akt) were blocked by the phosphatidylinositol 3-kinase inhibitors wortmannin (50 nM) and LY294002 (10 microM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 212-220 AKT serine/threonine kinase 1 Homo sapiens 123-126 11490019-7 2001 Phosphatidylinositol 3-phosphate kinase and Akt activities were also induced by C5b-9, and the phosphatidylinositol 3-phosphate kinase inhibitor LY294002 reversed the protective effect of C5b-9. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 44-47 11479233-9 2001 Inhibitors of MEK (U0126) and PI3K (LY294002) blocked p42/p44(erk) and Akt, respectively, and partially blocked HGF-induced production of IL-8 and VEGF, whereas the combination of U0126 and LY294002 completely inhibited expression of IL-8 and VEGF by UMSCC-11A. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 71-74 11350959-2 2001 Treatment with a phosphatidylinositol 3-kinase inhibitor, LY 294002, or expression of a dominant negative mutant of p85 (regulatory component of phosphatidylinositol 3-kinase) inhibited UVB-induced Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-67 AKT serine/threonine kinase 1 Homo sapiens 198-201 11418646-5 2001 Pretreatment of cells with N,N-dimethylsphingosine (DMS), an inhibitor of SphK, or LY 294002, an inhibitor of PI3K that acts upstream of Akt, increased the number of apoptotic cells induced by TNF-alpha in Ad5IkappaB-infected Huh-7 and Hc cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-92 AKT serine/threonine kinase 1 Homo sapiens 137-140 11254732-7 2001 We found that both of these events were linked to PI 3-kinase because the PI 3-kinase inhibitors, wortmannin and LY294002, inhibited LPS-induced phosphorylation of both AKT and GSK-3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 169-172 11457886-4 2001 Akt-1 was constitutively activated in human macrophages and addition of the PI3K inhibitor, LY294002, suppressed the activation of Akt-1 and induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 0-5 11457886-4 2001 Akt-1 was constitutively activated in human macrophages and addition of the PI3K inhibitor, LY294002, suppressed the activation of Akt-1 and induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 131-136 11457886-8 2001 However, after inhibition of the PI3K/Akt-1 pathway, a marked decrease in the expression of the antiapoptotic molecule Mcl-1, but not other Bcl-2 family members was observed, and Mcl-1 rescued macrophages from LY294002-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 210-218 AKT serine/threonine kinase 1 Homo sapiens 38-43 11552986-7 2001 LY294002, an inhibitor of phosphatidylinositol 3"-kinase, blocked Akt activation by plasma. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 66-69 11391701-7 2001 Western blotting analysis demonstrated that treatment with 17beta-estradiol induced the phosphorylation of Akt within 5 min, which was suppressed by pretreatment with LY294002 and ICI182780. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 107-110 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 0-3 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 4-7 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 165-168 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 169-172 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 165-168 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 169-172 11358816-4 2001 Akt/PKB activation was phosphatidylinositol 3-kinase-dependent and promoted survival because the phosphatidylinositol 3 inhibitors LY294002 and wortmannin inhibited Akt/PKB phosphorylation, Akt/PKB activity, and increased apoptosis only in cells with active Akt/PKB. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 0-7 11358816-6 2001 LY294002 greatly potentiated chemotherapy-induced apoptosis in cells with high Akt/PKB levels, but did not significantly increase chemotherapy-induced apoptosis in cells with low Akt/PKB levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 79-82 11358816-6 2001 LY294002 greatly potentiated chemotherapy-induced apoptosis in cells with high Akt/PKB levels, but did not significantly increase chemotherapy-induced apoptosis in cells with low Akt/PKB levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 83-86 11358816-7 2001 Combined with radiation in cells with active Akt/PKB, LY294002 additively increased apoptosis and inhibited clonogenic growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 45-52 11124266-7 2001 Surprisingly constitutively nuclear DAF-16 mutants that lack AKT/14-3-3 binding sites also show enhanced DNA binding and transcription activity in response to LY294002, pointing to a 14-3-3-independent mode of regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 AKT serine/threonine kinase 1 Homo sapiens 61-64 11278284-3 2001 Inhibition of PI 3-kinase using wortmannin and LY-294002 suppressed constitutive Akt activity and sensitized LNCaP cells to TRAIL. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-56 AKT serine/threonine kinase 1 Homo sapiens 81-84 11139588-8 2001 In addition, LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERalpha in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 63-66 11241670-9 2001 Akt activation by PDGF-BB was inhibited by PI 3-kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 0-3 11241670-11 2001 Epidermal growth factor (EGF) also activated Akt in osteoblastic cells which was inhibited by LY294002 but not by rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 45-48 11145953-7 2001 In contrast, disruption of the PI 3-kinase pathway with the specific inhibitor LY294002 reduced Akt (protein kinase B) phosphorylation and the levels of FLIP protein and mRNA in all cell lines evaluated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 96-99 11341977-4 2001 As expected, phosphorylation of protein kinase B/akt was blocked by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-132 AKT serine/threonine kinase 1 Homo sapiens 49-52 11062076-6 2000 Akt activation is inhibited in the presence of the phosphoinositide 3-kinase (PI-3K) inhibitors wortmannin and LY294002, and by treatment with the platelet-derived growth factor (PDGF) receptor (PDGFR) inhibitor AG1295, indicating a requirement for PDGFR and PI-3K in mediating peroxynitrite-induced Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 0-3 11162904-4 2000 IGF-I induces Akt phosphorylation at Ser473, an event which may be blocked by pretreatment with a PI-3K inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 14-17 11156376-3 2000 Blocking of the Akt pathway by a dominant-negative Akt or an inhibitor LY294002 abrogates the HER-2/neu-induced AR signaling and cell survival/growth effects in the absence or presence of androgen. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 16-19 11145615-0 2001 Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 44-47 11145615-6 2001 LY is much less effective in blocking the phosphorylation of Akt than p70(S6K); at concentrations which completely inhibit phosphorylation of p70(S6K), phosphorylation of Akt is only partially inhibited by LY. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-2 AKT serine/threonine kinase 1 Homo sapiens 61-64 11145615-6 2001 LY is much less effective in blocking the phosphorylation of Akt than p70(S6K); at concentrations which completely inhibit phosphorylation of p70(S6K), phosphorylation of Akt is only partially inhibited by LY. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-2 AKT serine/threonine kinase 1 Homo sapiens 171-174 11145615-6 2001 LY is much less effective in blocking the phosphorylation of Akt than p70(S6K); at concentrations which completely inhibit phosphorylation of p70(S6K), phosphorylation of Akt is only partially inhibited by LY. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 206-208 AKT serine/threonine kinase 1 Homo sapiens 171-174 11228049-8 2000 PD98059 inhibited activation of Erk and LY294002 repressed activation of Akt in response to IGF-I, but did not affect tyrosine phosphorylation of the IGF-IR, IRS-1, IRS-2, or Shc. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 73-76 10927021-10 2000 Analyses of the phosphorylation status of Akt-1, an in vivo substrate of PI 3-kinase, demonstrated that concentrations of LY294002 >/= 50 microM and Wortmannin >/= 10 nM completely suppressed PI 3-kinase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 42-47 10908564-6 2000 PI3K inhibitors, wortmannin or LY294002, significantly blocked the Akt kinase activity induced by EGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 67-70 10757809-10 2000 Transient transfection of a constitutively active PI3-kinase or an inducible Akt promoted myoblast viability in the absence of growth factors, while inhibition of PI3-kinase activity by the drug LY294002 selectively blocked IGF- but not PDGF-mediated muscle cell survival. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 195-203 AKT serine/threonine kinase 1 Homo sapiens 77-80 10961875-6 2000 The importance of MAPK and Akt/PKB signaling pathways in regulating the expression of Mcl-1 and cell survival was further supported by the observation that inhibition of MEK by PD98059 or phosphatidylinositol-3 kinase (PI-3K) by LY294002 independently resulted in the reduction of Mcl-1 expression and loss of cell viability. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 229-237 AKT serine/threonine kinase 1 Homo sapiens 31-34 10869359-6 2000 Furthermore, expression of Akt inhibits epidermal growth factor-induced B-Raf activity and inhibition of Akt with LY294002 up-regulates B-Raf activity, suggesting that Akt negatively regulates B-Raf in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 105-108 10869359-6 2000 Furthermore, expression of Akt inhibits epidermal growth factor-induced B-Raf activity and inhibition of Akt with LY294002 up-regulates B-Raf activity, suggesting that Akt negatively regulates B-Raf in vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 105-108 10910908-5 2000 EPO-induced phosphorylation of Akt was completely blocked by a PI3K-specific inhibitor, LY294002, at 10 micromol/L, indicating that activation of Akt by EPO is dependent on PI3K activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 31-34 10910908-5 2000 EPO-induced phosphorylation of Akt was completely blocked by a PI3K-specific inhibitor, LY294002, at 10 micromol/L, indicating that activation of Akt by EPO is dependent on PI3K activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 146-149 10900165-6 2000 It was found that CT-1 phosphorylated and activated Akt, and the effect was blocked by the PI3K inhibitors LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 107-115 AKT serine/threonine kinase 1 Homo sapiens 52-55 10900165-7 2000 CT-1 also phosphorylated the pro-apoptotic factor, BAD, and the BAD phosphorylation was inhibited by LY294002, suggesting that phosphorylation of BAD is one of the key events by which the PI3K/Akt pathway mediates CT-1-induced survival signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 193-196 10913180-4 2000 In contrast, cell proliferation and the associated transient phosphorylation of Akt and p70(rsk) induced by sst(2(b)) receptors were blocked by the PI 3-K inhibitor LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 165-174 AKT serine/threonine kinase 1 Homo sapiens 80-83 10871858-11 2000 However, the effects of roscovitine appear to be distinct from those of LY294002, since roscovitine did not affect Akt activity while LY294002 significantly decreased the activity of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 134-142 AKT serine/threonine kinase 1 Homo sapiens 183-186 10963053-5 2000 The PI 3-kinase inhibitors wortmannin and LY294002 blocked IGF-I induced increases in PI 3-kinase activity and phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 130-133 10872812-5 2000 While the IGF-I-induced activation of PKB/Akt was inhibited by PI3-K inhibitor LY294002 but not by MEK inhibitor PD98059, the activation of both MEK and ERK by IGF-I was inhibited by both. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 38-41 10872812-5 2000 While the IGF-I-induced activation of PKB/Akt was inhibited by PI3-K inhibitor LY294002 but not by MEK inhibitor PD98059, the activation of both MEK and ERK by IGF-I was inhibited by both. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 42-45 10748004-6 2000 LY294002 potentiates the activation of mitogen-activated protein kinases and stress-activated protein kinases by TNF and IL-1, suggesting Akt inhibits these responses. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 138-141 10799549-5 2000 Expression of a dominant negative mutant of p85 (regulatory component of PI3-K) and treatment with inhibitors of PI3-K (wortmannin and LY294002) prevented H(2)O(2)-induced Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 172-175 10891487-4 2000 TCR-induced Akt/PKB activation is inhibited either by PI 3-kinase inhibitors (LY294002 and wortmannin) or by overexpression of a dominant negative mutant of Rac1 but not Cdc42. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 AKT serine/threonine kinase 1 Homo sapiens 12-15 10891487-4 2000 TCR-induced Akt/PKB activation is inhibited either by PI 3-kinase inhibitors (LY294002 and wortmannin) or by overexpression of a dominant negative mutant of Rac1 but not Cdc42. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 AKT serine/threonine kinase 1 Homo sapiens 16-19 10891487-6 2000 Similar to TCR stimulation, L61Rac-induced Akt/PKB kinase activity is also LY294002 and wortmannin sensitive. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 AKT serine/threonine kinase 1 Homo sapiens 43-46 10891487-6 2000 Similar to TCR stimulation, L61Rac-induced Akt/PKB kinase activity is also LY294002 and wortmannin sensitive. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 AKT serine/threonine kinase 1 Homo sapiens 47-50 10748004-3 2000 Phosphorylation of Akt is blocked by LY294002 or wortmannin, inhibitors of phosphatidylinositol 3-kinase (PI 3-kinase). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 19-22 10777606-7 2000 Both cAMP- and cGMP-elevating agents led to marked increases in Akt activation that was inhibited by the phosphatidylinositol 3"-kinase inhibitors, LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 64-67 10754327-8 2000 GM-CSF-dependent Akt and BAD phosphorylation was blocked by the PI 3-kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 17-20 10754327-9 2000 A role for the PI 3-kinase/Akt pathway in GM-CSF-stimulated delay of apoptosis was indicated by the ability of LY294002 to attenuate apoptosis delay. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 27-30 10754327-13 2000 LY294002 blocked IL-8-dependent Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 32-35 11467775-5 2000 Similarly, P1-3 kinase inhibitors, Wortmannin and LY294002, strongly suppressed the FN-dependent secretion of MMP-9 together with the inhibition of Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 148-151 10749120-4 2000 LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 189-192 10702262-11 2000 However, treatment with LY 294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), inhibited basal Akt activity, up-regulated p27, and recruited cells in G(1). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-33 AKT serine/threonine kinase 1 Homo sapiens 105-108 10617634-6 2000 Akt kinase activity and Rac1 peptide phosphorylation were down-regulated by the treatment of SK-MEL28 cells with wortmannin or LY294002 (a phosphoinositide 3-kinase inhibitor), but JNK/SAPK kinase activity was up-regulated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 0-3 10493495-5 1999 Phosphorylation of AKT and GSK-3beta by CR-1 can be blocked by LY294002, a specific inhibitor of PI3K, thus leading to apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 19-22 10467260-6 1999 Both neo-transfected and the c-Akt dominant-negative transfected F-11 cells showed increased ceramide formation (twofold) in response to staurosporine, wortmannin, or LY294002; whereas cells with a constitutively active Akt (Myr-Akt) showed no increase in ceramide when treated with staurosporine, wortmannin, or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 31-34 10467260-6 1999 Both neo-transfected and the c-Akt dominant-negative transfected F-11 cells showed increased ceramide formation (twofold) in response to staurosporine, wortmannin, or LY294002; whereas cells with a constitutively active Akt (Myr-Akt) showed no increase in ceramide when treated with staurosporine, wortmannin, or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 313-321 AKT serine/threonine kinase 1 Homo sapiens 31-34 10428852-5 1999 Both angiotensin II and H(2)O(2) stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 48-51 10428852-5 1999 Both angiotensin II and H(2)O(2) stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 52-55 10428852-5 1999 Both angiotensin II and H(2)O(2) stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 250-253 10428852-5 1999 Both angiotensin II and H(2)O(2) stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 254-257 10428852-5 1999 Both angiotensin II and H(2)O(2) stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-198 AKT serine/threonine kinase 1 Homo sapiens 48-51 10428852-5 1999 Both angiotensin II and H(2)O(2) stimulation of Akt/PKB are abrogated by the phosphatidylinositol 3-kinase (PI3-K) inhibitors wortmannin and LY294002 (2(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), suggesting that PI3-K is an upstream mediator of Akt/PKB activation in VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-198 AKT serine/threonine kinase 1 Homo sapiens 52-55 10412024-8 1999 Phosphorylation of the PI3K signaling target, Akt, was measured; TX14(A) and IGF-I increased Akt activity by 12-fold and 22-fold, respectively, that was inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 166-174 AKT serine/threonine kinase 1 Homo sapiens 46-49 10412024-8 1999 Phosphorylation of the PI3K signaling target, Akt, was measured; TX14(A) and IGF-I increased Akt activity by 12-fold and 22-fold, respectively, that was inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 166-174 AKT serine/threonine kinase 1 Homo sapiens 93-96 10362672-6 1999 ANG II-stimulated Akt/PKB activation was inhibited by the tyrosine kinase inhibitors genistein and herbimycin A and by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-195 AKT serine/threonine kinase 1 Homo sapiens 18-21 10411946-6 1999 Protracted treatment with selective PI 3-K inhibitors, wortmannin and LY294002, abolished Akt-1 activity and induced neuronal death that could be reduced by long-term lithium pretreatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 90-95 10362672-6 1999 ANG II-stimulated Akt/PKB activation was inhibited by the tyrosine kinase inhibitors genistein and herbimycin A and by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-195 AKT serine/threonine kinase 1 Homo sapiens 22-25 10051597-6 1999 The inhibition of myotube formation and the reduced expression of muscle-specific proteins caused by the PI 3-kinase inhibitor LY294002 are completely reversed by constitutively active forms of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 194-197 10454216-4 1999 The crucial role of lipid second messengers in PKB activation has been dissected through the use of the PI 3-kinase-specific inhibitors wortmannin and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 47-50 10051597-7 1999 Wild-type cellular Akt effects a partial reversal of LY294002-induced inhibition of myogenic differentiation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 19-22 9829964-6 1998 Akt/PKB induced CREB activity only in response to serum stimulation, and this effect was suppressed by the phosphatidylinositol 3-kinase inhibitor LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 147-156 AKT serine/threonine kinase 1 Homo sapiens 0-7 9878764-3 1999 Akt activity decreased following the addition of 10 microM LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 0-3 9710127-6 1998 The stimulation of Akt phosphorylation by shear stress thereby seemed to be mediated by the phosphoinositide 3-OH kinase (PI3K), as evidenced by the significant inhibition of shear stress-induced Akt phosphorylation by the PI3K inhibitors wortmannin (20 nmol/L) and Ly294002 (10 micromol/L). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 266-274 AKT serine/threonine kinase 1 Homo sapiens 19-22 9722592-6 1998 The selective PI3K inhibitors wortmannin and LY294002 blocked phosphorylation of this site, previously shown to be necessary for Akt enzymatic activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 129-132 9710127-6 1998 The stimulation of Akt phosphorylation by shear stress thereby seemed to be mediated by the phosphoinositide 3-OH kinase (PI3K), as evidenced by the significant inhibition of shear stress-induced Akt phosphorylation by the PI3K inhibitors wortmannin (20 nmol/L) and Ly294002 (10 micromol/L). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 266-274 AKT serine/threonine kinase 1 Homo sapiens 196-199 9234699-4 1997 The PI 3-kinase inhibitors wortmannin and LY294002 significantly decreased the integrin-induced accumulation of the 3-PPIs and activation of AKT kinase, without having significant effects on the levels of PI(4,5)P2 or tyrosine phosphorylation of paxillin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 141-144 9394803-5 1997 Pretreatment of serum-starved Jurkat cells with 100 nM wortmannin (WT) or 10 microM LY294002, two unrelated pharmacological inhibitors of PI 3-K, markedly suppressed the catalytic activity of both PI 3-K and Akt/PKB in Jurkat cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 208-215 34875308-15 2022 rHDL-apoE3 also increased the phosphorylation of ERK1/2, AKT, eNOS and p38 MAPK in these cells, while PD98059 and LY294002 inhibited rHDL-apoE3-induced phosphorylation of ERK1/2, AKT and p38 MAPK, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 179-182 34678088-8 2022 PI3K pathway inhibitor LY294002 or MEK pathway inhibitor U0126, or Warburg effect inhibitor DCA was used to carry out western blot and glucose metabolism experiments, and the results showed that PDGFBB/PDGFRbeta mainly activated the PI3K/AKT/mTOR/ c-Myc pathway to promote aerobic glycolysis in osteosarcoma HOS cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 238-241 25351625-0 2015 LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3-kinase/Akt/fatty acid synthase signaling pathway in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 112-115 25351625-8 2015 The results demonstrated that LY294002 suppressed the PI3K/Akt/FASN signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 59-62 25351625-10 2015 The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 116-119 34958867-6 2022 Co-treatment of TAL with LY294002 considerably suppressed the activation of PI3K, Akt1 and mTOR expression and phosphorylated protein levels in TNBC cells and caused changes in the multiple kinase phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 82-86 34913077-8 2022 After addition of the PI3K/AKT/mTOR signaling pathway inhibitor LY294002 or activator 740Y-P, cell function analysis was performed. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 27-30 34935059-11 2022 Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM-induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 25-28 34956168-8 2021 This was further confirmed by the finding that both inhibitors of PI3K-Akt and its main downstream signaling mTOR, LY294002, and rapamycin, respectively, can reverse the increase of IFN-gamma production and cytotoxicity in NK cells promoted by Daphnetin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 115-123 AKT serine/threonine kinase 1 Homo sapiens 71-74 34813998-5 2022 Notably, next generation pharmacogenomic analysis identified the PI3K/Akt modulator LY294002 as the most highly ranked small molecule with both pro- and anti-oligodendroglial concentration-dependent effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 70-73 34500338-8 2022 We observed that the expression of p-AKT was upregulated which means that the AKT signaling pathway could be activated by LIPUS, while inhibitor LY294002 of the AKT signaling pathway effectively blocked LIPUS-induced angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 37-40 34500338-8 2022 We observed that the expression of p-AKT was upregulated which means that the AKT signaling pathway could be activated by LIPUS, while inhibitor LY294002 of the AKT signaling pathway effectively blocked LIPUS-induced angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 161-164 34761752-4 2021 Previous studies have reported the potential of LY294002 (LY) as a PI3K/Akt inhibitor that suppresses the HSC activation and fibrosis development; however, its poor water solubility impedes further investigation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 72-75 34761752-4 2021 Previous studies have reported the potential of LY294002 (LY) as a PI3K/Akt inhibitor that suppresses the HSC activation and fibrosis development; however, its poor water solubility impedes further investigation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-60 AKT serine/threonine kinase 1 Homo sapiens 72-75 34938752-8 2021 Administering LY294002, an Akt inhibitor, decreased p-mTOR levels, but did not change the levels of total and phosphorylated AMPKalpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 27-30 34146182-11 2021 The PI3K/Akt signaling suppression using LY294002 reversed the inhibitive effect of higenamine on IL-1beta-caused apoptosis, and this effect was weakened by ROS inhibition. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 9-12 34820336-0 2021 LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 121-124 34820336-8 2021 PI3K inhibitor, LY294002, can block PI3K/AKT signaling, further inhibit glycolysis to disturb ATP production, and finally induce cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 41-44 34771123-8 2021 Furthermore, HMH inhibited the PI3K/AKT/mTOR pathway by significantly reducing p-AKT expression in combination with LY294002, an AKT inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 129-132 34912580-11 2021 Inhibition of Akt activity by LY294002 promoted ET-1 production. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 14-17 34224057-9 2021 Further studies demonstrated that MGC27382-mediated inhibition on NSCLC progression can be impaired by LY294002, which is a frequently used inhibitor of AKT/GSK3beta pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-111 AKT serine/threonine kinase 1 Homo sapiens 153-156 34741867-7 2021 To dissect the signaling pathway leading to SGK1 upregulation, we pretreated THP-1-derived macrophages with specific inhibitors of Notch (DAPT), AKT (LY294002) or ERK (U0126). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 150-158 AKT serine/threonine kinase 1 Homo sapiens 145-148 34741867-8 2021 Among these inhibitors, only LY294002 decreased the SGK1 mRNA levels in M(IL-4), indicating that the AKT pathway plays a key role in SGK1 transcription in M(IL-4). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 101-104 34799978-2 2021 First, western-blot and real-time quantitative PCR were used to detect the effect of simvastatin or LY294002 on the expression levels of AKT, miR-9 and KLF5, or determine the effect of miR-9. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 100-108 AKT serine/threonine kinase 1 Homo sapiens 137-140 34799978-3 2021 Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin dose-dependently upregulated the expression of PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 147-155 AKT serine/threonine kinase 1 Homo sapiens 22-25 34799978-5 2021 LY294002 abrogated the upregulation of p-AKT expression levels induced by simvastatin, and LY294002 induced the miR-9 expression and simvastatin dose-dependently inhibited the expression of miR-9, by contrast, LY294002 reduced the KLF5 expression and simvastatin dose-dependently promoted the expression of KLF5. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 41-44 34846946-6 2022 Mechanistically, PI3K/Akt pathway was mediated by SET8 and inhibition of PI3K/Akt signaling pathway by giving LY294002 or transfecting Akt phosphorylation inactivated mutation plasmid increased apoptosis and calcification. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 22-25 34846946-6 2022 Mechanistically, PI3K/Akt pathway was mediated by SET8 and inhibition of PI3K/Akt signaling pathway by giving LY294002 or transfecting Akt phosphorylation inactivated mutation plasmid increased apoptosis and calcification. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 78-81 34830972-7 2021 Such a defect in PI3K/AKT signaling was responsible for reduced MCS growth and cell evasion, as demonstrated by the inhibition of the pathway in control MCS using LY294002 or Perifosine, which did not significantly affect Tau-depleted MCS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 163-171 AKT serine/threonine kinase 1 Homo sapiens 22-25 34822557-6 2021 Moreover, we observed that inhibition of phosphoinositide 3 kinase (PI3K)/AKT using LY294002 (50 microM) could reverse the alterations in FOXA2 and MUC5AC expression -by IL-13 and BV. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 74-77 34497513-7 2021 In addition, eHSP90alpha induced ER stress in fibroblasts via the phosphoinositide-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (AKT) signaling pathway, which could be blocked by the PI3K/AKT inhibitor LY294002, and blockade of eHSP90alpha by 1G6-D7 markedly inhibited ER stress in the model, indicating preventive and therapeutic applications. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 207-215 AKT serine/threonine kinase 1 Homo sapiens 134-137 34605863-8 2021 Mechanistic studies identified that lung cancer cell-derived exosomes activated the PI3K/Akt pathway, and transfection of si-FOXD3-AS1 or treatment with the PI3K inhibitor LY294002 reversed the activation of the PI3K/Akt axis induced by exosomes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 89-92 34605863-8 2021 Mechanistic studies identified that lung cancer cell-derived exosomes activated the PI3K/Akt pathway, and transfection of si-FOXD3-AS1 or treatment with the PI3K inhibitor LY294002 reversed the activation of the PI3K/Akt axis induced by exosomes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 217-220 34399087-5 2021 Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 141-144 34603025-11 2021 Additionally, administration of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway inhibitors MK-2206 and LY294002 abolished the beneficial effects of gastrodin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 73-76 34540654-11 2021 This effect was attenuated by the Akt inhibitor ly294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 34-37 34437815-8 2021 siCEMIP or PI3K/AKT signaling inhibitor (Akti-1/2 and LY294002) partly reversed the effects of miR-4677-3p on the cellular growth and metastasis of gastric cancer. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 16-19 34339756-11 2021 Gene and protein detection showed that DG-8d or DG-8d combined with LY294002 could down-regulate signaling molecules of Bcl-2, PI3k, p-Akt, p-FoxO3a and up-regulate signaling molecules of Bax snd Bim. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 135-138 34530574-20 2021 Compared with NC group, overexpression of CacyBP inhibited E-cadherin expression while promoted the expressions of N-cadherin, Snail1, Vimentin and p-Akt, which could be restored by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-190 AKT serine/threonine kinase 1 Homo sapiens 150-153 34697781-4 2021 LY294002 (a PI3K/Akt inhibitor) and IGF-1 (a PI3K/Akt activator) were employed to investigate the expression of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 17-20 34697781-4 2021 LY294002 (a PI3K/Akt inhibitor) and IGF-1 (a PI3K/Akt activator) were employed to investigate the expression of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 117-120 34697781-11 2021 Western blotting results showed that JB and LY294002 treatment significantly inhibited the levels of Bcl-2, p-PI3K, and p-Akt while the levels of Bax, cleaved caspase-3, and PTEN protein significantly increased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 122-125 34168289-12 2021 LY294002 inhibited Akt phosphorylation induced by TGF-beta1 but failed to prevent EMT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 19-22 34168289-6 2021 In addition, the effects of a TGF-beta type I receptor inhibitor (A8301) and PI3K-Akt inhibitor (LY294002) on EMT were evaluated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 82-85 34419144-17 2021 LY294002, a PI3K inhibitor, attenuated the phosphorylation of PI3K, AKT, and NF-kappaB p65, and the nuclear translocation of NF-kappaB p65. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 68-71 34497513-7 2021 In addition, eHSP90alpha induced ER stress in fibroblasts via the phosphoinositide-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (AKT) signaling pathway, which could be blocked by the PI3K/AKT inhibitor LY294002, and blockade of eHSP90alpha by 1G6-D7 markedly inhibited ER stress in the model, indicating preventive and therapeutic applications. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 207-215 AKT serine/threonine kinase 1 Homo sapiens 193-196 34413821-12 2021 Akt inhibitor LY294002 reversed the promotion of silencing GAS5 on ECM synthesis of degenerative NPCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 0-3 34184087-5 2021 LY294002 and insulin-like growth factor I (IGF-I) were used to inhibit and promote PI3K/AKT phosphorylation, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 88-91 34522167-5 2021 Specific inhibitor of the PI3K-Akt signaling cascade, LY294002 markedly inhibited the expression of p-Akt and significantly reduces the hypoxia-induced proliferation of cholesteatoma keratinocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 31-34 34522167-5 2021 Specific inhibitor of the PI3K-Akt signaling cascade, LY294002 markedly inhibited the expression of p-Akt and significantly reduces the hypoxia-induced proliferation of cholesteatoma keratinocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 102-105 34184087-7 2021 The present study found that LY294002 inhibited PI3K/AKT phosphorylation, decreased the proliferation and invasion of NOZ cells and suppressed the activity of ERRalpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 53-56 34366628-15 2021 Finally, YB-1 suppressed the inactivation of the PI3K/Akt signaling pathway induced by sorafenib, and the blockade of the PI3K/Akt signaling pathway by LY294002 mitigated YB-1-induced sorafenib resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 152-160 AKT serine/threonine kinase 1 Homo sapiens 127-130 34326958-13 2021 LY294002 abolished the dcOC-mediated (1 h) promotion of Akt phosphorylation and glucose uptake without affecting GLUT1 protein expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 56-59 34299056-4 2021 We found that TIGAR expression was induced in stimulated lymphocytes through the PI3K/AKT pathway, since Akti-1/2 and LY294002 inhibitors prevented the upregulation of TIGAR in response to ConA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 86-89 34238315-17 2021 The Akt/GSK-3beta/Snail signaling pathway was activated by overexpression of CHN1 in vitro, and activation of this pathway was inhibited by the signaling pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 4-7 34295885-11 2021 We further demonstrated that the AKT activation was abolished by the use of a PI3K inhibitor (LY294002), which negatively affected STX2-mediated functions on trophoblasts. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 33-36 34227646-6 2021 Subsequently, it was demonstrated treatment with PI3K/AKT pathway inhibitor (LY294002) or Wnt/beta-catenin pathway inhibitor (Dickkopf-1, DKK-1) could further enhance the anti-inflammatory and antioxidant effects of RSV by downregulating the expression of IL-1beta, IL-6, IL-8 and TNFalpha, and the production of MDA, and increasing the activity of SOD and GSH-Px in LPS-induced HGFs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 54-57 34182538-4 2021 Activated GPR30 increased extracellular HMGB1 secretion by CAFs, which was reduced by blocking PI3K/AKT signaling using G15 or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 100-103 34202670-6 2021 The MNG-induced expression of Nrf2, HO-1, and NQO1 were abolished by Nrf2 siRNA, while the MNG-induced expression of Nrf2 and HO-1 was abated and the AKT phosphorylation was blocked by LY294002 (a PI3K inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 185-193 AKT serine/threonine kinase 1 Homo sapiens 150-153 34154621-14 2021 Moreover, the promotion effects of Cornuside I on osteogenic differentiation of BMSCs were partially blocked by PI3K/Akt inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 117-120 35605918-12 2022 The mechanism underlying the effect of DPH5 in alleviating IR was related to the PI3K/AKT- and Nrf2/HO-1-mediated regulation of the GSK3beta signaling pathway, and the results were further confirmed using the specific inhibitors LY294002 and ML385. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 229-237 AKT serine/threonine kinase 1 Homo sapiens 86-89 33269749-11 2021 Both LY294002 (20 muM) and rapamycin (500 nM), which are inhibitors of the PI3K/Akt/mTOR pathway, significantly attenuated the inhibition of autophagy and apoptosis caused by apelin-13. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 AKT serine/threonine kinase 1 Homo sapiens 80-83 34284400-9 2021 RESULTS: The results demonstrated that TGF-beta1, simultaneous with the induction of MF differentiation, confers significant protection against anoikis-induced cell death, which could be partly reversed by treatment with the PI3K/Akt pathway inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 253-261 AKT serine/threonine kinase 1 Homo sapiens 230-233 33290316-2 2021 LY294002 was originally reported to be a selective inhibitor of PI3K-Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 69-72 34105476-6 2021 In addition, the PI3K/Akt signaling pathway-specific inhibitor LY294002 and TRIM31-shRNA lentivirus were used to interfere with U266 cells, and the cell proliferation, apoptosis, and protein expression of p-Akt (Ser473) and Akt were detected by CCK-8, flow cytometry and Western blot, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 22-25 34076985-10 2021 Notably, inhibitory effects of Baicalein treatment on MMP levels and invasiveness in glioma were blocked by the application of LY294002 (PI3K/Akt inhibitor), and stimulated by the application of IGF-1 (PI3K/Akt activator). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 142-145 35461041-9 2022 The agonist 740Y-P and inhibitor LY294002 reversed the effect of KB-1980E6.3 knockdown and overexpression on the PI3K/AKT pathway in BC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 118-121 35413475-10 2022 In addition, our rescuing experiments verified that miR-K12-1 promoted cell proliferation via activating the PI3K/Akt pathway, and inhibition of the PI3K/Akt pathway by LY294002 abrogated the tumor-promoting effects of miR-K12-1 in HIV-related gastrointestinal KS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 154-157 35623361-8 2022 However, although LY294002 can achieve the same inhibitory effect as TLR4 siRNA by blocking the PI3K/AKT signaling pathway, it could not affect the expression of TLR4. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 101-104 35607451-15 2022 To determine whether AKT phosphorylation at serine 473 induced beta-catenin nuclear translocation through GSK3beta phosphorylation at serine 9, the PI3K/AKT inhibitor LY294002 was cotreated with melatonin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 153-156 35602302-12 2022 Pretreatment with LY294002 significantly restored iHAX-1-induced decline in PI3K/AKT/mTOR/eNOS phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 81-84 35514261-6 2022 As previously shown, LY294002 and ARC69931MX abolished 2MeSADP-induced Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 71-74 35001339-10 2022 Importantly, the PI3K/AKT inhibitor LY294002 strongly abolished the role of shVLCAD in HCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 22-25 35478128-11 2022 The PI3K/Akt-pathway inhibitor, LY294002, did not significantly affect micromass growth but significantly decreased mineralization (p<0.001). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 9-12 35149293-10 2022 The phenomenon, which was dependent on PI3K/AKT/mTOR and TGF-beta/SMAD signaling, could be blocked by LY294002 and LY2109761. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 AKT serine/threonine kinase 1 Homo sapiens 44-47 35218761-10 2022 Finally, an AKT inhibitor (LY294002) was used to pretreat hPDLCs before rSEMA7A stimulation to determine the role of AKT signaling activation in this process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 12-15 35218761-13 2022 Furthermore, we found that the proinflammatory role of SEMA7A could be inhibited by the application of the AKT inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 107-110 35176991-10 2022 In vitro, Fangchinoline and LY294002 inhibited proliferation, induced cell cycle arrest, and promoted apoptosis in Raji and Daudi cells by altering Akt/mTOR signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 148-151 35387349-6 2022 We added LY294002 to inhibit the PI3K/AKT pathway, and the results indicated that the osteogenic effect of metformin was also blocked. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 38-41 35007896-8 2022 The PI3K/Akt pathway inhibitor LY294002 significantly inhibited the proliferation and migration of LPS-induced reactive astrocytes after Ski overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 9-12 35277194-12 2022 The PI3K/AKT pathway inhibitor, LY294002 could partially attenuate the effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 9-12 35129008-8 2022 Treatment of FL cells with LY294002, the inhibitor of Akt, could delete the MF-induced SK1 activation under the condition of calcium-free medium. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 54-57 35333664-6 2022 Finally, after the addition of P13K/Akt pathway inhibitor LY294002, cell apoptosis, ECM and inflammation in KuA-treated NPCs induced by LPS were again examined by the same methods. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 36-39 35218109-6 2022 The PI3K/AKT signaling pathway suppressor, LY294002, was applied to treat the cells and the changes of KCNQ1OT1 expression and LOXL2, p-AKT, and AKT protein expressions were examined. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 9-12 35218109-6 2022 The PI3K/AKT signaling pathway suppressor, LY294002, was applied to treat the cells and the changes of KCNQ1OT1 expression and LOXL2, p-AKT, and AKT protein expressions were examined. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 136-139 35218109-6 2022 The PI3K/AKT signaling pathway suppressor, LY294002, was applied to treat the cells and the changes of KCNQ1OT1 expression and LOXL2, p-AKT, and AKT protein expressions were examined. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 145-148 35218109-13 2022 Additionally, LY294002 treatment caused low KCNQ1OT1 RNA expression and decreased LOXL2 and p-AKT protein expressions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 94-97 35242234-10 2022 In addition, the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway inhibitor LY294002 suppressed the migration and invasion of DLD-1 cells by decreasing the expression of YAP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 50-53 35222803-6 2022 LY294002, the phosphatidylinositol-3-kinase (PI3K)/Akt inhibitor, abolished KGF-2"s effect to some extent, demonstrating that KGF-2 protected HLECs via the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 51-54 35222803-6 2022 LY294002, the phosphatidylinositol-3-kinase (PI3K)/Akt inhibitor, abolished KGF-2"s effect to some extent, demonstrating that KGF-2 protected HLECs via the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 161-164 35164673-9 2022 In order to bring out the mechanism underlying PI3K/AKT depressing Raf/MEK/ERK, we used PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-111 AKT serine/threonine kinase 1 Homo sapiens 52-55 35111045-6 2021 The results show that L-4F significantly upregulates protein levels of HIF-1alpha, Akt, and ERK, which can be inhibited by the PI3K inhibitor, LY294002, or ERK inhibitor, PD98059, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 83-86 35255737-10 2022 This function of miR-379-5p was exerted through PI3K/Akt pathway and could be blocked by the PI3K/Akt pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 53-56 34974760-3 2022 Moreover, Akt activation is followed by the upregulation of Cyclin D1 and HK2 expression in L-02-As cells, since inhibition of Akt activity by Ly294002 attenuated the colony formation in soft agar and decreased the levels of Cyclin D1 and HK2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 10-13 34974760-3 2022 Moreover, Akt activation is followed by the upregulation of Cyclin D1 and HK2 expression in L-02-As cells, since inhibition of Akt activity by Ly294002 attenuated the colony formation in soft agar and decreased the levels of Cyclin D1 and HK2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 127-130 34949154-10 2022 We found that overexpression of DHCR24 increased the phosphorylation level of PI3K and AKT, however, the PI3K inhibitor LY294002 (LY) eliminated the protective effect of DHCR24 in ALI. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 87-90 35255737-10 2022 This function of miR-379-5p was exerted through PI3K/Akt pathway and could be blocked by the PI3K/Akt pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 98-101 34036396-5 2021 Furthermore, the PI3K/AKT inhibitor LY294002 mirrored the effects of CD9 knockdown in SUP-B15 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 22-25 33848808-9 2021 And inhibition of PI3K/AKT pathway using LY294002 was accompanied by enhanced apoptosis and decreased autophagy which suggested that PI3K/AKT pathway promoted rMV-Hu191-induced autophagy and inhibited rMV-Hu191-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 23-26 33848808-9 2021 And inhibition of PI3K/AKT pathway using LY294002 was accompanied by enhanced apoptosis and decreased autophagy which suggested that PI3K/AKT pathway promoted rMV-Hu191-induced autophagy and inhibited rMV-Hu191-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 138-141 33737080-7 2021 LY294002 (PI3K inhibitor) and 740Y-P (PI3K agonist) were utilized to interfere with PI3k/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 89-92 33737080-13 2021 Furthermore, we found that GDF15 deficiency inhibited activation of the PI3K/Akt pathway, LY294002 treatment further enhanced the role of GDF15 suppression in inflammation and MUC5AC expression, while 740Y-P administration partly reversed the biological activities of GDF15 silencing. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 77-80 33627540-12 2021 In addition, further studies have shown that treatment with LY294002 enhanced the effects of ARG on the expression of proteins associated with apoptosis and autophagy , indicating that ARG may induce apoptosis and autophagy through PI3K/Akt/mTOR pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 237-240 33982772-7 2021 The effects of LY-294002 and MK-2206 on the abnormal activation of PI3K/AKT pathway and hypoxia inducible factor (HIF)-1alpha protein level in HepG2R cells were detected using western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-24 AKT serine/threonine kinase 1 Homo sapiens 72-75 33982772-9 2021 Compared with the AKT inhibitor MK2206, the PI3K inhibitor LY-294002 more effectively downregulated the phosphorylation levels of p85, p110alpha, p110beta, p110gamma and AKT in the PI3K/AKT pathway in HepG2R cells, and more effectively inhibited the proliferation of the cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-68 AKT serine/threonine kinase 1 Homo sapiens 18-21 33982772-9 2021 Compared with the AKT inhibitor MK2206, the PI3K inhibitor LY-294002 more effectively downregulated the phosphorylation levels of p85, p110alpha, p110beta, p110gamma and AKT in the PI3K/AKT pathway in HepG2R cells, and more effectively inhibited the proliferation of the cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-68 AKT serine/threonine kinase 1 Homo sapiens 170-173 33982772-9 2021 Compared with the AKT inhibitor MK2206, the PI3K inhibitor LY-294002 more effectively downregulated the phosphorylation levels of p85, p110alpha, p110beta, p110gamma and AKT in the PI3K/AKT pathway in HepG2R cells, and more effectively inhibited the proliferation of the cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-68 AKT serine/threonine kinase 1 Homo sapiens 170-173 33982772-12 2021 It was concluded that LY-294002 enhanced the chemosensitivity of liver cancer cells to oxaliplatin by inhibiting the PI3K/AKT signaling pathway, which may be related to the inhibition of HIF-1alpha expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-31 AKT serine/threonine kinase 1 Homo sapiens 122-125 33881516-7 2021 Rescue experiments found that the PI3K/AKT inhibitor LY294002 reversed the effects of FN1-siRNA on apoptosis and autophagy in HUVECs cultured in serum from patients with PE. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 39-42 34020670-7 2021 LY294002 inhibited the biological function of HUVECs through inhibition of the PI3K/AKT/eNOS pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 84-87 34001063-8 2021 Furthermore, the insulin receptor beta was stimulated with insulin treatment, subsequently, the phosphorylation of AKT and mTOR was positively activated, which was adversely suppressed in the presence of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 204-212 AKT serine/threonine kinase 1 Homo sapiens 115-118 33989758-5 2021 In order to clarify, we showed that the phosphatidylinositol 3-kinase inhibitor, LY294002, inhibited FLC-induced Akt-mediated deactivation of Forkhead box O class 3a (FoxO3a) and increased catalase activity in proximal tubule cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 113-116 33982772-0 2021 LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1alpha pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-9 AKT serine/threonine kinase 1 Homo sapiens 92-95 34057012-6 2021 The protein expressions of PI3K/AKT pathway associated factors were detected after overexpression of miR-2053 or administration with the pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 155-163 AKT serine/threonine kinase 1 Homo sapiens 32-35 33997938-8 2022 The expression of pp65, pAKT and MMP2 in sh-ADAMTS18 was down-regulated after being treated with PDTC (NF-kappa B inhibitor) and LY294002 (AKT inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 25-28 33737010-12 2021 P13/Akt pathway inhibitor LY294002 inhibited the proliferation of CRC cells, and the P13/Akt signaling was required for BzATP induced the proliferation of CRC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 4-7 33404163-6 2021 Mechanistically, the oncogenic effects of Girdin could be reversed by LY294002 (an AKT pathway inhibitor) and Metformin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 83-86 33856720-5 2021 Furthermore, AKT inhibitor LY294002 blocked the expression of p-AKT, c-Myc, HK2, PKM2, and pro-cas3 in HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 13-16 33747186-8 2021 FK18 also increased the Bcl-2/Bax ratio and decreased the level of cleaved-caspase-3 in SY5Y cells, which was reversed by the Akt pathway inhibitor LY294002, but not by the Erk pathway inhibitor U0126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 126-129 33906701-9 2021 Culture in 1 ng/ml leptin with LY294002 decreased the normal follicles and increased apoptosis, inhibited follicle activation (P < 0.05), and reduced p-Akt immunostaining, compared with the medium containing 1 ng/ml leptin without PI3K inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 152-155 33856720-5 2021 Furthermore, AKT inhibitor LY294002 blocked the expression of p-AKT, c-Myc, HK2, PKM2, and pro-cas3 in HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 64-67 33732339-11 2021 Furthermore, PI3K inhibitor LY294002 inhibited activation of the PI3K/AKT signaling pathway and decreased the proliferation and migration of HaCaT keratinocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 70-73 33898501-10 2021 Correspondingly, the protective effect of CM was dramatically blocked after interference with phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002, indicating that the protective effect of CM on cell oxidative damage was attributed to PI3K/Akt-mediated Nrf2/HO-1 signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 131-134 33898501-10 2021 Correspondingly, the protective effect of CM was dramatically blocked after interference with phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002, indicating that the protective effect of CM on cell oxidative damage was attributed to PI3K/Akt-mediated Nrf2/HO-1 signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 145-153 AKT serine/threonine kinase 1 Homo sapiens 247-250 33611830-8 2021 The protective effects mediated by MARCH5 overexpression on ECs could be inhibited by eNOS inhibitor L-NAME and Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 112-115 33508440-9 2021 However, wortmannin and LY294002, inhibitors of the PI3K/Akt pathway, abolished the up- and down-regulation of E- and N-cadherin expression respectively, and inhibition of migration induced by DHEA in MDA-MB-231 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 57-60 33226571-7 2021 Furthermore, blockade of PI3K/AKT signal with LY294002 significantly reduced melatonin-induced apoptosis inhibition in H2O2-treated HUVECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 30-33 33754417-6 2021 The cells were subjected to various assays and treated with the selective Akt inhibitor LY294002 or co-transfected with galectin-3-binding protein (LGALS3BP) siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 74-77 33621956-8 2021 And miR-483-5p inhibitor, SATB2-overexpressed lentiviruses (Lv-SATB2) or LY294002 (PI3K/AKT inhibitor) significantly reversed the above results. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 73-81 AKT serine/threonine kinase 1 Homo sapiens 88-91 33621956-9 2021 Similarly, PI3K/AKT signaling was activated by miR-483-5p mimic, and was inhibited in miR-483-5p inhibitor, Lv-SATB2 or LY294002 treated cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 16-19 33535306-13 2021 The expression levels of p-Akt, p-GSK3beta and beta-catenin were decreased when the PI3K/Akt pathway was blocked using the PI3K inhibitor LY294002 (P<0.05), and the expression levels of N-Cadherin, vimentin and Snail were also significantly decreased (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 AKT serine/threonine kinase 1 Homo sapiens 27-30 33535306-13 2021 The expression levels of p-Akt, p-GSK3beta and beta-catenin were decreased when the PI3K/Akt pathway was blocked using the PI3K inhibitor LY294002 (P<0.05), and the expression levels of N-Cadherin, vimentin and Snail were also significantly decreased (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 AKT serine/threonine kinase 1 Homo sapiens 89-92 33516933-12 2021 The expression of NCX3 protein was reduced in the SK-N-SH cells treated with Akt phosphorylation inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 77-80 33485844-5 2021 Furthermore, PCGF3 affected both the proliferation and migration of lung cancer cells by regulating the PI3K/AKT pathway, as verified by inhibiting this pathway using LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 109-112 33412213-16 2021 It is worth noting that the effect of CNOT7 overexpression in A2780 and SKOV3 cells could be partially or completely eliminated by treatment with AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 160-168 AKT serine/threonine kinase 1 Homo sapiens 146-149 33258087-9 2021 HMC-EVs-carried miR-24 could target AQP4 to activate the P38 MAPK/ERK1/2/P13K/AKT pathway, and thus promoted the proliferation and migration of SH-SY5Y cells after H/R injury, which were reversed by LY294002 and PD98095. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 199-207 AKT serine/threonine kinase 1 Homo sapiens 78-81 33681258-12 2021 Treatment with LY294002 significantly increased the apoptosis of NPCs and reduced the levels of their downstream substrates (p-AKT, p-mTOR, and p-GSK3beta). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 127-130 33535178-11 2021 Pre-incubation with IMD17-47 (IMD receptors blocking peptide) and the phosphatidylinositol 3-kinase/protein kinase b (PI3K/Akt) inhibitor LY294002 reversed ADAM10 level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 AKT serine/threonine kinase 1 Homo sapiens 123-126 33446037-9 2021 Moreover, LY294002, an inhibitor of the PI3K/AKT pathway, restored the chemosensitivity of CRC cells expressing high levels of NPM1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 45-48 33613982-5 2021 In addition, pro-inflammatory cytokine expressions of TNF-alpha and IL-6 induced by the binary mixture of Phe and Flu were all alleviated by co-treatment with PI3K/AKT and NF-kappaB specific inhibitors (LY294002 and BAY11-7082). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 203-211 AKT serine/threonine kinase 1 Homo sapiens 164-167 33468992-7 2021 Pharmacologic inhibition of Akt using LY294002 and Akt1/2 knockdown using shRNA in sarcoma CSCs decreased Nanog expression and spheroid formation and reversed chemotherapy resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 28-31 33227289-8 2021 Additionally, we found that coptisine suppressed the phosphorylation of phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR), and this effect was notably enhanced by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 217-225 AKT serine/threonine kinase 1 Homo sapiens 151-154 33217443-8 2021 Additionally, the addition of Akt inhibitor LY294002 reversed the effects of RECQL5 overexpression on cell migration, invasion and EMT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 30-33 33505496-9 2021 Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 305-313 AKT serine/threonine kinase 1 Homo sapiens 154-157 33505496-9 2021 Both hypoxia and IL-8 may promote angiogenesis which was suppressed by JR. Western blot showed that IL-8 upregulated the expression of phosphorylation of AKT, ERK, NF-kappaB, and VEGFR, which were inhibited by JR. On the other hand, effects of IL-8 on the increase of p-AKT and p-ERK were also blocked by LY294002 and U0126, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 305-313 AKT serine/threonine kinase 1 Homo sapiens 270-273 33853342-9 2021 Additionally, inhibition of Akt by LY294002 reversed the effects of FBXO17 overexpression on cellular behaviors of glioma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 28-31 33391425-4 2021 HnRNP-F expression was significantly decreased by treatment with the PI3K/AKT signalling pathway inhibitor LY294002, whereas hnRNP-F knockdown did not significantly affect PI3K or AKT expression, suggesting that hnRNP-F is likely a downstream target of the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 107-115 AKT serine/threonine kinase 1 Homo sapiens 74-77 33438566-10 2021 LY294002 was used to verify whether anlotinib overcomes the drug-resistance of CRC cells by inactivating the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 114-117 33438566-14 2021 We found anlotinib and LY294002 overcame the drug resistance of HCT-8/5-FU cells by reducing the expression of PI3K/p-AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 118-121 33486250-9 2021 Curcumin-mediated attenuation of caspase-3 activation was reversed by Akt inhibitor LY294002 (LY). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 70-73 33486250-9 2021 Curcumin-mediated attenuation of caspase-3 activation was reversed by Akt inhibitor LY294002 (LY). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-86 AKT serine/threonine kinase 1 Homo sapiens 70-73 33241954-5 2021 In addition, CXCL6-induced HBMEC permeability and inhibition of HBMEC proliferation were counteracted by Sirt3 overexpression, and the AKT inhibitor LY294002 counteracted the effect of CXCL6 recombinant proteins on Sirt3, p-AKT, and p-FOXO3a expressions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 135-138 33241954-5 2021 In addition, CXCL6-induced HBMEC permeability and inhibition of HBMEC proliferation were counteracted by Sirt3 overexpression, and the AKT inhibitor LY294002 counteracted the effect of CXCL6 recombinant proteins on Sirt3, p-AKT, and p-FOXO3a expressions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 149-157 AKT serine/threonine kinase 1 Homo sapiens 224-227 32393798-7 2021 In addition, blocking PI3K/Akt pathway using LY294002 partially counteracted the cell viability-enhancing effect of JE-133. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 27-30 33706561-11 2021 Meanwhile, the inhibition of glioma cell proliferation and invasiveness induced by ANXA1 down-regulation was further enhanced by combined treatment with AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 167-175 AKT serine/threonine kinase 1 Homo sapiens 153-156 33212374-9 2021 Additionally, our experiments where specific inhibitors of MEK (U0126) and PI3K (LY294002) were utilized verified that BR enhanced cell proliferation and wound healing through stimulating the MAPK and PI3K/Akt signal transduction pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 206-209 31462074-7 2021 After inhibition of PI3K/Akt pathway by PI3K inhibitor LY294002, the levels of IL-25 and IL-17RB and HIF-1alpha were decreased by LPS stimulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 25-28 33167006-6 2020 Moreover, we presumed that LY294002, an inhibitor of the PI3K/AKT pathway, may enhance the cytotoxic effects of cisplatin through upregulating FOXO1 and FOXO3a. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 62-65 33308227-9 2020 Both alpha and gamma-ENaC protein expressions were increased after AT2 cells were transfected with siPTEN, which could be reversed by the co-administration of PI3K/AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 178-186 AKT serine/threonine kinase 1 Homo sapiens 164-167 33039386-15 2020 P-c-Met overexpression resulted in activation of the PI3K/Akt pathway, and inhibition of PI3K/Akt signaling with LY294002 reversed chemoresistance and EMT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 113-121 AKT serine/threonine kinase 1 Homo sapiens 94-97 33291082-6 2020 Moreover, AIM2 could modulate Protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway and the increased Gli1 expression and EMT progress induced by AIM2 depletion was reversed after incubation with AKT inhibitor Ly294002 in CRC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 236-244 AKT serine/threonine kinase 1 Homo sapiens 222-225 33290750-9 2020 Furthermore, LY294002, the PI3K/Akt pathway inhibitor, could reverse the effect of si-ARID1A on the ovarian GCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 32-35 33173956-5 2020 Additionally, the PI3K/AKT inhibitor LY294002 was also used in mechanistic experiments. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 23-26 33299325-13 2020 Notably, the effect of NUPR1 overexpression in A2780 cells could be partially or completely eliminated by treatment with the AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 125-128 32946868-10 2020 Furthermore, administration of the PI3K/AKT signaling pathway inhibitor LY294002 abolished the beneficial effects of ECT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 40-43 33231603-6 2020 Transwell assays were used to examine the changes in cell motility after alterations in ARHGEF39 expression and treatment with LY294002 (an AKT inhibitor) or PD98059 (an ERK inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 140-143 33312368-9 2020 The AKT pathway was blocked by LY294002 treatment and then the cell activities were assessed. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 4-7 33148324-14 2020 Conversely, the antioxidant effects of hPMSCs were blocked by the Akt inhibitor LY294002 and Nrf2 inhibitor ML385 in senescent CD4+ T cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 66-69 33037575-8 2021 Conversely, U0126 and LY294002, which respectively inhibited phosphorylation of ERK1/2 and Akt, partially prevented S727 phosphorylation, but had limited effects on the level of pY705, suggesting that phosphorylation of Y705 and S727 is regulated via independent mechanisms in FD-treated brains. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 91-94 33317626-15 2020 Additionally, ELA treatment induced the phosphorylation of AKT and ERK, while the blockade of PI3K/AKT and ERK1/2 pathways with respective inhibitors, LY294002 and U0126, suppressed the action of ELA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 99-102 32668495-9 2020 LY294002 (the inhibitor of the PI3K/AKT signalling pathway) could reverse the facilitating effects of IL-17F treatment on PCa cell viability, proliferation, migration, invasion and stemness. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 36-39 33334784-6 2020 Inhibition of Akt with LY294002 significantly increased Btg2 mRNA expression while activation of Akt with insulin decreased Btg2 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 14-17 32877639-8 2020 Mechanistically, PP9-suppressed PI3K/Akt/GSK3beta signaling, while the PI3K inhibitor LY294002 augmented PP9-mediated apoptosis, G2/M arrest and effects on PI3K/Akt/GSK3beta related proteins. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 161-164 32070170-7 2020 Interestingly, the levels ofboth phosphorylated Ser473-Akt and phosphorylated Ser9-GSK-3beta were increased by glucocorticoid and IGF-1 cotreatment.Pharmacological manipulation with LY294002 and LiCl was employed to inhibit Akt and GSK-3beta, respectively.We found that cellular differentiability was inhibited by LY294002 and enhanced by LiCl, indicating that theAkt/GSK-3beta signaling pathway is activated by glucocorticoid and IGF-1 treatment to promote myogenic differentiation.Conclusions: Glucocorticoids together with IGF-1 promote myogenic differentiation through the Akt/GSK-3betapathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 182-190 AKT serine/threonine kinase 1 Homo sapiens 224-227 33023074-6 2020 Pretreatment with LY294002 (Akt inhibitor) and PD980559 (ERK inhibitor) inhibited LPS-induced Nrf2 nuclear translocation and HO-1 protein expression in ELF-EMF-exposed cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 28-31 33001018-9 2021 Treatment with the Akt inhibitor LY294002 partially reversed the protective effects of perampanel. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 19-22 32622012-15 2020 The overexpression of miR-199a-3p obviously restrained the HG-stimulated PI3K/AKT signalling pathway and angiogenesis, which could be further inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 155-163 AKT serine/threonine kinase 1 Homo sapiens 78-81 32622012-16 2020 Moreover, LY294002 could slightly ameliorate the miR-199a-3p inhibitor-stimulated PI3K/AKT signalling pathway and angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 87-90 32926102-7 2020 The PI3K inhibitor, LY294002, was used to elucidate the PI3K/Akt/mTOR signaling pathway in rCSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 61-64 32900356-9 2021 LY294002 and rapamycin inhibited PI3K/Akt/mTOR and AQP1 expression (P<0.01), prevented the change of AQP1 location in SRA01/04 plasma membrane (P<0.01). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 38-41 32964954-6 2020 LY294002 was also used to inhibit the activity of PI3K/Akt signaling pathway to verify the mechanism of Tra2beta to protect chondrocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 55-58 32964954-10 2020 However, LY294002 attenuated the protective effect of Tra2beta on chondrocytes by inhibiting the PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 102-105 32770981-12 2020 Hence, the PI3K/AKT inhibitor LY294002 was used to determine the relationship between USP18 and AKT in cervical cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 96-99 32272509-11 2020 Inhibition of protein kinase B (AKT) phosphorylation after irradiation by LY294002 reversed the dexamethasone-induced decrease of autophagy and cell death in U373 cells but provoked no effect on both autophagy and cell survival in LN229 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 32-35 33164477-8 2020 However, LY294002, an inhibitor of the PI3K/Akt signaling pathway, alleviated the protective effect of FGF-2 on lung tissue. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 44-47 32825931-7 2020 However, MMP2 upregulation induced by Rab11a can be inhibited by the PI3K/AKT pathway inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 74-77 32929367-11 2020 Cadherin-11 was down-regulated by siRNA or up-regulated with a plasmid, with or without inflammatory factor stimulation, and PI3K/Akt was inhibited with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 153-161 AKT serine/threonine kinase 1 Homo sapiens 130-133 32811251-4 2021 We performed concentration response curves of LY294002, a pan-PI3 kinase inhibitor, on platelet aggregation and Akt phosphorylation, in washed human and mouse platelets. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 112-115 32762281-8 2022 Treatment of PI3K inhibitor LY294002 significantly increased the apoptosis rate of HBMVECs, and this effect was significantly reversed by transfection of miR-17-5p mimics, while further dramatically enhanced by overexpression of PTEN.Conclusion: MiR-17-5p could amelioratecerebral I/R injury-induced cell apoptosis by directly targeting PTEN and regulation of PI3K/AKT/mTOR signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 365-368 32638014-9 2020 In addition, the inhibitory effects of ISL on TGF-beta1-induced fibrogenic features in MRC-5 cells were enhanced by pretreatment with autophagy activator Rapmycin and PI3K/AKT inhibitor LY294002 and reversed by autophagy inhibitor 3-methyladenine and PI3K/AKT activator IGF-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-194 AKT serine/threonine kinase 1 Homo sapiens 172-175 32385839-0 2020 Pyrroloquinoline Quinine and LY294002 Changed Cell Cycle and Apoptosis by Regulating PI3K-AKT-GSK3beta Pathway in SH-SY5Y Cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 90-93 32275808-8 2020 Pretreatment with a PI3K/AKT inhibitor, LY294002, mimicked the ABA-mediated effects on cytotoxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 25-28 32385839-11 2020 Mn can cause apoptosis and necrosis, varying cell cycle of SH-SY5Y cells, which could be changed by PQQ and LY294002 by regulating PI3K-AKT-GSK3beta pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 136-139 32765028-12 2020 When the PI3K/AKT signaling pathway was inhibited by LY294002 (AKT inhibitor), the protective effect of EGCG on HG-treated HUVECs was weakened. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 14-17 32774685-8 2020 Pretreatment with the inhibitor of PI3K/Akt signaling (LY294002) completely blocked these EE-TT-upregulated mRNA expressions and abolished the improvement of cell viability in H2O2-treated ARPE-19 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 40-43 32774743-8 2020 However, these beneficial effects can be inhibited by PI3K/AKT inhibitor LY294002 and MEK/ERK inhibitor PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 73-81 AKT serine/threonine kinase 1 Homo sapiens 59-62 32765028-12 2020 When the PI3K/AKT signaling pathway was inhibited by LY294002 (AKT inhibitor), the protective effect of EGCG on HG-treated HUVECs was weakened. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 63-66 31504249-10 2020 Importantly, pharmacological inhibition of PI3K/AKT by LY294002 diminished EF-induced activation of AKT and restored the cytotoxicity of osimertinib suppressed by EFs, which proved that AKT activation was essential for EFs to attenuate the efficacy of osimertinib. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 48-51 31504249-10 2020 Importantly, pharmacological inhibition of PI3K/AKT by LY294002 diminished EF-induced activation of AKT and restored the cytotoxicity of osimertinib suppressed by EFs, which proved that AKT activation was essential for EFs to attenuate the efficacy of osimertinib. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 100-103 31504249-10 2020 Importantly, pharmacological inhibition of PI3K/AKT by LY294002 diminished EF-induced activation of AKT and restored the cytotoxicity of osimertinib suppressed by EFs, which proved that AKT activation was essential for EFs to attenuate the efficacy of osimertinib. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 100-103 32622431-11 2020 Moreover, PI3K inhibitor (LY294002) significantly decreased A549 cell viability rate induced by LS, abrogated the activation of p-PI3K/PI3K and p-AKT/AKT in the presence of LS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 146-149 32622431-11 2020 Moreover, PI3K inhibitor (LY294002) significantly decreased A549 cell viability rate induced by LS, abrogated the activation of p-PI3K/PI3K and p-AKT/AKT in the presence of LS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 150-153 32196840-6 2020 Most important, all the changes induced by TRIM25 overexpression in Huh7 were reversed with additional treatment of LY294002 (an AKT pathway inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 129-132 32077518-9 2020 Treatment with LY294002, an inhibitor of Akt, reversed the induction effects of CTRP6 overexpression on ROS production, inflammation and ECM accumulation in MCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 41-44 32463592-7 2020 Cystic fibrosis transmembrane conductance regulator activates Akt/Bcl2 pathway, and suppression of PI3K/Akt pathway abolishes CFTR overexpression-induced up-regulation of Bcl2 (MK-2206 and LY294002) and cell viability (MK-2206). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 189-197 AKT serine/threonine kinase 1 Homo sapiens 104-107 32386481-9 2020 More important, preconditioning with PI3K/AKT inhibitor LY294002 or mTOR inhibitor rapamycin both aggravated KLK10 knockdown-suppressed cancer cell growth and glucose metabolism. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 42-45 32691555-4 2020 With LY294002 pretreatment, the mitochondrial transmembrane potential level and the expressions of p-PI3K, p-AKt and Bcl-2 were decreased, the expression of Bax and the apoptosis rate were increased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 AKT serine/threonine kinase 1 Homo sapiens 109-112 32742458-14 2020 Importantly, mechanistic investigations suggested that dnMST4 significantly elevated the phosphorylation levels of key members of PI3K/AKT pathway, and the selective PI3K inhibitor LY294002 can reverse the proliferation-promoting effect of dnMST4. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 181-189 AKT serine/threonine kinase 1 Homo sapiens 135-138 32630394-8 2020 Further, the use of the inhibitors PD98059 and LY294002 also showed that Erk1/2 and Akt signaling pathways were involved in the neuroprotection mediated by ESC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 84-87 32655764-7 2020 Interestingly, we highlight that PI3K/AKT inhibitor (LY294002) markedly increased the expression of Nrf2 antioxidant pathway, PPARalpha, and downregulated SREBP-1c in FFA-stimulated HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 38-41 32606946-5 2020 L740Y-P (activator of PI3K/AKT pathway) and LY294002 (inhibitor of PI3k/AKT pathway) were used to interfere with PI3k/Akt signaling pathway in osteosarcoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 72-75 32606946-5 2020 L740Y-P (activator of PI3K/AKT pathway) and LY294002 (inhibitor of PI3k/AKT pathway) were used to interfere with PI3k/Akt signaling pathway in osteosarcoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 118-121 32538764-6 2020 The HepG2 cells were also treated with PI3K/Akt signaling pathway inhibitor LY294002, and its effect on cell proliferation, migration, invasion, and apoptosis, and expressions of PIK3, Akt, and p-Akt proteins were determined. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 44-47 32538764-11 2020 After treatment of HepG2 cells with PI3K/Akt signaling pathway inhibitor LY294002, the proliferative, migratory and invasive abilities of cells in the treatment group were significantly enhanced, while cell apoptosis was significantly reduced (p < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 73-81 AKT serine/threonine kinase 1 Homo sapiens 41-44 32665986-10 2020 Pharmacological inhibition of PI3K/Akt by LY294002 abrogated E2-induced expression of PPARgamma (0.24 +-0.09-fold; n = 3; p vs. E2 = 0.0017). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 35-38 32581555-9 2020 Upon inhibiting the PI3K/Akt pathway with LY294002 prior to cotreatment, we detected enhanced PARP cleavage compared to that in the cotreatment only group. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 25-28 32200003-8 2020 These protective effects of hypothermia on pyroptosis-related proteins and pro-inflammatory cytokines were partially reversed by the specific PI3K/Akt inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 147-150 31758290-7 2020 While TMZ treated cells did not show alteration in any of the Wnt ligands, PI3K inhibitor (LY294002) treatment repressed Akt activation and abolished the TMZ-mediated induction of Wnt/beta-catenin pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 121-124 32051533-6 2020 These phenomena could be reversed by the PI3K-Akt inhibitor LY294002, mTOR inhibitor rapamycin, PFKFB3 inhibitor 3PO, or PFKFB3 silencing by specific shRNA, or aerobic glycolysis inhibitor 2-DG. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 46-49 32222636-10 2020 The abolishment of the PI3K/AKT via a pharmacological inhibitor (LY294002) repressed anti-H/R capabilities of SH2B1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 28-31 32173422-4 2020 Furthermore, inhibition of PI3K-Akt pathway by pharmacological inhibitor, LY294002 enhanced the apoptotic cell death induced by alpha-santalol as determined by cell viability, cellular morphology, active caspase-3 activity and expression of cleaved PARP, cleaved caspase-3 levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 32-35 32347651-7 2020 LY294002 or Akt-siRNA inhibited the PI3K/Akt/FoxO3a pathway and promoted the Pristimerin-induced apoptosis, while Pristimerin effects were partially abolished in FoxO3a knockdown UM-1 cell cultures. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 41-44 31748028-8 2020 Inhibitors of PI3K (LY294002) enhanced the phosphorylation of P38, AKT, and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 67-70 32547216-7 2020 LY294002 was used to inhibit the activation of PI3K/AKT signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 52-55 32061800-7 2020 NAC and the pharmacological inhibitor of Akt (LY294002), ERK1/2 (PD980590), and AMPKalpha (Compound C) markedly abrogated the Cr(VI)-induced activation of Akt, ERK1/2, and AMPKalpha signal, respectively, with the concomitant inhibition of mitochondrial dysfunction and caspase activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 54-57 32552933-7 2020 After K562/ADR cells were treated with PI3K/AKT pathway inhibitor LY294002, the protein expressions of NF-kappaB and P-gp were analyzed to determine the regulation of AKT on the expression of NF-kappaB and P-gp. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 167-170 32552933-15 2020 The protein expressions of p-AKT, P-gp and the activity of NF-kappaB were inhibited significantly by using PI3K/AKT inhibitor LY294002 (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 29-32 32552933-15 2020 The protein expressions of p-AKT, P-gp and the activity of NF-kappaB were inhibited significantly by using PI3K/AKT inhibitor LY294002 (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 112-115 32547216-12 2020 Moreover, suppression of the PI3K/AKT signaling with LY294002 treatment apparently rescued TOP2A-mediated promotions in cell migration, invasion and EMT in Hela cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 34-37 32276610-10 2020 However, an AKT inhibitor (LY294002), an ERK inhibitor (U0126), a JNK inhibitor (SP600125), and a p38 inhibitor (SB203580) inhibited the increase of mineralization induced by PTHrP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 12-15 32553076-5 2020 PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 5-8 32553076-5 2020 PI3K/AKT inhibitor LY294002 and ERK inhibitor U0126 decreased the expression of p-AKT, p-ERK and alpha-SMA, and increased the expression of E-Cadherin and Claudin-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 82-85 32382053-6 2020 Interruption of the AKT pathway with the specific inhibitor LY294002 could reverse the expression of MMPs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 20-23 31997489-8 2020 LY294002, a PI3K inhibitor, inhibited AKT phosphorylation and rescued the tumor-promoting effect of EVA1 overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 38-41 31912683-11 2020 In Ishikawa 3-H-12 cells, radiosensitization effects and inhibition of AKT were achieved by PTEN restoration plus treatment with the phosphoinositide-3-kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 71-74 32431202-6 2020 LY294002 was used to inhibit the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 70-73 32431202-11 2020 Inhibiting PI3K/AKT signaling pathway by using LY294002 blocked the positive role of NLRC5 in migration and invasion of AN3CA cells and expression of MMP9. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 16-19 32392915-11 2020 Furthermore, PD98059 (a selective ERK1/2 inhibitor) and LY294002 (a selective Akt inhibitor) decreased VSMC migration and proliferation by inhibiting phosphorylation of Akt and ERK1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 78-81 32392915-11 2020 Furthermore, PD98059 (a selective ERK1/2 inhibitor) and LY294002 (a selective Akt inhibitor) decreased VSMC migration and proliferation by inhibiting phosphorylation of Akt and ERK1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 169-172 32395075-11 2020 Furthermore, PD98059 (a selective ERK1/2 inhibitor) and LY294002 (a selective Akt inhibitor) decreased VSMC migration and proliferation by inhibiting phosphorylation of Akt and ERK1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 78-81 32395075-11 2020 Furthermore, PD98059 (a selective ERK1/2 inhibitor) and LY294002 (a selective Akt inhibitor) decreased VSMC migration and proliferation by inhibiting phosphorylation of Akt and ERK1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 169-172 31935492-5 2020 This reduction was prevented by the PI3K inhibitor LY294002, indicating that there is a link between the PI3K/Akt pathway and the formation of ROS in the protective mechanisms of PostC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 110-113 32393432-8 2020 Moreover, the phosphorylation levels of Akt and Erk were upregulated in CCN2-over expressed cells, and LY294002 and U1026 (which inhibited the Akt and Erk signaling pathways, respectively) reversed the effect of CCN2 on autophagy and cell survival enhancement. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-111 AKT serine/threonine kinase 1 Homo sapiens 40-43 32393432-8 2020 Moreover, the phosphorylation levels of Akt and Erk were upregulated in CCN2-over expressed cells, and LY294002 and U1026 (which inhibited the Akt and Erk signaling pathways, respectively) reversed the effect of CCN2 on autophagy and cell survival enhancement. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-111 AKT serine/threonine kinase 1 Homo sapiens 143-146 32458975-9 2020 When LY294002 was used to inhibit PI3K/AKT/mTOR signaling pathway, the effect of pcDNA3.1-SIK2 on aerobic glycolysis of breast cancer cells could be reversed. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 AKT serine/threonine kinase 1 Homo sapiens 39-42 32318240-7 2020 Following the addition of LY294002, the levels of p-AKT, p-ERK1/2, and p-NF-kappaB decreased significantly. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 52-55 32033754-5 2020 CLEC5A-mediated GC proliferation and anti-apoptosis were impaired by blocking the PI3K/AKT/mTOR pathway with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 87-90 31753588-9 2020 CXCL16 stimulated the activation of PI3K/AKT/FOXO3a signaling pathway in MRC-5 cells, and the inhibition by specific inhibitors Wortmannin and LY294002, or knockdown of CXCR6 by siRNA also suppressed the biological functions of MRC-5 cells mediated by CXCL16. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 143-151 AKT serine/threonine kinase 1 Homo sapiens 41-44 31889370-5 2020 Further, LY294002, a PI3K/AKT antagonist, was employed to explore the mechanism underlying the effects of CCN5 in the regulation of OSCC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 26-29 31889370-10 2020 Inhibiting PI3K/AKT signaling with LY294002 rescued the apoptotic process in CCN5-silenced OSCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 16-19 32222858-11 2020 Conversely, the use of LY294002 (an inhibitor of PI3K) blocked the activation of the PI3K/AKT signaling pathway and prevented the beneficial effects of rutin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 90-93 32057901-11 2020 Moreover, accumulation of ubiquitinated Arl4c protein was increased by HCPT and LY294002 (an AKT inhibitor) treatment whereas the proteasome inhibitor MG-132 attenuated the inhibitory effect of HCPT and LY294002 on Arl4c expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 93-96 32319377-6 2020 LY294002 decreased p-AKT expression, cell colony-forming ability and tumorigenicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 21-24 31918333-11 2020 The PI3K/Akt/FoxO pathway was identified to play a pivot role in TCS-induced glycolysis, which was further confirmed by inhibitor tests using specific inhibitors LY294002 and MK2206. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 162-170 AKT serine/threonine kinase 1 Homo sapiens 9-12 32016453-11 2020 Finally, the inhibition of the PI3K/AKT/mTOR signaling pathway by LY294002 resulted in decreased fibroblast proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 36-39 32271399-5 2020 The inhibitor LY294002 was used to inhibit the PI3K/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 52-55 32110051-12 2020 Vice versa, inhibition of PI3K/Akt pathway by LY294002 could resist the effect of FOXO6 overexpression on chemotherapy, cytotoxicity and glycolysis of HCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 31-34 32041571-9 2020 LY294002, a PI3K-AKT inhibitor, was able to reverse the promotive effect of EEC-CM or rhCXCL12 on EEC migration and invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 17-20 31701812-9 2020 Inhibition of Akt (LY294002) resulted a significant increase in degeneration compared to HUCPVC co-cultures (48 +- 7% degeneration). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 14-17 32103904-13 2020 Importantly, the cytoprotective effect of H2S against HG-induced injury was inhibited by LY294002 (an inhibitor of PI3K/Akt/eNOS signaling pathway). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 120-123 31836533-7 2020 PlGF promoted the protein expression of eNOS by up-regulating AKT, and the AKT and eNOS protein levels were decreased after adding LY294002 (all P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 75-78 30940294-8 2020 We further showed that downregulation of AKT signaling activity by using AKT inhibitor LY294002 markedly inhibited NSCLC cell proliferation and resistance to doxorubicin induced by VASH2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 41-44 30940294-8 2020 We further showed that downregulation of AKT signaling activity by using AKT inhibitor LY294002 markedly inhibited NSCLC cell proliferation and resistance to doxorubicin induced by VASH2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 73-76 32071545-8 2020 Inhibition of PI3K/AKT with LY294002 or FAM49B expression abrogated Myc-TASP1/Lv-shTASP1-induced GBC cell proliferation and motility. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 19-22 32174780-6 2020 S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 53-56 32175411-12 2020 Furthermore, the inhibition of PI3K/Akt/MMP-9 by LY294002 and SB-3CT enhanced the anticancer effects of fentanyl. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 36-39 31732769-0 2020 Notch1 and PI3K/Akt signaling blockers DAPT and LY294002 coordinately inhibit metastasis of gastric cancer through mutual enhancement. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 16-19 31732769-3 2020 In this study, we aimed to investigate the effects of combined treatment with Notch1 signaling blocker DAPT and PI3K/Akt signal blocker LY294002 on metastasis of gastric cancer. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 136-144 AKT serine/threonine kinase 1 Homo sapiens 117-120 31732769-8 2020 In addition, DAPT and LY294002 coordinately inhibited the levels of Notch1, HES1, and p-Akt in gastric cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 88-91 31727367-6 2020 We also found that the PI3K/AKT pathway inhibitor LY294002 could revert the changes caused by FAM60A upregulation in HGC-27 and AGS cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 28-31 32051827-5 2020 Moreover, the PI3K/AKT inhibitor LY294002 was used to examine the relationship between TRIM32 and AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 98-101 31669540-9 2020 15-Keto PGE2 activated AKT signaling, and the pharmacological AKT inhibitor, LY294002 suppressed the 15-keto PGE2-induced HO-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 23-26 31669540-9 2020 15-Keto PGE2 activated AKT signaling, and the pharmacological AKT inhibitor, LY294002 suppressed the 15-keto PGE2-induced HO-1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 62-65 31891674-6 2020 Mechanistically, hUC-MSCs activated AKT pathway in macrophages, resulting in upregulation of M2-associated molecule Arg1, which was partly abolished by PI3K inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 168-176 AKT serine/threonine kinase 1 Homo sapiens 36-39 31894254-8 2020 In addition, LY294002, an Akt inhibitor, inhibited the phosphorylation of ERK, and U0126, an ERK inhibitor, inhibited the phosphorylation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 26-29 31939617-7 2020 In addition, the GSK-3beta phosphorylation and c-Fos expression were suppressed by PI3K/Akt pathway inhibitors, LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 88-91 31789415-6 2020 In addition, the effects of leptin stimulation were significantly counteracted by the AKT inhibitor LY294002, whereas the effects of leptin silencing were counteracted by AKT activator insulin-like growth factor 1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 100-108 AKT serine/threonine kinase 1 Homo sapiens 86-89 31974627-9 2020 The present results showed that LY294002 downregulated the expression of PI3K, CYP2E1, AKT, mTOR and P70S6K (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 87-90 31868203-5 2020 Notably, we determined that bFGF activates PI3K/Akt signaling, and treatment with the PI3K/Akt inhibitor LY294002 inhibited bleomycin-induced cell morphology changes and EMT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 91-94 32027262-1 2020 OBJECTIVE: To investigate the proliferation inhibition and pro-apoptosis effect of LY294002 (PI3K/AKT inhibtor) combined with daunorubicin (DNR) on the chronic myeloid leurenia cell line K562 and its possible mechanisms. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-91 AKT serine/threonine kinase 1 Homo sapiens 98-101 31992313-9 2020 However, when the PI3K/Akt pathway was inhibited by LY294002, the cell apoptosis and caspase 3 activity significantly increased while the cell viability was obviously inhibited. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 23-26 31940823-6 2020 None of these changes had an influence on apoptosis; however, the inhibition of PI3K using the LY294002 compound revealed that the PI3K/AKT/FoxO3a pathway was involved in apoptosis evasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 136-139 31712854-12 2020 Besides, the expression of p-AKT (Ser473) and p-PI3K was significantly upregulated by employing miR-140-5p inhibitor, but retrieved after treating with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 152-160 AKT serine/threonine kinase 1 Homo sapiens 29-32 31809756-11 2020 When Akt and p53 were suppressed by LY294002 and PFTalpha, respectively, sesamin exerted no additional effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 5-8 31998447-6 2020 Inhibiting the PI3K/Akt pathway with LY294002 partly reversed the therapeutic effects of metformin on SCI in vitro and vivo. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 20-23 32054305-9 2020 In addition, PD98059 (ERK inhibitor) and LY294002 (AKT inhibitor) obviously reduced cell invasion and expression of metastasis-associated proteins. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 51-54 32864999-11 2020 Inhibition of the PI3K/Akt pathway by a specific inhibitor, LY294002, partially reduced the protective effect of HuMSC-EVs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 23-26 31605630-7 2020 Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with melatonin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 121-124 31746379-10 2020 The PI3K specific inhibitor LY294002 significantly decreased 4EBP1 expression and reduced p-AKT and p-mTOR expression compared with the mechanical stress group. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 92-95 31536856-8 2020 Pretreatment with 1,25(OH)2 D3 and LY294002 (phosphoinositide 3-kinase [PIK3] inhibitor) significantly inhibited the IS-induced phosphorylation of Akt and beta-catenin, nuclear beta-catenin accumulation, and EMT-associated protein expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 147-150 31614141-8 2019 Compound C (an AMPK inhibitor) and LY294002 (a PI3K inhibitor) markedly reversed the alleviating effect of 10-HDA on the expression of tight junction proteins, indicating that 10-HDA inhibited LPS-induced BBB dysfunction by triggering the activation of the AMPK/PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 267-270 31600563-5 2020 These protective effects of DHPG and VU0092273 were prevented by inhibition of PI3K/Akt pathway by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 99-107 AKT serine/threonine kinase 1 Homo sapiens 84-87 31905887-11 2019 LY294002 as specific AKT inhibitor was used to confirm that AKT inactivation may promote anticancer effect of sorafenib. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 21-24 31905887-11 2019 LY294002 as specific AKT inhibitor was used to confirm that AKT inactivation may promote anticancer effect of sorafenib. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 60-63 31920339-10 2019 Moreover, a PI3K/AKT inhibitor LY294002 was utilized to examine the connection between ARHGAP10 and AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 17-20 31920339-10 2019 Moreover, a PI3K/AKT inhibitor LY294002 was utilized to examine the connection between ARHGAP10 and AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 100-103 31920339-11 2019 Our findings demonstrated that the AKT inhibitor LY294002 could rescue the function of ARHGAP10 in CRC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 35-38 31885790-7 2019 Moreover, blocking AKT with the PI3K/AKT inhibitor LY294002 or knocking down AKT via RNA interference significantly decreased PBX1 expression, while increasing p16 and p21 expression and the number of SA-beta-gal-positive cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 19-22 31885790-7 2019 Moreover, blocking AKT with the PI3K/AKT inhibitor LY294002 or knocking down AKT via RNA interference significantly decreased PBX1 expression, while increasing p16 and p21 expression and the number of SA-beta-gal-positive cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 37-40 31885790-7 2019 Moreover, blocking AKT with the PI3K/AKT inhibitor LY294002 or knocking down AKT via RNA interference significantly decreased PBX1 expression, while increasing p16 and p21 expression and the number of SA-beta-gal-positive cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 37-40 31807174-8 2019 Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 80-83 31576676-8 2019 LY294002 and imatinib were used to inhibit the activity of PI3K/Akt and platelet-derived growth factor receptor (PDGFR) beta. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 64-67 31963684-9 2020 Moreover, Rg5-induced apoptosis and autophagy could be dramatically strengthened by the PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 107-115 AKT serine/threonine kinase 1 Homo sapiens 93-96 30471105-8 2019 Inhibitor AG1024 and LY294002 significantly inhibited ECM synthesis and the phosphorylation of IGF-1R, PI3K, and AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 113-116 31658358-6 2019 Importantly, the enhanced PI3K, Akt, mTOR and S6K expression by miR-365 inhibitor (anti-miR-365) was abrogated by treatment with LY294002, a PI3K inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 32-35 31448474-8 2019 Furthermore, LY294002, a specific inhibitor of PI3K/Akt pathway, attenuated the activation of NK-kappaB and osteogenic differentiation of HASMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 52-55 31885775-4 2019 These effects were suppressed by LY294002, an inhibitor of the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 68-71 31376806-6 2019 Blockage of the PI3K/AKT pathway with its inhibitor LY294002 eliminated the inhibitory effect of CLU on Cr(VI)-induced premature senescence. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 21-24 31747880-10 2019 Furthermore, either 1G6-D7 or PI3K inhibitor LY294002 suppressed the significant phosphorylation of AKT, which caused by secreted and recombinant Hsp90alpha, resulting in the restoration of epithelial barrier function. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 100-103 31545483-8 2019 In cultured HCAECs, IGFBP1 was shown to protect ECs against passage- or H2O2-induced senescence, and these protective effects of IGFBP1 may be partially reversed by LY294002, a known Akt signaling inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 165-173 AKT serine/threonine kinase 1 Homo sapiens 183-186 31719796-9 2019 In addition, an AKT inhibitor LY294002 was used to determine the connection between TRIM27 and AKT in ESCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 16-19 31719796-9 2019 In addition, an AKT inhibitor LY294002 was used to determine the connection between TRIM27 and AKT in ESCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 95-98 31719797-10 2019 Further, LY294002, a specific AKT inhibitor, was utilized to examine the connection between TRIM11 and AKT in human chordoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 30-33 31302247-7 2019 Mechanically, LGALS3BP regulated OSCC proliferation and migration via PI3K/AKT pathways, which was abrogated by PI3K inhibitor LY294002 in a dose-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 75-78 31466050-5 2019 PI3K/AKT signaling was inhibited using LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 5-8 31684995-10 2019 When we stimulated HCC cells with exogenous IL-8, cell invasion and the levels of integrin beta3, p-PI3K, and p-Akt increased, which could be effectively reversed by adding PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 112-115 31807064-9 2019 The results also demonstrated that the overexpression of CLDN12 increased the activation of Thr308 site in Akt in fetal osteoblast cells, and the PI3K inhibitor LY294002 partially decreased CLDN12-promoted proliferation and metastasis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 161-169 AKT serine/threonine kinase 1 Homo sapiens 107-110 31072420-9 2019 Pretreatment with LY294002 significantly enhanced the ability of MPA to suppress proliferation and to induce apoptosis in the parental and Ishikawa-PR cells via the inhibition of AKT activation and upregulation of PRB transcriptional activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 179-182 31342299-6 2019 Akt inhibition (by LY294002 and MK-2206) or CRISPR-Cas9-mediated Akt1 knockout completely abolished SC79-induced DA neuroprotection against MPP+. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 0-3 31872599-14 2019 LY294002 also induced a further inhibition of expression of AKT and p-AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 60-63 31872599-14 2019 LY294002 also induced a further inhibition of expression of AKT and p-AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 70-73 31637210-9 2019 The addition of the PI3K/AKT pathway inhibitor LY294002 to SERPIND1-overexpressing cells could reverse the promoting effect of SERPIND1 on the malignant biological behavior of ovarian cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 25-28 31209930-10 2019 Notably, LY294002, as an inhibitor of AKT signaling pathway, could significantly weaken the effects of HMGB2 overexpression, which indicated that HMGB2 might promote cell proliferation by activating AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 38-41 31209930-10 2019 Notably, LY294002, as an inhibitor of AKT signaling pathway, could significantly weaken the effects of HMGB2 overexpression, which indicated that HMGB2 might promote cell proliferation by activating AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 199-202 31807423-8 2019 LY294002 was used to block the activation of PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 50-53 31551535-5 2019 LY-294002, an inhibitor of phosphatidylinositol 3-kinase, inhibited the phosphorylation of Akt and decreased the expression levels of CLDN1 and CLDN11. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-9 AKT serine/threonine kinase 1 Homo sapiens 91-94 31680984-7 2019 The inhibition of the PI3K/Akt pathway by the specific inhibitor LY294002 partially reversed the therapeutic effects of FGF10 both in vivo and in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 27-30 31243899-7 2019 This promotion of fibrosis by FSH occurred through the activation of AKT/GSK-3beta/beta-catenin pathway, which could be attenuated by silencing FSHR by siRNA or by LY294002 or MK2206. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 164-172 AKT serine/threonine kinase 1 Homo sapiens 69-72 30672370-6 2019 Pre-treatment of spinal neurons with a PI3K inhibitor, LY294002 or mammalian target of rapamycin (mTOR) inhibitor, rapamycin blocked bpV activation of Akt and ribosomal protein S6 activity, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 151-154 31404628-11 2019 The apoptotic cell death induced by PPVI was confirmed, and it was significantly suppressed by the overexpression of AKT, ERK and mTOR, and the induced autophagic cell death which was depended on the Atg7 was decreased by the inhibitors, such as LY294002 (LY), Bafilomycin A1 (Baf), Compound C (CC) and SBI-0206965 (SBI). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 246-254 AKT serine/threonine kinase 1 Homo sapiens 117-120 31489995-11 2019 Moreover, AKT-specific inhibitor LY294002 restored the effect of LINC00462 knockdown on apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 10-13 31228450-7 2019 LY294002 effectively inhibited the PI3K/AKT/mTOR signaling pathway, repressed cell viability and induced apoptosis in OS cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 40-43 31483776-5 2019 Cells were treated with the PI3K/Akt pathway inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 33-36 31483776-11 2019 In cells that overexpressed BGN, inhibition of the PI3K/Akt pathway by LY294002 increased the sensitivity of human WERI-Rb-1 retinoblastoma cells to rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 56-59 30882397-10 2019 OA significantly increased Akt phosphorylation and reduced FOXA1 expression in SW579 cells, but only PI3K/Akt inhibitor LY294002 attenuated OA-induced FOXA1 downregulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 106-109 31348616-12 2019 The phosphorylation of AKT and ERK, as well as the expression of the vascular endothelial growth factor, can be inhibited using the LY294002 and U0126 inhibitors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 23-26 31270642-10 2019 This was accompanied by an increase in the phosphorylation of Akt and ERK in third stage cell clusters, which was prevented by the addition of the inhibitors PD98059 and LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 62-65 31502574-8 2019 However, an AKT inhibitor (LY294002) only effected on MMP9 and p-AKT, not on c-Met. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 12-15 31502574-8 2019 However, an AKT inhibitor (LY294002) only effected on MMP9 and p-AKT, not on c-Met. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 65-68 31786865-3 2019 The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 788-791 31786865-3 2019 The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 798-801 31340168-13 2019 In contrast, inhibition of the PI3K/Akt pathway by LY294002 or glycolysis by 2-deoxyglucose resisted the effect of ALC1 overexpression on cisplatin cytotoxicity in ESCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 36-39 31404628-11 2019 The apoptotic cell death induced by PPVI was confirmed, and it was significantly suppressed by the overexpression of AKT, ERK and mTOR, and the induced autophagic cell death which was depended on the Atg7 was decreased by the inhibitors, such as LY294002 (LY), Bafilomycin A1 (Baf), Compound C (CC) and SBI-0206965 (SBI). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 246-248 AKT serine/threonine kinase 1 Homo sapiens 117-120 31497671-4 2019 Proliferation assays indicated that vGPCR cell number decreased in presence of LY294002 (PI3K/Akt inhibitor) likewise 1alpha,25(OH)2D3 or TX 527 (10 nM, 48 h). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 94-97 31443676-10 2019 The phosphatidylinositol 3-kinase/AKT inhibitor LY294002 was used to inhibit the phosphorylation and activity of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 34-37 31443676-10 2019 The phosphatidylinositol 3-kinase/AKT inhibitor LY294002 was used to inhibit the phosphorylation and activity of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 113-116 31438633-7 2019 Moreover, genistein inactivated the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, while LY294002, a PI3K/Akt inhibitor, increased the apoptosis-inducing effect of genistein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 115-118 31383790-10 2019 Pretreatment of cells with the Phosphoinositide 3-kinase (PI3K) inhibitor LY294002 (LY) and small interfering RNAs (siRNAs) GLP-1R abrogated the liraglutide-induced activation of Akt and the protective effects on NPCs" apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 179-182 31427725-8 2019 The AKT signaling pathway was activated in H446-BR and H526-BR cells accompanied by EMT progression, and AKT inhibitor LY294002 reversed the EMT progression in resistant cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 4-7 31427725-8 2019 The AKT signaling pathway was activated in H446-BR and H526-BR cells accompanied by EMT progression, and AKT inhibitor LY294002 reversed the EMT progression in resistant cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 105-108 31173156-7 2019 Furthermore, when the Akt phosphorylation inhibitor Ly294002 was added, the improvement by TFEB to high glucose-induced apoptosis was significantly reduced. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 22-25 30421162-7 2019 However, with the addition of PI3K-Akt-mTOR pathway-specific inhibitor LY294002, the expression of PI3K, P-Akt, P-mTOR, RUNX2, COL1, ALP, OCN, and P1NP decreased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 35-38 30421162-7 2019 However, with the addition of PI3K-Akt-mTOR pathway-specific inhibitor LY294002, the expression of PI3K, P-Akt, P-mTOR, RUNX2, COL1, ALP, OCN, and P1NP decreased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 107-110 31316618-6 2019 Furthermore, inhibition of Akt signaling by GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 (FGFR3S249C) cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 27-30 30659604-7 2019 Pharmacological inhibitors of PI3K/Akt signaling (LY294002 or A443654) reduced the expression of MT1-MMP and impaired BMSC invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 35-38 31340906-4 2019 The effects of matrine and the PI3K specific inhibitor LY294002 (10 nmol/L) on AKT pathway and autophagy-related proteins in A549 cells were investigated using Western blotting. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 79-82 31340906-8 2019 Treatment of the cells with 1.6 g/L matrine and 10 nmol/L LY294002 resulted in significantly lowered expressions of p-AKT and p-mTOR proteins and increased the expression of light chain 3B (LC 3B), an autophagy-related protein, as compared with those in the control cells (P &lt; 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 118-121 31309931-12 2019 Inhibition of Nrf2 using small interfering RNA (siRNA), or cotreatment with LY294002, an inhibitor of PI3K/Akt, abolished the protective effect on high glucose-induced injury, oxidative stress, and pro-inflammatory cytokines production by apigenin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 107-110 31213575-7 2019 Moreover, LY294002, the inhibitor of PI3K/AKT pathway, could reverse oncogenic action caused by PAR-2 activation.Conclusion: PAR-2 can promote OSCC growth and progression via activating PI3K/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 42-45 31213575-7 2019 Moreover, LY294002, the inhibitor of PI3K/AKT pathway, could reverse oncogenic action caused by PAR-2 activation.Conclusion: PAR-2 can promote OSCC growth and progression via activating PI3K/AKT signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 191-194 31034822-12 2019 U0126 and LY294002, inhibitors of Erk and Akt respectively, block SNP-enhanced KDFs proliferation effectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 42-45 31277394-6 2019 LY294002 (PI3K inhibitor) dramatically blocked piceatannol-mediated increasing of Nrf2 nuclear translocation, HO-1 expression, and cytoprotective activity, indicating the involvement of PI3K/Akt pathway in the cytoprotective effect of piceatannol. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 191-194 31186081-7 2019 Furthermore, ATAD2 modulated the glycometabolism of LUAD via AKT-GLUT1/HK2 pathway, as assessed using LY294002 (an inhibitor of PI3K/AKT pathway). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 AKT serine/threonine kinase 1 Homo sapiens 61-64 31186081-7 2019 Furthermore, ATAD2 modulated the glycometabolism of LUAD via AKT-GLUT1/HK2 pathway, as assessed using LY294002 (an inhibitor of PI3K/AKT pathway). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 AKT serine/threonine kinase 1 Homo sapiens 133-136 30925325-7 2019 In contrast, the effects of resistin on RAW264.7 macrophages could be abrogated by specific inhibitors for LPL (LPL-siRNA) and PI3K/AKT signaling pathway (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 155-163 AKT serine/threonine kinase 1 Homo sapiens 132-135 30600586-8 2019 Inhibitor (LY 294002, a specific inhibitor of PI3K-Akt) test result indicated that PI3K-Akt signaling pathway was involved in the inhibition of FA-induced apoptosis by Hsp70 overexpression and also active in the maintenance of GLI2 level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-20 AKT serine/threonine kinase 1 Homo sapiens 51-54 31200125-5 2019 With the administration of LY294002, the bFGF induced HPAECs survival and PI3k/Akt signaling activation were successfully blocked. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 79-82 30648253-7 2019 In addition, the protein kinase B (Akt) signal pathway inhibitor LY294002 significantly reduced the expression of TRIM27 and inhibited the dysfunction of mesangial cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 35-38 31077419-7 2019 These inductions were suppressed by Akt inhibitor LY294002 as well as antioxidant N-acetylcysteine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 36-39 31056260-10 2019 Importantly, CDDP combined with LY294002, inhibitor of phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) signaling, markedly decreased the expression of NRF2, HO-1, NQO1 and GCLC in drug-resistant cervical cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 88-91 31218332-9 2019 Meanwhile, LY294002 (PI3K inhibitor) decreased the protein expression levels of MDR1, beta-catenin and Survivin, as well as the phosphorylation levels of Akt and GSK3beta in SKOV3/VCR cells (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-19 AKT serine/threonine kinase 1 Homo sapiens 154-157 31226829-7 2019 The effect of NAP on the downregulation of p-ERK and p-AKT was enhanced by the LY294002 (a PI3K inhibitor), while the inhibitor PD98059 had no obvious effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 55-58 31192119-7 2019 We demonstrate that apoptosis is induced in a p53-dependent manner when cells are treated with pifithrin-alpha (a p53 inhibitor) and LY294002 (an Akt inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 133-141 AKT serine/threonine kinase 1 Homo sapiens 146-149 30243029-7 2019 Mechanistically, ANO1 knockdown attenuated phosphorylation of PI3K/Akt, and inhibition of PI3K/Akt signaling by specific inhibitor LY294002 resulted in suppression of ovarian cancer cells growth promoted by ANO1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 95-98 31057403-6 2019 Inhibition of PI3K and AKT by LY294002 and MK2206, respectively, or knockdown of AKT expression by siRNA blocked DAPT-induced activation of Cdc42. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 23-26 30863710-9 2019 Interestingly, LY294002 decreased the expression of p-AKT and attenuated the neuroprotective effect of EPO; while, U0126 decreased the expression of p-Erk1/2 and enhanced the neuroprotective effect of EPO. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 54-57 30673304-10 2019 Furthermore, inhibition of the PI3K/Akt pathway by LY294002 abrogated the ANXA4 overexpression-mediated effects on trophoblast behavior. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 36-39 31071387-6 2019 A pretreatment with an AKT inhibitor, LY294002, attenuated the ability of MTAQ to activate an insulin-like signaling pathway and to enhance basal and insulin-stimulated glucose uptake and stimulate GLUT4 translocation to the plasma membrane. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 23-26 31111658-5 2019 Meanwhile, we found that DMY could promote the expression of phosphorylated FoxO3a and Akt, and affect the nuclear localization of FoxO3a, when treated with the PI3K inhibitor LY294002, the effect of DMY was blocked. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 176-184 AKT serine/threonine kinase 1 Homo sapiens 87-90 31216656-9 2019 Western blot confirmed that levels of p-PI3K and p-Akt were significantly reduced in the C89- or LY294002 (PI3K inhibitor)-treated groups compared with controls. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 51-54 31216656-10 2019 Moreover, we found cooperative functions of C89 and LY294002 in inducing FGSC autophagy through suppressing the PI3K-Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 117-120 31196027-10 2019 In the following experiments, we found that CDCA2 regulated CCND1 expression through activating the PI3K/AKT pathway, and confirmed this using a specific PI3K inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 105-108 31239711-4 2019 Methods: LY294002 or insulin-like growth factor 1 (IGF-1) were used to block or stimulate the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) pathway in OSCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 149-152 31239711-10 2019 Moreover, PI3K/AKT signaling was blocked by LY294002, and activated by IGF-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 15-18 31281371-13 2019 These effects were associated with the increase in p-Akt/Akt and p-eNOS, which could be abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 53-56 31281371-13 2019 These effects were associated with the increase in p-Akt/Akt and p-eNOS, which could be abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 57-60 31201145-9 2019 After blockage of Akt signaling pathway by an Akt inhibitor, LY294002, the regulatory effects of LINC00184 on the glycolysis and mitochondrial OXPHOS of EC cells were reversed. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 61-69 AKT serine/threonine kinase 1 Homo sapiens 18-21 30707387-5 2019 Inhibitors of PI3K (LY294002) significantly suppressed the expression of IL-10, IL-37, p-PI3K, and p-Akt; however, it had no effect on the expression levels of PI3K and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 101-104 30742066-11 2019 LY294002 and wortmanin, PI3K/Akt inhibitors, can abolish CAPS1-induced increase of Akt/GSK3beta activity, as well as increase of Snail protein level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 29-32 30742066-11 2019 LY294002 and wortmanin, PI3K/Akt inhibitors, can abolish CAPS1-induced increase of Akt/GSK3beta activity, as well as increase of Snail protein level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 83-86 31088549-11 2019 To verify that the Akt/ERK/GSK-3beta pathway affected HDP cell proliferation, we treated HDP cells with LY294002 (an Akt inhibitor), BIO (a GSK-3beta inhibitor), and PD98059 (an ERK inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 19-22 31058093-9 2019 Finally, the introduction of PHLDA2 cDNA lacking the 3"-UTR or treatment with Akt inhibitor LY294002 partially abrogated miR-214-induced radioresistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 78-81 31001468-8 2019 Treatment with the PI3K/Akt inhibitor LY294002 restored the chemosensitivity of CACAN2D3-knockdown cells to cisplatin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 24-27 30600586-8 2019 Inhibitor (LY 294002, a specific inhibitor of PI3K-Akt) test result indicated that PI3K-Akt signaling pathway was involved in the inhibition of FA-induced apoptosis by Hsp70 overexpression and also active in the maintenance of GLI2 level. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-20 AKT serine/threonine kinase 1 Homo sapiens 88-91 30968158-10 2019 In addition, treatment with the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT inhibitor, LY294002, attenuated the pro-proliferative effects of exogenous FABP5 expression in Caki-1 and 786O cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 86-89 30881494-10 2019 The PI3K/AKT inhibitor LY294002 significantly suppressed the induction of BAG3 by proteasome inhibitors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 31008108-6 2019 PI3K/Akt pathway inhibitor, LY294002, restored the reduced melanin content that was induced by loratadine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 5-8 30794828-9 2019 Additionally, the expression of FOXG1 and FGF2 significantly decreased when the Akt pathway were inhibited by LY294002 in SH-SY5Y cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 80-83 30584986-7 2019 Inhibition of PI3K/Akt/mTOR pathway by LY294002 abrogated ID-1-mediated pro-proliferation and anti-apoptosis effects in HDECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 19-22 30815818-9 2019 Moreover, after ginkgolides and BB treatments, p-Akt and p-Nrf2 were significantly upregulated, which could be inhibited by LY294002 in a dose-dependent manner, meanwhile, GB exhibited more effective than GA and GK. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-132 AKT serine/threonine kinase 1 Homo sapiens 49-52 30737086-8 2019 Selected PI3K/mTOR/Akt inhibitors-Wortmannin (WM), LY294002, AZD8055, and two others indeed blocked REDD1/FKBP51expression in human keratinocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 19-22 30270549-9 2019 The inhibitor of PI3K/Akt (LY294002) abolished the protective effects of higenamine on OGD/R-induced neuronal cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 22-25 30272818-10 2019 These effects were associated by an increase in p-Akt/Akt and p-eNOS, and a decrease in cleaved caspase-3 could be abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 50-53 30272818-10 2019 These effects were associated by an increase in p-Akt/Akt and p-eNOS, and a decrease in cleaved caspase-3 could be abolished by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 54-57 30661291-10 2019 And both Akt inhibitor LY294002 and IKK inhibitor Bay117082 neutralized the p65 and p-p65 nuclear translocation induced by RPS15A overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 30989579-8 2019 In L6 myotubes treated with lipopolysaccharide (LPS) and NRG-1beta, PI3K/Akt signaling pathway-related protein expression was further determined using the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 73-76 30709701-11 2019 Inhibition of the Akt/HO-1 pathway by LY294002 or ZnPP attenuated the effects of Oxy on oxidative stress and apoptosis in H2O2-stimulated HLECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 18-21 30664164-6 2019 In addition, suppression of the PI3K/AKT pathway using LY294002 or rapamycin counteracted the protective effects of ABCG2 against chemotherapeutic drug treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 37-40 30316647-9 2019 However, silence of Akt by siRNA transfection or pharmacological inhibitors (wortmannin and LY294002) bypassed IA-induced Girdin phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 20-23 31217064-8 2019 The inhibition of Akt expression with LY294002 or STAT3 expression with AG490 abolished the TCDD-induced cyclin D1 upregulation and cell proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 18-21 30813318-12 2019 However, the phosphorylation of Akt was significantly blocked by PI3K inhibitor (LY294002), which in turn reduced the SPCP-induced proliferation and migration of CCD-986sk cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 32-35 30863067-14 2019 LY294002, a PI3K (phosphatidylinositol 3-kinase)/AKT inhibitor, also suppressed the expression of TNF-alpha, IL-6 and TGF-beta, and simultaneously, reduced the production of alpha-SMA and collagen I in HKFs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 49-52 30642632-7 2019 By using PI3K/AKT inhibitor LY294002 and NF-kappaB shRNA, the increased PLK1 was reversed and cells proliferation was inhibited. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 14-17 30132214-6 2019 PI3 K inhibitor LY294002 and MDM2 inhibitor Nutlin-3a block Pgp3-induced inhibition of HeLa cell apoptosis, suggesting a critical role for the PI3K/AKT pathway and its effect on the MDM2-p53 axis in Pgp3 anti-apoptotic activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 148-151 30582908-6 2019 ENO1 could modulate AKT signaling pathway in GC cells and the enhanced proliferation and migration ability induced by ENO1 overexpression was impaired after incubation with PI3K inhibitor Ly294002 in SGC7901 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 188-196 AKT serine/threonine kinase 1 Homo sapiens 20-23 30668826-11 2019 Treatment with PI3K/Akt inhibitor LY294002 in KFs with miR-188-5p inhibitor did not further reduce their proliferation, migration, and invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 20-23 30569107-8 2019 The antioxidant N-acetylcysteine, the phosphoinositide 3-kinase (PI3K)/AKT inhibitor LY294002 and the mTOR inhibitor rapamycin ameliorated the effects of high glucose. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 71-74 30483804-8 2019 Notably, docetaxel-inhibited SOX2 expression and growth of human CD133-expressing HCC stem cells were partially restricted following the block of the PI3K/AKT signaling pathway using the inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 197-205 AKT serine/threonine kinase 1 Homo sapiens 155-158 30675253-9 2019 A specific PI3K inhibitor (LY294002) enhanced the Tan-IIA-inhibited expression of AKT and JNK. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 82-85 30296564-14 2019 LY294002, an AKT inhibitor, blocked the effect of TCF21 on Bcl-xL, caspase 3 and CDDP-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 13-16 30365941-13 2019 The suppression of ROS and succeeding apoptosis was achieved by pretreatment with LY294002, a PI3K/Akt pathway inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 99-102 30551489-8 2019 Importantly, LY294002, a specific PI3K inhibitor, abrogated the anti-apoptosis effect of icariin, implicating the involvement of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 134-137 31527329-6 2019 Moreover, cordycepin effectively inactivated the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, while LY294002, a PI3K/Akt inhibitor, increased the apoptosis-inducing effect of cordycepin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 128-131 31132019-7 2019 Inhibition of Akt by LY294002 reversed the migration and invasion abilities of liver cancer cells, and inhibited the ability of cells growth and angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 14-17 31739764-10 2019 Treatment with 10 mumol/L Schisandrin of SH-SY5Y cells with the p-Akt inhibitor LY294002 demonstrated that the herbal-induced rise in p-Akt protein expression was diminished by this inhibitor indicating that signal transduction occurred in the observed cellular effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 66-69 30745840-9 2019 Moreover, overexpression of RRM2 failed to increase the expression of cyclin B1, cyclin D1, and N-cadherin when phosphorylation of AKT and ERK1/2 was suppressed by LY294002 or PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 164-172 AKT serine/threonine kinase 1 Homo sapiens 131-134 30353649-10 2019 LY294002 treatment also attenuated the IL-17A causing increases of protein levels of PI3K, AKT, MMP-2/9, Twist and the decreases of protein level of ZO-1 in the U87MG and U251 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 91-94 30009832-8 2019 Inactivation of the phosphoinositide 3-kinase and Akt pathways using small interfering RNA or selective inhibitors (LY294002 and MK2206) reduced the proliferative effects of CRNN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 50-53 31739764-10 2019 Treatment with 10 mumol/L Schisandrin of SH-SY5Y cells with the p-Akt inhibitor LY294002 demonstrated that the herbal-induced rise in p-Akt protein expression was diminished by this inhibitor indicating that signal transduction occurred in the observed cellular effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 136-139 30655908-7 2019 Notably, pretreating C666-1 cells with the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 suggested that with increasing concentrations of LY294002, triptolide exhibited decreasing ability to suppress proliferation and induce apoptosis in these cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 80-83 30655908-7 2019 Notably, pretreating C666-1 cells with the phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor LY294002 suggested that with increasing concentrations of LY294002, triptolide exhibited decreasing ability to suppress proliferation and induce apoptosis in these cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 152-160 AKT serine/threonine kinase 1 Homo sapiens 80-83 30098425-8 2018 Moreover, the specific PI3-K inhibitor LY294002 abolished the discrepancy in the growth and metastatic capacity between THOR-silenced HCC cells and control cells, which further confirmed that AKT was required in THOR-driven HCC cell growth and metastasis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 192-195 30471283-11 2019 To explore the underlying mechanism, we used LY294002 to block PI3K/Akt/GSK-3beta signaling pathway, the results from Western bolt showed that the expression of related proteins in PI3K signaling pathway were decreased with LY294002 treated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 68-71 30471283-11 2019 To explore the underlying mechanism, we used LY294002 to block PI3K/Akt/GSK-3beta signaling pathway, the results from Western bolt showed that the expression of related proteins in PI3K signaling pathway were decreased with LY294002 treated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 224-232 AKT serine/threonine kinase 1 Homo sapiens 68-71 30612403-7 2018 In addition, LY294002, a PI3K/AKT pathway inhibitor, increased PRDM1 and PTEN expression in a dose dependent manner in YT cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 30-33 30622592-8 2018 The effect of GST preventing mitochondrial dysfunction was antagonized by pretreatment of PD98059 and LY294002, selective inhibitors of ERK and Akt, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 102-110 AKT serine/threonine kinase 1 Homo sapiens 144-147 30300626-12 2018 Additionally, co-treatment with ERK1/2 (U0126) or an AKT inhibitor (LY294002) plus chrysophanol reduced cell proliferation, whereas P38 (SB203580) and a JNK inhibitor (SP600125) showed synergic effects only in BT-474 cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 53-56 30195142-10 2018 Importantly, the combined treatment of T-cadherin with the PI3K inhibitor LY294002 enhanced the inhibitory effect of T-cadherin on cellular proliferation and the PI3K/AKT/mTOR pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 167-170 30280183-5 2018 The function of protein kinase B (AKT) and heme oxygenase-1 (HO-1) activation on luteolin mediated I/R injury protection was assessed by administration of phosphoinositide-3-kinase/AKT inhibitor LY294002 and HO-1 inhibitor ZNPP. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 195-203 AKT serine/threonine kinase 1 Homo sapiens 181-184 29478280-10 2018 The effect of miR-139-5p was mediated by PI3K inhibition, as suggested by the decrease in proliferation and phosphorylation of AKT and p70 S6K after treatment with the direct PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 127-130 30450569-8 2018 Subsequently, LY294002, as the phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) pathway inhibitor, was used to further confirm the regulatory mechanism of STXBP5-AS1, which showed that knockdown of STXBP5-AS1 could rescue the expression of STXBP5 and p-AKT1 protein expression levels in A549 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 84-87 30510432-5 2018 In addition, a specific AKT inhibitor LY294002 was utilized to examine the correlation between the expression of TRIM37 and AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 24-27 30510432-5 2018 In addition, a specific AKT inhibitor LY294002 was utilized to examine the correlation between the expression of TRIM37 and AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 124-127 30464533-6 2018 GLUT-1 siRNA, LY294002 and cisplatin effectively inhibited the mRNA expressions and protein expressions of GLUT-1, Akt, PI3k and HIF-1alpha in Hep-2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 115-118 30464533-9 2018 Conclusion: This study showed that inhibiting GLUT-1, by a GLUT-1 siRNA and inhibiting PI3K/Akt by Ly294002, could suppress the proliferation of Hep-2 alone and together with cisplatin synergistically, which demonstrated the potentials to treat laryngeal carcinoma in the future therapy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 99-107 AKT serine/threonine kinase 1 Homo sapiens 92-95 30585261-11 2018 Akt activation was inhibited the PI3K inhibitors LY294002 and Wortmannin, resulting in the inhibition of cell viability and increase of cytochrome c release. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 0-3 29322615-13 2018 We also found that VO-OHpic (PTEN inhibitor) could counteract Abeta-induced neuronal damage, and LY294002 (AKT inhibitor) suppressed the protective effect of melatonin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 107-110 29286212-7 2018 LY294002 were used to inhibit PI3 K/Akt signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 36-39 30119206-0 2018 Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 127-130 30464533-10 2018 Additionally, the synergistic effect between LY294002 and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt, PI3k and HIF-1alpha; the synergistic effect between GLUT-1 siRNA and cisplatin to suppress the proliferation of Hep-2 might not be from GLUT-1, Akt and PI3k and might be more or less related to HIF-1alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 282-285 30377685-6 2018 The effect of icaritin on the proliferation of MG63 cells was significantly decreased by pretreating the cells with U0126 (an ERK signaling pathway blocker) and LY294002 (an AKT signaling pathway blocker), respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 161-169 AKT serine/threonine kinase 1 Homo sapiens 174-177 30145138-8 2019 The HSP27 phosphorylation induced by visfatin was also blocked by the specific PI3K/Akt inhibitor LY294002 and ERK 1/2 inhibitor U0126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 98-106 AKT serine/threonine kinase 1 Homo sapiens 84-87 30144329-6 2018 IGF-1 downregulated FoxO1 and involucrin but upregulated p-Akt expression in HPKs, which was blocked by pretreatment with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 59-62 30348950-9 2018 Azithromycin showed the same effect in imitated SLE macrophages, with distinct Akt phosphorylation at 30 min and 12 h. After inhibiting Akt phosphorylation by LY294002, the down-regulation of CD80, IL-1beta, IL-6, and TNF-alpha caused by azithromycin raised again, meanwhile, the up-regulation of CD206, Arg-1, Fizz-1, and IL-10 due to azithromycin was abolished. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 AKT serine/threonine kinase 1 Homo sapiens 79-82 30348950-9 2018 Azithromycin showed the same effect in imitated SLE macrophages, with distinct Akt phosphorylation at 30 min and 12 h. After inhibiting Akt phosphorylation by LY294002, the down-regulation of CD80, IL-1beta, IL-6, and TNF-alpha caused by azithromycin raised again, meanwhile, the up-regulation of CD206, Arg-1, Fizz-1, and IL-10 due to azithromycin was abolished. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 AKT serine/threonine kinase 1 Homo sapiens 136-139 30402135-16 2018 LY294002 and BSYX evidently downregulated the proteins levels of FSHR, p-Akt/Akt, Gankyrin, and cyclinD1 and upregulated the expression of HIF-alpha protein, and FSH was on the opposite. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 73-76 30402135-16 2018 LY294002 and BSYX evidently downregulated the proteins levels of FSHR, p-Akt/Akt, Gankyrin, and cyclinD1 and upregulated the expression of HIF-alpha protein, and FSH was on the opposite. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 77-80 30107164-9 2018 The combination of resveratrol and the PI3K inhibitor LY294002 had a synergistic effect on the inhibition of Akt phosphorylation and TLR4 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 109-112 30119206-7 2018 Mechanistic assay revealed that knockdown of Rictor could attenuate LY294002-induced phosphorylation of Akt (Ser473)/PRAS40 (Thr246). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 104-107 30119206-4 2018 We found LY294002 obviously restrained cell proliferation in dose-dependent and time-dependent manners by inhibiting PI3K/Akt/mTOR/p70S6K signaling pathway, whereas triggered mTORC2-medicated phosphorylation of Akt (Ser473)/PRAS40 (Thr246) in ECa109 and EC9706 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 122-125 30119206-4 2018 We found LY294002 obviously restrained cell proliferation in dose-dependent and time-dependent manners by inhibiting PI3K/Akt/mTOR/p70S6K signaling pathway, whereas triggered mTORC2-medicated phosphorylation of Akt (Ser473)/PRAS40 (Thr246) in ECa109 and EC9706 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 211-214 29981360-5 2018 When LY294002 (AKT inhibitor) and U0126 (ERK1/2 inhibitor) were treated with avobenzone, the anti-proliferative effect of avobenzone was alleviated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 5-13 AKT serine/threonine kinase 1 Homo sapiens 15-18 29956071-6 2018 Significantly, inhibition of PI3K/Akt pathway by Ly294002 attenuated platelet activation and CD40L production. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 34-37 29402343-10 2018 The increased phosphorylations of PI3K, AKT, and mTOR, and the upregulation of CXCL8 induced by miR-204 suppression were all abolished by the addition of LY294002 and AZD8055 (inhibitors of PI3K/AKT and mTOR, respectively). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 40-43 29940752-8 2018 LY294002 (PI3K/AKT inhibitor, 200 nM) further promoted YWHAZ silencing-induced apoptosis and autophagy in BGC-823 cells, while insulin-like growth factor-1 (IGF-1; PI3K/AKT agonist, 10 ng/ml) had the opposite role. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 15-18 29940752-8 2018 LY294002 (PI3K/AKT inhibitor, 200 nM) further promoted YWHAZ silencing-induced apoptosis and autophagy in BGC-823 cells, while insulin-like growth factor-1 (IGF-1; PI3K/AKT agonist, 10 ng/ml) had the opposite role. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 169-172 30195866-7 2018 RESULTS: Pretreatment with L-NAME and LY294002 significantly decreased the LCE-induced NO production, as well as eNOS and Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 122-125 30258464-9 2018 LY294002, an inhibitor of the Akt pathway, was used to confirm the associated signaling pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 30-33 29964051-15 2018 However, Ly294002 alleviated these exosome-induced changes, suggesting that exosomes from ADSCs could promote and optimize collagen deposition in vitro and in vivo and further promote wound healing via the PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 211-214 29402343-10 2018 The increased phosphorylations of PI3K, AKT, and mTOR, and the upregulation of CXCL8 induced by miR-204 suppression were all abolished by the addition of LY294002 and AZD8055 (inhibitors of PI3K/AKT and mTOR, respectively). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 195-198 30025893-8 2018 Inhibition of PI3K/Akt signaling with LY294002 similarly increased CREB phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 19-22 30208576-6 2018 Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 19-22 30208576-6 2018 Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 184-187 30547894-7 2018 Using the PI3K inhibitor, LY294002, we revealed that AKT is a key regulator in the inhibitory mechanism of morin against PDGF-induced proliferation of VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 53-56 30323976-6 2018 Finally, we showed that LY294002, an inhibitor of PI3K/Akt signaling, attenuated the effects of mutant RasGRP3 on thyroid cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 55-58 29636230-10 2018 Furthermore, p-PI3K, p-Akt, and p-GSK3beta expressions were significantly increased after SX treatment, while they were all reduced after administration of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 23-26 29956736-13 2018 The combined administration of LY294002 with DCA significantly decreased lactate concentration, promoted the depolarisation of the DeltaPsim and repressed HIF-1alpha upregulation and HK-2 activation in PASMCs treated with PDGF, which was attributed to the potentiation of DCA-induced PDK-1 inhibition by LY294002 via blockade of the Akt/GSK-3beta/HIF-1alpha signalling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 333-336 29749659-10 2018 Expressions of AKT1 and AKT2 were decreased in the GCs under exposure to bicalutamide or LY294002 (P <= 0.05 vs R1881). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 15-19 29749659-11 2018 AKT1, AKT2, and AKT3 showed decreased rates of expressions in the LY294002 + bicalutamide group (P <= 0.05 vs R1881). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 0-4 30460698-3 2018 The same inhibiting effect is shown in platelets pretreated with LY294002, an inhibitor of phosphatidylinositol 3 kinase (PI3K), or with MK2206, an inhibitor of protein kinase B (AKT), suggesting that AMPK is downstream of the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 232-235 30347925-11 2018 Furthermore, the inhibition of PI3K/Akt by LY294002 or that of mTOR by rapamycin augmented LCA-induced autophagy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 36-39 29908183-10 2018 LY294002, an inhibitor of PI3K/Akt signaling, attenuated the enhancement of Nrf2 protein and protective effect of MIF in OGD-treated cochlear cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 31-34 30122991-9 2018 These effects were reversed by the AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 35-38 30112565-10 2018 WGS and LY294002 (PI3K inhibitor) both remarkably decreased the phosphorylation level of Akt (P < 0.05), down-regulated the protein level of Nrf2 (P < 0.05), increased the content of ROS (P < 0.05), up-regulated the protein level of cleaved Caspase-3 (P < 0.05), and induced apoptosis (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 8-16 AKT serine/threonine kinase 1 Homo sapiens 89-92 30112032-10 2018 Furthermore, inhibition of the phosphorylation/activity of Akt by LY294002 and knockdown of phosphatase and tensin homologue (PTEN) with simultaneous upregulation or knockdown of MIST1 revealed that SNAI1 improved the phosphorylation of Akt by inhibiting the expression of PTEN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 59-62 29907326-9 2018 Furthermore, the protective effects of FGF21 were prevented by PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 68-71 29901173-7 2018 Furthermore, the AKT pathway inhibitor LY294002, the ERK pathway inhibitor PD98059 and the TAK1 pathway inhibitor 5Z-7 inhibited the expression of PD-L1 in A549 and H1650 cells, but not in H1975 cells, during the EMT process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 17-20 29753186-5 2018 As a downstream gene activated by PI3K/Akt signal pathway, we assumed that the targeted depletion of Plk1 could contribute to the chemosensitization induced by synergistic drug interaction of PI3K inhibitor LY294002 together with gemcitabine. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 207-215 AKT serine/threonine kinase 1 Homo sapiens 39-42 29917165-7 2018 Both AKT inhibitor LY294002 and ERK1/2 inhibitor U0126 reduced the ability of angiogenesis and VM formation, as well as mosaic vessel formation induced by HGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 5-8 30013652-11 2018 Inhibition of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt pathway by LY294002 augmented juglone-mediated GSK-3beta activity by inhibiting Ser9 phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 72-75 29753186-7 2018 Both inhibition of PI3K/Akt signal pathway through PI3K inhibitor LY294002 and targeted depletion of Plk1 via recombinant adenoviral shRNA can cause chemosensitization, and the targeted depletion of Plk1 can enhance the chemosensitization of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 24-27 29792861-7 2018 Conversely, Akt-mTORC1 inhibitors (RAD001 and LY294002) reduced NLGN3-induced HO1, NOQ1 and GCLC mRNA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 12-15 29708815-12 2018 The homozygous H2189Y mutation was sensitive to the mTOR inhibitor, everolimus, and the AKT inhibitors AZD5363 and MK-2206 2HCL,and the phosphoinositide 3-kinase inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 173-181 AKT serine/threonine kinase 1 Homo sapiens 88-91 29980193-13 2018 Combination treatment with PI3K/AKT pathway inhibitor LY294002 dramatically accelerated the suppression effect of temozolomide. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 32-35 29976410-5 2018 The Akt inhibitor LY294002, mTOR inhibitor rapamycin and c-Myc inhibitor 10058-F4 significantly suppressed RPS19 expression and transactivation activities. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 4-7 30061946-10 2018 PI3K/AKT inhibitor LY294002 restored DTX-induced caspase-3 activation and Bcl-2 phosphorylation, reversed the effect of CCL2 on the viability of A549 cells and enhanced DTX-induced cytotoxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 5-8 30087712-8 2018 Finally, an activator (740Y-P) and inhibitor (LY294002) of the PI3K/AKT signaling pathway were used in the western blot assays and the following rescue experiments, demonstrating that SNHG1 facilitates cell proliferation and tumorigenicity partly via the PI3K/AKT signaling pathway in PDAC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 68-71 29709474-9 2018 Whereas Akt-mTOR inhibitors (LY294002, AZD2014 and RAD001) abolished KGF-induced Nrf2 activation and anti-OGDR cytoprotection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 8-11 29610946-12 2018 Ly294002 (an Akt inhibitor) decreased the cell inhibition ability of shZNF84, indicating the involvement of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 13-16 29610946-12 2018 Ly294002 (an Akt inhibitor) decreased the cell inhibition ability of shZNF84, indicating the involvement of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 108-111 30195330-8 2018 It appeared that treatment with LY294002, which inhibits all Akt isoforms (Akt1, Akt2, Akt3), not only failed to restore the invasive phenotype of melanoma cells but further attenuated their invasive activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 61-64 30195330-8 2018 It appeared that treatment with LY294002, which inhibits all Akt isoforms (Akt1, Akt2, Akt3), not only failed to restore the invasive phenotype of melanoma cells but further attenuated their invasive activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 75-79 29627441-11 2018 The results showed that the pharmacological inhibitor of PI3K/AKT (LY294002) or p38 (SB 203580), but not ERK1/2 (U0126), abrogated AFN-induced Nrf2 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 62-65 29568936-10 2018 In addition, in the A375/ISL1 cells treated with the LY294002 inhibitor for 24 and 48 h, the level of Akt was also found to increase compared to the control A375/GFP cells (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 102-105 29393377-8 2018 These effects of BCL6B were empowered by treatment with the specific phosphoinositide 3 kinase (PI3K)/AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 102-105 29970718-0 2018 Baicalein and Ly294002 induces liver cancer cells apoptosis via regulating phosphatidyl inositol 3-kinase/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 106-109 29970718-9 2018 Baicalein and LY294002 significantly suppressed PI3K/Akt signaling pathway-related molecule activity at both mRNA and protein levels (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 53-56 29658572-14 2018 Ly294002 (10 microM), a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling inhibitor, partially reversed the rotenone-induced alleviation of endotoxin tolerance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 78-81 29928327-9 2018 In L428 cells overexpressing TNFR2, the beta-catenin blocker, DKK1, or the AKT inhibitor, LY294002, abrogated the increase in proliferation induced by TNFR2 and increased cell inhibition rate upon treatment with ADM. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 75-78 29928334-8 2018 The use of LY294002, a PI3K inhibitor, was able to suppress the activation of Akt and extracellular signal-regulated kinase 1/2, attenuated the migratory and invasive capacities of resistant cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-19 AKT serine/threonine kinase 1 Homo sapiens 78-81 29620222-7 2018 Inhibition of PI3K/AKT by LY294002 downregulated IL-13-induced YY1 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 19-22 29572181-4 2018 A phosphoinositide 3-kinase (PI3K) inhibitor LY294002 was used to inhibit the activity of endogenous Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 101-104 29572181-8 2018 LY294002 treatment reduced the phosphorylation levels of Akt1 and 4E-BP1, and the protein levels of type I collagen and alphaSMA in pBOO bladder. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 57-72 29512729-14 2018 Furthermore, the levels of p-Akt and p-NF-kappaB caused by SOD could be offset by treatment with curcumin and LY 294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-119 AKT serine/threonine kinase 1 Homo sapiens 29-32 29687528-7 2018 Meanwhile, LY294002, an inhibitor of PI3K/Akt, abolished the protective effect of nobiletin against H2 O2 -induced decreased cell viability and increased caspase-3/7 activity in ARPE-19 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-19 AKT serine/threonine kinase 1 Homo sapiens 42-45 29488612-7 2018 In addition, LY294002, an protein kinase B (Akt) inhibitor, greatly suppressed the expression level of phospho (p)-Akt, matrix metalloproteinase (MMP)-9 and p-mammalian target of rapamycin (mTOR), suggesting that the activation of the Akt/mTOR/MMP-9 signaling pathway may participate in regulating cell migration in PCa. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 44-47 29488612-7 2018 In addition, LY294002, an protein kinase B (Akt) inhibitor, greatly suppressed the expression level of phospho (p)-Akt, matrix metalloproteinase (MMP)-9 and p-mammalian target of rapamycin (mTOR), suggesting that the activation of the Akt/mTOR/MMP-9 signaling pathway may participate in regulating cell migration in PCa. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 115-118 29488612-7 2018 In addition, LY294002, an protein kinase B (Akt) inhibitor, greatly suppressed the expression level of phospho (p)-Akt, matrix metalloproteinase (MMP)-9 and p-mammalian target of rapamycin (mTOR), suggesting that the activation of the Akt/mTOR/MMP-9 signaling pathway may participate in regulating cell migration in PCa. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 115-118 29588342-8 2018 The AKT inhibitor LY294002 also suppressed TGFbeta2-induced up-regulation of nuclear Snail and reduced phosphorylation of GSK3beta. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 4-7 29908644-11 2018 LY294002, a specific inhibitor of PI3K, blocked CdCl2-evoked Akt phosphorylation in JEG-3 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 61-64 29729706-10 2018 TGFbeta1 significantly induced the PI3K/Akt pathway and the PI3K/Akt pathway inhibitor LY294002 significantly downregulated basal as well as TGFbeta1 induced alternative splicing of EDA+Fn in human podocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 65-68 29556314-7 2018 Research into the molecular mechanism was performed and the results identified that protein kinase B (AKT) and extracellular signal-related kinase signal pathways were both stimulated by VASH1, but only AKT inhibitor LY294002 was identified to efficiently counteract increases in P-gp expression that had been induced by silencing of VASH1 in U-2OS cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 217-225 AKT serine/threonine kinase 1 Homo sapiens 203-206 29524402-7 2018 Akt and mTOR/P70S6K phosphorylation was inhibited by LY 294002 but not by PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-62 AKT serine/threonine kinase 1 Homo sapiens 0-3 29805303-5 2018 Elongator-driven migration and invasion and the expression of MMP-2 and MMP-9 were reduced in HCC cells treated with AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 117-120 29393372-5 2018 After adding the phosphatidylinositol 3-kinase (PI3K)/AKT signaling inhibitor LY294002 or wortmannin to the LIF differentiation group, LIF-induced changes in the protein expression of TUJ1 and MAP2 were reversed, but this effect could not be prevented by rapamycin, a mechanistic target of rapamycin signaling inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 AKT serine/threonine kinase 1 Homo sapiens 54-57 29552203-13 2018 Furthermore, overexpression of S100A6 in HeLa cells activated the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, and treatment with the PI3K inhibitor LY294002 partially repressed S100A6-enhanced proliferation and migration of cervical cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-187 AKT serine/threonine kinase 1 Homo sapiens 117-120 29662626-5 2018 LY294002 and MK2206, two inhibitors of the PI3K/Akt pathway, mimicked the effect of the inhibition of EGFR/ErbB2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 48-51 30090596-10 2018 Furthermore, both LY294002 (an inhibitor of PI3K) and MK-2206 (an inhibitor of Akt) could significantly decrease the elevated TNF-alpha gene expressions, suggesting that the PI3K/Akt pathway was involved in the regulation of TNF-alpha expressions induced by 1-AP and 3-AF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 179-182 29463070-6 2018 CSE increased the transcription of IL-17RA/RC and surface membrane expression of IL-17R, which was suppressed by an inhibitor of the phosphoinositide 3-kinase (PI3K)/Akt pathway (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 179-187 AKT serine/threonine kinase 1 Homo sapiens 166-169 29319206-8 2018 Furthermore, pretreatment of cells with LY294002 (an AKT inhibitor) and U0126 (ERK1/2 inhibitor) revealed that ERK1/2 activity is also involved in BP-mediated signal transduction in HTR8/SVneo cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 53-56 29470962-5 2018 Such events were also duplicated with a cell-permeable C2-ceramide and Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 71-74 29556265-7 2018 Furthermore, the aforementioned changes were mediated by the AOPP-phosphorylated phosphoinositide 3-kinase3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway; this was verified by treatment with LY294002, a PI3K inhibitor, which reversed the AOPP-induced changes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 227-235 AKT serine/threonine kinase 1 Homo sapiens 140-143 29330470-6 2018 Subsequently, Akt-dependent NF-kappaB activation is required for Bcl-2 upregulation, but not Bax downregulation, in response to beta-Ecd, which was validated by the use of LY294002 and Bay11-7082. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 14-17 29435803-10 2018 The addition of LY294002, a PI3K inhibitor, could suppress phosphorylation of Akt and CREB and activate GSK-3beta, resulting in abolishment of neuroprotective effects of rifampicin on cells exposed to rotenone. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 78-81 29552230-9 2018 Furthermore, treatment with the AKT inhibitor LY294002 or the ERK inhibitor U0126 inhibited the upregulation of VEGF-A induced by FAP expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 32-35 29588573-5 2018 Further study disclosed that Vit enhanced the phosphorylation of PI3K and Akt which was downregulated by MPP+ in SH-SY5Y cells, the effect of which could be blocked by PI3K inhibitor LY294002 and activated by PI3K activator IGF-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 74-77 25588050-8 2018 PI3K/AKT inhibitor (LY294002), while not ERK inhibitor (PD98059), significantly abolished G-1 induced up regulation of MMP-9 in both AHCN and OS-RC-2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 5-8 29052277-8 2018 Moreover, LY294002, the AKT inhibitor, significantly inhibited EGF-induced upregulation of ZEB1 and ZEB2 as well as EMT and migration stimulated by EGF in gastric cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 24-27 29217185-8 2018 Moreover, LY294002, the specific phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) inhibitor, significantly alleviated the effects of sAPS on autophagy and PCV2 replication. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 82-85 29497316-9 2018 Pretreatment with an AKT inhibitor LY294002 markedly attenuated IL-33-induced cell migration and invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 21-24 29459421-5 2018 IGF-1-induced activation of Akt and the protective effect of IGF-1 on MPP+-induced apoptosis were abolished by chemical inhibition of PDK1 (GSK2334470) or PI3K (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 161-169 AKT serine/threonine kinase 1 Homo sapiens 28-31 28238097-5 2018 Inhibition of the PI3K/Akt pathway by the PI3K-specific inhibitor, LY294002 or inhibition of Akt by Akt-specific inhibitors Akt inhibitor VIII or SN-38, or downregulation Akt with siRNA specific for Akt blocked the effect of IGF-1 on hRPE. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 23-26 28871449-7 2018 Mechanistically, we found that overexpressed ARHGEF39 significantly increased the phosphorylation level of Akt (p-Akt), and its effect on cell proliferation was attenuated by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 107-110 28871449-7 2018 Mechanistically, we found that overexpressed ARHGEF39 significantly increased the phosphorylation level of Akt (p-Akt), and its effect on cell proliferation was attenuated by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 112-117 29328421-11 2018 It is worth noting that the inhibition of mTOR by rapamycin or of PI3K/Akt by LY294002 augmented curcumin-induced apoptosis and autophagy, leading to significant inhibition of cell proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 AKT serine/threonine kinase 1 Homo sapiens 71-74 29581767-7 2018 Moreover, upon inhibition of PI3K/AKT pathway by PI3K-inhibitor LY294002 or AKT-inhibitor mk2206, the radiosensitivity of ARID1A-deficient pancreatic cancer cells is improved in vitro via increased apoptosis and weakened DDR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 34-37 29556340-6 2018 In contrast, blocking PI3K and AKT using LY294002 and MK-2206, respectively, decreased PTRF expression, showing that PTRF is regulated in the EGFR/PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 31-34 29444190-7 2018 These protective effects could be blocked by both a miR-21 inhibitor and the PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 82-85 33052635-10 2018 Western blot analysis showed that PDCD4 overexpression or PI3K inhibition by LY294002 significantly reduced the expression of phospho-PI3K, phospho-Akt, phospho-mammalian target of rapamycin and phospho-p70s6k, but not their total protein levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 148-151 29461611-5 2018 Finally, Western blot was used to detect the expressions of Akt and extracellular regulated protein kinases 1/2 (Erk1/2) signal pathway-associated proteins after nucleus pulposus cells were treated with LY294002, the phosphatidylinositol 3-kinase (PI3K) inhibitor, and PD98059, the extracellular regulated protein kinases (MEK) inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 203-211 AKT serine/threonine kinase 1 Homo sapiens 60-63 29207170-7 2018 The phosphatidylinositol 3-kinase inhibitor LY294002 and the agonist IGF-1 were employed to suppress or induce the phosphorylation of Akt to determine whether BMI-1 induces radioresistance in ESCC cells via activation of the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 134-137 29439547-6 2018 However, these factors were down-regulated by DP2 antagonist (TM30089) and AKT inhibitor (LY294002) as well as DP2 knockdown in hDPCs decreased AR expression and AKT signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 75-78 29207091-9 2018 Molecular mechanism analysis demonstrated that p-ERK and p-Akt in SW1116 and HT29 cells were affected by alterations in FAP-alpha expression, and treatment with a p-ERK inhibitor (U0126) and p-Akt inhibitor (LY294002) ameliorated VEGF-A upregulation induced by FAP-alpha overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 59-62 29207091-9 2018 Molecular mechanism analysis demonstrated that p-ERK and p-Akt in SW1116 and HT29 cells were affected by alterations in FAP-alpha expression, and treatment with a p-ERK inhibitor (U0126) and p-Akt inhibitor (LY294002) ameliorated VEGF-A upregulation induced by FAP-alpha overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 193-196 29207170-14 2018 Additionally, the inhibitory effect of the downregulation of p-Akt by LY294002 on tumour cell viability was identical to that of BMI-1 knockdown, while the kinase agonist IGF-1 reversed the effects of BMI-1 knockdown on cell viability and radiosensitivity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 63-66 29137974-9 2018 In addition, the increasing levels of Nestin, MAP2 and pAKT in the MMP2 group were declined by pretreatment with the phosphoinositide 3-kinase (PI3K)/AKT inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 165-173 AKT serine/threonine kinase 1 Homo sapiens 56-59 29386059-7 2018 The phosphatidylinositol 3-kinase inhibitor LY294002 was used to inhibit Akt to verify miR-150 increase NK/T cell lymphoma cell radiorsensitivity through suppress the PI3K/AKT/mTOR pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 73-76 29386059-7 2018 The phosphatidylinositol 3-kinase inhibitor LY294002 was used to inhibit Akt to verify miR-150 increase NK/T cell lymphoma cell radiorsensitivity through suppress the PI3K/AKT/mTOR pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 172-175 29263137-8 2018 Using the signaling pathway inhibitor LY294002, we found that Bcl-2 expression and eNOS phosphorylation after Ninj1 blockade were regulated via PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 149-152 29329563-9 2018 Furthermore, an AKT inhibitor (LY294002), NF-kappaB inhibitor (BAY11-7082), and STAT3 inhibitor (Stattic) significantly down-regulated O-PMs-induced ICAM-1 expression as well as the adhesion of U937 cells to epithelial cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 16-19 29198702-11 2018 Furthermore, the protective effects of hydrogen were abrogated by PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 85-93 AKT serine/threonine kinase 1 Homo sapiens 71-74 29229447-6 2018 Inhibition of PI3K/Akt signaling by LY294002 suppressed the expression of hnRNP A1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 19-22 29248464-10 2018 Pre-treatment of cells with selective inhibitors of AKT (LY294002) and ERK1/2 (U0126) revealed that the AKT and ERK1/2 signaling pathways regulated by DA displayed cross-talk in HTR8/SVneo cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 52-55 29248464-10 2018 Pre-treatment of cells with selective inhibitors of AKT (LY294002) and ERK1/2 (U0126) revealed that the AKT and ERK1/2 signaling pathways regulated by DA displayed cross-talk in HTR8/SVneo cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 104-107 28914370-7 2018 LY-294002 was used for the inhibition of PI3K-Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-9 AKT serine/threonine kinase 1 Homo sapiens 46-49 29115424-5 2018 Additionally, it was observed that following inhibition of PI3K/Akt by LY294002, the levels of p-Akt and p-mTOR were markedly decreased, and the LC3-II/LC3-I ratio and beclin-1 were increased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 64-67 29133128-6 2018 Blockage of AKT signalling pathway by a specific AKT inhibitor LY294002 impaired BCA3 mediated phenotypes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 12-15 29133128-6 2018 Blockage of AKT signalling pathway by a specific AKT inhibitor LY294002 impaired BCA3 mediated phenotypes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 49-52 29641644-11 2018 Pre-treatment of endothelial cells with NADPH oxidase (DPI and apocynin) and PI3K/Akt pathway (LY294002) inhibitors reduced ROS production, bacterial intracellular viability, and generation of actin stress fibres in HUVECs infected with S. agalactiae. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 82-85 28766166-8 2018 miR-363 mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which suggested that rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 AKT serine/threonine kinase 1 Homo sapiens 49-52 29115424-5 2018 Additionally, it was observed that following inhibition of PI3K/Akt by LY294002, the levels of p-Akt and p-mTOR were markedly decreased, and the LC3-II/LC3-I ratio and beclin-1 were increased. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 97-100 29387228-4 2018 NSCLC cells were treated with insulin in the absence or presence of LY294002, an inhibitor of the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 103-106 29577981-9 2018 In addition, pretreatment with AKT inhibitor LY294002 could obviously attenuate PFOS-induced NF-kappaB activation and IL-1beta secretion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 31-34 29387228-9 2018 However, the effects of insulin on NSCLC cells was inhibited by the PI3K/Akt pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 73-76 29953987-6 2018 Knockdown of XPC using siRNA or inactivation of AKT by pharmacological inhibitor PI3K inhibitor (LY294002) enhanced the cytotoxic effects of etoposide. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 48-51 29295560-4 2017 A cell viability assay revealed that pharmacological suppression of AKT using LY294002 enhanced the anti-cancer effect of fascaplysin in various cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 78-86 AKT serine/threonine kinase 1 Homo sapiens 68-71 29435149-9 2018 The adding of PI3K inhibitor LY294002 played an opposite role to miR-361-5p mimic by inducing autophagy and chemoresistance to docetaxel of gastric cancer cells compared with docetaxel + miR-361-5p mimic group, indicating that miR-361-5p suppressed autophagy-induced chemoresistance via the PI3K/Akt/mTOR pathway in gastric cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 296-299 29241458-9 2017 IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 198-206 AKT serine/threonine kinase 1 Homo sapiens 13-16 29228922-16 2017 Furthermore, the PI3K inhibitor LY294002 could effectively reversed SALL2 siRNA-induced phosphorylation of Akt, migration and invasion of A2780 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 107-110 29296070-9 2017 Fisetin combined with LY294002 (an inhibitor of AKT) prevented the EGF-induced migration involved in downregulation of Sp1 and MMP-9 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 48-51 28833753-7 2017 As expected, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the MAPK inhibitor U0126 inhibited Lf-induced phosphorylation of Akt1 and ERK1/2, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 142-146 28983584-9 2017 The application of PD98059, an ERK inhibitor, and LY-294002, an AKT inhibitor, attenuated the protective effect induced by DRSAb in the U251 cells subjected to H/R. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-59 AKT serine/threonine kinase 1 Homo sapiens 64-67 28940899-9 2017 ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and Akt, respectively, which in turn reduced the LIPUS-induced proliferation of hAD-MSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 121-124 29130099-6 2017 PI3K inhibitor (LY294002) or survivin inhibitor (YM155) suppressed PI3K/AKT/survivin signaling and increased the anticancer effects of miR-542-3p on the apoptosis in colon cancer. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 72-75 29344198-0 2017 Combination of cecropinXJ and LY294002 induces synergistic cytotoxicity, and apoptosis in human gastric cancer cells via inhibition of the PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 144-147 28811223-9 2017 RESULTS: Our study showed that ALA-PDT respectively combined with AG1478, LY294002 could synergistically reduce the growth and migration ability of the Eca-109 cells in vitro and significantly down-regulate the protein expression of EGFR/PI3K and PI3K/AKT, meanwhile, significantly down-regulate the gene expression of EGFR when combining with AG1478. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 252-255 29312623-4 2017 Pretreatment with the Akt inhibitor LY294002 synergistically enhanced the R7 anti-proliferation and anti-apoptosis effects in HeLa cells, confirming that R7 acts through the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 22-25 29312623-4 2017 Pretreatment with the Akt inhibitor LY294002 synergistically enhanced the R7 anti-proliferation and anti-apoptosis effects in HeLa cells, confirming that R7 acts through the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 179-182 29296214-10 2017 Notably, PI3K inhibitor LY294002 obviously attenuated the effects of NCOA5 on p-AKT, Cyclin D1, P27 and MMP9. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 80-83 28271613-9 2017 Similarly, LY294002 interrupted the beneficial effects of QL with down-regulated phospho-Akt, phospho-mTOR, HIF-1alpha and VEGF expressions. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-19 AKT serine/threonine kinase 1 Homo sapiens 89-92 28844616-8 2017 LY294002, an inhibitor of Akt activation, abrogated the phosphorylation of Akt and abolished the positive effect of miR-21 on promoting BMSCs migration and upregulating MMP-2/MMP-9 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 26-29 28844616-8 2017 LY294002, an inhibitor of Akt activation, abrogated the phosphorylation of Akt and abolished the positive effect of miR-21 on promoting BMSCs migration and upregulating MMP-2/MMP-9 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 75-78 29290940-15 2017 LPC-induced apoptosis, and IL-8 expression/secretion was attenuated by LY294002, a PI3K/Akt inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 71-79 AKT serine/threonine kinase 1 Homo sapiens 88-91 28712871-3 2017 Inhibitory experiments using a PI3K selective inhibitor, LY294002 or NVP-BEZ235, significantly enhanced the BITC-induced antiproliferation and apoptotic cell population with the attenuation of the BITC-induced activation of the PI3K/Akt/FoxO survival pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 233-236 28738539-8 2017 Finally, results of studies which used an agonist (740Y-P) and an inhibitor (LY294002) of the PI3K/AKT signaling pathway, as well as the results of western blot assays, indicated that lncRNA AB073614 exerts its effects by targeting the PI3K/AKT-mediated signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 99-102 28587873-6 2017 Suppression of endogenous PI3K/Akt activity during colitis or NGF treatment with a specific PI3K inhibitor LY294002 reduced TRPV1 protein production in DRG neurons, and also reduced colitis-evoked TRPV1-mediated visceral hypersensitivity tested by hyper-responsiveness to colorectal distention (CRD) and von Frey filament stimulation of abdomen. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 107-115 AKT serine/threonine kinase 1 Homo sapiens 31-34 29035583-11 2017 In addition, a combination of resveratrol and the PI3K/AKT inhibitor LY294002 exhibited a stronger inhibitory effect on the SKM-1 cells, compared with resveratrol alone. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 55-58 28944825-5 2017 Additionally, PI3K/AKT/FOXO3a signaling was inhibited using Ly294002 and the effect on the protective function of mild hypothermia pretreatment was evaluated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 19-22 28944825-9 2017 However, inhibiting p-AKT and p-FOXO3a using Ly294002 suppressed the liver protection produced by mild hypothermia. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 22-25 29113186-12 2017 Notably, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 abrogated the decreased phosphorylation of Akt, suggesting that the PI3K/Akt signaling pathway is involved in mediating the anticancer effects of puerarin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 112-115 29113186-12 2017 Notably, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 abrogated the decreased phosphorylation of Akt, suggesting that the PI3K/Akt signaling pathway is involved in mediating the anticancer effects of puerarin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 142-145 29017592-16 2017 Furthermore, omentin-1 enhanced Akt phosphorylation; however, blockade of the PI3K/Akt pathway with an inhibitor, LY294002 (20 muM), suppressed the above beneficial effects of omentin-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 114-122 AKT serine/threonine kinase 1 Homo sapiens 83-86 29245957-5 2017 In addition, LC3-II and p-Akt was suppressed in the presence of LY294002, a well-known inhibitor of P13K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 26-29 28981091-6 2017 On another hand, inhibiting the PI3K/Akt pathway with LY294002 partially reversed the therapeutic effects of FGF10. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 37-40 28708672-8 2017 Treatment of LNCaP cells with the PI3-kinase inhibitor LY294002, which inhibits the PI3-kinase-dependent activation of AKT-1, prevented the artemisinin-induced AR degradation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 119-124 28757460-8 2017 PI3K/AKT inhibitor (LY294002) and HO-1inhibitor (ZnPP-IX) both increased olaquindox-induced apoptosis and S-phase arrest. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 5-8 29071206-8 2017 The expression of p-p65, p-AKT and Bcl-2 was significantly reduced by LY294002, but increased by ERbeta siRNA (p < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 27-30 28677724-9 2017 On a molecular mechanism level, TNFR2 significantly affected the phosphorylation of AKT serine/threonine kinase 1 (AKT) in both cell lines, and treatment with the AKT inhibitor LY294002 effectively abrogated TNFR2-induced PARP expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 84-113 28677724-9 2017 On a molecular mechanism level, TNFR2 significantly affected the phosphorylation of AKT serine/threonine kinase 1 (AKT) in both cell lines, and treatment with the AKT inhibitor LY294002 effectively abrogated TNFR2-induced PARP expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 84-87 28677724-9 2017 On a molecular mechanism level, TNFR2 significantly affected the phosphorylation of AKT serine/threonine kinase 1 (AKT) in both cell lines, and treatment with the AKT inhibitor LY294002 effectively abrogated TNFR2-induced PARP expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 115-118 28731179-5 2017 LY294002, an inhibitor of PI3K, suppressed PI3K/AKT/mTOR signaling, induced apoptosis, inhibited cell proliferation, increased caspase-3 and Bax protein expression, and decreased PDK1 protein expression in A2058 cells following miR-138 overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 48-51 28927052-0 2017 Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL-60 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 75-78 28927052-1 2017 The aim of the present study was to investigate the synergistic effect of phenylhexyl isothiocyanate (PHI) and LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] on the PI3K/protein kinase B (Akt) signaling pathway, modulating histone acetylation, inhibiting cell viability and inducing apoptosis in HL-60 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 201-204 28927052-9 2017 PHI and/or LY294002 were identified to dephosphorylate proteins in the PI3K/Akt signaling pathway, with a synergistic effect observed when used in combination. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 11-19 AKT serine/threonine kinase 1 Homo sapiens 76-79 29130665-8 2017 1H7 and LY294002 decreased the expression of PI3K and pAkt protein,but no obvious inhibitory effect on total Akt protein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 8-16 AKT serine/threonine kinase 1 Homo sapiens 55-58 28739349-7 2017 Following administration of the PI3K-specific inhibitor LY294002, the phosphorylation levels of Akt and mTOR decreased, and the ratio of autophagy-specific protein microtubule-associated protein 1 light chain (LC3)II/I was higher in the inhibitor-treated injury group than in the simple-injury group. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 96-99 28938602-9 2017 We further demonstrated that lapatinib-induced CIP2A downregulation can be recapitulated by LY294002, suggesting that Akt mediates CIP2A upregulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 92-100 AKT serine/threonine kinase 1 Homo sapiens 118-121 28454878-5 2017 Knockdown of TS using small interfering RNA (siRNA) or inhibiting AKT activity with PI3K inhibitor LY294002 enhanced the cytotoxicity and cell growth inhibition of erlotinib. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 99-107 AKT serine/threonine kinase 1 Homo sapiens 66-69 28371277-6 2017 Compared to the blank group, PI3K, Akt and eNOS were down-regulated in the miR-138 mimic and LY294002 groups but were up-regulated in the miR-138 inhibitor group. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 93-101 AKT serine/threonine kinase 1 Homo sapiens 35-38 28656233-7 2017 Additionally, resveratrol was identified to act synergistically with LY-294002, a phosphorylation inhibitor of AKT, but antagonistically with insulin-like growth factor-1, an agonist of AKT phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-78 AKT serine/threonine kinase 1 Homo sapiens 111-114 28656239-7 2017 The specific PI3K inhibitors, LY294002 and wortmannin, markedly inhibited the EPO-mediated increases in p-AKT (Ser473), p-FOXO1 (Ser256) and p-GSK-3beta (Ser9) in the PA-induced HepG2 cells (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 106-109 28716053-13 2017 Overexpression of the active Akt protein decreased ibrutinib-induced autophagy, while inhibiting Akt by LY294002 treatment enhanced ibrutinib-induced autophagy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 97-100 28968999-9 2017 Furthermore, the association between Akt and mTOR can be regulated by serum, insulin and LY294002, but not by rapamycin or MAPK kinase inhibitors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 37-40 31966870-7 2017 The expression of MMP9 and MMP2 was decreased when PI3K/AKT signaling inhibitor LY294002 and NF-kappaB inhibitor PDTC were used respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 56-59 28545028-5 2017 Moreover, PI3K inhibitor LY294002, AKT-shRNA and IkappaBalpha-shRNA could decrease the protein content of phospho-P65 (Ser536), phospho-IkappaBalpha, phospho-AKT and phospho-IKKbeta while increasing the level of P65 compared to STC1 overexpression groups in cervical cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 158-161 28671020-3 2017 In addition, we confirmed that the phosphoinositide 3-kinase/Akt and Wnt/beta-catenin signaling pathways were correlated with tumorigenesis, progression, and maintenance of gastric cancer using the phosphoinositide 3-kinase inhibitor LY294002 and an inhibitor of the beta-catenin/TCF4 complex, FH535. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 234-242 AKT serine/threonine kinase 1 Homo sapiens 61-64 28524116-9 2017 Pretreatment with LY294002, an autophagy and PI3K inhibitor, enhanced the salinomycin-induced apoptosis by decreasing the AKT and mTOR activities and suppressing autophagy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 122-125 28592228-8 2017 LY294002 (Akt inhibitor) was used to examine whether Akt phosphorylation was a downstream mechanism of TGF-beta1 induced expression of procollagen1A1, fibronectin, and alpha-smooth muscle actin in HIFs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 10-13 28386751-11 2017 This anti-apoptotic effect of RLX was attenuated by co-administration of the Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 91-99 AKT serine/threonine kinase 1 Homo sapiens 77-80 28823274-6 2017 CONCLUSION: LY294002 can inhibit U266 cell proliferation via suppresion of activation of PI3K/AKT signal pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 94-97 28417539-10 2017 Inhibition of the AKT pathway by its specific inhibitor LY294002 resulted in downregulation of MRP1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 18-21 28639894-7 2017 Moreover, phosphoinositide 3-kinase/AKT pathway inhibitor LY294002 and Janus kinase/signal transducer and activator of transcription pathway inhibitor AG490 could downregulate cell division cycle protein 6 expression in K562 cells, but not RAS/mitogen-activated protein kinase pathway inhibitor PD98059 had such effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 36-39 28478808-14 2017 In addition, 10muM LY294002 (a specific inhibitor of PI3K/Akt) combination with 40muM harmine significantly increased the cytotoxicity to the gastric cancer cells and up-regulated both the apoptosis-related protein (cleaved-PARP, cleaved-caspase-3) and autophagy-related protein (Beclin-1, LC3-II, and p62). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 58-61 28383489-6 2017 An examination of the PI3K/Akt upstream pathway revealed that UF-pretreated cells showed a decreased relative density of Akt, PI3K, and TrkA, and increased the phosphorylation of Akt, PI3K, and NGF; the PI3K inhibitor, LY294002, partially prevented this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 219-227 AKT serine/threonine kinase 1 Homo sapiens 27-30 28915637-7 2017 Further mechanism study revealed that BTK activated AKT signaling leading to down-regulation of P27 expression and hindered RB activity while AKT inhibitor, LY294002, overcame BTK-overexpression induced cellular senescence resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 157-165 AKT serine/threonine kinase 1 Homo sapiens 142-145 28193579-8 2017 Inhibition of PI3K signaling by LY294002 counteracted zinc promotion, as shown by a decrease in AP activity, TEER, the abundance of ZO-1 and phosphorylation of AKT and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 160-163 28250059-9 2017 More intriguingly, preconditioning with LY294002 (PI3K/AKT antagonist) or NG-monomethyl-l-arginine (eNOS inhibitor) antagonized netrin-1-induced activation of the PI3K/AKT-eNOS pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 55-58 28250059-9 2017 More intriguingly, preconditioning with LY294002 (PI3K/AKT antagonist) or NG-monomethyl-l-arginine (eNOS inhibitor) antagonized netrin-1-induced activation of the PI3K/AKT-eNOS pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 168-171 26993294-2 2017 It is demonstrated that LY294002, a small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K)/Akt signal pathway, can inhibit proliferation and promote neuronal differentiation of mesenchymal stem cells (MSCs). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 101-104 26993294-8 2017 In conclusion, PCL/collagen electrospun scaffolds with Ly294002 have potential for being used in neural tissue engineering because of its bioactive and three-dimensional structure which enhances viability and differentiation of hEnSCs into neurons through inhibition of the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 279-282 28440481-3 2017 In the present study, the effect of matrine and LY294002 on the expression of the Akt/FoxO3a signaling pathway was examined by western blot analyses and RT-PCR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 82-85 28521450-6 2017 Further investigation revealed that phosphorylation of RAC-alpha serine/threonine-protein kinase (AKT) increased in response to PM2.5 exposure in HCC cells, and the AKT antagonist LY294002 reduced PM2.5-induced migration, invasion and MMP-13 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 180-188 AKT serine/threonine kinase 1 Homo sapiens 165-168 28460455-7 2017 Cell proliferation promoted by CCDC106 via Cyclin A2 and Cyclin B1 was rescued by treatment with the AKT inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 101-104 28122716-12 2017 Pretreatment with LY294002 or MK-2206, to inhibit the phosphatidylinositol 3-kinase-Akt/protein kinase B cell survival pathway, significantly blunted the cytoprotective effect of relaxin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 84-87 27473470-11 2017 LY294002, a PI3K/Akt pathway inhibitor, led to increased autophagy and apoptosis in U251 RLIP76-depleted cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 17-20 28104444-7 2017 We also found that pretreatment with inhibitors of PI3K/AKT (LY294002), JAK/STAT (AG490) and NF-kB (BAY 11-7082) significantly reduced leptin-induced upA expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 61-69 AKT serine/threonine kinase 1 Homo sapiens 56-59 28197636-7 2017 Inhibitors of the PI3K-Akt and ERK1/2 pathways, LY294002 and U0126, significantly suppressed the EMT phenotype. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 23-26 27400655-6 2017 Moreover, PD 98059, LY294002 and Bay 117082, which respectively inhibited the histamine and 4-methylhistamine induced phosphorylation of ERK1/2, Akt and NFkappaB-p65 respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 145-148 28076326-6 2017 Treatment with the AKT inhibitor, LY294002, reduced the effects of THUMPD1 overexpression in breast cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 19-22 28442995-7 2017 Inhibition of AKT activity with the PI3-K inhibitor LY294002 could downregulate AKT and PTEN phosphorylation and suppress axon outgrowth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 14-17 28442995-7 2017 Inhibition of AKT activity with the PI3-K inhibitor LY294002 could downregulate AKT and PTEN phosphorylation and suppress axon outgrowth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 80-83 28386321-8 2017 However, the PI3K/Akt inhibitor LY294002 reversed the protective effects of aFGF on neurofunctional deficits and junction protein expression and significantly suppressed p-Akt and GTP-Rac1 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 18-21 28185818-6 2017 Further study disclosed that AF enhanced the phosphorylation of PI3K, Akt and ERK1/2 down-regulated by MPP+ in SH-SY5Y cells, the effect of which could be blocked by LY294002, the inhibitor of PI3K. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 166-174 AKT serine/threonine kinase 1 Homo sapiens 70-73 28199981-7 2017 Moreover, a PI3K inhibitor LY294002 inhibited AKT/GSK-3beta/beta-catenin pathway activated by GDF15 and attenuated GDF15-induced proliferation, colony formation and invasion of SCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 46-49 28085149-9 2017 Similarly, transfection of the dominant-negative form of Akt in NSC-34 motor neurons and treatment with the selective PI3K inhibitor LY294002 prevented ApoSOD1- and SOD1-mediated neuroprotective effects in L-BMAA-treated motor neurons. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 133-141 AKT serine/threonine kinase 1 Homo sapiens 57-60 28412208-10 2017 Consequently, we revealed that BzATP accelerated the proliferation of CRC cells, whereas co-incubation with PI3K/Akt inhibitor LY294002 significantly impaired BzATP-induced proliferation of CRC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 113-116 28260056-11 2017 Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 185-193 AKT serine/threonine kinase 1 Homo sapiens 41-44 28110104-8 2017 PI3K/Akt inhibitor LY294002 reversed Q3GA-induced Akt phosphorylation and cyclin D1 expression, thereby reducing Q3GA-induced proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 5-8 28110104-8 2017 PI3K/Akt inhibitor LY294002 reversed Q3GA-induced Akt phosphorylation and cyclin D1 expression, thereby reducing Q3GA-induced proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 50-53 28454373-10 2017 In addition, inhibition of the Akt signaling pathway using the Akt inhibitor LY294002 restored CYFIP2-knockdown SGC7901 cell chemosensitivity to 5-FU. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 31-34 28454373-10 2017 In addition, inhibition of the Akt signaling pathway using the Akt inhibitor LY294002 restored CYFIP2-knockdown SGC7901 cell chemosensitivity to 5-FU. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 63-66 27590258-10 2017 In addition, the antiapoptotic effect of PCr enhanced p-Akt/Akt protein ratio, NO synthase (eNOS) activation, NO production and cGMP levels and also was partially suppressed by a PI3K inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 195-203 AKT serine/threonine kinase 1 Homo sapiens 56-59 27590258-10 2017 In addition, the antiapoptotic effect of PCr enhanced p-Akt/Akt protein ratio, NO synthase (eNOS) activation, NO production and cGMP levels and also was partially suppressed by a PI3K inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 195-203 AKT serine/threonine kinase 1 Homo sapiens 60-63 28381172-9 2017 Furthermore, PI3K/AKT pathway and SOX2 were found necessary to maintain the stemness of CD147+ BCSCs by using LY294002 or lentiviral-si-SOX2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 18-21 28446279-3 2017 At the same time, the the inhibitor LY294002 of PI3K/AKT signaling pathway was used to treat the cells, so as to explore whether the changes of HL-60 sensitivity is associated with the activation of PI3K/AKT signal pathway after co-culture of cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 53-56 28355296-10 2017 Interestingly, a specific phosphoinositide 3-kinase (PI3K)/Akt inhibitor (LY294002) augmented the As4O6 induced cell death; whereas p38 mitogen-activated protein kinases (p38 MAPK) inhibitor (SB203580) abrogated the cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 59-62 28386321-8 2017 However, the PI3K/Akt inhibitor LY294002 reversed the protective effects of aFGF on neurofunctional deficits and junction protein expression and significantly suppressed p-Akt and GTP-Rac1 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 172-175 28099936-6 2017 In addition, Akt activity manipulated by PI3K inhibitor LY294002 or Akt mutants was shown to negatively affect FOXO1-mediated HBP1 promoter activation and gene expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 13-16 28367103-8 2017 PI3K/AKT inhibitor LY294002 and mTORC1 inhibitor Rapamycin inhibit alpha-MSH-induced dendrites. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 5-8 28025122-7 2017 The pharmaceutical inhibitors, such as KN-93 (CaMKII inhibitor) and LY294002 (Akt inhibitor) suppressed rutaecarpine-induced HO-1 expression and cytoprotection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 78-81 28000865-4 2017 Inhibiting AKT phosphorylation by treatment with AKTi-1/2 or wortmannin further enhanced LY294002-induced cell death in PK59 and KLM1-R cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 11-14 28000865-6 2017 Thus, our results reveal that LY294002 displays the opposite effect on PI3K-dependent AKT phosphorylation, which maintains cell survival from the cytotoxicity introduced by LY294002 itself in GEM-resistant pancreatic cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 86-89 28000865-6 2017 Thus, our results reveal that LY294002 displays the opposite effect on PI3K-dependent AKT phosphorylation, which maintains cell survival from the cytotoxicity introduced by LY294002 itself in GEM-resistant pancreatic cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 173-181 AKT serine/threonine kinase 1 Homo sapiens 86-89 27171670-9 2017 In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 36-39 27171670-9 2017 In addition, the phosphorylation of AKT and ERK1/2 was suppressed by LY294002 and U0126 in JEG-3 cells treated with chrysophanol, whereas, the AKT protein was activated by pre-treatment of JEG-3 cells with U0126. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 143-146 27506476-7 2017 These IPPKKNQDKTE-mediated protection effects were reversed by PI3K/Akt inhibitor LY294002, showing the mediatory role of PI3K/Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 68-71 27506476-7 2017 These IPPKKNQDKTE-mediated protection effects were reversed by PI3K/Akt inhibitor LY294002, showing the mediatory role of PI3K/Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 127-130 28103884-13 2017 Importantly, inhibition of PI3K/Akt pathway by LY294002 completely blocked the TCDD-induced SP cells expansion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 32-35 27702388-10 2017 Moreover, AG1478, LY294002, and U0126 significantly decreased p-EGFR, p-AKT, and p-ERK1/2 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 72-75 26970256-8 2016 Moreover, treatment of JAR and JEG3 cells with both apigenin and pharmacological inhibitors of PI3K/AKT (LY294002) and ERK1/2 (U0126) revealed synergistic anti-proliferative effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 105-113 AKT serine/threonine kinase 1 Homo sapiens 100-103 28000865-0 2017 PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 60-63 28000865-3 2017 In this study, LY294002 (but not wortmannin) showed an abnormal ability to enhance AKT phosphorylation (at Ser472) specifically in gemcitabine (GEM)-resistant pancreatic cancer (PC) cell lines PK59 and KLM1-R. LY294002 was shown to activate AKT and accumulate phospho-AKT at the intracellular membrane in PK59, which was abolished by treatment with AKTi-1/2 or wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 83-86 28000865-3 2017 In this study, LY294002 (but not wortmannin) showed an abnormal ability to enhance AKT phosphorylation (at Ser472) specifically in gemcitabine (GEM)-resistant pancreatic cancer (PC) cell lines PK59 and KLM1-R. LY294002 was shown to activate AKT and accumulate phospho-AKT at the intracellular membrane in PK59, which was abolished by treatment with AKTi-1/2 or wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 241-244 28000865-3 2017 In this study, LY294002 (but not wortmannin) showed an abnormal ability to enhance AKT phosphorylation (at Ser472) specifically in gemcitabine (GEM)-resistant pancreatic cancer (PC) cell lines PK59 and KLM1-R. LY294002 was shown to activate AKT and accumulate phospho-AKT at the intracellular membrane in PK59, which was abolished by treatment with AKTi-1/2 or wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 241-244 29259641-7 2017 When the PI3K/AKT pathway was blocked by LY294002, a specific inhibitor of this pathway, the protective effect of icariin was impaired. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 14-17 28072855-3 2017 SDF-1alpha-induced platelet aggregation and Akt phosphorylation are inhibited by pretreatment with the CXCR4 antagonist AMD3100 or the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 150-158 AKT serine/threonine kinase 1 Homo sapiens 44-47 27746366-12 2017 For further validation, results of the present study also demonstrated that PTEN/Akt/FOXO1 signaling was responsible for the ADR-resistance of breast cancer cells since LY294002, an inhibitor of Akt signaling, partially increased the sensitivity of MCF-7/S cells to ADR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 81-84 27746366-12 2017 For further validation, results of the present study also demonstrated that PTEN/Akt/FOXO1 signaling was responsible for the ADR-resistance of breast cancer cells since LY294002, an inhibitor of Akt signaling, partially increased the sensitivity of MCF-7/S cells to ADR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 169-177 AKT serine/threonine kinase 1 Homo sapiens 195-198 28691020-6 2017 Moreover, LY294002, a highly selective inhibitor of PI3K, blocked phosphorylation of Akt and the effects of miR-200c. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 85-88 28540295-16 2017 However, with preadministration of PI3K/Akt pathway inhibitor LY294002, the effect of RLX was blocked. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 40-43 28985493-6 2017 Moreover, the expression of p-Akt and p-mTOR was down-regulated after treatment with kaempferol in ox-LDL-treated HUVECs, which is similar to the effect of PI3K inhibitor (LY294002) or mTOR inhibitor [rapamycin (RAP)]. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 30-33 28176634-4 2017 Several agents have been developed to target the Akt/PI3K pathways, including PI3K inhibitors, (e.g. LY294002, Wortmannin), PI3K/mTOR inhibitors (e.g. BEZ235), or Akt inhibitors (e.g. perifosine, MK2206), which have been tested alone or in combinations with DNA-targeted agents (e.g., gemcitabine and fluorouracil) in pancreatic ductal adenocarcinoma (PDAC). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 49-52 27510267-4 2017 We found that neuroserpin enhanced the activation of AKT in cultures subjected to oxidative stress and that the AKT inhibitor Ly294002 blocked this neuroprotective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 53-56 27510267-4 2017 We found that neuroserpin enhanced the activation of AKT in cultures subjected to oxidative stress and that the AKT inhibitor Ly294002 blocked this neuroprotective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 126-134 AKT serine/threonine kinase 1 Homo sapiens 112-115 27840966-10 2017 In addition, HS-1793 suppressed Akt and the phosphatidylinositol-3 kinase/Akt inhibitor LY294002 was found to enhance its induction of apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 74-77 29057033-9 2017 These results and the experiments involving N-acetyl cysteine (antioxidant), Cyclosporin A (mitochondrial protector), and LY294002 (Akt inhibitor) suggest that PD prevents MGO-induced HUVEC apoptosis, at least in part, through inhibiting oxidative stress, maintaining mitochondrial function, and activating Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 132-135 27222231-10 2017 In addition, LY294002 inhibited 17beta-estradiol-induced activation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 71-74 27813328-12 2017 Moreover, the combination of ALDH1A1-short hairpin RNA and PI3K/AKT pathway inhibitor LY294002 markedly inhibited cell viability, enhanced apoptotic cell death, and increased cisplatin sensitivity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 64-67 28097093-5 2017 Treatment of human umbilical vein endothelial cells (HUVECs) with Akt inhibitor LY294002 results in diminished miR-20a and miR-31 production, while Erk inhibitor U0126 prevented VEGF-stimulated expression of miR-20a but not that of miR-31. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 66-69 27666600-5 2016 Knockdown of TS using small interfering RNA (siRNA) or inhibiting AKT activity with PI3K inhibitor LY294002 enhanced the cytotoxicity and cell growth inhibition of salinomycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 99-107 AKT serine/threonine kinase 1 Homo sapiens 66-69 27167250-5 2016 This carbachol effect was almost completely blocked by the PI3K inhibitor LY294002, implying that PI3K is responsible for the Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 126-129 27167250-7 2016 This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 174-177 26687235-8 2016 Inhibition of the PI3K/Akt or Rac-1 by specific inhibitors LY294002 or si-Rac-1, respectively, partially reduces the protective effect of bFGF on BBB integrity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 23-26 27840989-8 2016 The protein levels of phosphorylated (p) AKT and pGSK-3beta were decreased following pretreatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 155-163 AKT serine/threonine kinase 1 Homo sapiens 41-44 27895401-3 2016 Using HER2-positve GC cell lines SNU-216 and NCI-N87, HER2 expression was silenced by RNA interference, and the activations of JNK and AKT were suppressed by SP600125 and LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 171-179 AKT serine/threonine kinase 1 Homo sapiens 135-138 28250891-6 2017 In contrast, inhibition of Akt by LY294002 during ventilation reestablished lung damage, neutrophil influx, and proinflammatory cytokine release despite the presence of H2S. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 27-30 27748934-8 2016 Treatment with PI3K inhibitor LY294002 augmented the effects of salidroside on the expression of Akt and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 97-100 27806094-7 2016 Similarly, the specific PI3K inhibitor LY294002, suppressed AKT and ERK phosphorylation showing that VEGF feedback is PI3K-dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 60-63 27811956-5 2016 MDA-MB-468 breast and HCT8 colorectal cancer cells were treated with inhibitors including LY294002, MK2206, rapamycin, AZD8055 targeting key kinases in/associated with Akt pathway and the consistency of changes in 31P-NMR-detecatable metabolite content of tumour cells was examined. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 168-171 27619643-6 2016 The reduction of phospho-Akt was observed in both LY294002 and siRNA groups, suggested that the phosphatidylinositol 3-kinase/Akt pathway may be the probable signaling pathway underlying CD147 induced up-regulation of VEGF in U937-derived foam cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 25-28 27619643-6 2016 The reduction of phospho-Akt was observed in both LY294002 and siRNA groups, suggested that the phosphatidylinositol 3-kinase/Akt pathway may be the probable signaling pathway underlying CD147 induced up-regulation of VEGF in U937-derived foam cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 126-129 27421985-3 2016 Previous studies using the broad PI3K inhibitor, LY294002 allowed to propose that PI3 kinase>Akt pathway is a key element in the determination of axonal polarity in hippocampal neurons. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 96-99 27793908-0 2016 Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 116-119 27641443-8 2016 Recruitment of ERalpha and PR to chromatin and subsequent PR mRNA induction were dependent upon rapid activation of MAPK/ERK and AKT; inhibition of these kinase pathways via U0126 or LY294002 blocked these events. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 129-132 26942921-9 2016 The inhibitor of Akt (LY 294002) or ERK1/2 (PD98059) can inhibit VEGF alone and cooperatively reinforce the suppression effects of VPA on HIF-1alpha and VEGF expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-31 AKT serine/threonine kinase 1 Homo sapiens 17-20 27666419-4 2016 The effects of inhibiting phosphoinositide 3-kinase (PI3K)/Akt signaling using LY294002 were investigated in hypoxic HUVECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 59-62 27580711-8 2016 LY294002, the specific inhibitor of PI3-K, significantly abrogated the protein expression of up-regulated phosphorylated Akt offered by Z-LIG. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 121-124 27699665-10 2016 Importantly, Adr resistance induced by miR-222 overexpression through PTEN/Akt/p27 was completely blocked by LY294002, an Akt inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 75-78 27699665-10 2016 Importantly, Adr resistance induced by miR-222 overexpression through PTEN/Akt/p27 was completely blocked by LY294002, an Akt inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 109-117 AKT serine/threonine kinase 1 Homo sapiens 122-125 27774951-10 2016 Moreover, LY294002, an inhibitor of PI3K/Akt, significantly suppressed the biological effect activated by LIPUS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 41-44 27602956-5 2016 More importantly, we found that uPAR expression is associated with sensitivity to cisplatin in MM through the PI3K/AKT pathway, which was demonstrated with specific inhibitors, LY294002 and Akti-1/2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 177-185 AKT serine/threonine kinase 1 Homo sapiens 115-118 27777878-8 2016 Akt inhibitors, e.g., MK-2206 and perifosine, or PI3K modulators, e.g., LY294002 and Wortmannin, have shown some promising results in favor of sensitizing the cancer cells to the therapy in vitro and in vivo, which have provided the rationale for incorporation of these novel agents into multimodality treatment of different malignancies. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 0-3 27321870-9 2016 Blockage of Akt signaling by Akt inhibitor AZD5363 or PI3K inhibitor LY294002, led to an inhibitory effect of WISP1-induced proliferation and migration in human VSMCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 12-15 27038254-9 2016 Both inhibitors of ERK1/2 (PD98059) and Akt (LY294002) can attenuate BPA-induced ERRgamma expression and cell invasion of MDA-MB-231 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 40-43 27426724-6 2016 Activation of TLR4 signaling by LPS in PANC-1 cells resulted in increased VEGF and phosphorylation of AKT, which were abolished by TLR4 silencing with siRNA and PI3K/AKT signaling inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 102-105 27426724-6 2016 Activation of TLR4 signaling by LPS in PANC-1 cells resulted in increased VEGF and phosphorylation of AKT, which were abolished by TLR4 silencing with siRNA and PI3K/AKT signaling inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 190-198 AKT serine/threonine kinase 1 Homo sapiens 166-169 27604954-11 2016 The effects of nm23 siRNA (si-nm23) and the PI3K inhibitor LY294002 on the downstream effects of nm23 on the PI3K-Akt-mTOR signaling pathway were estimated by western blot. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 114-117 27580020-4 2016 Furthermore, phosphorylation of protein kinase B (AKT) and glycogen synthase kinase-3beta (GSK3beta) in model cells was recovered after treated with MAE, leading to an up-regulation of glycogen synthase 2 (GYS2), and this effect was blocked by the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 295-303 AKT serine/threonine kinase 1 Homo sapiens 50-53 27572688-9 2016 Additionally, inhibition of AKT by LY294002 abrogated CXCR7-induced angiogenic capacity in HCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 28-31 29441927-4 2016 A PI3K/Akt inhibitor LY294002 was used to block the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 7-10 29441927-4 2016 A PI3K/Akt inhibitor LY294002 was used to block the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 57-60 27738772-9 2016 Conversely, blocking Akt activation with the PI3K inhibitor LY294002 effectively suppressed the protective effects of DMY against I/R-induced injury. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 21-24 28955964-10 2016 All of the above mentioned ARA-S-induced effects were reduced by the treatment with LY294002 (inhibitor of PI3/Akt kinase), except MAPK kinase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 111-114 27489353-4 2016 HPV16 E6-E7 induced PI3K/Akt signaling pathway activation and this affect could be effectively inhibited by LY294002, a specific PI3K inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 108-116 AKT serine/threonine kinase 1 Homo sapiens 25-28 27498673-9 2016 Furthermore, a specific phosphatidylinositol 3 kinase (PI3K) inhibitor, LY294002, enhanced the pro-apoptotic and anti-invasive effects induced by oleuropein, which suggested that oleuropein suppressed the growth and invasion of glioma cells via inhibition of AKT activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 259-262 25986942-13 2016 Akt pathway inhibition by LY294002 or Akt siRNA reduced SOX2 mRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 0-3 27195653-7 2016 CMX-2043 stimulation of Akt phosphorylation was abolished by the phosphatidylinositide 3-kinase inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 AKT serine/threonine kinase 1 Homo sapiens 24-27 27485415-11 2016 Additionally, the present study demonstrated that the effect of NC on the proliferation and apoptosis of ovarian cancer cells was Akt-dependent by using the phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt signaling pathway inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 237-245 AKT serine/threonine kinase 1 Homo sapiens 130-133 27378570-10 2016 LY294002 totally abrogated the infarct-limiting effect of GYY4137 and inhibited Akt, eNOS and GSK-3beta phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 80-83 27240591-11 2016 Specific inhibitors, LY294002 and PD98059, suppressed activation of AKT and ERK, which attenuated DU-145 cell clone formation and invasion induced by S100A16 overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 68-71 27306214-10 2016 The effect of CP in the combination was replicated by the prototype AKT inhibitor LY294002, further supporting the role of AKT inhibition in the synergism. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 68-71 27557491-7 2016 Inversely, inhibition of AKT by LY294002 treatment markedly enhanced Sal B-induced autophagy and cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 25-28 27018134-9 2016 On inhibiting Akt (by PI3K inhibitor, LY294002) and ERK1/2 (by ERK1/2 inhibitor, PD98059) specifically, caspase 3 got activated abolishing mangiferin"s protective role on As-induced hepatotoxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 14-17 27430327-10 2016 The JNK agonist, anisomycin, and the Akt inhibitor, LY294002, both significantly blocked the effects of propofol on hippocampal neuronal cell viability and apoptosis in IBI. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 37-40 27545131-12 2016 (6) The expression of AKT/p-AKT was significantly lower in GSNO group than in the blank control group (P< 0.05), which could be significantly upregulated by pretreatment with high, medium and low concentration ICA in a concentration-dependent manner, above effects could be blocked by LY294002 (all P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 288-296 AKT serine/threonine kinase 1 Homo sapiens 22-25 27545131-12 2016 (6) The expression of AKT/p-AKT was significantly lower in GSNO group than in the blank control group (P< 0.05), which could be significantly upregulated by pretreatment with high, medium and low concentration ICA in a concentration-dependent manner, above effects could be blocked by LY294002 (all P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 288-296 AKT serine/threonine kinase 1 Homo sapiens 28-31 26143260-5 2016 Inhibition of PI3K/Akt with LY294002 reduced proliferation and inhibited dopaminergic neuronal differentiation of these cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 19-22 27147558-11 2016 Moreover, EGCG was similar to the phosphatidylinositol 3-kinase inhibitors wortmannin and LY-294002 to decrease protein kinase B (AKT) phosphorylation, cell number, and BrdU incorporation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-99 AKT serine/threonine kinase 1 Homo sapiens 130-133 27233800-7 2016 Pre-treatment with the PI3K inhibitor LY294002 inhibited Akt phosphorylation in sigmaA- and sigmaNS-expressing cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 57-60 26346882-9 2016 The PI3/Akt inhibitor, LY294002, impeded the changes induced by agmatine, while ERK inhibitor (PD98059) did not disturb the effects of agmatine, and by itself, it preserved the cells against 6-OHDA toxicity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 8-11 27357907-8 2016 Phosphoinositide-3-kinase (PI3K) inhibitor, LY294002 suppressed p-AKT and p-mTOR, indicating PI3K is a common upstream mediator. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 66-69 27446405-10 2016 Furthermore, inhibition of PI3K/Akt with LY294002 augmented CD147-mediated function. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 32-35 26960693-9 2016 After administration with Nar, we found that phosphorylation of AKT was inhibited, and this inhibitory action could be mildly enhanced by the combination treatment of Nar and AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 189-197 AKT serine/threonine kinase 1 Homo sapiens 64-67 26960693-9 2016 After administration with Nar, we found that phosphorylation of AKT was inhibited, and this inhibitory action could be mildly enhanced by the combination treatment of Nar and AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 189-197 AKT serine/threonine kinase 1 Homo sapiens 175-178 27126362-4 2016 Inhibition of AKT by wortmannin/LY294002 or overexpression of DAPK3 reverts the proliferative function of AKT in CaP cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 14-17 27323826-9 2016 PI3K/Akt inhibitor (LY294002) and ERK inhibitor (PD98059) suppressed simvastatin-induced Nrf2 and HO-1 expression in both HT-29 and HCT 116 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 20-28 AKT serine/threonine kinase 1 Homo sapiens 5-8 27207584-8 2016 Furthermore, inhibition of miR-138-5p downregulated PTEN protein expression and promoted activation of PI3K/AKT, and knockdown of either SIRT1 or the PI3K/Akt inhibitor (LY294002) abolished the effect of miR-138-5p on NP cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 155-158 27130665-9 2016 Inhibition of the PI3K/AKT pathway by LY294002 significantly attenuated MMP1-mediated cell proliferation and migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 23-26 27216460-7 2016 We also found that the inhibition of PI3K/Akt activation by LY294002, a PI3K inhibitor, reduced cell proliferation and protein level of GATA4. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 42-45 32263421-8 2016 Activation of Akt signaling pathways was observed in MSCs cultured with SiO2@Ru and these enhancement effects could be blocked by the Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 14-17 32263421-8 2016 Activation of Akt signaling pathways was observed in MSCs cultured with SiO2@Ru and these enhancement effects could be blocked by the Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 134-137 27196724-6 2016 LY294002, the specific inhibitor of phosphoinositide 3-kinase, significantly abrogated the upregulated phosphorylated AKT and phosphorylated GSK3beta offered by Soya-I, suggesting that the neuroprotection of Soya-I was mainly dependent on the activation of the phosphoinositide 3-kinase/AKT/GSK3beta signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 118-121 27196724-6 2016 LY294002, the specific inhibitor of phosphoinositide 3-kinase, significantly abrogated the upregulated phosphorylated AKT and phosphorylated GSK3beta offered by Soya-I, suggesting that the neuroprotection of Soya-I was mainly dependent on the activation of the phosphoinositide 3-kinase/AKT/GSK3beta signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 287-290 27176045-10 2016 The PI3K/Akt signaling pathway is of importance in regulating MMP2 expression in Sk-hep-1 cells, since Robo1 overexpression stimulated phosphorylation of Akt while the PI3K inhibitor LY294002, significantly inhibited the upregulation of MMP2 and also the enhanced cell invasion induced by Robo1 overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 183-191 AKT serine/threonine kinase 1 Homo sapiens 9-12 27176505-11 2016 Of note, the PI3K pathway inhibitor LY-294002 significantly enhanced the apoptotic potential of TRAIL and PBOX-15 validating the importance of Akt downregulation in the TRAIL/PBOX-15 synergistic combination. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-45 AKT serine/threonine kinase 1 Homo sapiens 143-146 26154142-6 2016 Furthermore, PI3K/AKT inhibition (by LY294002) completely blocked CCL20-induced Snail and NF-kB activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 18-21 27221674-6 2016 Knockdown of HIF-1alpha by shRNA and LY294002 was used to inhibit the activity of PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 87-90 27347100-9 2016 LY294002 blocked the PI3K/AKT/mTOR pathway and induced autophagy and apoptosis of A549 cells, however, no synergistic effect was observed following combined treatment with gefitinib and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 26-29 26994872-6 2016 LY294002, the specific inhibitor of PI3-K, significantly abrogated the up-regulated phosphorylated Akt and phosphorylated GSK3beta offered by TA, suggesting that the neuroprotection of TA was mainly dependent on the activation of PI3-K/Akt/GSK3beta signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 99-102 26994872-6 2016 LY294002, the specific inhibitor of PI3-K, significantly abrogated the up-regulated phosphorylated Akt and phosphorylated GSK3beta offered by TA, suggesting that the neuroprotection of TA was mainly dependent on the activation of PI3-K/Akt/GSK3beta signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 236-239 30090420-9 2016 In T-HaCaT cells, blocking the activation of Akt by LY294002 inhibited the EMT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 45-48 26994515-8 2016 However, the phosphorylation of AKT, P70S6K, P90RSK and S6K was reduced in naringenin-induced pTr cells pre-treated with a PI3K inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 32-35 28881576-5 2017 LY294002, a PI3K inhibitor, defined the contribution of the PI3K/Akt/mTOR signaling pathway in CCSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 65-68 28881576-6 2017 LY294002-treated CCSCs showed decreases in proliferation, sphere formation and self-renewal, in phosphorylation-dependent activation of Akt, and in expression of cyclin D1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 136-139 27338800-6 2016 An AKT inhibitor LY294002 blocked VEGF-A expression and AKT phosphorylation in HepG2 cells and NLRC5-overexpressing HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 AKT serine/threonine kinase 1 Homo sapiens 3-6 27338800-6 2016 An AKT inhibitor LY294002 blocked VEGF-A expression and AKT phosphorylation in HepG2 cells and NLRC5-overexpressing HepG2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 AKT serine/threonine kinase 1 Homo sapiens 56-59 27119510-6 2016 Furthermore, miR-93 mimic significantly increased p-Akt levels under H/R, which was partially released by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 AKT serine/threonine kinase 1 Homo sapiens 52-55 30634213-20 2016 p-Akt protein expression in HUVECs was inhibited after adding specific P13K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 2-5 26568302-10 2016 The specific inhibitor (Ly294002) of PI3K/AKT pathway significantly decreased expression of miR-21 and CSC markers and upregulated the expression of PTEN, which indicates that miR-21 and PTEN are the downstream effectors of PI3K/AKT and that expression of these two effectors are related to the development of NPC CSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 42-45 26568302-10 2016 The specific inhibitor (Ly294002) of PI3K/AKT pathway significantly decreased expression of miR-21 and CSC markers and upregulated the expression of PTEN, which indicates that miR-21 and PTEN are the downstream effectors of PI3K/AKT and that expression of these two effectors are related to the development of NPC CSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 229-232 27125675-10 2016 Furthermore, JNK inhibitor SP600125 and Akt (Ser473) inhibitor LY294002 enhanced the inhibition of curcumol on NF-kappaB p65 nuclear translocation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 40-43 26733168-9 2016 Using the Akt inhibitor LY294002 or knocking down Snail expression via RNA interference (RNAi) reversed the effects of oxaliplatin on the EMT and metastasis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 24-32 AKT serine/threonine kinase 1 Homo sapiens 10-13 27144449-6 2016 The administration of both PI3K/Akt inhibitor LY294002 and mTOR inhibitor rapamycin demonstrated that Akt/mTOR-regulated autophagy was involved in the hypoxia/reperfusion-induced microglia apoptosis/death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 32-35 27144449-6 2016 The administration of both PI3K/Akt inhibitor LY294002 and mTOR inhibitor rapamycin demonstrated that Akt/mTOR-regulated autophagy was involved in the hypoxia/reperfusion-induced microglia apoptosis/death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 102-105 26940012-8 2016 Moreover, the inhibitory effect of LY294002 (a specific PI3K inhibitor) on the activities of AKT and ERK1/2 was partially recovered by overexpression of MAT2B in porcine intramuscular adipocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 93-96 29771028-4 2016 PI3K-Akt pathway was inhibited by LY294002 in CNE 1 and CNE 1+ LMP1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 5-8 29771028-9 2016 With 1 mumol/ml LY294002 pretreatment for 8 hours, p-Akt expression was both downregulated in CNE 1 and CNE 1+ LMP1, but there was no significant difference between them(P >0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 53-56 26919896-11 2016 Inhibition of the phosphatidylinositol 3-kinase/Akt pathway using LY294002 prevented cytomix-induced ERK activation and augmented cytomix-induced caspase-3 cleavage. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 48-51 27156963-6 2016 Treatment of PI3K inhibitor LY294002 markedly prevented phosphorylation of AKT and subsequently counteract aggressive phenotype mediated by siRNA of 14-3-3sigma. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 75-78 26833879-6 2016 In addition, a PI3K/Akt signalling pathway inhibitor (LY294002) alleviated the tumorigenic effects of FGF2. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 20-23 26951965-8 2016 This was further confimed by pre-treatment with the PI3K/Akt inhibitor, LY294002, which markedly attenuated the miR-214-induced increase in cell viability and resistance to apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 57-60 26460717-4 2016 In platelets pretreated with LY294002 or MK2206, inhibitors of PI3K/AKT pathway, and with U73122, inhibitor of phospholipase C pathway, only a partial prevention was shown. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 68-71 26460717-10 2016 The PI3K/AKT pathway and PKC participate to this PDE3A phosphorylation/activation mechanism as it was greatly inhibited by platelet pretreatment with LY294002, MK2206, U73122, or the PKC specific inhibitor GF109203X. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 150-158 AKT serine/threonine kinase 1 Homo sapiens 9-12 26814361-10 2016 CTRP9 could inhibit cell apoptosis and eNOS expression reduction in the cells pretreated with the PI3K/Akt inhibitor LY294002 and resist LY294002-induced ET-1 and MMP-2 secretion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 103-106 26814361-10 2016 CTRP9 could inhibit cell apoptosis and eNOS expression reduction in the cells pretreated with the PI3K/Akt inhibitor LY294002 and resist LY294002-induced ET-1 and MMP-2 secretion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 103-106 26810470-8 2016 LY294002, an inhibitor of Akt activation, abolished the protective effects of miR-21-up-regulated cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 26-29 25789966-8 2016 (PI3-K/AKT) inhibitor LY294002 effectively abolished MC-LR-enhanced migration and invasion and MMP-13 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 7-10 27107990-9 2016 In addition, COMP-Ang1-mediated activation of Akt and c-Jun was suppressed by treating each of pharmacological inhibitors specific to phosphoinositide 3-kinase (PI3K) (LY294002 and Wortmannin) or MAPKs (PD98059, SB203580, and SP600125). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 168-176 AKT serine/threonine kinase 1 Homo sapiens 46-49 27110775-9 2016 Inhibition of PI3K/AKT pathway by LY294002 restored chemosensitivity of smad3-deficiency cells to cisplatin in HCC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 19-22 27114702-7 2016 Moreover, Andro-induced apoptosis is enhanced by AKT-selective inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 73-81 AKT serine/threonine kinase 1 Homo sapiens 49-52 26922319-6 2016 The inhibitor of Akt, LY294002, but not the inhibitor of ERK1/2, PD98059, suppressed the upregulation of HIF-1alpha and the proliferation of A549-H and CCL-185-H cellsin vitro Thein vivoresults confirmed that insufficient RFA could trigger the tumor growth, upregulate the HIF-1alpha expression, and activate Akt in A549 xenograft tumors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 17-20 27176825-10 2016 Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 116-124 AKT serine/threonine kinase 1 Homo sapiens 102-105 27671480-6 2016 In addition, Rh2-O down-regulated the phosphorylation of Akt, and its inhibitor LY294002 promoted Rh2-O-induced G1 phase arrest. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 57-60 26922319-6 2016 The inhibitor of Akt, LY294002, but not the inhibitor of ERK1/2, PD98059, suppressed the upregulation of HIF-1alpha and the proliferation of A549-H and CCL-185-H cellsin vitro Thein vivoresults confirmed that insufficient RFA could trigger the tumor growth, upregulate the HIF-1alpha expression, and activate Akt in A549 xenograft tumors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 309-312 26821334-13 2016 However, this inductive effect was blunted in the presence of the AKT inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 81-89 AKT serine/threonine kinase 1 Homo sapiens 66-69 26800397-6 2016 Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 27-30 26915319-7 2016 Luteolin, LY294002 (an inhibitor of Akt signaling) and PD98059 (an inhibitor of Erk1/2 signaling) could inhibit the expression of p-Akt and p-Erk1/2 respectively in MCF-7 cells induced by EGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 36-39 26909550-11 2016 However, when co-administrating LY294002, an inhibitor of PI3K/AKT pathway, an increased apoptosis was observed. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 63-66 26775845-11 2016 PlGF induced PI3K/Akt phosphorylation in HIMECs and pretreatment of PlGF-stimulated HIMECs with PI3K inhibitor (LY294002) significantly inhibited the PlGF-induced cell migration and tube formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 18-21 26747727-9 2016 This event was largely abolished by LY294002 pre-treatment, suggesting that ATRA and Wnt3A at least partially promote osteogenic differentiation via activating the PI3K/AKT/GSK3beta signalling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 169-172 26608500-11 2016 Furthermore, the expression of COX-2 was attenuated by both Akt inhibitor (LY294002) and ERK inhibitor (U0126), and IkappaBalpha degradation was suppressed by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 AKT serine/threonine kinase 1 Homo sapiens 60-63 26647778-6 2016 Treatment of with LY294002 (20 microM) inhibited the activation of Akt and mTOR and effectively prevented TGF-beta2-induced EMT in the HLECs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 67-70 26719016-8 2016 LY294002 was used to specifically block the phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homologue (PI3K/Akt) pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 76-79 26506538-7 2016 And, PI3K/Akt inhibitor (LY294002) blocked MC-LR-induced Akt/S6K1 activation and proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 10-13 26506538-7 2016 And, PI3K/Akt inhibitor (LY294002) blocked MC-LR-induced Akt/S6K1 activation and proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 57-60 26830479-5 2016 Cells were also treated with an Akt inhibitor, LY294002, to examine the mechanism of the protective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 32-35 27822469-7 2016 Furthermore, using the PI3K/AKT pathway blocker LY294002, we confirmed that the PI3K/AKT pathway was involved in mediating these effects of PTEN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 28-31 27822469-7 2016 Furthermore, using the PI3K/AKT pathway blocker LY294002, we confirmed that the PI3K/AKT pathway was involved in mediating these effects of PTEN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 85-88 27802437-5 2016 However, the MAPK inhibitor PD98059 and/or PI3K inhibitor LY294002 were able to antagonize the effects of VPA by abolishing ERK/Akt activations and cancelling GSK3beta suppression, thus it impaired VPA apoptosis-inducing effects on glioma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 128-131 26949405-7 2016 BNC increased phosphorylation of Akt following OGD/R, while LY294002 attenuated BNC induced increase of phosphorylated Akt expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 119-122 26820593-8 2016 Targeting the PI3K/Akt pathway by its specific inhibitor LY294002, or by Akt small interfering RNA (siRNA) resulted in reduced capacity in invasion of FTC-238. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 19-22 26686574-8 2016 Inhibition of Pi3K/Akt pathway with LY294002 or silencing of Nrf2 expression partially blocked the reversal of redox impairment induced by CA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 19-22 27470628-2 2016 METHODS: MHCC-97H cultures were treated with the PI3K/AKT pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 54-57 27470628-10 2016 LY294002 also reduced the tumorigenicity of CD90(+) subpopulation and the expression of CD90, SHP2, and P-AKT in related HCC stem cells, but it did not significantly affect the expression of AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 106-109 27007368-8 2016 LY294002, a PI3K/Akt inhibitor, inhibited isoquercitrin-induced GSK3beta phosphorylation and increase of Mcl-1 expression, which indicated that regulation of isoquercitrin on Mcl-1 expression was likely related to the modulation of Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 17-20 27007368-8 2016 LY294002, a PI3K/Akt inhibitor, inhibited isoquercitrin-induced GSK3beta phosphorylation and increase of Mcl-1 expression, which indicated that regulation of isoquercitrin on Mcl-1 expression was likely related to the modulation of Akt activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 232-235 26824621-6 2016 The Danggui Buxue Tang-induced phosphorylation of endothelial nitric oxide synthase and Akt kinase in human umbilical vein endothelial cells were fully blocked by treatment with an endothelial nitric oxide synthase inhibitor (L-NAME), a PI3K/Akt inhibitor (LY294002), and a Ca(2+) chelator (BAPTA-AM). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 257-265 AKT serine/threonine kinase 1 Homo sapiens 88-91 26774220-5 2016 These neuroprotective effects could be blocked by the PI3-K/Akt inhibitor LY294002, indicating the involvement of PI3-K/Akt activation in the therapeutic action. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 60-63 26774220-5 2016 These neuroprotective effects could be blocked by the PI3-K/Akt inhibitor LY294002, indicating the involvement of PI3-K/Akt activation in the therapeutic action. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 120-123 26915319-7 2016 Luteolin, LY294002 (an inhibitor of Akt signaling) and PD98059 (an inhibitor of Erk1/2 signaling) could inhibit the expression of p-Akt and p-Erk1/2 respectively in MCF-7 cells induced by EGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 132-135 26796279-10 2016 Moreover, LY294002 further inhibited the phosphorylation of Akt in Bcl-2+ MCF-7 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 60-63 25784559-7 2016 Further, the signals G protein-coupled estrogen receptor 1 (GPER)/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) mediated the BDE-47-induced upregulation of MMP-9 and in vitro migration of SH-SY5Y cells since G15 (GPER inhibitor) and LY 294002 (PI3K/Akt inhibitor) significantly abolished the effects of BDE-47. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 264-273 AKT serine/threonine kinase 1 Homo sapiens 138-141 25784559-7 2016 Further, the signals G protein-coupled estrogen receptor 1 (GPER)/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) mediated the BDE-47-induced upregulation of MMP-9 and in vitro migration of SH-SY5Y cells since G15 (GPER inhibitor) and LY 294002 (PI3K/Akt inhibitor) significantly abolished the effects of BDE-47. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 264-273 AKT serine/threonine kinase 1 Homo sapiens 280-283 26620226-8 2016 The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 30-33 26788032-9 2016 U0126 decreased the phosphorylation of ERK1/2, and LY294002 decreased the phosphorylation of AKT; each could significantly inhibit LDR-induced 2BS cell proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 93-96 26584949-5 2016 PAN reduces Akt phosphorylation levels of GSK3beta, LY294002 can promote podocyte apoptosis induced by PAN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 12-15 26870244-11 2016 Phosphoinositide 3-kinase (PI3K)/Akt activation was observed in PC9/G cells in the presence of gefitinib and the sensitivity of PC9/G cells to gefitinib was also able to be restored by PI3K/Akt pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 212-220 AKT serine/threonine kinase 1 Homo sapiens 33-36 27098148-6 2016 Pretreatment with a nuclear factor-kappaB (NF-kappaB) inhibitor (PDTC) or PI3K/AKT inhibitor (LY294002) was proven to abolish the promoting effect of IL-17A on the invasion ability of colorectal cancer cells and upregulation of MMP-2/9. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 94-102 AKT serine/threonine kinase 1 Homo sapiens 79-82 26505797-8 2015 AKT inhibitors (LY294002 and perifosine) blocked escin-induced AKT activation, and dramatically inhibited Nrf2 phosphorylation, its cytosol accumulation and nuclear translocation in RPE cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 0-3 26505797-8 2015 AKT inhibitors (LY294002 and perifosine) blocked escin-induced AKT activation, and dramatically inhibited Nrf2 phosphorylation, its cytosol accumulation and nuclear translocation in RPE cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 63-66 26256949-8 2015 Inhibition of endogenous Akt by LY294002 resulted in decreased expression of Sox2, ALDH1, and CD133, leading to enhancement of cobalt chloride-mediated apoptotic events due to altered ratio of bcl-2 to bax expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 25-28 26653561-11 2015 PS473 Akt and pT308 Akt expression level was increased significantly as well, which were almost the same with those transfected with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 133-141 AKT serine/threonine kinase 1 Homo sapiens 6-9 26653561-11 2015 PS473 Akt and pT308 Akt expression level was increased significantly as well, which were almost the same with those transfected with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 133-141 AKT serine/threonine kinase 1 Homo sapiens 20-23 26453509-6 2015 Interestingly, PI3K inhibitor LY294002 completely blocked the TNF-alpha-induced activation of p85, Akt and the whole cascade of the NF-kappaB signaling components and suppressed inflammatory cytokines production in mRNA and protein levels similarly as CuE. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 99-102 26497980-7 2015 Furthermore, proliferation of SAS aggregates is also inhibited by LY294002 and MK2206, which are inhibitors of PI3K and AKT, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 120-123 26012840-7 2015 Finally, we demonstrated that an inhibitor of PI3-K/Akt (LY294002) but not MAPK/ERK1/2 (U0126) pathway blocked the protection mediated by UDA in all tested models of SH-SY5Y cell injury. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 52-55 25900259-12 2015 LY294002 inhibited only Akt phosphorylation, and FAK phosphorylation was not influenced under periostin stimulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 24-27 26350566-5 2015 Furthermore, we demonstrated that inhibition of Akt phosphorylation (LY294002) abrogated the Lcn2-promoted proliferation in cultured human pulmonary artery smooth muscle cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 48-51 26165503-12 2015 MK-2206 and LY294002, the PI3K/Akt inhibitors, repressed Dex-induced up-regulation of FOXO3. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 31-34 26363213-7 2015 Further, 10(-8) M BPA significantly increased the phosphorylation of ERK1/2, p38-MAPK, and Akt in SkBr3 cells, while only PI3K/Akt inhibitor LY294002 attenuated the BPA induced down regulation of FOXA1 and E-Cadherin (E-Cad). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 127-130 26310353-8 2015 The use of the AKT inhibitor, LY294002, in combination with cisplatin, induced an increase in apoptosis compared to treatment with cisplatin alone, although this effect was not as prominent as that exerted by butein in combination with cisplatin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 30-38 AKT serine/threonine kinase 1 Homo sapiens 15-18 26397153-8 2015 Moreover, C/EBPalpha expression was reduced by PI3K inhibitor LY294002 and mTOR inhibitor RAD001 in NB4 cells, suggesting that inactivation of the PI3K/Akt/mTOR pathway was responsible for C/EBPalpha suppression in APL cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-70 AKT serine/threonine kinase 1 Homo sapiens 152-155 26302186-10 2015 Finally, both AKT and ERK inhibitors (LY294002 and UO126) blocked effects of LPS on the depression of ENaC-gamma. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 14-17 26557022-4 2015 Both Akt phosphorylation and CCL11 expression induced by thrombin were attenuated in the presence of pertussis toxin (PTX), an inhibitor of Gi protein-coupled receptor, or LY294002, a PI3K inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 172-180 AKT serine/threonine kinase 1 Homo sapiens 5-8 26364578-8 2015 The elevation of PI3 kinase (PI3K) and p-Akt/Akt activities induced by ZnO NP was significantly decreased by esculetin or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 41-44 26364578-8 2015 The elevation of PI3 kinase (PI3K) and p-Akt/Akt activities induced by ZnO NP was significantly decreased by esculetin or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 45-48 26324335-8 2015 Moreover, MHY-449 downregulated the phosphorylation of Akt, and the phosphatidylinositol-3 kinase/Akt inhibitor LY294002 was found to enhance its induction of apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 98-101 26311737-9 2015 Furthermore, the inhibition of PI3K/Akt by LY294002/si-Akt or of mTOR by rapamycin augmented LicA-induced apoptosis and autophagy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 36-39 26225471-6 2015 Inhibiting the Akt activation by the PI3K inhibitor LY294002 markedly enhanced GRP78 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 15-18 25860846-7 2015 LY294002 (an AKT inhibitor) addition enhanced caudation-induced AKT inhibition, indicating that caudatin inhibited U251 cells growth in an AKT-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 13-16 25860846-7 2015 LY294002 (an AKT inhibitor) addition enhanced caudation-induced AKT inhibition, indicating that caudatin inhibited U251 cells growth in an AKT-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 64-67 25860846-7 2015 LY294002 (an AKT inhibitor) addition enhanced caudation-induced AKT inhibition, indicating that caudatin inhibited U251 cells growth in an AKT-dependent manner. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 64-67 26411419-8 2015 And the PI3K/Akt inhibitor, LY294002, markedly deteriorated the cisplatin-mediated viability reduction of Hela or Caski cells, indicating the involvement of PI3K/Akt pathway in the cisplatin resistance in cervical cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 13-16 26411419-8 2015 And the PI3K/Akt inhibitor, LY294002, markedly deteriorated the cisplatin-mediated viability reduction of Hela or Caski cells, indicating the involvement of PI3K/Akt pathway in the cisplatin resistance in cervical cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 162-165 26420965-15 2015 Moreover, Akt inhibition by Ly294002 could not prevent but led to enhanced G0/G1 arrest and apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 10-13 26366999-5 2015 In contrast, LY294002, a specific inhibitor of PI3K/AKT, reduced the level of AKT phosphorylation and GAP-43 expression, increased active caspase-3 expression and thus significantly weakened IL-10-mediated protective effect in the OGD-induced injury model. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 52-55 26366999-5 2015 In contrast, LY294002, a specific inhibitor of PI3K/AKT, reduced the level of AKT phosphorylation and GAP-43 expression, increased active caspase-3 expression and thus significantly weakened IL-10-mediated protective effect in the OGD-induced injury model. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 78-81 26027660-9 2015 Treatment with rapamycin or RAD001 significantly increased the phosphorylation of AKT in both LKB1 wild-type and LKB1 mutant NSCLC cells, which was attenuated by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 181-189 AKT serine/threonine kinase 1 Homo sapiens 82-85 25989537-6 2015 RESULTS: SLE serum promoted senescence of MSCs, which was reversed by the phosphatidylinositol 3-kinase (PI3K)/Akt signaling inhibitor LY294002 but not by the JAK/STAT inhibitor AG490 and not by the MEK/ERK inhibitor PD98059. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 111-114 25989537-9 2015 Inhibition of PI3K/Akt signaling with LY294002 reduced leptin- and NAP-2-induced senescence in MSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 19-22 25917210-10 2015 However, inhibitors of PI3K/AKT and ERK1/2 (LY294002 or U0126) not only suppressed geraniin-induced nuclear translocation of Nrf2 but also abolished the expression of HO-1, NQO1 and GSH. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 28-31 25882870-19 2015 However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 88-96 AKT serine/threonine kinase 1 Homo sapiens 110-113 25644787-7 2015 Furthermore, exposure to PCB118 was associated with a significant increase of the protein levels of p-Akt and p-FoxO3a, and these effects were blocked by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 102-105 25925728-13 2015 Pretreatment with PI3K inhibitors, LY294002 and wortmannin, as well as Akt siRNA, decreased ghrelin-induced Akt phosphorylation, Snail promoter binding activity and migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 108-111 26062523-7 2015 Notably, interruption of the AKT pathway by treatment with LY294002, a specific PI3K inhibitor, attenuated IRX2-induced cell proliferation and invasive ability, and the upregulation of MMP2 and VEGF. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 59-67 AKT serine/threonine kinase 1 Homo sapiens 29-32 26008990-7 2015 NO production and eNOS phosphorylation in response to Pts were significantly abolished by the phosphoinositide 3-kinase (PI3K)/Akt inhibitor LY294002, but not by the ERalpha antagonist ICI182780. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 141-149 AKT serine/threonine kinase 1 Homo sapiens 127-130 25935536-8 2015 Additionally, LY294002 (Akt pathway inhibitor) or U0126 (ERK pathway inhibitor) significantly suppressed SOX-2-overexpression-induced migration and invasion in SiHa cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 24-27 25388642-5 2015 In ex vivo tissue cultures p-AKT(Ser473) levels were increased upon irradiation and treatment with the PI3K inhibitor LY294002 inhibited both basal and irradiation induced AKT(Ser473) phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 29-32 26623104-5 2015 In the HCC827 cells, the effect of PI3K pathway inhibitor LY294002 on the expressions of PI3K/Akt/mTOR pathway components under the effect of PEBP4 was determined using Western blotting, and the effects of LY294002 on the cell viability, proliferation, and migration capabilities under the overexpression of PEBP4 were determined using MTT method, flow cytometry, and Transwell migration assay. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 94-97 26623104-8 2015 Treatment with LY294002 significantly inhibited the protein expressions of p-Akt and p-mTOR in HCC827 cells (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 77-80 26278786-8 2015 Chemical inhibitors for AKT (LY294002) and PKR (C16) disrupted their angiogenic potentials, suggesting that RNF213 and its upstream pathways cooperatively organize the process of angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 24-27 26367737-8 2015 Interestingly, NO production and eNOS phosphorylation in response to Pic were significantly abolished by the phosphoinositide 3-kinase (PI3K)/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 142-145 26052821-3 2015 Here, we propose a novel mechanism by which the PI3K/AKT pathway regulates NOTCH1 in T-ALL, starting from the evidence that the inhibition of PI3K/AKT signaling induced by treatment with LY294002 or transient transfection with a dominant negative AKT mutant downregulates NOTCH1 protein levels and activity, without affecting NOTCH1 transcription. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 53-56 26052821-3 2015 Here, we propose a novel mechanism by which the PI3K/AKT pathway regulates NOTCH1 in T-ALL, starting from the evidence that the inhibition of PI3K/AKT signaling induced by treatment with LY294002 or transient transfection with a dominant negative AKT mutant downregulates NOTCH1 protein levels and activity, without affecting NOTCH1 transcription. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 147-150 26052821-3 2015 Here, we propose a novel mechanism by which the PI3K/AKT pathway regulates NOTCH1 in T-ALL, starting from the evidence that the inhibition of PI3K/AKT signaling induced by treatment with LY294002 or transient transfection with a dominant negative AKT mutant downregulates NOTCH1 protein levels and activity, without affecting NOTCH1 transcription. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 147-150 26066464-6 2015 In addition, the blockage of PI3K/Akt by Ly294002 or knockdown of Akt by siRNA reduced the level of p-MDM2 and increased the level of p53. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 34-37 26031366-5 2015 The phosphatidylinositol 3-kinase inhibitor LY294002 was used to inhibit phosphorylation of Akt, to verify whether miR-20a affects HCC cell radioresistance through activating the PTEN/PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 92-95 26101183-5 2015 Furthermore, the Akt inhibitor, LY294002, partly eliminated the protective effect of puerarin on DEX-induced apoptosis, and puerarin combined with the JNK inhibitor, SP600125, suppressed DEX-induced apoptosis to a lesser extent than in the cells treated with SP600125 alone. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 17-20 25736988-5 2015 Inhibition of PI3K/Akt pathway by chemical LY294002 or Phosphase and tensin homology deleted on chromosome ten (PTEN) prevented the phenotypic transition. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 19-22 25640606-6 2015 Inactivating these pathways using the PI3K/Akt pathway inhibitor LY294002 or the MAP kinase pathway inhibitor PD98059 renders the DU145-TxR cells more sensitive to paclitaxel. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 43-46 26279749-10 2015 The effects of BK-PC were abrogated by HOE140 (B2R antagonist) and LY294002 (Akt antagonist). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 77-80 25754021-5 2015 The PI3K/AKT inhibitor LY294002 or the MEK/ERK inhibitor U0126 attenuated the effect of morroniside on human OA chondrocytes, indicating that the activation of AKT and ERK contributed to the regulation of morroniside in human OA chondrocytes. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 160-163 25957503-7 2015 Moreover, the inhibition of the activation of AKT with LY294002 significantly promoted the apoptosis and metastasis induced by baicalein. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 46-49 26622553-7 2015 Furthermore, the proliferation and migration abilities of cells were attenuated following inhibition of the PI3K/AKT/mTOR pathway by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 133-141 AKT serine/threonine kinase 1 Homo sapiens 113-116 26223322-8 2015 Inhibition of integrin beta4 and Akt signalling using blocking antibody and the inhibitor LY294002, respectively, significantly attenuated p53(R248)-mediated ovarian cancer-mesothelial adhesion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 90-98 AKT serine/threonine kinase 1 Homo sapiens 33-36 26328006-10 2015 The effects of BK-PC were abrogated by HOE140 (B2R antagonist) and LY294002 (Akt antagonist). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 77-80 25212570-6 2015 LY294002 (PI3K inhibitor) decreased p-Akt and Akt, resulting in enhancing MEIB-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 38-41 25212570-6 2015 LY294002 (PI3K inhibitor) decreased p-Akt and Akt, resulting in enhancing MEIB-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 46-49 26026718-8 2015 SDF-1 promoted F5M2 cell migration by activating the AKT and Wnt/beta-catenin signaling pathway, which was abrogated by preincubation with AMD3100 and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 53-56 25738331-7 2015 LY294002, an Akt-inhibitor, was able to increase the inhibition of p-Akt through MeoTR and combination treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 13-16 25738331-7 2015 LY294002, an Akt-inhibitor, was able to increase the inhibition of p-Akt through MeoTR and combination treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 69-72 25388642-5 2015 In ex vivo tissue cultures p-AKT(Ser473) levels were increased upon irradiation and treatment with the PI3K inhibitor LY294002 inhibited both basal and irradiation induced AKT(Ser473) phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 172-175 25773677-7 2015 Furthermore, activation of PAR-2 induced the activation of PI3K and AKT, and PI3K/AKT inhibitor LY294002 attenuated the invasion and migration of RCC cells stimulated by PAR-2 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 82-85 25821107-9 2015 Treatment of cervical cancer-derived cell lines with the PI3K inhibitor LY294002 resulted in a reduced AKT1 activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 103-107 25964092-9 2015 In addition, ACh stimulated the activation of PI3K and AKT via EGFR activity, and blocking of PI3K/AKT pathway by special inhibitor LY294002 suppressed the ACh-mediated proliferation, invasion, and migration of NSCLC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 55-58 25640278-10 2015 The PI3K/Akt inhibitor LY294002 potentiated BMP9"s viability and migration suppression, and apoptosis induction, which was associated with reduced expression of snail and VEGF and increased expression of E-cadherin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 25900077-6 2015 We show that phosphorylation of Akt and mTOR is required for OPC proliferation stimulated by growth factors (PDGF-AA and bFGF) or by CB1/CB2 agonists (ACEA/JWH133), since it was strongly decreased after LY294002 or rapamycin treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 203-211 AKT serine/threonine kinase 1 Homo sapiens 32-35 25997735-5 2015 We also showed that odorant stimulation activated Akt, and that Akt activation was completely blocked by incubation with both a PI3K inhibitor (LY294002) and Akt1 small interfering RNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 AKT serine/threonine kinase 1 Homo sapiens 50-53 25997735-5 2015 We also showed that odorant stimulation activated Akt, and that Akt activation was completely blocked by incubation with both a PI3K inhibitor (LY294002) and Akt1 small interfering RNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 AKT serine/threonine kinase 1 Homo sapiens 64-67 25663277-9 2015 Increased Akt and ERK phosphorylation was observed in UTP-treated cultures, effect that was inhibited by SRC inhibitor 1 and PI3K blocker LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 138-146 AKT serine/threonine kinase 1 Homo sapiens 10-13 25964092-9 2015 In addition, ACh stimulated the activation of PI3K and AKT via EGFR activity, and blocking of PI3K/AKT pathway by special inhibitor LY294002 suppressed the ACh-mediated proliferation, invasion, and migration of NSCLC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 132-140 AKT serine/threonine kinase 1 Homo sapiens 99-102 26000878-10 2015 Correspondingly, treatment with LY294002, a phosphatidylinositol-3-kinase inhibitor, mimicked PTEN overexpression effect in KYSE-150/RR cells, further suggesting a role for the Akt/GSK-3beta/Snail signaling in effects mediated through PTEN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 177-180 26021873-10 2015 These effects could be interrupted by the PI3K/Akt pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 47-50 25903737-7 2015 Pre-treatment with inhibitors of the pathway, LY294002 and rapamycin, decreased the expression of p-Akt and p70S6K and alleviated the morphological changes induced by IL-1beta in hippocampal neurons. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 100-103 24372557-9 2015 Additionally, periostin overexpression increased the expression of survivin and the phosphorylation of Akt, which was reversed by pretreatment with the phosphatidylinositol 3-kinase (PI3K)-specific inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 208-216 AKT serine/threonine kinase 1 Homo sapiens 103-106 25712031-7 2015 MMP-2 production and activity enhanced by 18% stretch were inhibited by the PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 81-84 25738334-6 2015 The pharmacological inhibition of ERK (using U0126) or Akt (using LY294002) suppressed the 20GPPD-induced expression of HAS2, whereas treatment with an epidermal growth factor receptor (EGFR) inhibitor (AG1478) or an intracellular Ca2+ chelator (BAPTA/AM) did not exert any observable effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 55-58 25748730-6 2015 Combining paeoniflorin with U0126 or LY294002 at low doses showed supra-additive inhibition of not only phospho-ERK1/2 and phospho-Akt by 46.4% and 35.0%, but also IL-8 release by 42.4% and 36.1% and IL-8 mRNA expression by 43.5% and 31.8%, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 131-134 26062301-0 2015 The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K/Akt signaling pathway inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 139-147 AKT serine/threonine kinase 1 Homo sapiens 107-110 26062301-1 2015 We aimed to investigate whether a combination of resistance to arsenic trioxide (As2O3) and the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway inhibitor LY294002 can inhibit the proliferation of AML cells in the bone marrow microenvironment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 161-169 AKT serine/threonine kinase 1 Homo sapiens 129-132 26062301-4 2015 The PI3K/Akt signaling pathway was detected by Western Blot in co-cultured AML cells cultured alone or treated with As2O3 alone or in combination with LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 9-12 25724180-9 2015 Akt inhibitor LY294002 reversed the role of TRIM24 on chemoresistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 0-3 25672876-9 2015 Moreover, we found that the growth inhibitory effects of resveratrol were enhanced by treatment with LY294002 [a phosphatidylinositol 3-kinase (PI3-K) inhibitor] more so than by treatment with PD98059 (a MEK inhibitor), which indicates that resveratrol exerts its inhibitory effects on sebocyte proliferation through the inhibition of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 335-338 26124933-4 2015 Therefore, we evaluated the effects of novel approaches including siRNA directed against BCRP and targeted therapy against PI3K/Akt signaling pathway using LY294002 (LY) to re-sensitize breast cancer MCF7 cell line to mitoxantrone (MTX) chemotherapy. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 156-164 AKT serine/threonine kinase 1 Homo sapiens 128-131 25784556-8 2015 A direct correlation between Ser(P)(473)-AKT and Ser(P)(401)-GATA2 was evident, and inhibition of AKT phosphorylation by the PI3K inhibitor LY294002 blocked Ser(401)-GATA2 phosphorylation and the increase in GRB10 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 41-44 25784556-8 2015 A direct correlation between Ser(P)(473)-AKT and Ser(P)(401)-GATA2 was evident, and inhibition of AKT phosphorylation by the PI3K inhibitor LY294002 blocked Ser(401)-GATA2 phosphorylation and the increase in GRB10 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 140-148 AKT serine/threonine kinase 1 Homo sapiens 98-101 25913171-13 2015 P-eNOS and P-Akt expression can be unregulated by RNH-6270 treatment and blocked by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 84-92 AKT serine/threonine kinase 1 Homo sapiens 13-16 25875646-12 2015 LY294002 could block the PI3K/Akt signaling pathway and rescue the promotion caused by suppressing miR-223 in mast cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 30-33 25638063-8 2015 Blocking the activation of Akt and Erk with their potent inhibitors LY294002 and PD98059, respectively, markedly attenuated the octacosanol-induced proliferation and migration of HUVEC. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 68-76 AKT serine/threonine kinase 1 Homo sapiens 27-30 26045756-8 2015 The ERK1/2 inhibitor U0126 and the Akt inhibitor LY294002 also inhibited hypoxia-induced HIF-1alpha and VEGF production. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 35-38 25581901-6 2015 EGCG-induced NO production was diminished by pretreatment with LY294002 (an Akt inhibitor), KN62 (a CaMKII inhibitor), and compound C (an AMPK inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 76-79 26101705-6 2015 Interestingly, LY294002, a special inhibitor to PI3K/AKT signaling which was determined as a downstream pathway of netrin-1, restored the reduction in BVES caused by netrin-1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 53-56 25630653-9 2015 The Akt inhibitor, LY294002, inhibited the effect of atorvastatin on inducing Akt phosphorylation and on suppressing H2O2-mediated caspase up-regulation and cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 4-7 25630653-9 2015 The Akt inhibitor, LY294002, inhibited the effect of atorvastatin on inducing Akt phosphorylation and on suppressing H2O2-mediated caspase up-regulation and cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 78-81 25308861-5 2015 After Protein Kinase B (PKB/Akt) signal pathway was inhibited by the p-Akt inhibitor (LY294002) and the expression of MRP1 was restrained by siRNA of MRP1, CCK-8 was used to examine the cell proliferation after treatment with cisplatin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 24-31 25908029-9 2015 The PI3K/Akt inhibitor LY294002 completely blocked BDE-99-induced Snail and invasion of HCT-116 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 9-12 25938832-7 2015 Moreover, Pretreatment with LY294002 inhibited the palmitate sodium induced-phosphorylation of PI3K and Akt, and promoted upregulation of CHOP and Bax induced by palmitate sodium. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 28-36 AKT serine/threonine kinase 1 Homo sapiens 104-107 24531716-9 2015 Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or by Akt small interfering RNA resulted in the reduced chemosensitivity of HL60/ADR cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 18-21 25643147-6 2015 In parallel, the phosphorylation level of Akt kinase was markedly increased by the oil treatment, which was partially attenuated by PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 42-45 25643147-6 2015 In parallel, the phosphorylation level of Akt kinase was markedly increased by the oil treatment, which was partially attenuated by PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 137-140 25661377-9 2015 In addition, the AKR1C3 mediated DOX resistance can be conquered by the Akt inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 72-75 25308520-8 2015 In addition, the aforementioned promotive effects afforded by CTI were abolished by blocking PI3K/AKT pathway with addition of LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 98-101 25488290-0 2015 Inhibition of the PI3K/Akt pathway by Ly294002 does not prevent establishment of persistent Junin virus infection in Vero cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 23-26 25488290-4 2015 Treatment of infected cultures with Ly294002, an inhibitor of the PI3K/Akt pathway, produced an apoptotic response similar to that observed for uninfected cells treated with the drug. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 71-74 25855199-6 2015 Targeting the PI3K/Akt pathway by its specific inhibitor LY294002, or by Akt RNA interfering reversed the MDR phenotype of K562/ADR cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 19-22 25638174-14 2015 Blocking Akt and/or ERK with the PI3K inhibitor, LY294002, or the ERK inhibitor, PD98059, induced down-regulation of MMP9 and up-regulation of cleaved caspase-3 and PARP-1, resembling the effects of luteolin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 9-12 25355053-9 2015 Notably, treatment with the PI3K inhibitor, LY294002, decreased the levels of phosphorylated (p)-PI3K, p-Akt and p-mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 105-108 25476740-8 2015 In addition, inhibition of PI3K/AKT pathway by specific inhibitor LY294002 suppressed the CXCL13-mediated growth, migration, and invasion of colon cancer cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 32-35 25652862-8 2015 Leptin promoted the expression of p-AKT in HFL-1, and this effect was blocked by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 36-39 26075254-5 2015 LY294002-mediated inhibition of phosphatidylinositol-3 kinase, which is an upstream effector for Akt activation, increased cleavage of poly(ADP-ribosyl) polymerase (PARP) but ERK inhibition by U0126 did not. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 97-100 25701261-5 2015 Treatment with ERK or Akt specific inhibitors, U0126 or LY294002, respectively, suppressed estradiol-induced growth. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 22-25 25173778-5 2015 The PI3K inhibitor LY294002 was used to investigate the possible mechanism relating the PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 93-96 25714853-7 2015 Treatment with Dovitinib in combination with PI3K/Akt/mTOR signaling inhibitors Ly294002 or RAD001 resulted in additive inhibition of cell invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 50-53 26488172-10 2015 This enhancement was also markedly abolished by co-incubation with LY294002, paralleled with suppressed Akt phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 104-107 25833462-8 2015 VEGFR2 inhibitor SU-1498, AKT inhibitor LY294002 and FAK inhibitor 14 (FAK inhibitor) blocked the Robo4 knockdown-mediated alteration in glioma angiogenesis in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 26-29 25531265-10 2015 Only PI3K/AKT inhibitor (LY294002), but not ERK inhibitor (PD98059), completely blocked the 6-OH-BDE-47 induced up regulation of Snail and down regulation of E-Cad, suggesting that PI3K/AKT pathway is important for 6-OH-BDE-47-mediated Snail stabilization and EMT in A549 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 10-13 25434308-8 2015 Meanwhile, FZD treatment inhibited both the activation and expression of Akt, and PI3K/Akt inhibitor LY294002 promoted FZD-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 101-109 AKT serine/threonine kinase 1 Homo sapiens 87-90 25078983-5 2014 LY294002 was applied to inhibit PI3K/Akt signaling. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 37-40 25510413-6 2015 In parallel, the interaction between the level of BCL2, BAX and PTEN with the specific PI3K/AKT inhibitor-LY294002 was highly significant for BCL2 and nearly significant for PTEN and BAX. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 106-114 AKT serine/threonine kinase 1 Homo sapiens 92-95 25969626-10 2015 Here, LY294002, a specific PI3K/Akt inhibitor, suppressed PUN-induced HO-1 expression and led to ROS accumulation in macrophages. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 6-14 AKT serine/threonine kinase 1 Homo sapiens 32-35 26273426-7 2015 But the ERK inhibitor U0126 or PI3K/Akt inhibitor LY294002 produced no obvious effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 36-39 25266803-7 2015 The blockade of the PI3K/Akt pathway by LY294002 resulted in abolishment of the effects of RhoGDI2 shRNA in Akt phosphorylation and MMP-9 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 25-28 25266803-7 2015 The blockade of the PI3K/Akt pathway by LY294002 resulted in abolishment of the effects of RhoGDI2 shRNA in Akt phosphorylation and MMP-9 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 40-48 AKT serine/threonine kinase 1 Homo sapiens 108-111 25310590-3 2014 LY294002 is a commonly used pharmacologic inhibitor, which selectively inhibits the phosphoinositide 3-kinase-AKT nexus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 110-113 25344912-5 2014 Inhibition of the PI3K/AKT pathway with specific inhibitors, wortmannin and LY294002, significantly reduced Bcl-xL expression, induced caspase-3-dependent apoptosis, and repressed cell proliferation and tumor growth in vitro and in vivo without obvious toxic effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 23-26 25257463-10 2014 BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 AKT serine/threonine kinase 1 Homo sapiens 35-38 25257463-10 2014 BBR can increase the level of PI3K/Akt/eNOS mRNA and the protein level of PI3K, p-Akt, eNOS and p-eNOS, which can be blocked by PI3K inhibitor (LY294002) and eNOS inhibitor (l-NAME). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 144-152 AKT serine/threonine kinase 1 Homo sapiens 82-85 25230779-12 2014 Notably, Akt inhibition by LY294002 restored the 5-FU cytotoxicity suppressed by CD133 overexpression, while Akt activation by epidermal growth factor reversed the 5-FU cytotoxicity enhanced by CD133 silencing. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 27-35 AKT serine/threonine kinase 1 Homo sapiens 9-12 25149157-5 2014 Moreover, treatment of A549 cells with LicA-inhibited activation of the phosphorylation of Akt and inhibition of Akt by LY294002 (PI3K inhibitor) or transfection with the constitutive active-Akt (CA-Akt) expression vector significantly abolished the LicA-inhibited migration and invasion through activation of the Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 113-116 25149157-5 2014 Moreover, treatment of A549 cells with LicA-inhibited activation of the phosphorylation of Akt and inhibition of Akt by LY294002 (PI3K inhibitor) or transfection with the constitutive active-Akt (CA-Akt) expression vector significantly abolished the LicA-inhibited migration and invasion through activation of the Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 113-116 25149157-5 2014 Moreover, treatment of A549 cells with LicA-inhibited activation of the phosphorylation of Akt and inhibition of Akt by LY294002 (PI3K inhibitor) or transfection with the constitutive active-Akt (CA-Akt) expression vector significantly abolished the LicA-inhibited migration and invasion through activation of the Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 113-116 25149157-5 2014 Moreover, treatment of A549 cells with LicA-inhibited activation of the phosphorylation of Akt and inhibition of Akt by LY294002 (PI3K inhibitor) or transfection with the constitutive active-Akt (CA-Akt) expression vector significantly abolished the LicA-inhibited migration and invasion through activation of the Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 113-116 25449069-5 2014 LY294002 could reduce the phosphorylation of Akt and GSK3beta (P< 0.01, P< 0.05), and also decrease the DRD2 mRNA (P<0 .05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 45-48 25382615-9 2014 Additionally, the PI3K/Akt inhibitor, LY294002, in treating MGC-803 cells potently suppressed cell invasion and migration as well as expression of MMP-9. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 23-26 25340291-6 2014 Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 179-182 25119993-8 2014 Moreover, IK inhibited the phosphorylation of AKT/mTOR protein and cell proliferation induced by LY294002, a PI3K inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 46-49 25216292-5 2014 When the PI3K/AKT pathway was suppressed by LY294002, the effect of estrogen was attenuated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 14-17 25374071-2 2014 METHODS: The HEK293 cells transfected stably with B7-H4, named B7-H4/HEK293, were treated with the PI3K/AKT specific inhibitor LY294002 and/or the nuclear export inhibitor leptomycin B (LMB). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 104-107 25345853-10 2014 Furthermore, PI3K/Akt inhibitor LY294002 enhanced anti-metastatic potential of EEOS to attenuate the expression of uPA and MMP-9 in OPN treated NCI-H 460 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 18-21 25419430-4 2014 These results indicated that IRS-4 was very likely to be involved in PI3K/Akt path way, which was further confirmed by the fact that the PI3K/Akt blocker LY294002 attenuated the proliferation and migration of the hepatoblastoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 74-77 25419430-4 2014 These results indicated that IRS-4 was very likely to be involved in PI3K/Akt path way, which was further confirmed by the fact that the PI3K/Akt blocker LY294002 attenuated the proliferation and migration of the hepatoblastoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154-162 AKT serine/threonine kinase 1 Homo sapiens 142-145 25550859-8 2014 After HUVEC was intervened by PI3K/AKT pathway inhibitor LY294002, the expression level of phosphorylated eNOS was significantly lower than that in the rhACE2 30 min treatment group (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 35-38 25550859-9 2014 rhACE2 may reduce the activity of Ang II inhibited endothelial cell eNOS, which can be blocked by PI3K/AKT pathway inhibitor LY294002, suggesting PI3K/AKT signaling pathway plays an important role in rhACE2"s promotion of the activity of endothelial cell eNOS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 AKT serine/threonine kinase 1 Homo sapiens 103-106 25550859-9 2014 rhACE2 may reduce the activity of Ang II inhibited endothelial cell eNOS, which can be blocked by PI3K/AKT pathway inhibitor LY294002, suggesting PI3K/AKT signaling pathway plays an important role in rhACE2"s promotion of the activity of endothelial cell eNOS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 AKT serine/threonine kinase 1 Homo sapiens 151-154 24939823-5 2014 Jaceosidin-induced proliferation and migration of human umbilical vascular endothelial cells were strongly inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002 and NF-kappaB inhibitor BAY11-7082, indicating that the PI3K/AKT/NF-kappaB signaling pathway is involved in jaceosidin-induced angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 164-172 AKT serine/threonine kinase 1 Homo sapiens 234-237 24770666-6 2014 Inhibition of PI3K/Akt pathway by LY294002 reversed the EMT transition in breast cancer cell lines MCF-7 and BT-20 induced by IL-7delta5. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 19-22 25078983-8 2014 LY294002 pre-treatment significantly alleviated Ang II-induced HUVEC senescence, and partly reversed the elevation of TERT, UCP2, p-Akt, c-myc and p53 protein levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 132-135 25146167-8 2014 Treatment of the human meningioma cell line HBL-52 with the PI3K inhibitor LY294002 resulted in reduction of p-AKT, p-p70S6K and p-ERK1/2 protein levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 75-83 AKT serine/threonine kinase 1 Homo sapiens 111-114 25027404-8 2014 By using the PI3K/Akt inhibitor LY294002, we further demonstrated that NC-induced apoptosis might be Akt-specific or dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 18-21 25027404-8 2014 By using the PI3K/Akt inhibitor LY294002, we further demonstrated that NC-induced apoptosis might be Akt-specific or dependent. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 101-104 25257523-9 2014 LY294002 not only mitigated the up-regulated protein level of phosphor Akt at Ser473 caused by GRb1, but also reversed the inhibitory effect of GRb1 on OGD and transient ischemia-induced elevation in protein levels of LC3II and Beclin1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 71-74 25223735-5 2014 The undifferentiated cell phenotype could be reversed by LY294002, which is an inhibitor of the PI3K/AKT signaling pathway, and this reversal was accompanied by a significant reduction in CSC phenotypic markers and functional properties. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 57-65 AKT serine/threonine kinase 1 Homo sapiens 101-104 25152024-9 2014 Furthermore, pretreatment with JNK inhibitor SP600125 and p38 inhibitor SB203580, or with AKT inhibitor LY294002 abolished the effects of mig-2 on cisplaxtin-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 104-112 AKT serine/threonine kinase 1 Homo sapiens 90-93 24953795-6 2014 Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or Akt short hairpin RNA (shRNA) resulted in the reduced MDR of HL60/ADR cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 18-21 25068805-11 2014 Inhibition of AKT in Ishikawa cells with LY294002 resulted in a significant reduction in the levels of phospho-ERK1/2, whereas inhibition of ERK1/2 with PD98059 exerted no effects on AKT activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 41-49 AKT serine/threonine kinase 1 Homo sapiens 14-17 25157276-6 2014 Inhibition of PI3K by LY294002 decreased the level of p-AKT1 and activated FOXO1 transcription factor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 22-30 AKT serine/threonine kinase 1 Homo sapiens 56-60 24132578-8 2014 APN neutralization antibody and LY294002 blocked the APN-mediated effects via inhibition of activated AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 102-105 25245523-6 2014 Interestingly, ectopic overexpression of MTA1-induced CSCs properties and CDDP resistance were reversed in CNE1 cells after inhibition of PI3K/Akt by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 150-158 AKT serine/threonine kinase 1 Homo sapiens 143-146 24506791-6 2014 In addition, we established that thrombin stimulated the phosphorylation of c-Src, PDGFR, Akt and p65, which were inhibited by pre-treatment with their respective inhibitors PP1, AG1296, LY294002 or Bay11-7082. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 90-93 25085593-7 2014 Moreover, both ZJW and a PI3K specific inhibitor (LY294002) suppressed phosphorylation of Akt (Ser473) and NF-kappaB, which is necessary in the activation of the PI3K/Akt/NF-kappaB pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 90-93 25085593-7 2014 Moreover, both ZJW and a PI3K specific inhibitor (LY294002) suppressed phosphorylation of Akt (Ser473) and NF-kappaB, which is necessary in the activation of the PI3K/Akt/NF-kappaB pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 167-170 24974736-7 2014 Sunitinib or LY294002, but not erlotinib, significantly inhibited the platelet-induced proliferation of osteosarcoma cells, indicating that PDGF released from platelets plays an important role in the proliferation of osteosarcomas by activating the PDGFR and then Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 264-267 24506791-7 2014 In addition, thrombin also enhanced Akt and NF-kappaB translocation from the cytosol to the nucleus, which was reduced by PP1, AG1296 or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 36-39 24506791-8 2014 Thrombin induced NF-kappaB promoter activity and the formation of the p65-Akt-p300 complex, which were inhibited by AG1296, LY294002 or PP1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 124-132 AKT serine/threonine kinase 1 Homo sapiens 74-77 24816639-7 2014 Similarly, treatment with LY294002, an inhibitor of the PI3K/AKT pathway, inhibited the migration and invasion of RA-FLS. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 61-64 23837575-7 2014 Blocking the PI3K/Akt cascade with a PI3K inhibitor LY294002 (10 muM) increased the cytotoxic effect of vincristine and doxorubicin on SK-OV-3 cell line. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 18-21 24889918-10 2014 Treating CNE2Z cells with LY294002 inhibited p-Akt (Ser473), vimentin and alpha-SMA expression but upregulated E-cadherin expression, leading to significantly attenuated cell invasion and migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 47-50 24838617-7 2014 Using the potent PI3K/Akt inhibitor, LY294002, we explored the likely mechanism of HMGB1-induced NS/PC proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 22-25 24838617-10 2014 LY294002 effectively reduced phospho-Akt levels and reduced NS/PC proliferation induced by HMGB1 in vitro. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 37-40 25058399-10 2014 LY294002, a PI3K inhibitor, inhibited HPV-16 oncoprotein-induced activation of Akt, P70S6K, and P85S6K, expression of HIF-1alpha, VEGF, and IL-8, and in vitro angiogenesis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 79-82 25028796-6 2014 Fucoxanthin treatment increased phosphorylation of Akt (active form), an up-regulator of Nrf2 and exposure to LY294002, a phosphoinositide 3-kinase (PI3K)/Akt inhibitor, suppressed the fucoxanthin-induced activation of Akt, Nrf2, resulting in decreased GCLC and GSS expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 51-54 25028796-6 2014 Fucoxanthin treatment increased phosphorylation of Akt (active form), an up-regulator of Nrf2 and exposure to LY294002, a phosphoinositide 3-kinase (PI3K)/Akt inhibitor, suppressed the fucoxanthin-induced activation of Akt, Nrf2, resulting in decreased GCLC and GSS expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 155-158 25028796-6 2014 Fucoxanthin treatment increased phosphorylation of Akt (active form), an up-regulator of Nrf2 and exposure to LY294002, a phosphoinositide 3-kinase (PI3K)/Akt inhibitor, suppressed the fucoxanthin-induced activation of Akt, Nrf2, resulting in decreased GCLC and GSS expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 110-118 AKT serine/threonine kinase 1 Homo sapiens 155-158 24632945-6 2014 This effect was mediated by the NO/PI3K/Akt pathway since it was blocked by the following: (a) the NOS inhibitors L-NAME and 7-Nitroindazole, (b) the IP3K/Akt inhibitors LY294002, wortmannin and the Akt-negative dominant, (c) the NCX1 and NCX3 siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 40-43 24632945-6 2014 This effect was mediated by the NO/PI3K/Akt pathway since it was blocked by the following: (a) the NOS inhibitors L-NAME and 7-Nitroindazole, (b) the IP3K/Akt inhibitors LY294002, wortmannin and the Akt-negative dominant, (c) the NCX1 and NCX3 siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 155-158 24632945-6 2014 This effect was mediated by the NO/PI3K/Akt pathway since it was blocked by the following: (a) the NOS inhibitors L-NAME and 7-Nitroindazole, (b) the IP3K/Akt inhibitors LY294002, wortmannin and the Akt-negative dominant, (c) the NCX1 and NCX3 siRNA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 155-158 23475563-7 2014 The PI3K inhibitor LY294002 suppressed Akt activation similar to AMR-Me and potentiated AMR-Me induced apoptosis in MCF-7 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 39-42 24760275-17 2014 The phosphorylation levels of p65 were significantly decreased in Huh-7 and Hep3B cells after treatment with the Akt signaling inhibitor LY294002 and EP4R agonist for 24 h. Treatment with the NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) at 10 muM for 24 h blocked EP4R-agonist-induced Snail upregulation in Huh-7 and Hep3B cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 137-145 AKT serine/threonine kinase 1 Homo sapiens 113-116 24941119-8 2014 The PI3K inhibitor LY294002 reverses the AEG-1 dependent effects on Akt phosphorylation, Bcl-2 expression and anoikis resistance. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 68-71 25003810-10 2014 Moreover, LY294002 pretreatment prevented Akt hyperactivation and reactivated GSK3beta without altering Smad1 activation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 42-45 24936148-7 2014 These effects of S100A4 were abolished by treatment with either the specific PI3K/Akt inhibitor LY294002, or the specific mTOR/p70S6K inhibitor rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 82-85 22859221-9 2014 Inhibition of PI3K/Akt which negatively regulates GSK3 activity by LY294002 resulted in a decrease in arsenite-mediated beta-catenin nuclear accumulation, and VEGF expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 19-22 24700142-7 2014 Finally, LY294002, an inhibitor of PI3K, also markedly abolished SOX2-induced activation of the Akt/mTOR pathway and increased cell invasion and MMP-2 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 96-99 24878845-11 2014 In addition, LY294002 blocked AKT and STAT phosphorylation, and also up-regulated expression levels of type I and type III collagen (Col 1 and Col 3) and alpha-smooth muscle actin (alpha-SMA) in IL-10-treated cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 30-33 24634221-5 2014 LY294002, an inhibitor of PI3k, abolished HGF-induced PI3k (Tyr-458), and Akt (Thr-308 and Ser-473) phosphorylation and suppressed lamellipodia formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 74-77 24805814-6 2014 When the phosphorylation of ERK1/2 and PI3K/AKT was inhibited by PD98059 and LY294002, respectively, the decreased proliferation and invasion induced by BMP9 knock down were eliminated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 77-85 AKT serine/threonine kinase 1 Homo sapiens 44-47 24412919-10 2014 Conversely, LY294002, a highly selective inhibitor of PI3K, could block phosphorylation of Akt and effect of miR-200b. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 91-94 24599886-7 2014 We then showed that the DAF gene expression was up-regulated and the Dr(+) E. coli adhesion increased after the suppression of PI3K/Akt pathway in Ishikawa cells using inhibitor LY294002, and a plasmid which allowed the expression of PI3K/Akt regulatory protein PTEN. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 178-186 AKT serine/threonine kinase 1 Homo sapiens 132-135 24528157-8 2014 Intercepting Akt signaling by specific inhibitor LY294002 blocked the protective effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 13-16 24122208-11 2014 In addition, the PI3K/Akt signaling pathway was activated in iMSCs(Fn14) which allowed higher Akt phosphorylation (p-Akt) levels and SMA levels, whereas, it was attenuated by LY294002 (PI3K/Akt inhibitor). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 175-183 AKT serine/threonine kinase 1 Homo sapiens 22-25 24573187-5 2014 The treatment with the AMPK (compound C) and protein kinase Akt/protein kinase B (Akt; LY294002) inhibitor significantly suppressed the apelin-13-induced AMPK, Akt and eNOS phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 60-63 24573187-5 2014 The treatment with the AMPK (compound C) and protein kinase Akt/protein kinase B (Akt; LY294002) inhibitor significantly suppressed the apelin-13-induced AMPK, Akt and eNOS phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 82-85 24573187-5 2014 The treatment with the AMPK (compound C) and protein kinase Akt/protein kinase B (Akt; LY294002) inhibitor significantly suppressed the apelin-13-induced AMPK, Akt and eNOS phosphorylation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 87-95 AKT serine/threonine kinase 1 Homo sapiens 82-85 24425104-9 2014 After intervention by use of AFP monoclonal antibodies or LY294002 inhibitor, the PIK and Akt protein expression in HepG2 cell was significantly decreased (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 90-93 24685819-8 2014 The sustained hypoxic contraction was associated with altered phosphorylation of MLC and Akt, which was inhibited by LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 117-125 AKT serine/threonine kinase 1 Homo sapiens 89-92 24854554-6 2014 Exogenous Tbeta10 can promote the expression of VEGF-C mRNA and protein in lung cancer cell lines A549 and LK2 (P<0.05), and this effect can be inhibited by use AKT inhibitor LY294002 (P<0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 178-186 AKT serine/threonine kinase 1 Homo sapiens 164-167 24582967-7 2014 Akt inhibition by LY294002 abrogated the preventive effect of rTM on FK506-induced Akt inactivation and the suppressive effect of rTM on FK506-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 0-3 24582967-7 2014 Akt inhibition by LY294002 abrogated the preventive effect of rTM on FK506-induced Akt inactivation and the suppressive effect of rTM on FK506-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 83-86 24613819-7 2014 Furthermore, phosphorylation of TNF-alpha-induced phosphatidyl-inositol 3 kinase (PI3K)/Akt was significantly downregulated in the presence of GA accompanying with the inhibition of NF-kappaB activity, and as presumed, the specific PI3K/Akt inhibitor LY294002 significantly decreased MMP-9 and VEGF expression as well as activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 251-259 AKT serine/threonine kinase 1 Homo sapiens 88-91 24970817-6 2014 Treatment with LY294002, a PI3K inhibitor, resulted in cell cycle arrest without apoptosis and a concomitant down-regulation of cap-dependent translation by the suppression of the PI3K/AKT/mTOR pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 185-188 24967183-10 2014 In the presence of the LY294002, the potent PI3K inhibitor, the p-Akt was significantly attenuated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 23-31 AKT serine/threonine kinase 1 Homo sapiens 66-69 24955034-6 2014 The induction of lamellipodia was demonstrated to occur via the Akt pathway because the addition of the Akt inhibitor LY294002 inhibited lamellipodia in both Cav-1-overexpressing and H23 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 64-67 24955034-6 2014 The induction of lamellipodia was demonstrated to occur via the Akt pathway because the addition of the Akt inhibitor LY294002 inhibited lamellipodia in both Cav-1-overexpressing and H23 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 118-126 AKT serine/threonine kinase 1 Homo sapiens 104-107 24841907-4 2014 In addition, the PI3K/Akt inhibitor LY294002 enhanced Beclin-1, LC3-II, and poly(ADP-ribose) polymerase (PARP) cleavage levels. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 22-25 24563318-7 2014 TGF-beta1-induced alpha-SMA expression was significantly decreased by LY294002 and Akt siRNA indicating that these changes are mediated by the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 70-78 AKT serine/threonine kinase 1 Homo sapiens 148-151 24356998-7 2014 In A549 cells, stable knockdown of HtrA1 expression promoted cancer stem cell-like properties and CDDP insensitivity, however, these effects were blocked by inhibition of PI3K/Akt pathway using LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 194-202 AKT serine/threonine kinase 1 Homo sapiens 176-179 23604952-6 2014 PRPr led to the phosphorylation of Erk1/2 and Akt in HUVECs, and the induction of proliferation and migration by PRPr was suppressed by PRPr inhibitors PD98059 and LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 164-172 AKT serine/threonine kinase 1 Homo sapiens 46-49 24889918-12 2014 Our findings suggest that inhibiting the PI3K/Akt pathway using LY294002 attenuated NPC metastasis via induction of EMrT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 46-49 24774073-4 2014 beta-Hydroxy-beta-methylbutyrate up-regulated phosphorylation of Akt and mTOR, and these effects were completely abolished in the presence of PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 157-165 AKT serine/threonine kinase 1 Homo sapiens 65-68 24613761-14 2014 The 3-min OGD-induced neuroprotection was inhibited by LY294002, an Akt activation inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 68-71 24503054-9 2014 The pro-endocrine effect of T3 in the pancreatic explants and in the acinar cell line, was abrogated by the Akt inhibitor Ly294002 indicating the involvement of Akt signaling in this process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 108-111 24503054-9 2014 The pro-endocrine effect of T3 in the pancreatic explants and in the acinar cell line, was abrogated by the Akt inhibitor Ly294002 indicating the involvement of Akt signaling in this process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 122-130 AKT serine/threonine kinase 1 Homo sapiens 161-164 24530412-9 2014 It is noteworthy that a tyrosine kinase receptor inhibitor, K252a, an MEK-ERK inhibitor (U0126), and a PI3Kinase-Akt inhibitor (LY294002) remarkably attenuated TrkB, ERK, and Akt phosphorylation as well as increase of OPN mRNA expression in the HCEM cells, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 113-116 24530412-9 2014 It is noteworthy that a tyrosine kinase receptor inhibitor, K252a, an MEK-ERK inhibitor (U0126), and a PI3Kinase-Akt inhibitor (LY294002) remarkably attenuated TrkB, ERK, and Akt phosphorylation as well as increase of OPN mRNA expression in the HCEM cells, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 128-136 AKT serine/threonine kinase 1 Homo sapiens 175-178 24529326-9 2014 The neuroprotective effects of neuregulin-1ss were prevented by treatment with Ly294002, an inhibitor of the phosphatidylinositol-3-kinase/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 139-142 24535016-0 2014 PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 51-54 24535016-9 2014 Combination of ZD55-TRAIL with the PI3K inhibitor LY294002 in RPMI-8226 cells inhibited the virus-mediated activation of mTOR and AKT, thus, promoting cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-58 AKT serine/threonine kinase 1 Homo sapiens 130-133 24347489-7 2014 Interestingly, blocking PI3K/Akt signaling pathway by LY294002 or Akt siRNA could remarkably inhibit the PAK1 activation and cell invasion. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 54-62 AKT serine/threonine kinase 1 Homo sapiens 29-32 24669186-10 2014 The production of IL-1beta, IL-6, and IL-8 induced by TNF-alpha was decreased by the phosphatidylinositol-3 kinase inhibitor LY294002, suggesting that inhibition of Akt activation might inhibit IL-1beta, IL-6, and IL-8 production induced by TNF-alpha. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 AKT serine/threonine kinase 1 Homo sapiens 165-168 24441870-8 2014 On the other hand, TNF-alpha could induce Akt and p42/p44 MAPK translocation from the cytosol into the nucleus, which was inhibited by AG490, AG1296, or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 153-161 AKT serine/threonine kinase 1 Homo sapiens 42-45 24441870-10 2014 We also observed that TNF-alpha time dependently induced p300/Elk-1 and p300/Akt complex formation in HPAEpiCs, which was reduced by AG490, AG1296, or LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 151-159 AKT serine/threonine kinase 1 Homo sapiens 77-80 24603487-6 2014 PTEN and p-Akt downregulation could be abrogated by both the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 11-14 24603539-7 2014 Additionally, the increase in proliferation and cyclin D1 expression induced by miR-21 overexpression was almost completely blocked by Ly294002, an AKT inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 135-143 AKT serine/threonine kinase 1 Homo sapiens 148-151 24594691-7 2014 The radioresistance effect of hPEBP4 was reversed after given LY-294002 to inhibit Akt activation or antioxidant to abolish the ROS production. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 62-71 AKT serine/threonine kinase 1 Homo sapiens 83-86 24176823-11 2014 Pre-treating MDA-MB-231 cells with the specific PI3K inhibitor of LY294002 abolished the shear stress induced-Akt activation, and the expression of MMP-2, MMP-9, vascular endothelial growth factor (VEGF) and alphavbeta3 integrin were also down-regulated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 66-74 AKT serine/threonine kinase 1 Homo sapiens 110-113 24293123-8 2014 In contrast, downregulation of Rap2a promoted glioma migration and invasion, and raised the phosphorylation level of AKT, whereas these effects were inhibited by PI3K-specific inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 187-195 AKT serine/threonine kinase 1 Homo sapiens 117-120 25337568-8 2014 In addition, PEAL suppressed Akt activity and PEAL-induced apoptosis were significantly accentuated with Akt inhibitor (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 120-128 AKT serine/threonine kinase 1 Homo sapiens 105-108 25076559-7 2014 [3H]thymidine incorporation was blocked by lisuride, a 5-HT(2B) receptor antagonist, and also by LY-294002, a specific inhibitor of PI3K and Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-106 AKT serine/threonine kinase 1 Homo sapiens 141-144 24581171-5 2014 LY294002 (100 mg/kg), a potent inhibitor of Akt which reduced the levels of pAkt in HCCLM3 cell lines, was injected intraperitoneally into one group thrice weekly. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 44-47 24525337-5 2014 Inhibitors (LY294002, wortmannin, and deguelin) of phosphatidylinositol 3-kinases (PI3K) and AKT, but not inhibitors of MEK1/2, JNK, and p38-MAPK abolished the ActD-induced p53 expression in diverse cell types. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 12-20 AKT serine/threonine kinase 1 Homo sapiens 93-96 24057571-4 2014 Treatment with LY294002, a PI3K inhibitor, suppressed CdCl2-induced ATF4 expression and Akt phosphorylation at Thr308 with little effect on phosphorylation of eukaryotic translation initiation factor 2 subunit alpha at Ser51. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 88-91 23910058-7 2014 Molecularly, LY294002 treatment down-regulated AEG-1 expression, AKT and GSK3beta phosphorylation, and expression of cyclinD1, CDK4, VEGF and Bcl2, but up-regulated Bax and c-Myc expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 13-21 AKT serine/threonine kinase 1 Homo sapiens 65-68 24333105-8 2014 Furthermore, inhibition of PI3K/AKT signaling by LY294002 partially prevents ICT-induced nuclear translocation of Nrf2 and GCL transcription. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 49-57 AKT serine/threonine kinase 1 Homo sapiens 32-35 24378649-12 2014 Blockade of the PI3K/Akt signaling pathway by LY294002 abrogates the protection caused by thrombin treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 21-24 24451985-8 2014 The addition of LY294002, a PI3K inhibitor, decreased VEGF-induced phosphorylation of ERK1/2 and AKT1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 16-24 AKT serine/threonine kinase 1 Homo sapiens 97-101 24649094-5 2014 LY294002 was used to inhibit PI3K-Akt signaling to determine the mechanism involved. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 34-37 24649094-7 2014 Moreover, blocking the PI3K/Akt pathway by LY294002 effectively eliminated 2-DG-induced apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 28-31 24361488-11 2014 Pretreatment with LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), suppressed the phosphorylation of AKT and inhibited PCB29-pQ induced Nrf2/HO-1 activation, meanwhile, GSK-3beta expression was increased accordingly. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 124-127 24556678-8 2014 In contrast, although other phosphatidylinositol-3-kinase/Akt inhibitors (LY294002 and wortmannin) sensitized TRAIL-mediated apoptosis, c-FLIP(L) and Mcl-1 expressions were not altered. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 74-82 AKT serine/threonine kinase 1 Homo sapiens 58-61 24384683-8 2014 Suppression of phosphatidylinositol-3-kinase (PI3K)/Akt pathway by LY294002 restored chemosensitivity of Smad4-deficient cells to 5-FU. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 67-75 AKT serine/threonine kinase 1 Homo sapiens 52-55 24524196-5 2014 Pharmaceutical inhibition of PI3K with LY294002 significantly blocked the Wnt5a-induced activation of Akt (p-Ser473) and decreased Wnt5a-induced cell migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 102-105 24520418-8 2014 Also, the PI3K specific inhibitor (LY294002) abolished CSF2-induced increases in p-ERK1/2 and p-MTOR proteins, as well as CSF2-induced phosphorylation of AKT1. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 154-158 24398984-6 2014 However, the enhancement of migration of fibroblasts accelerated by AF-MSC-hypoCM was inhibited by SB505124 and LY294002, inhibitors of TGF-beta/SMAD2 and PI3K/AKT, suggesting that AF-MSC-hypoCM-enhanced wound healing is mediated by the activation of TGF-beta/SMAD2 and PI3K/AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 160-163 24398984-6 2014 However, the enhancement of migration of fibroblasts accelerated by AF-MSC-hypoCM was inhibited by SB505124 and LY294002, inhibitors of TGF-beta/SMAD2 and PI3K/AKT, suggesting that AF-MSC-hypoCM-enhanced wound healing is mediated by the activation of TGF-beta/SMAD2 and PI3K/AKT. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 112-120 AKT serine/threonine kinase 1 Homo sapiens 275-278 24269237-9 2014 To explore the potential mechanism, we investigated the effect of DT-13 on Akt and MAPK pathways and found that DT-13 was involved in Akt signaling confirmed by using PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-194 AKT serine/threonine kinase 1 Homo sapiens 134-137 24269237-9 2014 To explore the potential mechanism, we investigated the effect of DT-13 on Akt and MAPK pathways and found that DT-13 was involved in Akt signaling confirmed by using PI3K/Akt inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 186-194 AKT serine/threonine kinase 1 Homo sapiens 134-137 24144893-7 2014 In BXPC-3 cells, knockdown of Par-4 expression induces EMT and CDDP insensitivity, however, these effects were blocked by inhibition of PI3K/Akt pathway using LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 AKT serine/threonine kinase 1 Homo sapiens 141-144 24144893-11 2014 Inhibition of PI3K/Akt pathway using LY294002 reversed CDDP resistance in Par-4 siRNA-transfected BXPC-3 tumors. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 37-45 AKT serine/threonine kinase 1 Homo sapiens 19-22 24484591-6 2014 Additionally, LY294002, a PI3K-Akt inhibitor, could block the differentiation of U937 cells induced by UA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 31-34 24202965-11 2014 Furthermore, Akt inhibition by LY294002 treatment restored the CDDP cytotoxicity that was suppressed by FOXO1 overexpression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 13-16 24571890-10 2014 However, LY294002 administration significantly reduced the expression of p-Akt (Ser473) in all the three groups. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 73-78 24571890-11 2014 The results of immunocytochemistry further confirmed that PSMA knockdown or LY294002 treatment was associated with p-Akt (Ser473) down-regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 76-84 AKT serine/threonine kinase 1 Homo sapiens 115-120 25479544-7 2014 We further found that the PI3K/Akt inhibitor LY294002 down-regulated BCRP expression, hence showing that the Akt pathway is involved in the regulation of BCRP expression but not in its localization in these lung cancer cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 31-34 25479544-7 2014 We further found that the PI3K/Akt inhibitor LY294002 down-regulated BCRP expression, hence showing that the Akt pathway is involved in the regulation of BCRP expression but not in its localization in these lung cancer cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 45-53 AKT serine/threonine kinase 1 Homo sapiens 109-112 24057122-5 2014 We also found that rhEPO increased the expression of phosphorylated AKT, and the antiapoptotic role of rhEPO could be abolished by phosphoinositide 3-kinase (PI3K)/AKT inhibitor LY294002 or SH-5. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 178-186 AKT serine/threonine kinase 1 Homo sapiens 68-71 24057122-5 2014 We also found that rhEPO increased the expression of phosphorylated AKT, and the antiapoptotic role of rhEPO could be abolished by phosphoinositide 3-kinase (PI3K)/AKT inhibitor LY294002 or SH-5. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 178-186 AKT serine/threonine kinase 1 Homo sapiens 164-167 23948751-2 2013 Therefore, PI3K inhibitor LY294002 (LY) and MEK1/2 inhibitor PD98059 (PD) are used to sensitize many types of cancer cell lines to chemotherapeutic agents, where AKT and ERK pathways are over activated. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 26-34 AKT serine/threonine kinase 1 Homo sapiens 162-165 24072614-0 2014 LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 109-112 26168133-9 2014 Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt with LY294002 (LY) and p38 kinase with SB203580 (SB), respectively, decreased berberine-induced p53 and p21 expression and restored cell proliferation and expression of cyclin B1, cdc2, cdc25c, and pRb cell cycle progression proteins. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 51-54 24364919-7 2013 While LY294002 treatment markedly abolished miR-494-inducing Akt activation, HIF-1alpha and HO-1 increase under both normoxic and hypoxic conditions (p < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 6-14 AKT serine/threonine kinase 1 Homo sapiens 61-64 24312554-12 2013 The effects of BK PC were abrogated by the B2 receptor antagonist HOE140, the Akt and eNOS antagonists LY294002 and L-NAME, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 103-111 AKT serine/threonine kinase 1 Homo sapiens 78-81 23814023-6 2013 Moreover, LY294002 suppressed the activity of the PI3K/AKT/mTOR axis and mitigated the p-Ser473-AKT activation feedback loop in both cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 55-58 24219292-5 2013 LY294002, an inhibitor of PI3K-Akt pathway, and rapamycin, inhibitor of mammalian target of rapamycin (mTOR), significantly reversed the effect of 15(S)-HETE. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 31-34 24012499-9 2013 This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-91 AKT serine/threonine kinase 1 Homo sapiens 157-160 24012499-9 2013 This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-91 AKT serine/threonine kinase 1 Homo sapiens 221-224 23812937-6 2013 Inhibition of the PI3K/Akt pathway with wortmannin and Ly294002 caused a significant reduction in the expression of cytoplasmic wild-type survivin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 55-63 AKT serine/threonine kinase 1 Homo sapiens 23-26 24321071-9 2013 Further, leptin promoted migration and invasion of MCF-7 cells, which were attenuated by the JAK/STAT inhibitor AG490 (50 mumol/L), and the PI3K/AKT inhibitor LY294002 (10 mumol/L) (P < 0.05). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 159-167 AKT serine/threonine kinase 1 Homo sapiens 145-148 24055520-7 2013 When the cells were treated with IGF-II and PI3-kinase/Akt inhibitors, such as LY294002, wortmannin, or Akt inhibitor IV, STS expression induced by IGF-II was significantly blocked. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 79-87 AKT serine/threonine kinase 1 Homo sapiens 55-58 24260155-7 2013 The pretreatment of cells with specific ER inhibitors or PI3K/Akt (ICI182,780 and LY294002) increased Nrf2, HO-1, and NQO1 protein, impaired nuclear translocation of HA-Nrf2, and decreased ARE-luciferase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-90 AKT serine/threonine kinase 1 Homo sapiens 62-65 24228711-6 2013 Further analysis by using siRNA targeting the AKT-1 and the PI3K pathway inhibitor Ly294002 revealed that the AKT-1 siRNA reduced the WT1 expression effectively in A549 cells, and the same result was observed in Ly294002 treated cells, indicating that DDP treatment could down regulate WT1 expression through the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 83-91 AKT serine/threonine kinase 1 Homo sapiens 110-115 24228711-6 2013 Further analysis by using siRNA targeting the AKT-1 and the PI3K pathway inhibitor Ly294002 revealed that the AKT-1 siRNA reduced the WT1 expression effectively in A549 cells, and the same result was observed in Ly294002 treated cells, indicating that DDP treatment could down regulate WT1 expression through the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 212-220 AKT serine/threonine kinase 1 Homo sapiens 46-51 24228711-6 2013 Further analysis by using siRNA targeting the AKT-1 and the PI3K pathway inhibitor Ly294002 revealed that the AKT-1 siRNA reduced the WT1 expression effectively in A549 cells, and the same result was observed in Ly294002 treated cells, indicating that DDP treatment could down regulate WT1 expression through the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 212-220 AKT serine/threonine kinase 1 Homo sapiens 110-115 24228711-6 2013 Further analysis by using siRNA targeting the AKT-1 and the PI3K pathway inhibitor Ly294002 revealed that the AKT-1 siRNA reduced the WT1 expression effectively in A549 cells, and the same result was observed in Ly294002 treated cells, indicating that DDP treatment could down regulate WT1 expression through the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 212-220 AKT serine/threonine kinase 1 Homo sapiens 46-49 24225433-11 2013 Pre-treatment with NF-kappaB (SC514) and PI3K/Akt (LY294002) inhibitor partially abrogated CCL5 mRNA and protein expression levels as opposed to untreated controls after HIV-1 Vpr transfection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 51-59 AKT serine/threonine kinase 1 Homo sapiens 46-49 24244375-8 2013 Pre-treatment with SC514 (NF-kappaB inhibitor), LY294002 (PI3K inhibitor), AG490 (JAK2 inhibitor) and Janex-1 (JAK3 inhibitor) showed partial reduction of the Tat-mediated induction of CCL5 suggesting involvement of JAK, PI3K/Akt and NF-kappaB in CCL5 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 226-229 24227918-10 2013 Pretreatment with LY294002 and PD98059 abolished apelin-induced activation of Akt and Erk, proliferation, and collagen I expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 18-26 AKT serine/threonine kinase 1 Homo sapiens 78-81 24083989-9 2013 Since apelin-36 increased the level of phosphorylated Akt after H/I injury, we treated neonates with a specific PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 127-135 AKT serine/threonine kinase 1 Homo sapiens 54-57 24083989-10 2013 We found that LY294002 decreased the phosphorylated Akt level and attenuated protective effects of apelin-36 on apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 14-22 AKT serine/threonine kinase 1 Homo sapiens 52-55 24055799-8 2013 Additionally, PDGF-induced up-regulation of KCa3.1 and down-regulation of BSM contractile marker proteins were regulated by the ERK inhibitor U0126 and the AKT inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 156-159 24103747-8 2013 The phosphorylation of RXRalpha, Akt, and ERK proteins in HLF cells were markedly inhibited by treatment with ACR plus LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 119-127 AKT serine/threonine kinase 1 Homo sapiens 33-36 23742826-7 2013 The use of the phosphatidylinositol 3 kinase (PI3K) inhibitor, Ly294002, and/or of siRNA to reduce the expression of the serine/threonine kinase Akt showed that these effects are mediated by the PI3K/Akt signaling pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 63-71 AKT serine/threonine kinase 1 Homo sapiens 145-148 23911800-6 2013 Furthermore, a specific AKT inhibitor, LY294002, could enhance the anti-metastasis effects of NC, which indicated that NC suppressed metastasis of renal cancer cells partly via inhibition of AKT activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 24-27 23911800-6 2013 Furthermore, a specific AKT inhibitor, LY294002, could enhance the anti-metastasis effects of NC, which indicated that NC suppressed metastasis of renal cancer cells partly via inhibition of AKT activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-47 AKT serine/threonine kinase 1 Homo sapiens 191-194 24316214-8 2014 alpha-MSH-mediated S6K1 activation and pro-survival effect against H2O2 was inhibited by Akt inhibitors (perifosine, MK-2206 and LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 89-92 23814023-6 2013 Moreover, LY294002 suppressed the activity of the PI3K/AKT/mTOR axis and mitigated the p-Ser473-AKT activation feedback loop in both cell lines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 96-99 24156430-5 2013 Phosphorylation levels of PI3K/Akt signaling pathway protein p-Akt, p-mTOR, p-P70S6K decreased, the expression of apoptosis-related protein cyclin D1, Bcl-2, procaspase-3 was down-regulated.It is concluded that the LY294002 can inhibit Jeko-1 cell proliferation, which may be realized through down-regulating the phosphorylation level of p-Akt, p-mTOR, p-P70S6K, inhibiting the P13k/Akt signaling pathway, and promoting the cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 215-223 AKT serine/threonine kinase 1 Homo sapiens 31-34 24040255-6 2013 The specific inhibitor of phosphatidylinositol 3-kinase (PI3K), LY294002, significantly down-regulated ephrin-A1-induced expression of phosphorylated Akt(Ser473) as well as phosphorylation of eNOS(Ser1177). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-72 AKT serine/threonine kinase 1 Homo sapiens 150-153 23672191-6 2013 The inhibition of Akt, using LY294002, abolished the accumulation and nuclear translocation of beta-catenin induced by AIMP1, leading to a decrease in c-myc and cyclin D1 expression, which decreased the proliferation of BMMSCs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 29-37 AKT serine/threonine kinase 1 Homo sapiens 18-21 23928058-12 2013 Inhibition of the PI3K/Akt/mTOR pathway by LY294002 induced nSR100 expression, whereas the specific MEK/ERK inhibitor U0126 inhibited nSR100 expression. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 43-51 AKT serine/threonine kinase 1 Homo sapiens 23-26 23973711-10 2013 The Akt inhibitor, LY294002, augmented the effect of simvastatin on PTEN wild-type TNBC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 4-7 23707520-8 2013 Furthermore, Akt inhibition by LY294002 or ERK1/2 inhibition by PD98059 induced tube breakdown and cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 13-16 23744557-8 2013 P-gp expression was augmented in response to activation of the PI3K/Akt pathway, which could be modified by PI3K inhibitor LY294002 or multidrug resistance siRNA transfection. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 123-131 AKT serine/threonine kinase 1 Homo sapiens 68-71 23774231-9 2013 These effects were abrogated when cells were pretreated with the Akt inhibitor, LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 65-68 23765166-8 2013 The luciferase reporter gene assay showed that the activity of the MRP1 promoter was markedly increased by VEGF stimulation, while LY294002, an inhibitor of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, reduced this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 131-139 AKT serine/threonine kinase 1 Homo sapiens 216-219 23793038-6 2013 The findings showed that LY294002 attenuated DEHP-induced up-regulation of the selected genes (pi3k, akt, mtor and p70s6k) involved in PI3K-AKT-mTOR signaling pathway at both mRNA and protein levels thus inhibited the cell abnormal proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 101-104 23793038-6 2013 The findings showed that LY294002 attenuated DEHP-induced up-regulation of the selected genes (pi3k, akt, mtor and p70s6k) involved in PI3K-AKT-mTOR signaling pathway at both mRNA and protein levels thus inhibited the cell abnormal proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 25-33 AKT serine/threonine kinase 1 Homo sapiens 140-143 23711089-9 2013 Furthermore, consistent with inhibition of AKT activation by using the PI3K inhibitor LY294002, melatonin elevated the levels of CHOP (C/EBP-homologous protein) and reduced the levels of Survivin (a member of the inhibitor of apoptosis protein family)suggesting that inhibition of the PI3K/AKT pathway by melatonin-reversed ER stress-induced resistance to doxorubicin in human hepatocellular carcinoma cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 86-94 AKT serine/threonine kinase 1 Homo sapiens 43-46 23765731-10 2013 Consistently the PI3K/AKT inhibitor LY294002 mimicked the effects of DKK3 knockdown. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 22-25 23975168-6 2013 The Akt activation appeared to require the PI3K pathway as its activation was abolished by the PI3K inhibitors LY294002 and wortmannin. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 111-119 AKT serine/threonine kinase 1 Homo sapiens 4-7 23951091-9 2013 Addition of the PI3K-inhibitor LY294002 and the MEK-inhibitor U0126 to the HMEC-1 inhibited this effect, suggesting that both Akt and ERK pathways are involved in hDPSC-mediated HMEC-1 migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 31-39 AKT serine/threonine kinase 1 Homo sapiens 126-129 23679681-9 2013 Inhibition of COX-2 activity with the selective inhibitor, NS398, and inhibition of AKT activation using the PI3K inhibitor, LY294002, in tumor cells confirmed that melatonin-induced apoptosis was COX-2/PI3K/AKT-dependent, suggesting that the COX-2/PI3K/AKT pathway plays a role in melatonin inhibition of IAPs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 AKT serine/threonine kinase 1 Homo sapiens 84-87 23836295-10 2013 Furthermore, the anti-apoptotic function of FAM9C could be prevented when the PI3K-Akt pathway was in a loss-of-function caused by RNA interference against Akt or PI3K inhibitor LY294002 in HCC cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 178-186 AKT serine/threonine kinase 1 Homo sapiens 83-86 23990921-4 2013 We show that SopB-mediated Akt activation is only partially sensitive to PI3-kinase inhibitors LY294002 and wortmannin in HeLa cells, suggesting that Class I PI3-kinases play only a minor role in this process. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 27-30 23843462-6 2013 The AKT phosphorylation/activation was mediated mainly through the PI3K pathway because it was blocked by the PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 125-133 AKT serine/threonine kinase 1 Homo sapiens 4-7 23869765-8 2013 Finally, PI3K/AKT pathway inhibitor LY294002 reduced expressions of mesenchymal markers and stem-cell gene activity in spheroid cells, enhancing sensitivity of spheroid cells to paclitaxel treatment. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 36-44 AKT serine/threonine kinase 1 Homo sapiens 14-17 23951036-10 2013 Inhibition of Akt activation by treating with phosphoinositide 3-kinase (PI3K) inhibitor LY294002 decreased IR cell invasion, whereas inhibition of Erk1/2 activation by mitogen-activated protein kinase kinase (MEK) inhibitor U0126 did not. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 89-97 AKT serine/threonine kinase 1 Homo sapiens 14-17 23668972-6 2013 We treated Hela cells with GA to observe Akt degradation and found that LY294002 delayed Akt degradation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 72-80 AKT serine/threonine kinase 1 Homo sapiens 89-92 23403077-8 2013 The growth of the tumor spheres could also be reduced by the CXCR2 specific inhibitor SB225002 or the PI3K/AKT inhibitor LY294002, indicating that the endogenously produced CXCL8 plays an autocrine role in the growth of the tumor spheres. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 121-129 AKT serine/threonine kinase 1 Homo sapiens 107-110 23743572-2 2013 LY294002 is a commonly used pharmacological inhibitor that acts at the ATP-binding site of the PI3K enzyme, selectively inhibiting the PI3K/Akt pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 140-143 23743572-8 2013 We found that gastric cancer cells treated with LY294002 showed a significant inhibition of PI3K/Akt activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 97-100 23743572-12 2013 These results suggested that the PI3K/Akt inhibitor LY294002 can enhance chemosensitivity of human gastric cancer to VCR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 38-41 23791833-9 2013 An AKT inhibitor LY294002 effectively suppressed IKK/IkappaB/NF-kappaB signaling and PON1 gene expression induced by IL-6. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 17-25 AKT serine/threonine kinase 1 Homo sapiens 3-6 23935944-12 2013 However, the PI-3 kinase inhibitor LY294002, which abolished the effect of PUGNAc+glucosamine on Akt phosphorylation, did not impair the protective effects of PUGNAc+glucosamine against tamoxifen-induced cell death. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 97-100 23515290-12 2013 PGE2 and TGF-beta induced phosphorylation of AKT, which was blocked by antagonists of PGE2 (EP4) receptors (L161982, AH23848) and PI3K inhibitor (LY294002) in PC3 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 146-154 AKT serine/threonine kinase 1 Homo sapiens 45-48 23742697-8 2013 LY294002 (Akt/PI3-K inhibitor) or SB203580 (p38 MAPK inhibitor) abolished the effects of H2 S on eNOS phosphorylation, NO production, cell proliferation and tube formation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 10-13 23624876-7 2013 Interestingly, LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, blocked the increase in phosphorylation of Akt and abolished the neuroprotection associated with 4-HBA. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 118-121 23381397-4 2013 Analysis with the PI3K-specific inhibitor LY294002 confirmed that PI3K acted as the upstream activator for the virus-induced activation of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 42-50 AKT serine/threonine kinase 1 Homo sapiens 139-142 23381397-7 2013 Moreover, the suppression of phosphorylated Akt with LY294002 significantly inhibited the virus-induced cytopathic effect (CPE) on MARC-145 cells, but it had a negligible effect on virus propagation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 AKT serine/threonine kinase 1 Homo sapiens 44-47 23643356-9 2013 Inhibition of Akt signaling by specific inhibitor LY 294002 blocked miR-21-induced fibrogenic effects in LX-2 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 50-59 AKT serine/threonine kinase 1 Homo sapiens 14-17 23054210-7 2013 Wortmannin and LY294002, two PI3 kinase inhibitors, inhibited Akt but not JNK phosphorylation in ras-transformed cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 15-23 AKT serine/threonine kinase 1 Homo sapiens 62-65 23595342-9 2013 Furthermore, inhibition of the PI3K/AKT pathway by the inhibitor LY294002 led to attenuated differentiation, while differentiation remained stable with the inhibition of the MAPK/ERK pathway by PD0325901. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 65-73 AKT serine/threonine kinase 1 Homo sapiens 36-39 23624506-7 2013 Suppression of Akt phosphorylation and telomerase activity was also observed with PI3K inhibitor LY294002 further supporting the hypothesis that Akt signaling is involved in suppression of AR42-induced inhibition of telomerase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 15-18 23624506-7 2013 Suppression of Akt phosphorylation and telomerase activity was also observed with PI3K inhibitor LY294002 further supporting the hypothesis that Akt signaling is involved in suppression of AR42-induced inhibition of telomerase activity. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 97-105 AKT serine/threonine kinase 1 Homo sapiens 145-148 23708104-10 2013 In addition, the inhibitor of PI3K/Akt signaling pathway, LY294002, dramatically inhibited the growth of Ubc9 overexpressing cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 58-66 AKT serine/threonine kinase 1 Homo sapiens 35-38 23691130-8 2013 Furthermore, inhibiting AKT phosphorylation by LY294002 rescued the phenotype induced by SENP2 deficiency in MEFs. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 24-27 23376468-2 2013 PI3K/AKT signaling was manipulated using the activator (IGF-1) and the inhibitor (LY 294002) of the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-91 AKT serine/threonine kinase 1 Homo sapiens 5-8 23376468-2 2013 PI3K/AKT signaling was manipulated using the activator (IGF-1) and the inhibitor (LY 294002) of the PI3K/AKT pathway. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 82-91 AKT serine/threonine kinase 1 Homo sapiens 105-108 23660824-10 2013 However, LY294002, a PI3K inhibitor, attenuated the anti-apoptotic effect of salidroside and blocked the increase of Akt and mTOR; however, did not affect the antioxidative effect of salidroside. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 9-17 AKT serine/threonine kinase 1 Homo sapiens 117-120 23328930-8 2013 Activation of PI3K/Akt signaling pathway exists in TNF-alpha-induced production of IL-1beta and MMP3 on RA FLS, which is hampered by PI3K inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 148-156 AKT serine/threonine kinase 1 Homo sapiens 19-22 23328930-9 2013 Immunofluorescence staining showed that TNF-alpha alone increased the production of P-Akt, whereas LY294002 and 50 muM resveratrol suppressed the TNF-alpha-stimulated expression of P-Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 99-107 AKT serine/threonine kinase 1 Homo sapiens 183-186 23815230-6 2013 LGI3 treatment increased beta-catenin protein and nuclear localization, whereas LY294002 prevented LGI3-induced focal adhesion kinase and Akt activation as well as beta-catenin accumulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 80-88 AKT serine/threonine kinase 1 Homo sapiens 138-141 23546450-8 2013 Results of the present study also demonstrated that Akt signaling is involved in the ADR resistance of breast cancer cells since LY294002, an inhibitor of Akt signaling, partially restored the sensitivity of MCF-7/ADR cells to ADR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 52-55 23485815-7 2013 Selective inhibition of PI3K using LY294002 abolished PF-mediated phosphorylation of Akt-1 and NPC protection upon oxidative stress. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 35-43 AKT serine/threonine kinase 1 Homo sapiens 85-90 23564227-7 2013 Treatment with the PI3K inhibitor LY294002 abolished Der f 2-induced activation of Akt and NF-kappaB and the expression of IL-13. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 34-42 AKT serine/threonine kinase 1 Homo sapiens 83-86 23546450-8 2013 Results of the present study also demonstrated that Akt signaling is involved in the ADR resistance of breast cancer cells since LY294002, an inhibitor of Akt signaling, partially restored the sensitivity of MCF-7/ADR cells to ADR. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 129-137 AKT serine/threonine kinase 1 Homo sapiens 155-158 23188122-6 2013 The decrease in caspase-3 activity and caused by CCE were blocked by LY294002, a specific inhibitor of phosphatidylinositol 3-kinase, the upstream kinase of Akt. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 69-77 AKT serine/threonine kinase 1 Homo sapiens 157-160 23466500-8 2013 Inhibition of Akt using PI3K inhibitor LY 294002 could abrogate miR-21 induced cell survival. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 39-48 AKT serine/threonine kinase 1 Homo sapiens 14-17 23590596-9 2013 Targeting PI3K/Akt signaling by the inhibitor LY294002 (30 muM) significantly decreased the protein expression as well as DNA binding activity of HIF-1alpha and restored the apoptosis-inducing ability of cells in hypoxia Additionally, pretreatment with LY294002 sensitized A204 and A673 cells to TRAIL or doxorubicin induced apoptosis under hypoxia. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 15-18 23590596-9 2013 Targeting PI3K/Akt signaling by the inhibitor LY294002 (30 muM) significantly decreased the protein expression as well as DNA binding activity of HIF-1alpha and restored the apoptosis-inducing ability of cells in hypoxia Additionally, pretreatment with LY294002 sensitized A204 and A673 cells to TRAIL or doxorubicin induced apoptosis under hypoxia. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 253-261 AKT serine/threonine kinase 1 Homo sapiens 15-18 23755818-9 2013 Upon the addition of LY294002, 5C11-mediated up-regulation of p-AKT was inhibited. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 21-29 AKT serine/threonine kinase 1 Homo sapiens 64-67 23355370-7 2013 Interestingly, a short treatment with LY294002, an inhibitor of the PI3K/AKT pathway, specifically reverts a subset of Rh123(high) cells to the Rh123(low) phenotype, whereas treatment with inhibitors of mammalian target of rapamycin, phosphatase and tensin homolog or mitogen-activated protein kinase signaling does not. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 38-46 AKT serine/threonine kinase 1 Homo sapiens 73-76 23391508-6 2013 However, an addition of the PI3K/Akt inhibitor LY294002 inhibited these Ghr-mediated effects. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 33-36 23161148-10 2013 The enhanced activation of STAT3, ERK1/2, and AKT by IL-6 was abolished by AG490, PD98059, and LY294002, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 95-103 AKT serine/threonine kinase 1 Homo sapiens 46-49 23313788-11 2013 rHuEPO increased the expression of EPOR, and upregulated the expression of pAKT/AKT and pSTAT5/STAT5 in 3T3L1 adipocytes (p<0.05), which was blocked by siEPOR, the phosphatidylinositol-3-kinase (PI3K) inhibitor, LY294002, and a STAT5 inhibitor, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 215-223 AKT serine/threonine kinase 1 Homo sapiens 76-79 23212450-8 2013 Conversely, cell exposure to the PI3K inhibitor LY294002 increases HER2 phosphorylation, suggesting the involvement of PI3K/AKT in HER2 regulation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 48-56 AKT serine/threonine kinase 1 Homo sapiens 124-127 23585721-6 2013 In further experiments, an inhibitor of PI3K (LY294002) upstream of Akt increased expression of pro-inflammatory cytokines. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 46-54 AKT serine/threonine kinase 1 Homo sapiens 68-71 23208610-5 2013 CCN2-stimulated phosphorylation of Akt and GSK-3beta was sensitive to inhibition of PI3-kinase (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 96-104 AKT serine/threonine kinase 1 Homo sapiens 35-38 23442498-12 2013 LY294002 (PI3k/AKT inhibitor) inhibited AGEs-induced macrophage migration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 0-8 AKT serine/threonine kinase 1 Homo sapiens 15-18 23426781-4 2013 In Saos-2 cells, overexpression of TWIST significantly decreased ET-1 mRNA and protein expression levels, cell survival against cisplatin and phosphorylation of Akt at serine 473 (ser473), which was abolished by the selective phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, or the selective ETAR inhibitor, BQ123. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 274-282 AKT serine/threonine kinase 1 Homo sapiens 161-164 23879997-12 2013 When the AKT signaling was blocked by 10 micromol/L LY294002, the 0.001 and 0.01 micromol/L paclitaxel-induced early apoptosis rate in A375 cells was increased by 2.02- and 1.46-fold, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 52-60 AKT serine/threonine kinase 1 Homo sapiens 9-12 23363008-7 2013 The employment of protein kinase inhibitors LY294002, SB203580, SP600125, and U0126 revealed that PI3K/Akt signaling pathway interplayed with MAPK signaling pathways. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 103-106 23201927-7 2013 Conversely, blocking Akt activation with the PI3K inhibitor LY294002 effectively suppressed the protective effect of Sal B against ATO-induced cell apoptosis. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 60-68 AKT serine/threonine kinase 1 Homo sapiens 21-24 23219871-8 2013 Moreover, the expression of phosphorylated Akt (p-Akt) protein in TAO cells was up-regulated by IGF-1, while a specific PI3K inhibitor (LY294002) or an antibody of IGF-1R blocked this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 136-144 AKT serine/threonine kinase 1 Homo sapiens 43-46 23255002-7 2013 The PI3K inhibitor LY294002 also suppressed rapamycin-induced phosphorylation of Akt and combined treatment showed synergistic growth inhibition of MCF-7 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 19-27 AKT serine/threonine kinase 1 Homo sapiens 81-84 22926956-6 2013 Notably, the activation of CB peptide-induced osteogenic differentiation was completely blocked to the basal level by the specific inhibitors for ERK1/2 (U0126) and Akt (LY294002). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 170-178 AKT serine/threonine kinase 1 Homo sapiens 165-168 22887215-8 2013 Notably, disruption of the PI3K/Akt pathway by LY294002, a PI3K/Akt inhibitor potentiated apoptosis in A549 cells by BAI at a subcytotoxic concentration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 32-35 22887215-8 2013 Notably, disruption of the PI3K/Akt pathway by LY294002, a PI3K/Akt inhibitor potentiated apoptosis in A549 cells by BAI at a subcytotoxic concentration. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 47-55 AKT serine/threonine kinase 1 Homo sapiens 64-67 23392708-7 2013 Furthermore, Western blotting revealed that LY294002 combined with gemcitabine reduced the protein levels of p-Akt and MRP, which contributed to the inhibition of proliferation. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 44-52 AKT serine/threonine kinase 1 Homo sapiens 111-114 23192871-9 2013 Inhibition of Akt activity with LY294002 reduced the G(1) and M phase differences observed in cells infected with wild-type and ORF12 mutant viruses. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 32-40 AKT serine/threonine kinase 1 Homo sapiens 14-17 23229346-11 2013 Moreover, LY294002 inhibited phosphorylation of Akt and IkappaB-alpha in SKBR3 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 10-18 AKT serine/threonine kinase 1 Homo sapiens 60-63 23229870-9 2013 The inhibition of p38 and Akt kinases with SB203580 and LY294002 further increased resveratrol-induced MMP-9 as well as cell migration in the HT1080 cells. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 56-64 AKT serine/threonine kinase 1 Homo sapiens 26-29 23233127-4 2013 Enhanced proliferation in integrin alpha3-silenced cells is mediated by upregulation and nuclear localization of cyclin-dependent kinases, and these effects require the activation of Akt and ERK as evidenced by treatment with LY294002 and PD98059, respectively. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 262-270 AKT serine/threonine kinase 1 Homo sapiens 207-210 23469688-6 2013 Indeed, the specific inhibitors (LY294002 and U0126) of PI3K/PDK1/Akt and ERK showed similar anti-cancer properties to 8-TQ. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 33-41 AKT serine/threonine kinase 1 Homo sapiens 66-69 23219871-8 2013 Moreover, the expression of phosphorylated Akt (p-Akt) protein in TAO cells was up-regulated by IGF-1, while a specific PI3K inhibitor (LY294002) or an antibody of IGF-1R blocked this effect. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 136-144 AKT serine/threonine kinase 1 Homo sapiens 50-53